0001564590-22-008531.txt : 20220303 0001564590-22-008531.hdr.sgml : 20220303 20220303162809 ACCESSION NUMBER: 0001564590-22-008531 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 80 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220303 DATE AS OF CHANGE: 20220303 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Rain Therapeutics Inc. CENTRAL INDEX KEY: 0001724979 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 821130967 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40356 FILM NUMBER: 22709315 BUSINESS ADDRESS: STREET 1: 8000 JARVIS AVENUE STREET 2: SUITE 204 CITY: NEWARK STATE: CA ZIP: 94560 BUSINESS PHONE: (510) 953-5559 MAIL ADDRESS: STREET 1: 8000 JARVIS AVENUE STREET 2: SUITE 204 CITY: NEWARK STATE: CA ZIP: 94560 10-K 1 rain-10k_20211231.htm 10-K rain-10k_20211231.htm
false 2021 FY --12-31 0001724979 0.9260 true true P6M P12M P30D 2021 2017-04-30 P8M1D P0D P24M P5Y P9Y P8Y9M18D P8Y9M18D P8Y2M12D 0.008 0.002 0.013 0.009 1.132 0.969 1.187 1.162 P5Y P1Y6M P6Y1M6D P6Y1M6D P1Y4M24D P2Y8M12D 2031 2039 2041 2041 0001724979 2021-01-01 2021-12-31 xbrli:shares 0001724979 2022-02-17 iso4217:USD 0001724979 2021-06-30 0001724979 2021-12-31 0001724979 2020-12-31 0001724979 rain:SeriesAConvertiblePreferredStockMember 2021-12-31 0001724979 rain:SeriesAConvertiblePreferredStockMember 2020-12-31 0001724979 rain:SeriesBConvertiblePreferredStockMember 2021-12-31 0001724979 rain:SeriesBConvertiblePreferredStockMember 2020-12-31 iso4217:USD xbrli:shares 0001724979 rain:UndesignatedCommonStockMember 2021-12-31 0001724979 us-gaap:NonvotingCommonStockMember 2021-12-31 0001724979 2020-01-01 2020-12-31 0001724979 rain:SeriesAConvertiblePreferredStockMember 2019-12-31 0001724979 us-gaap:CommonStockMember 2019-12-31 0001724979 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001724979 us-gaap:RetainedEarningsMember 2019-12-31 0001724979 2019-12-31 0001724979 rain:SeriesBConvertiblePreferredStockMember 2020-01-01 2020-12-31 0001724979 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001724979 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001724979 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001724979 us-gaap:CommonStockMember 2020-12-31 0001724979 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001724979 us-gaap:RetainedEarningsMember 2020-12-31 0001724979 rain:SeriesAConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001724979 rain:SeriesBConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001724979 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001724979 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001724979 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001724979 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001724979 us-gaap:CommonStockMember 2021-12-31 0001724979 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001724979 us-gaap:RetainedEarningsMember 2021-12-31 0001724979 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001724979 rain:TwoThousandAndTwentyOneEmployeeSharePurchasePlanMember 2021-01-01 2021-12-31 rain:Segment xbrli:pure 0001724979 us-gaap:CommonStockMember 2021-04-16 2021-04-16 0001724979 us-gaap:CommonStockMember us-gaap:IPOMember 2021-04-27 2021-04-27 0001724979 us-gaap:CommonStockMember us-gaap:IPOMember 2021-04-27 0001724979 us-gaap:CommonStockMember us-gaap:OverAllotmentOptionMember 2021-05-11 2021-05-11 0001724979 rain:IPOAndOverAllotmentOptionMember 2021-01-01 2021-12-31 0001724979 rain:UndesignatedCommonStockMember 2021-04-27 2021-04-27 0001724979 us-gaap:NonvotingCommonStockMember 2021-04-27 2021-04-27 0001724979 2021-04-27 0001724979 us-gaap:IPOMember 2021-04-30 0001724979 srt:MinimumMember 2021-01-01 2021-12-31 0001724979 srt:MaximumMember 2021-01-01 2021-12-31 0001724979 2017-04-30 2021-12-31 0001724979 us-gaap:AccountingStandardsUpdate202006Member 2021-12-31 0001724979 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2021-12-31 0001724979 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-12-31 0001724979 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2021-12-31 0001724979 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0001724979 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember 2021-12-31 0001724979 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0001724979 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001724979 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001724979 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001724979 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001724979 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001724979 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0001724979 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001724979 us-gaap:CashMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001724979 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001724979 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001724979 us-gaap:FairValueInputsLevel3Member 2019-12-31 0001724979 us-gaap:FairValueInputsLevel3Member 2020-01-01 2020-12-31 0001724979 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember 2021-01-01 2021-12-31 0001724979 us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember 2021-01-01 2021-12-31 0001724979 us-gaap:MeasurementInputDiscountRateMember 2021-12-31 0001724979 rain:TwoThousandNineteenAndTwentyConvertiblePromissoryNotesMember 2020-09-30 0001724979 rain:ConvertiblePromissoryNotesMember 2020-09-01 2020-09-30 0001724979 rain:SeriesBConvertiblePreferredStockMember 2020-09-01 2020-09-30 0001724979 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001724979 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001724979 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001724979 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001724979 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001724979 us-gaap:ComputerEquipmentMember 2021-12-31 0001724979 us-gaap:ComputerEquipmentMember 2020-12-31 0001724979 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001724979 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001724979 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001724979 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001724979 rain:CertainHoldersOfPreferredStockInvestorsMember rain:TwoThousandAndNineteenNotesMember 2019-10-31 0001724979 rain:CertainHoldersOfPreferredStockInvestorsMember rain:TwoThousandAndTwentyNotesMember 2020-06-30 0001724979 rain:ConvertiblePromissoryNotesMember 2021-01-01 2021-12-31 0001724979 rain:TwoThousandAndNineteenNotesMember 2019-10-31 0001724979 rain:TwoThousandAndNineteenNotesMember 2021-01-01 2021-12-31 0001724979 rain:TwoThousandAndNineteenNotesMember srt:MinimumMember 2019-10-01 2019-10-31 0001724979 rain:TwoThousandAndNineteenNotesMember 2019-10-01 2019-10-31 0001724979 rain:TwoThousandAndNineteenNotesMember us-gaap:CommonStockMember 2019-10-01 2019-10-31 0001724979 rain:TwoThousandAndTwentyNotesMember 2020-06-30 0001724979 rain:TwoThousandAndTwentyNotesMember 2021-01-01 2021-12-31 0001724979 srt:MinimumMember rain:TwoThousandAndTwentyNotesMember 2020-06-30 2020-06-30 0001724979 rain:TwoThousandAndTwentyNotesMember 2020-06-30 2020-06-30 0001724979 us-gaap:CommonStockMember rain:TwoThousandAndTwentyNotesMember 2020-06-30 2020-06-30 0001724979 us-gaap:IPOMember 2021-04-16 0001724979 2021-04-16 0001724979 rain:UndesignatedPreferredStockMember 2021-04-16 0001724979 rain:UndesignatedCommonStockMember 2021-04-16 0001724979 us-gaap:NonvotingCommonStockMember 2021-04-16 rain:Vote 0001724979 us-gaap:NonvotingCommonStockMember 2021-01-01 2021-12-31 0001724979 us-gaap:NonvotingCommonStockMember srt:MaximumMember 2021-01-01 2021-12-31 0001724979 rain:SeriesAConvertiblePreferredStockMember 2018-04-30 0001724979 rain:SeriesAConvertiblePreferredStockMember 2018-12-31 0001724979 rain:SeriesAConvertiblePreferredStockMember 2018-04-01 2018-04-30 0001724979 rain:SeriesAConvertiblePreferredStockMember 2018-12-01 2018-12-31 0001724979 rain:SeriesBConvertiblePreferredStockMember 2020-09-30 0001724979 rain:SeriesAConvertiblePreferredStockMember 2018-04-01 2021-12-31 0001724979 rain:SeriesBConvertiblePreferredStockMember 2020-09-01 2021-12-31 0001724979 rain:TwoThousandAndEighteenStockIssuancePlanMember 2021-04-15 2021-04-15 0001724979 us-gaap:EmployeeStockOptionMember rain:TwoThousandTwentyOneEquityIncentivePlanMember srt:MaximumMember 2021-04-15 0001724979 us-gaap:EmployeeStockOptionMember rain:TwoThousandAndEighteenStockIssuancePlanMember 2021-12-31 0001724979 rain:TwoThousandTwentyOneEquityIncentivePlanMember 2021-04-15 2021-04-15 0001724979 rain:TwoThousandTwentyOneEquityIncentivePlanMember 2020-12-31 0001724979 rain:TwoThousandTwentyOneEquityIncentivePlanMember 2021-01-01 2021-12-31 0001724979 rain:TwoThousandTwentyOneEquityIncentivePlanMember 2021-12-31 0001724979 rain:TwoThousandTwentyOneEquityIncentivePlanMember 2020-01-01 2020-12-31 0001724979 rain:TwoThousandAndTwentyOneEmployeeSharePurchasePlanMember srt:MaximumMember 2021-04-15 0001724979 rain:TwoThousandAndTwentyOneEmployeeSharePurchasePlanMember 2021-04-15 0001724979 rain:TwoThousandAndTwentyOneEmployeeSharePurchasePlanMember 2021-04-15 2021-04-15 0001724979 rain:TwoThousandAndTwentyOneEmployeeSharePurchasePlanMember 2021-12-31 0001724979 rain:TwoThousandAndTwentyOneEmployeeSharePurchasePlanMember us-gaap:SubsequentEventMember 2022-01-01 2022-01-31 0001724979 rain:RestrictedStockPurchaseAgreementsMember 2017-12-31 0001724979 rain:RestrictedStockPurchaseAgreementsMember 2021-01-01 2021-12-31 0001724979 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001724979 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001724979 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0001724979 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-12-31 0001724979 srt:MinimumMember 2020-01-01 2020-12-31 0001724979 srt:MaximumMember 2020-01-01 2020-12-31 0001724979 us-gaap:EmployeeStockOptionMember 2021-12-31 0001724979 us-gaap:EmployeeStockOptionMember 2020-12-31 0001724979 rain:ReservedForFutureEquityAwardGrantsMember 2021-12-31 0001724979 rain:ReservedForFutureEquityAwardGrantsMember 2020-12-31 0001724979 rain:ReservedForFutureESPPIssuancesMember 2021-12-31 0001724979 rain:ReservedForFutureESPPIssuancesMember 2020-12-31 0001724979 us-gaap:ConvertiblePreferredStockMember 2021-12-31 0001724979 us-gaap:ConvertiblePreferredStockMember 2020-12-31 0001724979 rain:DaiichiSankyoLicenseAgreementMember 2021-01-01 2021-12-31 0001724979 rain:DaiichiSankyoLicenseAgreementMember 2020-01-01 2020-12-31 rain:FamiliesofPatent rain:Trial 0001724979 rain:DaiichiSankyoLicenseAgreementMember 2021-12-31 0001724979 rain:DaiichiSankyoLicenseAgreementMember 2021-07-01 2021-09-30 0001724979 rain:DrexelUniversityMember rain:DrexelLicenseAgreementMember 2021-01-01 2021-12-31 rain:Installment 0001724979 rain:DrexelUniversityMember rain:DrexelLicenseAgreementMember 2021-12-31 0001724979 rain:DrexelUniversityMember rain:DrexelLicenseAgreementMember 2020-01-01 2020-12-31 0001724979 rain:DrexelUniversityMember rain:DrexelLicenseAgreementMember srt:MinimumMember 2021-01-01 2021-12-31 0001724979 rain:DrexelUniversityMember rain:DrexelLicenseAgreementMember srt:MaximumMember 2021-01-01 2021-12-31 0001724979 2018-09-30 0001724979 2018-09-01 2018-09-30 0001724979 2020-06-01 2020-06-30 0001724979 rain:FederalPreTaxCutAndJobsActMember 2021-12-31 0001724979 rain:FederalPostTaxCutAndJobsActMember 2021-12-31 0001724979 us-gaap:CaliforniaFranchiseTaxBoardMember 2021-12-31 0001724979 rain:RDAndOrphanDrugCreditsFederalMember 2021-12-31 0001724979 rain:RDCreditsCaliforniaMember 2021-12-31 0001724979 srt:MinimumMember rain:FederalPreTaxCutAndJobsActMember 2021-01-01 2021-12-31 0001724979 srt:MinimumMember us-gaap:CaliforniaFranchiseTaxBoardMember 2021-01-01 2021-12-31 0001724979 srt:MinimumMember rain:RDAndOrphanDrugCreditsFederalMember 2021-01-01 2021-12-31 0001724979 srt:MaximumMember us-gaap:CaliforniaFranchiseTaxBoardMember 2021-01-01 2021-12-31 0001724979 srt:MaximumMember rain:RDAndOrphanDrugCreditsFederalMember 2021-01-01 2021-12-31 0001724979 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001724979 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001724979 rain:SeriesAConvertiblePreferredStockMember 2020-01-01 2020-12-31 0001724979 rain:SeriesBConvertiblePreferredStockMember 2020-01-01 2020-12-31 0001724979 us-gaap:EmployeeStockMember 2021-01-01 2021-12-31

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

(Mark One)

☒

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2021

OR

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO                     

Commission File Number 001-40356

 

Rain Therapeutics Inc.

(Exact name of Registrant as specified in its Charter)

 

 

Delaware

82-1130967

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

8000 Jarvis Avenue, Suite 204

Newark, CA

94560

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (510) 953-5559

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.001 per share

 

RAIN

 

The Nasdaq Global Select Market

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  Yes ☐ No ☒

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☒ No ☐

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).  Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

☐

  

Accelerated filer

 

☐

 

 

 

 

Non-accelerated filer

 

☒

  

Smaller reporting company

 

☒

 

 

 

 

 

 

 

Emerging growth company

 

☒

 

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  ☐

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  YES ☐ NO ☒

The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant as of June 30, 2021, the last business day of the Registrant’s most recently completed second fiscal quarter, was approximately $120,166,484, based on the closing price of the shares of common stock on The Nasdaq Global Select Market reported for such date. Shares of common stock held by each officer and director and by each person who is known to own 10% or more of the outstanding common stock have been excluded in that such persons may be deemed to be affiliates of the Registrant. This determination of affiliate status is not necessarily a conclusive determination for other purposes.

As of February 17, 2022, the registrant had 26,510,407 shares of common stock, $0.001 par value per share, outstanding, comprised of 18,782,937 shares of common stock, $0.001 par value per share, and 7,727,470 shares non-voting common stock, $0.001 par value per share.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the Registrant’s definitive proxy statement relating to its 2022 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year ended December 31, 2021 are incorporated herein by reference in Part III of this Annual Report on Form 10-K where indicated.

 

 

 

 

 

Table of Contents

 

 

 

Page

PART I

 

 

Item 1.

Business

1

Item 1A.

Risk Factors

30

Item 1B.

Unresolved Staff Comments

51

Item 2.

Properties

51

Item 3.

Legal Proceedings

51

Item 4.

Mine Safety Disclosures

51

 

 

 

PART II

 

 

Item 5.

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

52

Item 6.

Reserved

52

Item 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

53

Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

63

Item 8.

Financial Statements and Supplementary Data

64

Item 9.

Changes in and Disagreements With Accountants on Accounting and Financial Disclosure

91

Item 9A.

Controls and Procedures

91

Item 9B.

Other Information

91

Item 9C.

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

91

 

 

 

PART III

 

 

Item 10.

Directors, Executive Officers and Corporate Governance

92

Item 11.

Executive Compensation

92

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

92

Item 13.

Certain Relationships and Related Transactions, and Director Independence

92

Item 14.

Principal Accounting Fees and Services

92

 

 

 

PART IV

 

 

Item 15.

Exhibits, Financial Statement Schedules

93

Item 16.

Form 10-K Summary

95


 

i

 

 

NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Annual Report on Form 10-K includes “forward-looking statements” within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this Annual Report on Form 10-K, including statements concerning our plans, objectives, goals, strategies, future events, future revenues or performance, financing needs, plans or intentions relating to product candidates and markets and business trends and other information referred to under the sections titled “Business,” “Risk Factors,” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” are forward-looking statements. In some cases, you can identify forward looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,”, “design,” “estimate,” “predict,” “potential,” “plan” or the negative of these terms and similar expressions intended to identify forward-looking statements. Forward-looking statements are not historical facts and reflect our current views with respect to future events. Given the significant uncertainties, you should not place undue reliance on these forward-looking statements.

There are a number of risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this Annual Report on Form 10-K. Such risks, uncertainties and other factors include, among others, the risks, uncertainties and factors set forth in “Risk Factors,” and the following risks, uncertainties and factors:

 

•

the ability of our clinical trials to demonstrate safety and efficacy of our product candidates and other positive results;

 

•

the timing and focus of our ongoing and future preclinical studies and clinical trials and the reporting of data from those studies and trials;

 

•

our plans relating to commercializing our product candidates, if approved, including the geographic areas of focus and sales strategy;

 

•

the size of the market opportunity for our product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting;

 

•

our expectations regarding the approval and use of our product candidates as first, second or subsequent lines of therapy or in combination with other drugs;

 

•

the success of competing therapies that are or may become available;

 

•

our estimates of the number of patients that we will enroll in our clinical trials;

 

•

the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates;

 

•

the timing or likelihood of regulatory filings and approvals, including our expectation to seek an accelerated approval pathway and special designations, such as orphan drug designation, for our product candidates for various diseases;

 

•

our ability to obtain and maintain regulatory approval of our product candidates;

 

•

our plans relating to the further development of our product candidates, including additional indications we may pursue;

 

•

existing regulations and regulatory developments in the United States, Europe and other jurisdictions;

 

•

risks associated with the COVID-19 pandemic, which may adversely impact our business, preclinical studies and clinical trials;

 

•

our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available;

 

•

our continued reliance on third parties to conduct additional clinical trials of our product candidates and for the manufacture of our product candidates for preclinical studies and clinical trials;

 

•

our plans regarding, and our ability to obtain, and negotiate favorable terms of, any collaboration, licensing or other arrangements that may be necessary or desirable to develop, manufacture or commercialize our product candidates;

 

•

our plans to develop our product candidates in combination with other therapies;

 

•

the need to hire additional personnel and our ability to attract and retain such personnel;

 

•

our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;

 

•

our financial performance;

 

•

the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; and

 

•

our expectations regarding the period during which we will qualify as an emerging growth company under the JOBS Act.

 

ii

 

There may be other factors that may cause our actual results to differ materially from the forward-looking statements, including factors disclosed in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” You should evaluate all forward-looking statements made in this Annual Report on Form 10-K in the context of these risks and uncertainties.

We caution you that the risks, uncertainties and other factors referred to above may not contain all of the risks, uncertainties and other factors that are important to you. In addition, we cannot assure you that we will realize the results, benefits or developments that we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our business in the way expected. All forward-looking statements in this Annual Report on Form 10-K apply only as of the date made and are expressly qualified in their entirety by the cautionary statements included in this Annual Report on Form 10-K. We undertake no obligation to publicly update or revise any forward-looking statements to reflect subsequent events or circumstances.

 

 

 

iii

 

 

PART I

Item 1. Business.

Company Overview

We are a late-stage precision oncology company developing therapies that target oncogenic drivers for which we are able to genetically select patients we believe will be most likely to benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. We have in-licensed product candidates, each with a differentiated profile relative to available therapies, and we intend to continue strengthening our pipeline through focused business development and internal research efforts.

Our lead product candidate, milademetan (also known as RAIN-32) is a small molecule, oral inhibitor of mouse double minute 2 (MDM2), which may be oncogenic in numerous cancers. We in-licensed milademetan from Daiichi Sankyo Company, Limited (Daiichi Sankyo) in September 2020 based on the results of a Phase 1 clinical trial, which demonstrated meaningful antitumor activity in an MDM2-amplified subtype of liposarcoma (LPS) and other solid tumors. Data from well-differentiated/de-differentiated (WD/DD) LPS patients in the Phase 1 clinical trial of milademetan demonstrated median progression-free survival (mPFS) of approximately seven to eight months. Importantly, this result was accomplished with a rationally designed dosing schedule designed to mitigate safety concerns and widen the therapeutic window of MDM2 inhibition unlocking the potential for milademetan in a broad range of MDM2-dependent cancers. Milademetan is currently being evaluated in an ongoing Phase 3 clinical trial in patients with LPS (MANTRA), as well as a Phase 2 tumor-agnostic basket trial in certain solid tumors (MANTRA-2). We anticipate commencing a Phase 2 clinical trial of milademetan (MANTRA-3), for the treatment of patients with Merkel cell carcinoma who are polyoma virus-positive and refractory to immune checkpoint inhibition (ICI), in the second half of 2022 and a Phase 1 clinical trial to evaluate the safety, tolerability and efficacy of milademetan in combination with atezolizumab in patients with loss of cyclin-dependent kinase inhibitor 2A (CDKN2A) and wildtype p53 advanced solid tumors (MANTRA-4) in the second half of 2022. In addition to milademetan, we are also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Our Strategy

Our vision is to be a leading precision oncology company that develops and commercializes small molecule therapeutics through leveraging both an acquisition-based business model and internal research efforts. Our strategy to achieve this vision is as follows:

 

•

Rapidly advance our lead product candidate, milademetan, through clinical development toward approval in LPS and subsequently expand across a multitude of MDM2-dependent tumors. As the trials progress, we plan to accelerate efforts to engage with the regulatory authorities and, upon potential receipt of the requisite approvals, will initiate efforts to manufacture and commercially launch milademetan.

 

•

Increase probability of a clinically meaningful benefit for patients for our pipeline programs by utilizing biomarker driven patient selection. We employ widely available, comprehensive next generation sequencing (NGS) diagnostic tests and partner with industry-leading assay developers to identify patients for our clinical trials based on molecular biomarkers indicating oncogene addiction and dependency on specific cellular signaling networks. This pre-selection of patients is designed to target patients most likely to benefit from our therapies.

 

•

Maximize opportunity of commercial success for our pipeline programs by focusing on tumor-agnostic clinical trials. Through our MANTRA-2 open-label basket trial for milademetan, we are employing a tumor-agnostic development approach to the essential biological pathways and molecular machinery of cancer. This strategy leverages existing comprehensive next generation tumor sequencing in cancer patients and we believe will allow for rapid patient enrollment and subsequent collection of data and, as a result, the potential acceleration of clinical trial timelines. We believe our continued focus on this approach will maximize our total addressable patient population and the overall commercial opportunities for our pipeline programs.

 

•

Leverage our business development expertise to expand our pipeline of precision oncology candidates by identifying genetically or biologically defined subsets across solid tumors and hematologic malignancies in patients with limited treatment options. Our team has a diversity of

 

1

 

 

backgrounds from academia and drug research and development to biopharma industry experience. Our expansive networks in the biopharma landscape coupled with our analytical approach to business development allows us to screen and identify drug candidates and programs with potentially significant commercial opportunities. We are exploring pipeline programs in the following three categories: (1) small molecule programs focusing on novel oncogenic drivers, and with mechanisms of action that are distinct from existing and upcoming therapeutics; (2) programs that improve upon existing therapies with validated oncology targets and clinical efficacy, but which lack clinical utility due to a narrow therapeutic window; and (3) programs targeting emerging classes and/or biological targets of precision oncology, such as synthetic lethality.

 

•

Pursue global clinical and regulatory strategies enabling us to commercialize pipeline programs worldwide. We will pursue a global regulatory approach and take into consideration the differing requirements and criteria of the Food and Drug Administration (FDA), European Medicines Agency (EMA) and other regulatory agencies as our pipeline programs progress in their respective clinical trials. We plan to retain significant economic and commercial rights to our portfolio in the United States and certain other regions. We will evaluate partnership opportunities in regions in which we are unlikely to pursue commercialization on our own.

 

•

Pursue collaborations with leading academic clinical investigators to evaluate new therapeutic indications and combinations of pipeline programs. In addition to building a pipeline of therapies through internal research and business development efforts, we expect to continue to partner with academic and research institutions to expand the scope of our data.

Overview of Precision Oncology and Our Approach

Precision oncology broadly refers to the strategy of harnessing tumor biology to design drugs and clinical trial strategies to treat cancer more effectively in patients. Recent companion diagnostic approvals and reimbursement for multi-gene NGS assays have made it easier to translate and distil cancer biology into tenable biomarkers that can then be readily identified in tumor or blood samples from patients. This approach has accelerated over the last decade and has resulted in numerous targeted therapies for previously difficult to treat cancers such as lung adenocarcinoma, bladder cancer, and cholangiocarcinoma, among others. A recent development within the precision oncology strategy is the strategy of seeking regulatory approval of cancer drugs based solely on tumor biology and biomarkers across cancer types, rather than tumor histology or organ site-specific approvals. Successful examples of this strategy include larotrectinib, developed by Loxo Oncology, Inc., and entrectinib, developed by Ignyta, Inc., both for tumors harboring NTRK gene fusions, and pembrolizumab, developed by Merck, for microsatellite instability-high tumors. As a result, a new era of cancer drug development has emerged, demonstrating an unprecedented degree of insight into the critical drivers of cancer, tumorigenesis and its associated signaling networks.

With a biology-based approach that views a tumor’s biological driver as more important than tumor type for selecting treatment modalities, we believe that understanding the molecular machinery employed by a tumor is paramount to developing cancer therapeutics. We intend to pursue therapeutics that target genetic alterations in cell-signaling pathways that may be oncogenic, including synthetic lethal interactions. By understanding these biological dependencies in cancer cells, we hope to identify new therapies to meaningfully extend patients’ lives.

We seek to build a pipeline of precision oncology therapeutics for genetically-defined patients by discovering or licensing programs in three categories:

 

•

programs focusing on novel oncogenic drivers and small molecules with mechanisms of action that are distinct from existing and upcoming therapeutics;

 

•

programs that improve upon existing therapies with validated oncology targets and clinical efficacy, but which lack clinical utility due to a narrow therapeutic window; and

 

•

programs targeting emerging classes and/or biological targets of precision oncology, such as synthetic lethality.

Programs that capitalize on rational tumor targets are required to exhibit appropriate selectivity with a high degree of target engagement. We view the three key pillars of any successful program as:

 

•

targeting a tumor with unambiguous oncogenic addiction;

 

•

achieving sufficient exposure of therapeutics in plasma and the tumor; and

 

2

 

 

 

•

strong target engagement during the dosing window.

Our approach leverages currently available tumor genetic testing strategies to enroll and treat patients with advanced cancer. We employ companion diagnostics and partnerships with industry-leading assay developers to identify patients based on molecular biomarkers indicating oncogene addiction and dependency on specific cellular signaling networks. In our MANTRA-2 basket trial of milademetan, we are enrolling patients with advanced or metastatic cancer based on MDM2 gene amplification and p53 mutation status, both of which are widely available on existing commercial NGS assays. The significant expansion of the FDA-approved targeted therapies in non-small cell lung cancer (NSCLC), breast cancer, bladder cancer, melanoma, cholangiocarcinoma and tumor-agnostic indications has led to increasing adoption of multi-gene NGS assays to determine patient eligibility for an ever-expanding number of targeted therapies.

Our Development Pipeline

Our development pipeline is summarized below and is unified by a strategy to target oncogenic drivers through differentiated therapies for which we are able to genetically select the patients we believe will be most likely to benefit from treatment. We currently retain global development and commercialization rights to all of our product candidates.

 

Our Lead Product Candidate, Milademetan

Milademetan Overview

Our lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2 and is being developed in patients with MDM2-dependent cancers. Historically, MDM2 inhibition has presented treatment challenges due to dose-limiting, on-target hematologic toxicities. We believe an MDM2-targeted therapy must possess certain pharmacological characteristics related to potency, pharmacokinetics and drug accumulation to allow for the design of an optimized dosing schedule. An optimized dosing schedule is intended to improve peak drug exposure leading to apoptosis and cell cycle arrest during the dosing period, while permitting hematopoietic precursor cell recovery during the dosing break, thereby minimizing hematologic toxicity. Residual drug concentration, due to poor drug clearance or tissue accumulation during the dosing break may otherwise prevent recovery from thrombocytopenia. Milademetan’s differentiated profile, as a potent MDM2 inhibitor with rapid plasma clearance and lack of drug accumulation in tissues, has enabled a rationally designed dosing schedule that we believe has the potential to reduce toxicities while preserving activity. We anticipate that this dosing schedule may also be applicable to other MDM2-dependent cancer populations across solid and hematologic tumor types.

Overview of p53 and MDM2

Milademetan reactivates p53, known as the “guardian of the genome,” by inhibiting MDM2. p53 is present in every cell and acts as a key regulator of a variety of cellular processes including cell cycle, DNA repair and apoptosis. In a normal cell, the activity of p53 is controlled and regulated by the inhibitory protein MDM2. MDM2

 

3

 

binds to p53, thereby inducing degradation and allowing normal cells to function properly. In response to cell damage and other stress conditions, p53 is activated and prevents the formation of cancerous cells by inducing apoptosis.

In contrast to normal cells, in tumor cells, the two primary mechanisms by which p53 can be inactivated in tumor cells are mutations in p53 and activation or overexpression of MDM2. Approximately half of all tumors are characterized by mutations of the p53 gene. The remaining cancer patients have a p53 gene that is not mutated, and is otherwise known as WT p53, but can be functionally suppressed through the activation or overexpression of MDM2. We have identified MDM2 dependence in several solid tumors. This dependence is caused by overexpression of MDM2 through gene amplification or other mechanisms, loss of a negative regulator of MDM2 or other causes. Overexpression of MDM2 promotes the degradation of p53 and also eliminates p53’s ability to activate transcription. Milademetan, by binding MDM2 at the p53 interaction site, prevents the formation of the MDM2- p53 complex, allowing p53 reactivation and subsequent transcription of genes, such as MIC-1, that trigger cancer cell cycle arrest or apoptosis, among others.

 

Phase 1 Clinical Data

Milademetan has been evaluated by Daiichi Sankyo in various solid tumors, including WD/DD LPS, in a Phase 1 trial (U101) for initial assessment of safety, tolerability and preliminary efficacy. The largest population enrolled in the trial were WD/DD LPS patients (approximately 50% of the total patients enrolled). WD/DD LPS tumors have nearly universal MDM2 gene amplification and WT p53, and hence are nearly universally MDM2-dependent. Therefore, we believe these LPS patients represent an appropriate population for MDM2 inhibition therapy. In October 2020, Daiichi Sankyo reported comprehensive results from this Phase 1 trial covering 107 patients. Milademetan has demonstrated meaningful antitumor activity in an MDM2-amplified subtype of LPS and other solid tumors in a Phase 1 clinical trial, validating a rationally-designed dosing schedule to potentially mitigate safety concerns and widen the therapeutic window of MDM2 inhibition.

 

Clinical Observations to Support Pursuing Milademetan as a Treatment in LPS Patients

Historically, LPS treatment rarely produces tumor responses, regardless of therapy and line of treatment. As a result, efficacy in LPS has been assessed with an endpoint of PFS, and we are using PFS as the primary endpoint in our MANTRA Phase 3 LPS trial. Notwithstanding, tumor responses to milademetan were observed in the Phase 1 trial. Of the 53 patients with WD/DD LPS who received one or more doses of milademetan, two (3.8%) achieved partial response and 34 (64.2%) achieved stable disease.

The trial also identified the disease control rate (DCR) for the LPS population enrolled in the trial, which consisted primarily of patients with MDM2-amplified tumors, as compared to an unselected non-LPS population. The DCR in the LPS population was nearly double the DCR in the non-LPS population, 58.5% versus 32.4%, respectively, supporting our plan to select patients with MDM2 amplification in future clinical trials.

In July 2021, we provided an update on patients who received milademetan monotherapy from the concluded Phase 1 dose escalation and expansion study. As of July 1, 2021, three WD/DD LPS patients received therapy with milademetan monotherapy for greater than 51 months. Two of these patients received therapy with durations of 51 and 57 months without disease progression, and an additional patient received therapy for greater than 59 months before discontinuation in the second quarter of 2021. We believe this highlights the potential for milademetan to have a favorable long-term tolerability and safety profile.

Based on the Phase 1 data, we initiated a pivotal Phase 3 trial in WD/DD LPS patients (MANTRA) in July 2021.

 

Clinical Observations in Non-LPS Patients to Support Pursuing Milademetan as a Tumor-agnostic Treatment for Patients with MDM2-amplified Tumors

In contrast to LPS patients who rarely have tumor responses to treatment, certain non-LPS patients enrolled in the Phase 1 trial exhibited tumor responses when treated with milademetan. Of the ten non-LPS patients receiving milademetan in Schedule D of the completed Phase 1 clinical trial, three patients were characterized for MDM2 gene amplification. Patients characterized for MDM2 gene amplification included patients with breast cancer (copy number of 16.8), synovial sarcoma (copy number of 25.9) and small cell lung cancer

 

4

 

(SCLC) (copy number of 36.6). The first patient exhibited a confirmed tumor volume reduction. The latter two patients exhibited partial responses, one of which was a confirmed partial response.

Based on the available data from patients with non-LPS MDM2-amplified tumors, we initiated a Phase 2 tumor agnostic basket clinical trial (MANTRA-2) in November 2021.

Clinical Development Plan

Phase 3 Trial in WD/DD LPS Patients (MANTRA)

In July 2021, we initiated a randomized, multicenter, open-label, Phase 3 registrational trial (MANTRA) for patients with unresectable or metastatic DD LPS with or without a WD LPS component that has progressed on one or more prior systemic therapies, including at least one anthracycline-based therapy. This trial is an open label, 1:1 randomized trial comparing milademetan to trabectedin, an SOC therapeutic, in approximately 160 WD/DD LPS patients with at least one prior anthracycline-based therapy. The dosing schedule for the Phase 3 trial will be identical to the Schedule D dose of 260 mg (qd 3/14x2) employed in the Phase 1 trial. The primary objective of the trial is to compare PFS evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) criteria in blinded independent review between the milademetan treatment arm and the trabectedin control arm. Secondary endpoints include overall survival, PFS by investigator assessment, objective response rate, duration of response, disease control rate, safety and patient reported outcomes. We anticipate top-line data from this trial in 2023. Our commencement of a Phase 3 trial following the Phase 1 trial referenced above is based on the data observed in the Phase 1 trial and FDA feedback with respect to our development plan.

The PFS assumptions for statistical powering are based on a PFS assumption for the control arm of 3.0 months and 6.0 months for milademetan. The doubling of PFS corresponds to a hazard ratio of 0.5.

Phase 2 MDM2-amplified Tumor-agnostic Basket Trial (MANTRA-2)

In November 2021, the first patient was dosed in the multicenter, single arm, open-label, Phase 2 basket trial evaluating Milademetan for the treatment of MDM2-amplified advanced solid (MANTRA-2). The MANTRA-2 trial is designed to evaluate the safety and efficacy of milademetan in patients with advanced or metastatic solid tumors refractory or intolerant to standard-of-care therapy and that exhibit wild-type p53 and a prespecified minimum MDM2 gene copy number. Approximately 65 patients are anticipated to be enrolled to receive milademetan. The primary endpoint of the trial is objective response rate as measured by RECIST criteria. Secondary endpoints include duration of response, disease control rate progression-free survival by investigator assessment, overall survival, and growth modulation index. An interim analysis from MANTRA-2 is anticipated in the second half of 2022.

We are enrolling patients that have received and progressed on standard of care (SOC) therapy and will be unlikely to tolerate or derive clinically meaningful benefit from SOC therapy. Patients with MDM2 amplification will be selected using a commercially-available NGS-based diagnostic assay. Milademetan will be administered in doses of 260 mg using the Schedule D dosing schedule from the Phase 1 trial (qd 3/14x2). The primary endpoint of this trial will be ORR by RECIST, with secondary endpoints of PFS, Duration of Response (DOR), OS and growth-modulation index (GMI). We believe the basket trial is supported by data in the Phase 1 clinical trial, in which non-LPS patients with MDM2-amplified tumors exhibited tumor volume reductions and confirmed partial responses under RECIST criteria.

Phase 2 Trial for Milademetan in Merkel Cell Carcinoma (MANTRA-3)

An oncogenic Merkel cell polyoma virus (MCV) presents in approximately 80% of MCC tumors. MCV-positive MCC typically contains mutant retinoblastoma and WT p53. Inactivating mutations in p53 have rarely been found in MCC. MCV small T antigen functions as a transcriptional activator to increase levels of MDM2 and downregulate p53 levels. Notably, other MDM2 programs have demonstrated proof-of-concept in MCC with clinical responses. Other MDM2 inhibitors have demonstrated potent activity in virus-positive, WT p53 MCC cancer models, albeit with high toxicity due to a narrow therapeutic window.

Based on recent non-clinical data from the Dana-Farber Cancer Institute presented at the Triple Cancer Conference, we announced a plan to commence a Phase 2 clinical trial, named MANTRA-3, evaluating the efficacy of milademetan, an oral MDM2 inhibitor, as a monotherapy for the treatment of patients with MCC refractory to ICI. The MANTRA-3 trial is designed to evaluate the efficacy of milademetan, as a monotherapy in patients with MCC that have progressed on immune checkpoint inhibitors. Approximately 34 patients are expected to be enrolled to receive milademetan. The primary endpoint of the trial is objective response rate as

 

5

 

measured by RECIST criteria. Secondary endpoints include duration of response, disease control rate, progression free survival by investigator assessment, growth modulation index, overall survival and safety.

Phase 1 Trial for Milademetan in Combination with Atezolizumab in Patients with CDKN2A Loss and Wildtype p53 advanced solid tumors.

Cyclin-dependent kinase inhibitor 2A (CDKN2A) encodes for the tumor suppressor p14ARF, an inhibitor of MDM2, and the loss of CDKN2A may lead to MDM2-dependent cancers. This concept of MDM2 dependency is supported by nonclinical data demonstrating in vitro sensitivity to milademetan of cancer cell lines harboring CDKN2A loss and WT p53 as well as several in vivo models with CDKN2A loss showing anti-tumor activity of milademetan. Loss of p53 activity via MDM2 and/or CDKN2A loss has also been associated with poor clinical outcomes for patients treated with immune checkpoint inhibitors (ICI). Nonclinical data in an immune competent mouse model of colorectal cancer with CDKN2A loss demonstrated enhanced combinatorial activity of milademetan plus an anti-PD1 antibody compared to either agent alone.

In January 2022, we announced a clinical supply agreement with Roche for the supply of the anti-Programmed Death Ligand-1 (PD-L1) monoclonal antibody, atezolizumab. Clinical trials are planned to evaluate milademetan in combination with atezolizumab for the treatment of patients in genetically selected populations. Under this agreement, we are the sponsor of the anticipated clinical trials, and Roche will supply atezolizumab.

An initial Phase 1 clinical trial is planned to evaluate the safety, tolerability and efficacy of milademetan in combination with atezolizumab in patients with loss of CDKN2A and wildtype p53 advanced solid tumors who have previously progressed on ICI. We anticipate the start of the Phase 1 clinical trial in the second half of 2022. Subsequent Phase 2 clinical trials evaluating the combination of milademetan and atezolizumab may span various additional tumor types.

Preclinical RAD52 Program

We are also developing a preclinical program focused on targeting RAD52 in the DNA damage repair pathway. While our RAD52 program is in an early stage of development, we expect to develop this program for patients with a molecularly diagnosed HRD+, such as mutations and loss-of-function in BRCA1/2 or others that utilize RAD52 as an alternative DNA repair pathway, as well as for patients that may have relapsed to poly (ADP ribose) polymerase (PARP) inhibitor therapy. There are currently no approved therapies or clinical programs in development targeting RAD52.

Targeting RAD52 represents a novel strategy for tumors exhibiting tumor HRD+ or a loss of function, of several pathway constituents, including BRCA1/2 or others in tumor types frequently characterized by these deficiencies. These tumors include breast, prostate, pancreatic, ovarian and possibly other cancers. Developmental paths for RAD52 inhibitors include as a monotherapy in HRD+ patients relapsing on PARP inhibitor therapy, or in front-line combinations with PARP inhibitors in HRD+ tumors.

Our RAD52 program is currently in lead optimization stage. We anticipate evaluating identified RAD52 inhibitor candidates in animal models of patient tumors with HRD+ that have relapsed on PARP inhibitors and in HRD+ tumors with a loss-of-function mutation of BRCA1/2 in combination with PARP inhibitors.

Collaboration and License Agreements

Daiichi Sankyo License Agreement

On September 2, 2020, we entered into a license agreement with Daiichi Sankyo, a Japanese corporation (the Daiichi Sankyo License Agreement). Pursuant to the Daiichi Sankyo License Agreement, we obtained a worldwide, sublicensable (through multiple tiers), royalty-bearing, exclusive right and license under Daiichi Sankyo’s know how and seven families of patents and patent applications to make, have made, use, import and export milademetan (also known as RAIN-32) (the Licensed Compound) for all human prophylactic or therapeutic uses that derive therapeutic effect by binding to MDM2 for the prevention and treatment of any indication for the purpose of making, having made, using, offering for sale, selling, marketing, distributing, importing, and exporting products containing milademetan as an active pharmaceutical ingredient (the Products). See the section titled “Intellectual Property.”

While we are solely responsible under the Daiichi Sankyo License Agreement for the research, development and registration of the Licensed Compound and Products, Daiichi Sankyo will continue to conduct three ongoing clinical trials and prepare final reports with respect to these clinical trials. We have agreed to reimburse Daiichi Sankyo certain third-party expenses incurred by Daiichi Sankyo while conducting such trials.

 

6

 

We are obligated to use commercially reasonable efforts to develop, commercialize and manufacture the Products and to commercially launch the Products as soon as reasonably practicable after receiving the requisite marketing approvals from the authorities in any given country. We are also obligated to use commercially reasonable efforts to receive at least three full approvals for use in each of the following countries: France, Germany, Italy, Spain, the United Kingdom, the United States and one country outside of the United States and the European Union.

In accordance with the terms of the Daiichi Sankyo License Agreement, we have paid Daiichi Sankyo an initial upfront payment of $5.0 million. We are required to make aggregate future milestone payments of up to $222.5 million, contingent on the attainment of certain development, regulatory and sales milestones. In July 2021, we announced that the first patient has been randomized in the multicenter, open-label, Phase 3 registrational trial (MANTRA) evaluating milademetan for the treatment of DD LPS. Accordingly, pursuant to the Daiichi Sankyo License Agreement, we recorded $5.5 million in milestone fees as research and development expense in the statement of operations. Of the $5.5 million milestone fees, $2.5 million was paid in the third quarter of 2021 and $3.0 million was accrued as part of accrued research and development in the balance sheet as of December 31, 2021.

Pursuant to the Daiichi Sankyo License Agreement, Daiichi Sankyo had the right to continue to conduct three clinical trials and prepare final reports with respect to these clinical trials, and such right expires upon all subjects completing the study treatment. We have agreed to reimburse Daiichi Sankyo certain third-party expenses incurred while conducting such trials.

Additionally, we are required to pay Daiichi Sankyo a high single digit royalty based on the annual net sales of the Products, subject to reduction at an agreed rate upon the expiration of the licensed patent in the particular country where the Products are sold. To date, no royalty payments have been made to Daiichi Sankyo under the Daiichi Sankyo License Agreement. The royalty obligation terminates on a country-by-country and Product-by-Product basis on the later of: (i) loss of all market exclusivity for such Product in such country, (ii) the last-to-expire patent that covers the Licensed Compound or the Product in such country and (iii) twelve years from launch of the first Product sold by us in such country.

Unless sooner terminated, the Daiichi Sankyo License Agreement will remain in full force and effect until we, our affiliates and our sublicensees cease all development and commercial activity related to the Licensed Compound and Products. Either party may terminate the Daiichi Sankyo License Agreement for cause in the event of the other party’s uncured material breach after a certain cure period. With respect to Daiichi Sankyo’s uncured material breach, however, we may only terminate the Daiichi Sankyo License Agreement with respect to the countries affected by such uncured material breach. Daiichi Sankyo may also terminate the Daiichi Sankyo License Agreement in the event of our bankruptcy or insolvency. Additionally, Daiichi Sankyo may terminate the Daiichi Sankyo License Agreement immediately upon written notice if we, our affiliates or our sublicensors initiate or join any challenge to the validity or enforceability of a licensed patent, subject to certain exclusions. Furthermore, we may terminate the Daiichi Sankyo License Agreement in its entirety or on a country-by-country basis for bona fide material concerns regarding the (i) lack of safety for human use arising from toxicity of the Licensed Compound or Product(s), (ii) lack of efficacy of the Licensed Compound or Product(s) or (iii) adverse economic impact to us in connection with our continued development of the Products, in each case, upon six months’ prior written notice to Daiichi Sankyo. In addition, if we are acquired by a third party that is developing and commercializing a competing compound and the acquiring party decides not to discontinue the development or commercialization of such competing compound, such third party must terminate the Daiichi Sankyo License Agreement within 30 days of such acquisition if it does not discontinue such development or commercialization. Upon termination of the Daiichi Sankyo License Agreement by Daiichi Sankyo for our uncured material breach or by us for our bona fide material concerns regarding the safety, efficacy or adverse economic impacts relating to the Licensed Compound or Products, or our development thereof, we are required to, among other actions, if requested by Daiichi Sankyo (i) transfer to Daiichi Sankyo ongoing clinical trials, data, reports, records and materials, (ii) grant to Daiichi Sankyo an exclusive, irrevocable, sublicensable, fully paid-up license under any patents and know-how that are controlled and actually used by us at the time of termination in connection with the Products to allow Daiichi Sankyo exploit the Licensed Compound or Products in countries that are affected by the termination, (iii) grant to Daiichi Sankyo an exclusive, irrevocable, sublicensable, fully paid up license to use trademarks that are specific to the Products and (iv) assign any applicable sublicenses.

Agreement with Drexel University

On July 30, 2020, we entered into an intellectual property license agreement with Drexel University (Drexel) (the Drexel License Agreement). Pursuant to the Drexel License Agreement, Drexel granted to us (i) a

 

7

 

non-transferable (with certain exceptions), worldwide, exclusive, sublicensable (after the first anniversary, subject to certain conditions) license under Drexel’s patent rights relating to RAD52 inhibitors for the treatment of cancer to make, have made, use, import, offer for sale and sell licensed products in all fields of use covered by the licensed patent rights, and (ii) a non-transferable (with certain exceptions), worldwide, nonexclusive, sublicensable (after the first anniversary, subject to certain conditions) license under certain technical information and know-how related to the licensed patent rights to make, have made, use, import, offer for sale and sell products in all fields of use covered by the licensed patent rights. The foregoing license grant is subject to (i) Drexel’s retained rights to use, and to permit other non-commercial entities to use, the licensed patent rights for educational and research purposes, but excluding research sponsored by a commercial entity and the use of the licensed products in clinical trials, except for investigator-initiated clinical trials, and (ii) United States government rights, including but not limited to, any applicable requirement that the licensed products that are sold in the United States must be substantially manufactured in the United States.

We are obligated to use commercially reasonable efforts to (i) develop, commercialize, market and sell licensed products in a manner consistent with a development plan and (ii) achieve certain development, regulatory and clinical milestone events, including, among other things, receiving IND approval for a licensed product by the fourth anniversary of the effective date. Under the Drexel License Agreement, for a period of five years from the effective date and to the extent that there are no third-party obligations, we are granted the first option to license Drexel’s rights in certain improvements, developments or inventions developed by Drexel (or jointly by the parties) during the five-year period that are directly related to the licensed products or to RAD52 or compounds that have been generated to specifically target RAD52.

In addition to a one-time, non-refundable initiation fee of $20,000, the Drexel License Agreement requires us to make milestone payments to Drexel of up to $6.25 million in aggregate, for the achievement of specified development and regulatory milestones for each licensed product. We are also required to reimburse Drexel (i) after the filing of the first IND for the first licensed product, for all costs related to the filing, prosecution and maintenance of the licensed patent rights accumulated prior to the effective date, and (ii) for all reasonable costs related to the filing, prosecution and maintenance of the licensed patent rights after the effective date. In addition, we are also required to pay Drexel, on a quarterly basis, a low single digit royalty on net sales by us, our affiliates, and sublicensees of the licensed products, subject to specified reductions and a minimum quarterly royalty payment of $6,250. Lastly, we are also obligated to pay Drexel (i) an annual license maintenance fee of $15,000 commencing upon filing of the first IND for a licensed product until the first sale of the first licensed product, (ii) a sublicense fee of low double digits percentage on all consideration received by us from our sublicensees, subject to certain reductions and (iii) a one-time transaction fee equal to the actual amount of Drexel’s licensing and legal expenses in connection with the Drexel License Agreement and the Sponsored Research Agreement the parties simultaneously entered into with the Drexel License Agreement (the Sponsored Research Agreement).

Unless earlier terminated or extended, the term of the Drexel License Agreement with respect to any licensed product and country continues until the later of (i) the expiration or abandonment of the last-to-expire valid claim of the licensed patent rights that covers the sale of such licensed product in such country, (ii) the expiration of any granted statutory period of marketing and/or data exclusivity for such licensed product pursuant to which we have exclusive commercialization rights, (iii) the month of the first sale of a generic equivalent of such licensed product in such country and (iv) ten years after the first sale of the first licensed product.

We may terminate the Drexel License Agreement at any time by providing 60 days’ prior written notice to Drexel, in which case we will be required to cease exploitation of all licensed products, terminate all permitted sublicenses and pay all amounts owed to Drexel under the Drexel License Agreement and the Sponsored Research Agreement through the effective date of termination. Drexel may terminate the Drexel License Agreement for our uncured material breach (with 30-135 day cure periods), for our bankruptcy or insolvency, for our uncured material default under the Sponsored Research Agreement, or if we challenge the validity or enforceability of the licensed patent rights.

Manufacturing and Supply

We do not own or operate, and currently have no plans to establish any manufacturing facilities. We currently rely and expect to continue to rely for the foreseeable future, on third parties for the manufacture of our drug candidates for preclinical and clinical testing, as well as for commercial manufacture of any drugs that we may commercialize.

Clinical drug product supplies and active pharmaceutical ingredients (API) for the milademetan program were produced and supplied to us by Daiichi Sankyo. Clinical drug product manufactured in Daiichi Sankyo’s GMP production facilities was supplied to us as brite stock and is being used in our ongoing LPS trial and basket

 

8

 

trial. For the milademetan program, we have selected and transferred Daiichi Sankyo processes to suitable commercial contract manufacturing organizations to supply API and clinical drug product for our clinical trials and in preparation for submission of marketing applications and potential future commercial supplies.

We obtain our supplies from contract manufacturers on a purchase order basis. We do not currently have arrangements in place for redundant supply for APIs and drug product. We intend to identify and qualify additional manufacturers to provide the APIs and drug product for our future development plan for milademetan. All our drug candidates are compounds of low molecular weight, generally called small molecules. We expect to continue to develop drug candidates that can be produced cost-effectively at contract manufacturing facilities.

Manufacturing clinical products is subject to extensive regulations that impose various procedural and documentation requirements, which govern record keeping, manufacturing processes and controls, personnel, quality control and quality assurance. Our contract manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with Current Good Manufacturing Practice (cGMP) requirements which impose certain production, manufacturing, procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP requirements and other aspects of regulatory compliance.

Intellectual Property

We strive to protect the proprietary technologies, inventions and improvements that we believe are important to our business, including pursuing, obtaining, maintaining, defending and enforcing patent rights, whether developed internally or licensed from third parties, intended to cover the composition of matter of our product candidates, including milademetan, their methods of use, related technologies, such as biomarkers, solid state forms, formulations, etc. and other inventions that are important to our business. In addition to patent protection, we also rely on trade secrets, know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain our proprietary position in our field.

Our future commercial success depends in part upon our ability to obtain and maintain patent and other proprietary protection for our drug candidates and other commercially important technologies, inventions and know-how related to our business; defend and enforce our intellectual property, in particular, our patent rights; preserve the confidentiality of our trade secrets; and operate without infringing, misappropriating or violating the valid and enforceable intellectual property and proprietary rights of third parties. Our ability to stop third parties from making, using, selling, offering to sell or importing our products may depend on the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities.

The patent positions for biotechnology companies like us are generally uncertain and can involve complex legal, scientific and factual issues. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. We also cannot ensure that patents will be issued with respect to any patent applications that we or our licensors may file in the future, nor can we ensure that any of our owned or licensed patents or future patents will be commercially useful in protecting our product candidates and methods of manufacturing the same. In addition, the coverage claimed in a patent application can be significantly reduced before a patent is issued, and its scope can be reinterpreted and even challenged after issuance. Moreover, many jurisdictions permit third parties to challenge issued patents in administrative proceedings, which may result in further narrowing or even cancellation of patent claims. As a result, we cannot guarantee that any of our drug candidates will be protected or remain protectable by enforceable patents. Moreover, any patents that we hold may be challenged, circumvented or invalidated by third parties. For more information regarding the risks related to our intellectual property, please see “Risk Factors—Risks Related to Our Intellectual Property.”

We generally file patent applications directed to our key programs in an effort to secure our intellectual property positions vis-a-vis these programs. As of December 31, 2021, we owned or in-licensed eighteen U.S. patents, one allowed U.S. patent application, one hundred and fifteen foreign patents, two allowed foreign patent applications, six U.S. pending non-provisional patent applications, fifty-three foreign pending patent applications, and five pending Patent Cooperation Treaty (PCT) applications.

 

9

 

The intellectual property portfolio for our most advanced programs as of December 31, 2021, is summarized below. Prosecution is a lengthy process, during which the scope of the claims initially submitted for examination by the U.S. Patent and Trademark Office and foreign patent offices may be significantly narrowed before issuance, if issued at all. We expect this may be the case with respect to some of our pending patent applications referred to below.

Milademetan

With regard to milademetan, as of December 31, 2021, our patent portfolio contained fourteen issued U.S. patents, three pending U.S. non-provisional patent applications, ninety-seven issued foreign patents, and thirty-four pending foreign patent applications, all exclusively licensed from Daiichi Sankyo. One patent family in the milademetan portfolio is directed to the composition of matter of milademetan where we have issued patents in various jurisdictions including the United States, Japan, thirty-seven countries in Europe, Australia, Canada, China, Colombia, Indonesia, India, Israel, Korea, Malaysia, Mexico, New Zealand, Philippines, Russia, South Africa, Taiwan, Singapore, and Vietnam and pending patent applications in various jurisdictions including the United States, Brazil, Egypt, and Thailand, all of which are expected to expire in March 2032, excluding potential patent term adjustments or patent term extensions, where applicable. Another patent family supporting milademetan pertains to crystal-forms of milademetan. Under this patent family, we have eight issued U.S. patents and thirteen issued foreign patents in various jurisdictions including Japan, certain countries in Europe, Canada, China, Hong Kong, Korea, Russia and Taiwan, and pending patent applications in Brazil and India all of which are expected to expire in 2033, excluding potential patent term adjustments or patent term extensions, where applicable.

Furthermore, we exclusively licensed from Daiichi Sankyo five patent families directed to combination therapies with milademetan, methods of synthesis of milademetan, and dosing regimens of Milademetan within these five patent families, we have five issued U.S. patents, two pending U.S. patent applications, twenty-three issued foreign patents and twenty-six pending foreign patent applications, including in Japan, Europe, Canada, China, Hong Kong, Korea, India, Brazil and Taiwan, all of which are expected to expire between September 2034 and October 2037, excluding potential patent term adjustments or patent term extensions, where applicable. These combination therapy, method of synthesis, and method of use (dosing regimen) patents and patent applications will not present barriers to our competitors with respect to any unclaimed therapies or methods of synthesis or use involving milademetan.

We intend to pursue additional patent protection for milademetan and other development candidates relating to milademetan, its methods of use and related technologies that we consider important to our business.

RAD52

With regard to our RAD52 program, as of December 31, 2021, we exclusively licensed from Drexel two patent families directed to compositions of matter RAD52 inhibitors and their use in the treatment of cancer. One of the patent families comprises two issued U.S. patents and one pending U.S. non-provisional patent application, all of which are expected to expire in June 2036, excluding potential patent term adjustments or patent term extensions, where applicable. The second patent family comprises one PCT application. Patents that issue, if any, and claim priority to this PCT application will be expected to expire in October 2040, excluding potential patent term adjustments or patent term extensions. We intend to pursue additional patent protection for our RAD52 program and other development candidates relating to our RAD52 inhibitor, its methods of use and related technologies that we consider important to our business.

Patent Terms

The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the earliest date of filing a non-provisional patent application.

In the United States, the term of a patent covering an FDA-approved drug may, in certain cases, be eligible for a patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Act) as compensation for the loss of patent term during the FDA regulatory review process. The period of extension may be up to five years but cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. Only one patent applicable to an approved drug is eligible for extension and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar provisions are available in Europe and in certain other jurisdictions to extend the term of a patent that covers an approved drug. It is possible that issued U.S. patents covering milademetan, RAD52 or our

 

10

 

preclinical programs, if issued, and products from our intellectual property may or will be entitled to patent term extensions. If our drug candidates receive FDA approval, we intend to apply for patent term extensions, if available, to extend the term of patents that cover the approved use or the drug candidates. We also intend to seek patent term extensions in any jurisdictions where they are available; however, there is no guarantee that the applicable authorities, including the FDA, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions.

Protection of Proprietary Information

In addition to patent protection, we also rely on trade secret protection and confidential know-how for our proprietary information that is not amenable to, or that we do not consider appropriate for, patent protection, including certain aspects of our manufacturing processes. However, trade secrets can be difficult to protect. Although we take steps to protect our proprietary information, including restricting access to our confidential information, as well as entering into non-disclosure and confidentiality agreements with our employees, consultants, independent contractors, advisors, contract manufacturers, contract research organizations (CROs), hospitals, independent treatment centers, suppliers, collaborators and other third parties, such parties may breach such agreements and disclose our proprietary information including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Furthermore, these agreements may not provide meaningful protection. Third parties may also independently develop the same or similar proprietary information or may otherwise gain access to our proprietary information. Despite any measures taken to protect our intellectual property, unauthorized parties may attempt to copy aspects of our products or to obtain or use information that we regard as proprietary. As a result, we may be unable to meaningfully protect our trade secrets and proprietary information. For more information regarding the risks related to our intellectual property please see “Risk Factors—Risks Related to Our Intellectual Property.”

Government Regulations

Government authorities in the United States, at the federal, state, local levels, and in other countries and jurisdictions, including the European Union, extensively regulate, among other things, the research, development, testing, product approval, manufacture, quality control, manufacturing changes, packaging, storage, recordkeeping, labeling, promotion, advertising, sales, distribution, marketing, and import and export of drugs and biologic products. All of our foreseeable product candidates are expected to be regulated as drugs. The processes for obtaining regulatory approval in the United States and in foreign countries and jurisdictions, along with compliance with applicable statutes and regulations and other regulatory authorities both pre- and post-commercialization, are a significant factor in the production and marketing of our products and our research and development activities and require the expenditure of substantial time and financial resources.

Review and Approval of Drugs in the United States

In the United States, the FDA and other government entities regulate drugs under the Federal Food, Drug, and Cosmetic Act (FDCA) and its implementing regulations, as well as other federal and state statutes and regulations. Failure to comply with applicable legal and regulatory requirements in the United States at any time during the product development process, approval process, or after approval, may subject us to a variety of administrative or judicial sanctions, such as a delay in approving or refusal by the FDA to approve pending applications, withdrawal of approvals, delay or suspension of clinical trials, issuance of warning letters and other types of regulatory letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil monetary penalties, refusals of or debarment from government contracts, exclusion from the federal healthcare programs, restitution, disgorgement of profits, civil or criminal investigations by the FDA, U.S. Department of Justice, State Attorneys General, and/or other agencies, False Claims Act suits and/or other litigation, and/or criminal prosecutions.

An applicant seeking approval to market and distribute a new drug in the United States must typically undertake the following:

 

(1)

completion of pre-clinical laboratory tests, animal studies, and formulation studies in compliance with the FDA’s good laboratory practice (GLP) regulations or other applicable regulations;

 

(2)

submission to the FDA of an IND Application for human clinical testing, which must become effective without FDA objection before human clinical trials may begin;

 

(3)

approval by an independent institutional review board (IRB) or ethics committee representing each clinical site before each clinical trial may be initiated;

 

11

 

 

(4)

performance of adequate and well-controlled human clinical trials in accordance with good clinical practice (GCP) regulations, to establish the safety and effectiveness of the proposed drug product for each indication for which approval is sought;

 

(5)

preparation and submission to the FDA of a New Drug Application (NDA);

 

(6)

satisfactory review of the NDA by an FDA advisory committee, where appropriate or if applicable,

 

(7)

satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the drug is produced to assess compliance with current good manufacturing practice (cGMP) regulations and to assure that the facilities, methods, and controls are adequate to ensure the product’s identity, strength, quality, and purity, and of selected clinical investigation sites to assess compliance with GCP; and

 

(8)

payment of user fees, as applicable, and securing FDA review approval of the NDA.

Preclinical Studies and an IND

Preclinical studies can include in vitro and animal studies to assess the potential for adverse events and, in some cases, to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations. Other studies include laboratory evaluation of the purity, stability and physical form of the manufactured drug substance or active pharmaceutical ingredient and the physical properties, stability and reproducibility of the formulated drug or drug product. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, among other things, to the FDA as part of an IND. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. Some preclinical testing, such as longer-term toxicity testing, animal tests of reproductive adverse events and carcinogenicity, may continue after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to a proposed clinical trial and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.

Following commencement of a clinical trial under an IND, the FDA may place a clinical hold on that trial. A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND, such as restrictions on dosing or patient enrollment. No more than 30 days after imposition of a clinical hold or partial clinical hold, the FDA will provide the sponsor a written explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold, an investigation may only resume in full or in part, as applicable, after the FDA has notified the sponsor that the investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the investigation can proceed.

Human Clinical Trials in Support of an NDA

Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with Current Good Clinical Practices (cGCP) requirements, which include, among other things, the requirement that all research subjects provide their informed consent in writing before their participation in any clinical trial. Clinical trials are conducted under written study protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB or ethics committee representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review and reapprove the study at least annually. The IRB must review and approve, among other things, the study protocol and informed consent information to be provided to study subjects. An IRB must operate in compliance with FDA regulations. Some studies also include oversight by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. Information about certain clinical trials must be submitted within specific timeframes to the NIH for public dissemination on its ClinicalTrials.gov website.

 

12

 

Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined:

 

•

Phase 1: The product candidate is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness.

 

•

Phase 2: The product candidate is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.

 

•

Phase 3: The product candidate is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product.

Post-approval trials, sometimes referred to as Phase 4 studies, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA.

Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB’s requirements or if the drug has been associated with unexpected serious harm to patients.

During the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to submission of an IND, at the end of Phase 2, and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the meetings at the end of the Phase 2 trial to discuss Phase 2 clinical results and present plans for the pivotal Phase 3 clinical trials that they believe will support approval of the new drug.

Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug. In addition, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.

While the IND is active and before approval, progress reports summarizing the results of the clinical trials and nonclinical studies performed since the last progress report must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal or in vitro testing suggesting a significant risk to humans, and any clinically important increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator brochure.

Submission of an NDA to the FDA

Assuming successful completion of required clinical testing and other requirements, the results of the preclinical studies and clinical trials, together with detailed information relating to the product’s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the drug product for one or more indications. Under federal law, the submission of most NDAs is additionally subject to an application user fee, currently $3,117,218 for fiscal year 2022, for applications requiring clinical data, and the sponsor of an approved NDA is also subject to an annual program fee, currently $369,413 for fiscal year 2022. These fees are adjusted annually.

 

13

 

Under certain circumstances, the FDA will waive the application fee for the first human drug application that a small business, defined as a company with less than 500 employees, including employees of affiliates, submits for review. An affiliate is defined as a business entity that has a relationship with a second business entity if one business entity controls, or has the power to control, the other business entity, or a third-party controls, or has the power to control, both entities. In addition, an application to market a prescription drug product that has received orphan designation is not subject to a prescription drug user fee unless the application includes an indication for other than the rare disease or condition for which the drug was designated.

The FDA conducts a preliminary review of an NDA within 60 days of its receipt and informs the sponsor by the 74th day after the FDA’s receipt of the submission to determine whether the application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant to assure and preserve the product’s identity, strength, quality and purity. Under the Prescription Drug User Fee Act (PDUFA), the FDA has agreed to specified performance goals in the review process of NDAs. Specifically, the FDA has a goal of reviewing most NDAs for new molecular entities within ten months from the date of filing, and of reviewing most “priority review” NDAs within six months of the filing date. The review process may be extended by the FDA for three additional months to consider new information or clarification provided by the applicant.

The FDA is required to refer an application for a novel drug to an advisory committee or explain why such referral was not made. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.

Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with cGCP. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.

The FDA also may require submission of a risk evaluation and mitigation strategy (REMS) plan to mitigate any identified or suspected serious risks. The REMS plan could include medication guides, physician communication plans, assessment plans, and elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools.

The FDA’s Decision on an NDA

On the basis of the FDA’s evaluation of the NDA and accompanying information, including the results of the inspection of the manufacturing facilities and clinical sites, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A complete response letter indicates that the review cycle is complete, and the application will not be approved in its present form. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional clinical or nonclinical testing or other information in order for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA’s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months of receipt depending on the type of information included. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.

If the FDA approves a product, it may limit the approved indications for use for the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies be conducted to further assess the drug’s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including REMS, which can materially affect the potential market and profitability of the product. After approval, the FDA may seek to prevent or limit further marketing of a product based on the

 

14

 

results of post-market studies or surveillance programs. Some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.

Orphan Drug Designation

Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making available in the United States a drug for this type of disease or condition will be recovered from sales in the United States for that drug. Orphan drug designation entitles the applicant to incentives such as grant funding towards clinical trial costs, tax advantages, and waivers of FDA user fees. Orphan drug designation must be requested before submitting an NDA, and both the drug and the disease or condition must meet certain criteria specified in the Orphan Drug Act and FDA’s implementing regulations at 21 C.F.R. Part 316. The granting of an orphan drug designation does not alter the standard regulatory requirements and process for obtaining marketing approval.

After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other application to market the same drug for the same indication for seven years, except in very limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition.

A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or, as noted above, if a second applicant demonstrates that its product is clinically superior to the approved product with orphan exclusivity or the manufacturer of the approved product is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.

Expedited Review and Accelerated Approval Programs

A sponsor may seek approval of its product candidate under programs designed to accelerate the FDA’s review and approval of NDAs. For example, Fast Track Designation may be granted to a drug intended for treatment of a serious or life-threatening disease or condition and data demonstrate its potential to address unmet medical needs for the disease or condition. Fast Track Designation applies to the combination of the product candidate and the specific indication for which it is being studied. The sponsor of a Fast Track product candidate has opportunities for more frequent interactions with the applicable FDA review team during product development and, once an NDA is submitted, the product candidate may be eligible for priority review. A Fast Track product may also be eligible for rolling review, where the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. .

In addition, the Food and Drug Administration Safety and Innovation Act of 2012 established the Breakthrough Therapy Designation. A sponsor may seek FDA designation of its product candidate as a breakthrough therapy if the drug is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the Fast Track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product candidate, including involvement of senior managers.

Any marketing application for a drug submitted to the FDA for approval, including a product candidate with a Fast Track Designation and/or Breakthrough Therapy Designation, may be eligible for other types of FDA programs intended to expedite the FDA review and approval process, such as priority review and accelerated

 

15

 

approval. NDAs for drugs intended to treat serious or life-threatening conditions may be eligible for priority review where there is evidence that the product candidate, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, diagnosis, or prevention of a serious condition.

The FDA may grant accelerated approval for an NDA if the drug treats a serious or life-threatening condition, provides a meaningful advantage over available therapies, and demonstrates an effect on either (1) a surrogate endpoint that is reasonably likely to predict clinical benefit, or (2) on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. Post-marketing studies or completion of ongoing studies after marketing approval are generally required to verify the drug’s clinical benefit in relationship to the surrogate endpoint or ultimate outcome in relationship to the clinical benefit. Products receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the required post-marketing studies or if such studies fail to verify the predicted clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.

Post-approval Requirements

Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual program fee requirements for any marketed products.

In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.

Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events or problems with manufacturing processes of unanticipated severity or frequency, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:

 

•

restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;

 

•

fines, warning letters or holds on post-approval clinical trials;

 

•

refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals;

 

•

clinical holds on ongoing or planned clinical trials;

 

•

product seizure or detention, or refusal to permit the import or export of products; or

 

•

consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs

 

•

mandated modification of promotional materials and labeling and the issuance of corrective information;

 

•

injunctions or the imposition of civil or criminal penalties.

The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of

 

16

 

the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.

In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act (PDMA), which regulates the distribution of drugs and drug samples at the federal level and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution.

Marketing Exclusivity

Market exclusivity provisions authorized under the FDCA can delay the submission or the approval of certain marketing applications. The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not approve or even accept for review an abbreviated new drug application (ANDA), or an NDA submitted under Section 505(b)(2) (505(b)(2) NDA), submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder.

The FDCA alternatively provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to any preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.

Pediatric exclusivity is another type of marketing exclusivity available in the United States. Pediatric exclusivity provides for an additional six months of marketing exclusivity attached to another period of exclusivity if a sponsor conducts clinical trials in children in response to a written request from the FDA. The issuance of a written request does not require the sponsor to undertake the described clinical trials. In addition, orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity, except in certain circumstances.

FDA Approval and Regulation of Companion Diagnostics

If safe and effective use of a drug candidate depends on an in vitro diagnostic, then the FDA generally will require approval or clearance of that diagnostic, known as a companion diagnostic, at the same time that the FDA approves the therapeutic product. In August 2014, the FDA issued final guidance clarifying the requirements that will apply to approval of therapeutic products and in vitro companion diagnostics. According to the guidance, if FDA determines that a companion diagnostic device is essential to the safe and effective use of a novel therapeutic product or indication, FDA generally will not approve the drug or new indication if the companion diagnostic device is not approved or cleared for that indication. Approval or clearance of the companion diagnostic device will ensure that the device has been adequately evaluated and has adequate performance characteristics in the intended population. The review of in vitro companion diagnostics in conjunction with the review of our product candidates will, therefore, likely involve coordination of review by the FDA’s Center for Drug Evaluation and Research and the FDA’s Center for Devices and Radiological Health Office of In Vitro Diagnostics and Radiological Health.

Under the FDCA, in vitro diagnostics, including companion diagnostics, are regulated as medical devices. In the United States, the FDCA and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. Unless an exemption applies,

 

17

 

diagnostic tests require marketing clearance or approval from the FDA prior to commercial distribution. The two primary types of FDA marketing authorization applicable to a medical device are premarket notification, also called 510(k) clearance, and premarket approval (PMA).

The PMA process, including the gathering of clinical and preclinical data and the submission to and review by the FDA, can take several years or longer. It involves a rigorous premarket review during which the applicant must prepare and provide the FDA with reasonable assurance of the device’s safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing, and labeling. PMA applications are subject to an application fee. In addition, PMAs for certain devices must generally include the results from extensive preclinical and adequate and well-controlled clinical trials to establish the safety and effectiveness of the device for each indication for which FDA approval is sought. In particular, for a diagnostic, a PMA application typically requires data regarding analytical and clinical validation studies. As part of the PMA review, the FDA will typically inspect the manufacturer’s facilities for compliance with the Quality System Regulation (QSR), which imposes elaborate testing, control, documentation, and other quality assurance requirements.

PMA approval is not guaranteed, and the FDA may ultimately respond to a PMA submission with a not approvable determination based on deficiencies in the application and require additional clinical trial or other data that may be expensive and time -consuming to generate and that can substantially delay approval. If the FDA’s evaluation of the PMA application is favorable, the FDA typically issues an approvable letter requiring the applicant’s agreement to specific conditions, such as changes in labeling, or specific additional information, such as submission of final labeling, in order to secure final approval of the PMA. If the FDA’s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. The FDA may also determine that additional clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are conducted and then the data submitted in an amendment to the PMA. If the FDA concludes that the applicable criteria have been met, the FDA will issue a PMA for the approved indications, which can be more limited than those originally sought by the applicant. The PMA can include post-approval conditions that the FDA believes necessary to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and distribution. Once granted, PMA approval may be withdrawn by the FDA if compliance with post approval requirements, conditions of approval or other regulatory standards are not maintained or problems are identified following initial marketing.

After a device is placed on the market, it remains subject to significant regulatory requirements. Medical devices may be marketed only for the uses and indications for which they are cleared or approved. Device manufacturers must also establish registration and device listings with the FDA. A medical device manufacturer’s manufacturing processes and those of its suppliers are required to comply with the applicable portions of the QSR, which cover the methods and documentation of the design, testing, production, processes, controls, quality assurance, labeling, packaging and shipping of medical devices. Domestic facility records and manufacturing processes are subject to periodic unscheduled inspections by the FDA. The FDA also may inspect foreign facilities that export products to the United States.

Review and Approval of Drug Products in the European Union

In order to market any pharmaceutical product outside of the United States, a company must also comply with numerous and varying regulatory requirements of other countries and jurisdictions governing, among other things, research and development, testing, manufacturing, quality control, safety, efficacy, clinical trials, marketing authorization, packaging, storage, record keeping, reporting, export and import, advertising and other promotional practices involving pharmaceutical products, as well as commercial sales, distribution and post-approval monitoring and reporting of our products. Whether or not it obtains FDA approval for a pharmaceutical product, the company would need to obtain the necessary approvals by the comparable foreign regulatory authorities before it can commence clinical trials or marketing of the pharmaceutical product in those countries or jurisdictions. The approval process ultimately varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods, as evidenced by the preliminary feedback from the EMA on the design of our planned Phase 3 liposarcoma trial. The time required to obtain approval in other countries and jurisdictions might differ from and be longer and far more difficult than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.

 

18

 

The United Kingdom (UK) formally left the European Union (EU) on January 31, 2020 and the transition period, during which EU laws continued to apply to the UK, expired on December 31, 2020. This means EU laws now only apply to the UK in respect of Northern Ireland as laid out in the Protocol on Ireland and Northern Ireland. Following the end of the transition period, the EU and the UK concluded a trade and cooperation agreement (TCA), which applied provisionally from January 1, 2021 and entered into force on May 1, 2021.

The TCA includes provisions affecting the life sciences sector (including on customs and tariffs) but areas for further discussion between the EU and the UK remain. In addition, there are some specific provisions concerning pharmaceuticals. These include the mutual recognition of Good Manufacturing Practice (GMP) and issued GMP documents. The TCA does not, however, contain wholesale mutual recognition of UK and EU pharmaceutical regulations and product standards.

Since January 1, 2021, the EU laws which have been transposed into UK law through secondary legislation continue to be applicable in the UK as “retained EU law”. As there is no general power to amend these regulations, the UK government has enacted the Medicines and Medical Devices Act 2021. The purpose of the act is to enable the existing regulatory frameworks in relation to human medicines, clinical trials of human medicines, veterinary medicines and medical devices to be updated. The powers under the act may only be exercised in relation to specified matters and must safeguard public health.

Specified provisions of the Medicines and Medical Devices Act 2021 entered into force on February 11, 2021. The remaining provisions came into effect within two months of February 11, 2021 or will otherwise come into effect as stipulated in subsequent statutory instruments. The Medicines and Medical Devices Act 2021 supplements the UK Medical Devices Regulations 2002 (UK Regulations), which are based on the EU Medical Devices Directive as amended to reflect the UK’s post-Brexit regulatory regime. Notably, the UK Regulations do not include any of the revisions that have been made by the EU Medical Devices Regulation (EU) 2017/745, which, since May 26, 2021, now applies in all EU Member States.

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) conducted a comprehensive consultation between September and November 2021 on proposals to develop a new UK regime for medical devices in the UK. The proposals include more closely aligning definitions for medical devices and in vitro medical devices with internationally recognized definitions and changing the classification of medical devices according to levels or risk. The proposals are intended to improve patient and public safety and increase the appeal of the UK market. The new regime is planned to come into force on July 1, 2023, which will align with the date from which the UK is due to stop accepting CE marked medical devices and require UKCA (UK Conformity Assessed) marking. It is envisaged that, in Northern Ireland, the amended regime could run in parallel with any existing or future EU rules in accordance with the Protocol on Ireland and Northern Ireland.

Drug Development Process

The conduct of clinical trials is currently governed by the EU Clinical Trials Directive 2001/20/EC (Clinical Trials Directive), and will be gradually replaced by the EU Clinical Trials Regulation (EU) No. 536/2014 (CTR). The CTR introduces a complete overhaul of the existing regulation of clinical trials for medicinal products in the EU. It entered into force on January 31, 2022.

Under the current regime, which will expire after a transition period of one or three years, respectively, as outlined below in more detail, before a clinical trial can be initiated, it must be approved in each EU Member State in which the clinical trial is to be conducted. The approval must be obtained from two separate entities: the National Competent Authority (NCA) and one or more Ethics Committees. The NCA of the EU Member States in which the clinical trial will be conducted must authorize the conduct of the trial, and the independent Ethics Committee must grant a positive opinion in relation to the conduct of the clinical trial in the relevant EU Member State before the commencement of the trial. Any substantial changes to the trial protocol or other information submitted with the clinical trial applications must be submitted to or approved by the relevant NCA and Ethics Committees. Under the current regime all suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial must be reported to the NCA and to the Ethics Committees of the EU Member State where they occur.

A more unified procedure applies under the new CTR. A sponsor is able to submit a single application for approval of a clinical trial through a centralized EU clinical trials portal. One national regulatory authority (the reporting EU Member State proposed by the applicant) takes the lead in validating and evaluating the application consult and coordinate with the other concerned Member States. If an application is rejected, it may be amended and resubmitted through the EU clinical trials portal. If an approval is issued, the sponsor may start the clinical trial in all concerned Member States. However, a concerned EU Member State may in limited circumstances

 

19

 

declare an “opt-out” from an approval and prevent the clinical trial form being conducted in such Member State. The CTR also aims to streamline and simplify the rules on safety reporting, and introduces enhanced transparency requirements such as mandatory submission of a summary of the clinical trial results to the EU Database. After several postponements of the coming into effect of the CTR due to technical difficulties with the underlying IT systems, the “go live” of these systems and, accordingly, the coming into force of the regulation, took place on January 31, 2022. While Member States will work in CTIS immediately after the system has gone live, the CTR provides for two transition periods for sponsors: For one year, until 31 January 2023, clinical trial sponsors can still choose whether to submit an initial clinical trial application in line with the current system (Clinical Trials Directive) or via CTIS. From 31 January 2023, submission of initial clinical trial applications via CTIS becomes mandatory, and by 31 January 2025, all ongoing trials approved under the current Clinical Trials Directive will be governed by the new Regulation and have to be transitioned to CTIS.

Under both the current regime and the new CTR, national laws, regulations, and the applicable Good Clinical Practice and Good Laboratory Practice standards must also be respected during the conduct of the trials, including the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines on Good Clinical Practice (GCP) and the ethical principles that have their origin in the Declaration of Helsinki.

During the development of a pharmaceutical product, the European Medicines Agency (EMA) and national regulators within the EU provide the opportunity for dialogue and guidance on the development program. At the EMA level, this is usually done in the form of scientific advice, which is given by the Committee for Medicinal Products for Human Use (CHMP) on the recommendation of the Scientific Advice Working Party (SAWP). A fee is incurred with each scientific advice procedure, but is significantly reduced for designated orphan medicines. Advice from the EMA is typically provided based on questions concerning, for example, quality (chemistry, manufacturing and controls testing), nonclinical testing and clinical studies, and pharmacovigilance plans and risk-management programs. Advice is not legally binding with regard to any future marketing authorization application of the product concerned.

Marketing Authorization Procedures

In the EU and in Iceland, Norway, and Liechtenstein (together, the European Economic Area or EEA), pharmaceutical products may only be placed on the market after obtaining a Marketing Authorization (MA).

Marketing Authorizations have an initial duration of five years. After these five years, the authorization may be renewed on the basis of a reevaluation of the risk-benefit balance. Once renewed, the MA is valid for an unlimited period unless the EC or the national competent authority decides on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal. Applications for renewal must be made to the EMA at least nine months before the five-year period expires.

Data and Market Exclusivity in the European Union

As in the United States, it may be possible to obtain a period of market and/or data exclusivity in the European Union that would have the effect of postponing the entry into the marketplace of a competitor’s generic, hybrid or biosimilar product (even if the pharmaceutical product has already received an MA) and prohibiting another applicant from relying on the MA holder’s pharmacological, toxicological and clinical data in support of another MA for the purposes of submitting an application, obtaining MA or placing the product on the market.

New medicinal products authorized in the European Union, qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity. The overall ten-year period of market exclusivity can be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies.

The data exclusivity period prevents generic or biosimilar applicants from relying on the preclinical and clinical trial data contained in the dossier of the reference medicinal product when applying for a generic or biosimilar marketing authorization in the European Union during a period of eight years from the date on which the reference product was first authorized in the European Union. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the European Union until 10 years have elapsed from the initial authorization of the reference product in the European Union.

 

20

 

Orphan Drug Designation and Exclusivity

The criteria for designating an orphan medicinal product in the European Union are similar in principle to those in the United States. The EMA grants Orphan Drug Designation if the medicinal product is intended for the treatment, prevention or diagnosis of a disease that is life-threatening or chronically debilitating, affecting not more than five in 10,000 people in the European Union and for which no satisfactory method of diagnosis, prevention or treatment of the condition concerned can be authorized, or, if such a method exists, the medicine must be of significant benefit to those affected by the condition (prevalence criterion). In addition, Orphan Drug Designation can be granted if, for economic reasons, the medicinal product would be unlikely to be developed without incentives and if there is no other satisfactory method approved in the European Union of diagnosing, preventing, or treating the condition, or if such a method exists, the proposed medicinal product is a significant benefit to patients affected by the condition. An application for orphan drug designation (which is not a marketing authorization, as not all orphan-designated medicines reach the authorization application stage) must be submitted first before an application for marketing authorization of the medicinal product is submitted. The applicant will receive a fee reduction for the marketing authorization application if the orphan drug designation has been granted, but not if the designation is still pending at the time the marketing authorization is submitted, and sponsors must submit an annual report to EMA summarizing the status of development of the medicine. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. Designated orphan medicines are eligible for conditional marketing authorization.

The EMA’s Committee for Orphan Medicinal Products (COMP) reassesses the Orphan Drug Designation of a product in parallel with the review for a marketing authorization; for a product to benefit from market exclusivity it must maintain its Orphan Drug Designation at the time of marketing authorization review by the EMA and approval by the EC. Additionally, any marketing authorization granted for an orphan medicinal product must only cover the therapeutic indication(s) that are covered by the Orphan Drug Designation. Upon the grant of a marketing authorization, Orphan Drug Designation provides up to ten years of market exclusivity in the orphan indication. During this ten-year period, with a limited number of exceptions, the regulatory authorities of the EU Member States and the EMA may not accept applications for marketing authorization, accept an application to extend an existing marketing authorization or grant marketing authorization for other similar medicinal products for the same therapeutic indication. Conversely, the ten-year market exclusivity period may be reduced to six years if at the end of the fifth year, it is established that the product no longer fulfils the criteria for an Orphan Drug Designation.

Pediatric Development

In the EU, companies developing a new pharmaceutical product are obligated to study their product in children and must therefore submit a Pediatric Investigation Plan (PIP) together with a request for agreement to the EMA. Pharmaceutical products that are granted a marketing authorization on the basis of the pediatric clinical trials conducted in accordance with the approved PIP are eligible for a six month extension of the protection under a supplementary protection certificate (if any is in effect at the time of approval) or, in the case of orphan pharmaceutical products, a two year extension of the orphan market exclusivity is granted. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the approved PIP are developed and submitted. An approved PIP is also required when a marketing authorization holder wants to add a new indication, pharmaceutical form or route of administration for a medicine that is already authorized and covered by intellectual property rights.

Approval and Regulation of Companion Diagnostics

In Europe, in vitro diagnostic medical devices are currently regulated by Directive 98/79/EC which regulates the placing on the market, the CE-marking, the essential requirements, the conformity assessment procedures, the registration obligations for manufactures and devices as well as the vigilance procedure. In vitro diagnostic medical devices must comply with the requirements provided for in the Directive, and with further requirements implemented at national level (as the case may be). The Directive 98/79/EC will be replaced by the Regulation on In-Vitro Diagnostic Devices (No. 2017/746), which will apply from 26 May 2022, following a five-year transition period. In the meantime, manufacturers can opt to place in-vitro diagnostic devices on the market under Directive 98/79/EC or under the new Regulation if they fully comply with it.

Companion diagnostics can also be considered “combination products” which are governed by a different regulatory pathway depending on the mode of action of the products. A combination medicine/device product could either be regulated as a medicinal product or a medical device based on its primary mode of action. In principle, if a medical device incorporates a substance which, if used separately, is likely to be considered as a

 

21

 

medicinal product and act on the human body by an action ancillary to that of the device, the device must be evaluated and authorized in accordance with the medical device regulations. However, if the medicinal substance constitutes the main function of the product, then the product is considered as a medicinal product. Currently, for such combination products, the manufacturer will have to consult, prior to obtaining the CE marking of the device, the EMA or NCA to obtain scientific advice on the quality and safety of the medicinal substance, including the benefit/risk profile of its incorporation into the device.

The regulation of companion diagnostics will be subject to further requirements as of the entry into force of the in-vitro diagnostic devices Regulation (No 2017/746) which introduces a new classification system for companion diagnostics which are now specifically defined as diagnostic tests that support the safe and effective use of a specific medicinal product, by identifying patients that are suitable or unsuitable for treatment. Companion diagnostics will have to undergo a conformity assessment by a notified body. Before it can issue a CE certificate, the notified body must seek a scientific opinion from the EMA on the suitability of the companion diagnostic to the medicinal product concerned if the medicinal product falls exclusively within the scope of the centralized procedure for the authorization of medicines, or the medicinal product is already authorized through the centralized procedure, or a marketing authorization application for the medicinal product has been submitted through the centralized procedure. For other substances, the notified body can seek the opinion from a NCA or the EMA.

Post-approval Regulation

Similar to the United States, both marketing authorization holders and manufacturers of pharmaceutical products are subject to comprehensive regulatory oversight by the EMA, the EC and/or the competent regulatory authorities of the EU Member States.

The holder of an EU marketing authorization for a pharmaceutical product must also comply with EU pharmacovigilance legislation and its related regulations and guidelines, which entail many requirements for conducting pharmacovigilance, or the assessment and monitoring of the safety of pharmaceutical products.

Failure by us or by any of our third-party partners, including suppliers, manufacturers and distributors to comply with EU laws and the EU Member State laws implementing Directive 2001/83/EC on pharmaceutical products for human use and other core legislation relating to pharmaceutical products, and other EU Member State laws that apply to the conduct of clinical trials, manufacturing approval, marketing authorization of pharmaceutical products and marketing of such products, both before and after grant of marketing authorization, manufacturing of pharmaceutical products, statutory health insurance, bribery and anti-corruption or with other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials or to grant marketing authorization, product withdrawals and recalls, product seizures, suspension, withdrawal, or variation of the marketing authorization, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties.

Advertising and Promotion

In the EU, the advertising and promotion of our products is subject to EU regulation. This includes but is not limited to the promotion of pharmaceutical products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. Laws, regulations, industry self-regulation codes of conduct and physicians’ codes of professional conduct both at EU level and in the individual EU Member States may apply. These laws may limit or restrict the advertising and promotion of our products to the general public and may also impose limitations on its promotional activities with healthcare professionals. For instance, the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of pharmaceutical products is prohibited in the EU. Relationships with healthcare professionals and associations are subject to stringent anti-gift statutes and anti-bribery laws, the scope of which differs across the EU. In addition, payments made to physicians in certain EU Member States must be publicly disclosed. Moreover, agreements with physicians must often be the subject of prior notification and approval by the physician’s employer, his/her regulatory professional organization, and/or the authorities of the individual EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.

Pricing and Reimbursement Environment

Even if a pharmaceutical product obtains a marketing authorization in the European Union, there can be no assurance that reimbursement for such product will be secured on a timely basis or at all. The EU Member

 

22

 

States are free to restrict the range of pharmaceutical products for which their national health insurance systems provide reimbursement, and to control the prices and reimbursement levels of pharmaceutical products for human use. An EU Member State may approve a specific price or level of reimbursement for the pharmaceutical product, or alternatively adopt a system of direct or indirect controls on the profitability of the company responsible for placing the pharmaceutical product on the market, including volume-based arrangements, caps and reference pricing mechanisms.

To obtain reimbursement or pricing approval in some countries, including the EU Member States, we may be required to conduct studies that compare the cost-effectiveness of our product candidates to other therapies that are considered the local SOC. There can be no assurance that any country will allow favorable pricing, reimbursement and market access conditions for any of our products, or that we will be feasible to conduct additional cost-effectiveness studies, if required.

European Union Data Laws

The collection and use of personal health data and other personal information in the European Union is governed by the provisions of the European General Data Protection Regulation (EU) 2016/679 (GDPR), which came into force in May 2018, and related implementing laws in individual EU Member States.

The GDPR imposes a number of strict obligations and restrictions on the ability to process (processing includes collection, analysis and transfer of) personal data of individuals within the European Union and in the EEA, including health data from clinical trials and adverse event reporting. The GDPR also includes requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals prior to processing their personal data or personal health data, notification of data processing obligations to the national data protection authorities and the security and confidentiality of the personal data. EU Member States may also impose additional requirements in relation to health, genetic and biometric data through their national implementing legislation.

Under the GDPR, personal data can only be transferred within the EU Member States and the three additional European Economic Area countries (Norway, Iceland and Liechtenstein) that have adopted a national law implementing the GDPR. Appropriate safeguards are required to enable cross-border transfers of personal data from the EU and EEA Member States to a “third country” (a country outside the EU or EEA). This status has a number of significant practical consequences, in particular for international data transfers, competent supervisory authorities and enforcement of the GDPR.

In conclusion, the GDPR prohibits the transfer of personal data to countries outside of the European Union /EEA (including the United States) that are not considered by the European Commission to provide an adequate level of data protection, except if the data controller meets very specific requirements such as the use of standard contractual clauses (“SCCs”), issued by the European Commission. In this respect recent legal developments in Europe have created complexity and compliance uncertainty regarding certain transfers of personal data from the EU/EEA. For example, following the Schrems II decision of the Court of Justice of the European Union on July 16, 2020, in which the Court invalidated the Privacy Shield under which personal data could be transferred from the EU/EEA to United States entities who had self-certified under the Privacy Shield scheme, there is uncertainty as to the general permissibility of international data transfers under the GDPR. The Court did not invalidate the then current SCCs, but ruled that data exporters relying on these SCCs are required to verify, on a case-by-case basis, if the law of the third country ensures an adequate level of data protection that is essentially equivalent to that guaranteed in the EU/EEA. In light of the implications of this decision we may face difficulties regarding the transfer of personal data from the European Union/EEA to third countries. However, on June 4, 2021 the EU Commission issued a new set of SCCs for data transfers from controllers or processors in the EU/EEA to controllers or processors established outside the EU/EEA. These SCCs replace the old sets of SCCs that were adopted under the previous European Data Protection Directive 95/46. Since September 27, 2021, it is no longer possible to conclude contracts incorporating these previous versions of the SCCs. In addition, for contracts concluded before September 27, 2021, it is still possible to rely on the previous SCCs until the end of an additional 15 months transitional period (until December 27, 2022), provided that the processing operations which are the subject matter of the contract remain unchanged and reliance on previous SCCs ensures that the transfer is subject to appropriate safeguards. On November 11, 2021, the European Data Protection Board has adopted recommendations on such appropriate safeguards that supplement transfer mechanisms. These recommendations aim to assist data exporters with their duty to identify and implement appropriate supplementary measures where they are needed to ensure an essentially equivalent level of protection to the personal data they transfer to third countries.

 

23

 

Failure to comply with the requirements of the GDPR and the related national data protection laws of the EU Member States may result in significant monetary fines for noncompliance of up to €20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater, other administrative penalties and a number of criminal offenses (punishable by uncapped fines) for organizations and in certain cases their directors and officers as well as civil liability claims from individuals whose personal data was processed. Data protection authorities from the different EU Member States may still implement certain variations, enforce the GDPR and national data protection laws differently, and introduce additional national regulations and guidelines, which adds to the complexity of processing personal data in the European Union. Guidance developed at both EU level and at the national level in individual EU Member States concerning implementation and compliance practices are often updated or otherwise revised.

There is, moreover, a growing trend towards required public disclosure of clinical trial data in the European Union which adds to the complexity of obligations relating to processing health data from clinical trials. Such public disclosure obligations are provided in the new EU Clinical Trials Regulation, EMA disclosure initiatives and voluntary commitments by industry. Failing to comply with these obligations could lead to government enforcement actions and significant penalties against us, harm to our reputation, and adversely impact our business and operating results. The uncertainty regarding the interplay between different regulatory frameworks, such as the Clinical Trials Regulation and the GDPR, further adds to the complexity that we face with regard to data protection regulation.

With regard to the transfer of data from the European Union to the United Kingdom, the TCA provided for a transition period of up to six months as of January 1, 2021 to enable the European Commission to complete its adequacy assessment of the UK’s data protection laws. On June 28, 2021 the European Commission adopted two adequacy decisions for the United Kingdom – one under the GDPR and the other for the Law Enforcement Directive. Personal data may now freely flow from the European Union to the United Kingdom since the United Kingdom is deemed to have an adequate data protection level. Additionally, following the UK’s withdrawal from the European Union and the EEA, companies also have to comply with the UK’s data protection laws (including the UK GDPR, which is based on the EU GDPR), the latter regime having the ability to separately fine up to the greater of £17.5 million or 4% of global turnover. The adequacy decisions include a ‘sunset clause’ which entails that the decisions will automatically expire four years after their entry into force.

New Legislation and Regulations

From time to time, legislation is drafted, introduced and passed in the European Union, its Member States and other states of Europe that could significantly change the statutory provisions governing the testing, approval, manufacturing, marketing, coverage and reimbursement of pharmaceutical products. In addition to new legislation, pharmaceutical regulations and policies are often revised or interpreted by the EMA and national agencies in ways that may significantly affect our business and our products.

U.S. Pharmaceutical Coverage, Pricing and Reimbursement

Significant uncertainty exists as to the coverage and reimbursement status of products approved by the FDA and other government authorities. Sales of products will depend, in part, on the extent to which the costs of the products will be covered by third-party payors, including government health programs such as, in the United States, Medicare and Medicaid, commercial health insurers and managed care organizations. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not include all of the approved products for a particular indication.

In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable regulatory approvals. A payor’s decision to provide coverage for a drug product does not necessarily imply that an adequate reimbursement rate will be approved. Third-party reimbursement may not be sufficient to maintain price levels high enough to realize an appropriate return on our investment in product development.

The containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of drugs have been a focus in this effort. Third-party payors are increasingly challenging the prices charged for medical products and services and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. If these third-party payors do not consider a product to be cost effective compared to other available therapies, they may not cover the product after approval

 

24

 

as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit. Even if favorable coverage and reimbursement status is attained for one or more products that receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.

The U.S. government and state legislatures have shown significant interest in implementing cost containment programs to limit the growth of government-paid health care costs, including price controls, risk sharing, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. Adoption of such controls and measures and tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for pharmaceuticals. As a result, the marketability of any product which receives regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement.

U.S. Healthcare Reform

In the United States, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system. In addition, an increasing emphasis on managed care in the United States has increased and will continue to increase the pressure on drug pricing. Coverage policies, third-party reimbursement rates and drug pricing regulation may change at any time.

In particular, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively, the ACA, was signed into law and contained provisions that may reduce the profitability of drug products, including, for example, increasing rebates for drugs sold to Medicaid programs, extending Medicaid rebates to Medicaid managed care plans, requiring mandatory discounts for certain Medicare Part D beneficiaries and imposing annual fees based on pharmaceutical companies’ share of sales to federal health care programs. Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA. For example, in 2017, Congress enacted the Tax Cuts and Jobs Act, or the TCJA, which eliminated the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the “individual mandate.” On December 14, 2018, a U.S. District Court Judge in the Northern District of Texas ruled that the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the TCJA, the remaining provisions of the ACA are invalid as well. On December 18, 2019, the U.S. Court of Appeals for the 5th Circuit affirmed the District Court’s decision that the individual mandate was unconstitutional but remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. The U.S. Supreme Court heard the case, but overturned the decision on the basis that the plaintiffs lacked standing and did not address the constitutionality. The Supreme Court’s decision left open the opportunity for additional challenges to the ACA.

Other legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to providers of 2% per fiscal year and reduced payments to several types of Medicare providers, which will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through March 31, 2021 absent additional congressional action. Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted legislation designed, among other things, to bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for pharmaceutical products. Individual states in the United States have also become increasingly active in implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures and, in some cases, mechanisms to encourage importation from other countries and bulk purchasing. Furthermore, there has been increased interest by third party payors and governmental authorities in reference pricing systems and publication of discounts and list prices.

Healthcare Laws and Regulations

Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of drug products that are granted marketing approval. Arrangements with healthcare providers, physicians, third-party payors and customers are subject to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships

 

25

 

through which we market, sell and distribute products for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations, include the following:

 

•

the federal healthcare Anti-Kickback Statute prohibits, among other things, persons from soliciting, offering, receiving or providing any remuneration (in cash or in kind), directly or indirectly, to induce or reward either the referral of an individual for, or the purchase, lease, order or recommendation of, any item, facility or service for which payment may be made in whole or in part under a federal healthcare program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation;

 

•

the federal Foreign Corrupt Practices Act, or FCPA, prohibits, among other things, U.S. corporations and persons acting on their behalf from offering, promising, authorizing or making payments to any foreign government official (including certain healthcare professionals in many countries), political party, or political candidate in an attempt to obtain or retain business or otherwise seek preferential treatment abroad;

 

•

the federal False Claims Act, which may be enforced by the U.S. Department of Justice or private whistleblowers to bring civil actions (qui tam actions) on behalf of the federal government, imposes civil penalties, as well as liability for treble damages and for attorneys’ fees and costs, on individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent, making a false statement material to a false or fraudulent claim, or improperly avoiding, decreasing, or concealing an obligation to pay money to the federal government. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act;

 

•

the Department of Health and Human Services’ Civil Monetary Penalties authorities, which imposes administrative sanctions for, among other things, presenting or causing to be presented false claims for government payment and providing remuneration to government health program beneficiaries to influence them to order or receive healthcare items or services;

 

•

the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for, among other conduct, executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate it in order to have committed a violation;

 

•

HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes criminal and civil liability and penalties on those who violate requirements, including mandatory contractual terms, intended to safeguard the privacy, security, transmission and use of individually identifiable health information;

 

•

the federal false statements statute relating to healthcare matters prohibits falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services;

 

•

the federal Physician Payment Sunshine Act requires manufacturers of drugs (among other products) to report to the Centers for Medicare and Medicaid Services within the U.S. Department of Health and Human Services, or HHS, information related to payments and other transfers of value to physicians (as defined by statute), certain other healthcare providers beginning in 2022, and teaching hospitals, as well as physician ownership and investment interests in the reporting manufacturers;

 

•

similar state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by nongovernmental third-party payors, including private insurers;

 

•

certain state laws require pharmaceutical companies to comply with voluntary compliance guidelines promulgated by a pharmaceutical industry association and relevant compliance guidance issues by HHS Office of Inspector General; bar drug manufacturers from offering or providing certain types of payments or gifts to physicians and other health care providers; and/or require disclosure of gifts or payments to physicians and other healthcare providers; and

 

26

 

 

•

Various state and foreign laws also govern the privacy and security of health information in some circumstances; many of these laws differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.

Violation of any of such laws or any other governmental regulations that apply may result in penalties, including, without limitation, civil and criminal penalties, damages, fines, additional reporting obligations, the curtailment or restructuring of operations, exclusion from participation in governmental healthcare programs and imprisonment.

Competition

The biotechnology industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. While we believe that our technology and scientific knowledge provide us with competitive advantages, we face potential competition from many different sources, including pharmaceutical and biotechnology companies, ranging in size from early stage to major global companies, academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for the research, development, manufacturing and commercialization of cancer therapies. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future.

We compete in the segments of the pharmaceutical, biotechnology and other related markets that develop cancer therapies. We focus on the development of precision small molecule therapies for patients with cancers where there is a high unmet medical need. There are numerous other companies that have commercialized or are developing cancer therapies for the same or similar targets.

With respect to our lead product candidate, milademetan, there are no approved drugs targeting MDM2. There are multiple companies testing MDM2 inhibitors and degraders in various stages of development and various indications, including, Kartos (navtemadlin), Ascentage (alrizomadlin), Boehringer Ingelheim (BI-907828), Aileron (ALRN-6924), Kymera (KT-253), and others.

With respect to our RAD52 program, there are currently no other approved or clinical-stage therapeutics that inhibit RAD52. We are aware of academic groups working on discovery-stage RAD52 programs; however, we believe that our RAD52 program is currently the most advanced program for this target.

Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and commercializing and marketing approved drugs than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and enrolling subjects for our clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.

We could see a reduction or elimination of our commercial opportunities if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient to administer, are less expensive or obtain more favorable reimbursement than any products that we or our collaborators may develop. Our competitors also may obtain FDA or foreign regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we or our collaborators are able to enter the market. The key competitive factors affecting the success of all our product candidates, if approved, are likely to be their efficacy, safety, convenience, price, the effectiveness of companion diagnostics, if required, the level of biosimilar or generic competition, and the availability of reimbursement from government and other third-party payors.

Employees and Human Capital Resources

As of December 31, 2021, we had 44 full-time employees, of whom 31 were engaged in research and development activities and 13 were engaged in general and administrative activities. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good. Recruiting and retaining experienced and qualified scientific personnel to perform research and development work now and in the future will be critical to our business success. We may not be able to attract and retain personnel on acceptable terms given the competition among pharmaceutical and

 

27

 

biotechnology companies, academic and research institutions and government agencies for experienced scientists.

Our values—relentless, energetic, and committed to excellence—guide how we make decisions, and treat each other. All employees are responsible for upholding these values, the Rain Code of Conduct, and Employee Handbook form the foundation of our policies and practices and ethical business culture.

Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees.

Inclusion

Diversity and inclusion are instrumental in driving innovation and delivering stronger business growth. Among our 44 full-time employees, 48% are women. Over 21 languages are spoken by our employees and they hail from many countries around the world.

Compensation and Benefits

We strive to provide pay, benefits, and services that help meet the varying needs of our employees. Our total rewards package includes market-competitive pay, broad-based stock grants and bonuses, an employee stock purchase plan, healthcare and retirement benefits, paid time off and family leave, and flexible work schedules.

Growth and Development

We are dedicated to helping each employee take charge to lead, and to grow professionally and personally. Through our regular self-evaluation, goal setting and performance review, employees can voice learning and development experiences.

Health and Safety

We are committed to providing a safe and healthy work environment for our employees, and all other individuals working on our behalf.

Throughout our response to COVID-19, our priority has remained protecting the health and safety of our employees and other parties. Most of our employees are working remotely. We will continue to monitor the evolving situation related to the COVID-19 pandemic and may take further actions that alter our operations, including those that may be required by federal, state or local authorities, or that we determine are in the best interests of our employees and other third parties with whom we do business. In response to COVID-19, we continue to take the following safety measures to ensure the health and safety of our employees as well as the communities in which we operate:

 

•

allow employees to work remotely where feasible; and

 

•

restrict company travel to essential business travel that requires prior multi-level approvals

Environmental Matters

We are committed to operating our business in a manner that protects the environment as much as possible, and are further committed to compliance with all applicable environmental laws, regulations, and industry best practices, such as those that affect hazardous waste disposal, emissions, and water purity.

Corporate Information

We were incorporated in the State of Delaware on April 6, 2017. Our corporate offices are located at 8000 Jarvis Avenue, Suite 204, Newark, California 94560 and our telephone number is (510) 953-5559. Our website address is www.rainthera.com. Information contained on or accessible through our website is not a part of this Annual Report on Form 10-K, and the inclusion of our website address in this Annual Report on Form 10-K is an inactive textual reference only.

We file electronically with the SEC our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, proxy statements and any amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the Exchange Act). We make available on our website at www.rainthera.com, under “Investors,” free of charge, copies of these reports as soon

 

28

 

as reasonably practicable after filing or furnishing these reports with the SEC. The reports that we file or furnished to SEC can be obtained electronically by means of the SEC’s website at www.sec.gov.

Implications of Being an Emerging Growth Company and a Smaller Reporting Company

We are an emerging growth company, as defined in Section 2(a) of the Securities Act of 1933, as amended (the Securities Act), as modified by the Jumpstart Our Business Startups Act of 2012 (the JOBS Act), and we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including relief from the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended, less extensive disclosure obligations regarding executive compensation in our registration statements, periodic reports and proxy statements, exemptions from the requirements to hold a nonbinding advisory vote on executive compensation, and exemptions from stockholder approval of any golden parachute payments not previously approved. We may also elect to take advantage of other reduced reporting requirements in future filings. As a result, our stockholders may not have access to certain information that they may deem important and the information that we provide to our stockholders may be different than, and not comparable to, information presented by other public reporting companies. We could remain an emerging growth company until the earlier of (1) the last day of the year following the fifth anniversary of the completion of our initial public offering (IPO), (2) the last day of the year in which we have total annual gross revenue of at least $1.07 billion, (3) the last day of the year in which we are deemed to be a “large accelerated filer” as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of our common stock held by non-affiliates exceeded $700.0 million as of the last business day of the second fiscal quarter of such year or (4) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.

In addition, the JOBS Act also provides that an emerging growth company may take advantage of the extended transition period provided in the Securities Act for complying with new or revised accounting standards. An emerging growth company may therefore delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption and, as a result, will not be subject to the same implementation timing for new or revised accounting standards as are required of other public companies that are not emerging growth companies, which may make comparison of our financial information to those of other public companies more difficult.

We are also a smaller reporting company, as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as (i) our voting and non-voting common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter or (ii) our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter.

 

29

 

Item 1A. Risk Factors.

Investing in our common stock involves significant risks. You should carefully consider the risks and uncertainties described below, together with all of the other information in this Annual Report on Form 10-K, including “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our audited financial statements and related notes, and other filings we have made and make in the future with the Securities and Exchange Commission. If any of the following risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. In such case, the trading price of our common stock would likely decline, and you may lose all or part of your investment. Below is a summary of some of the risks we face. We caution you that the risks, uncertainties and other factors referred to below and elsewhere in this Annual Report on Form 10-K may not contain all of the risks, uncertainties and other factors that may affect our future results and operations. Moreover, new risks will emerge from time to time. It is not possible for our management to predict all risks.

Risk Factor Summary

An investment in our common stock involves significant risks. You should carefully consider the risks and uncertainties described below before making a decision to invest in our common stock. If we are unable to successfully address these risks and uncertainties, our business, financial condition, results of operations, or prospects could be materially adversely affected. In such case, the trading price of our common stock would likely decline, and you may lose all or part of your investment. Below is a summary of some of the risks we face.

 

•

We have a limited operating history, have not initiated, conducted or completed any clinical trials, and have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and likelihood of success and viability.

 

•

We have incurred significant losses since inception, and we expect to incur significant losses for the foreseeable future and may not be able to achieve or sustain profitability in the future. We have not generated any revenue from our product candidates and may never generate revenue or become profitable.

 

•

If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of development programs or future commercialization efforts.

 

•

Our future growth depends on our ability to identify and acquire or in-license products.

 

•

We are substantially dependent on the success of our lead product candidate, milademetan, and our anticipated clinical trials of milademetan may not be successful.

 

•

We may find it difficult to enroll patients in our clinical trials given the relatively small patient populations with the indications for which our product candidates are being developed.

 

•

The results of our preclinical testing and early clinical trials may not be predictive of the success of our later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA or other comparable foreign regulatory authorities.

 

•

We face substantial competition, which may result in others discovering, developing, licensing or commercializing products before or more successfully than we do.

 

•

The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable.

 

•

We currently rely, and plan to rely in the future, on third parties to conduct and support our preclinical studies and clinical trials.

 

•

We currently rely and expect to rely in the future on the use of manufacturing suites in third-party facilities or on third parties to manufacture our product candidates, and we may rely on third parties to produce and process our products, if approved.

 

•

We may, in the future, form or seek collaborations or strategic alliances or enter into licensing arrangements, and we may not realize the benefits of such collaborations, alliances or licensing arrangements.

 

30

 

 

•

Our ability to protect our patents and other proprietary rights is uncertain, exposing us to the possible loss of competitive advantage.

 

•

We may be subject to patent infringement claims or may need to file claims to protect our intellectual property, which could result in substantial costs and liability and prevent us from commercializing our potential products.

 

•

We license patent rights from third-party owners and we rely on such owners to obtain, maintain and enforce the patents underlying such licenses.

Risks Related to Our Limited Operating History, Business, Financial Condition, Results of Operations and Need for Additional Capital

We have a limited operating history, and have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and likelihood of success and viability.

We are a clinical-stage company with limited operating history. Since our inception in 2017, we have incurred significant operating losses and have utilized substantially all of our resources to date in-licensing and developing our product candidates, organizing and staffing our Company and providing other general and administrative support for our operations. We have no significant experience as a company in initiating, conducting or completing clinical trials, including global late-stage clinical trials. In particular, Daiichi Sankyo conducted the Phase 1 trial for our lead product candidate, RAIN-32, prior to our in-license of milademetan in September 2020. In part because of this lack of experience, we cannot be certain that our planned clinical trials will begin or be completed on time, if at all. In addition, we have not yet demonstrated an ability to obtain marketing approvals, manufacture a commercial-scale product or arrange for a third party to do so on our behalf, or conduct sales, marketing and distribution activities necessary for successful product commercialization. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history. Further, we may encounter unexpected expenses, challenges and complications from known and unknown factors such as the COVID-19 pandemic.

We have incurred significant losses since inception, and we expect to incur significant losses for the foreseeable future and may not be able to achieve or sustain profitability in the future. We have not generated any revenue from our product candidates and may never generate revenue or become profitable.

Investment in biopharmaceutical product development is a highly speculative undertaking and entails substantial upfront capital expenditures and significant risks that any product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval and become commercially viable. We have no products approved for commercial sale, we have not generated any revenue from product sales to date, and we continue to incur significant research and development and other expenses related to our ongoing operations. We do not expect to generate product revenue unless or until we successfully complete preclinical and clinical development and obtain regulatory approval of, and then successfully commercialize, at least one product candidate. We may never succeed in these activities and, even if we do, may never generate revenues that are significant or large enough to achieve profitability. If we are unable to generate sufficient revenue through the sale of our current product candidates or any future product candidates, we may be unable to continue operations without additional funding.

We have incurred significant net losses in each period since we commenced operations in April 2017. Our net losses were $51.4 million and $21.1 million for the years ended December 31, 2021 and 2020, respectively. We expect to continue to incur significant losses for the foreseeable future. Our failure to become profitable would decrease the value of our Company and could impair our ability to raise capital, maintain our research and development efforts, expand our business and/or continue our operations. A decline in the value of our Company could also cause you to lose all or part of your investment.

We will require substantial additional capital to finance our operations in the future. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of development programs or future commercialization efforts.

Developing biopharmaceutical products is a very long, time-consuming, expensive and uncertain process that takes years to complete. We expect our expenses to increase in connection with our ongoing activities, particularly as we conduct clinical trials of, and seek marketing approval for milademetan, and advance our other

 

31

 

product candidates and future product candidates. Even if one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with sales, marketing, manufacturing and distribution activities to launch any such product. Our expenses could increase beyond expectations if we are required by the FDA or other regulatory agencies to perform preclinical studies or clinical trials in addition to those that we currently anticipate. Because the design and outcome of our planned and anticipated clinical trials are highly uncertain, we cannot reasonably estimate the actual amount of funding that will be necessary to successfully complete the development and commercialization of any product candidate we develop. Our future capital requirements depend on many factors, including factors that are not within our control. We will also incur additional costs associated with operating as a public company. Accordingly, we will require substantial additional funding to continue our operations. Based on our current operating plan, we believe that our existing cash, cash equivalents and short-term marketable securities, will be sufficient to fund our operations for at least the next twelve months following the date of this Annual Report on Form 10-K. This estimate is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect.

We do not have any committed external sources of funds and adequate additional financing may not be available to us on acceptable terms, or at all. We may be required to seek additional funds sooner than planned through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources. Such financing may dilute our stockholders or the failure to obtain such financing may restrict our operating activities. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences and anti-dilution protections that adversely affect your rights as a stockholder. Debt financing may result in imposition of debt covenants, increased fixed payment obligations or other restrictions that may affect our business. If we raise additional funds through upfront payments or milestone payments pursuant to future collaborations with third parties, we may have to relinquish valuable rights to our product candidates or grant licenses on terms that are not favorable to us. Our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic. Our failure to raise capital as and when needed or on acceptable terms would have a negative impact on our financial condition and our ability to pursue our business strategy, and we may have to delay, reduce the scope of, suspend or eliminate one or more of our research-stage programs, clinical trials or future commercialization efforts.

Our future growth depends on our ability to identify and acquire or in-license products.

We have in-licensed the rights to all of our current product candidates from third parties who conducted the initial development of each product candidate. An important part of our business strategy is to continue to develop a pipeline of product candidates by acquiring or in-licensing products, businesses or technologies. Future in-licenses or acquisitions, however, may entail numerous operational and financial risks. In addition, we may compete with competitors in pursuing these in-licensing opportunities and such competitors may have access to greater financial resources than us and may have greater experience in identifying and evaluating new opportunities.

If we breach any of the agreements under which we license rights to our product candidates from others, we could lose the ability to develop and commercialize our product candidates.

In September 2020, we entered into a worldwide, exclusive license agreement with Daiichi Sankyo relating to milademetan for all human prophylactic or therapeutic uses and in July 2020 we entered into a license agreement with Drexel University relating to our RAD52 research program. Because we have in-licensed the rights to all of our product candidates from third parties, if there is any dispute between us and our licensors regarding our rights under these license agreements, our ability to develop and commercialize these product candidates may be adversely affected. Any uncured, material breach under these license agreements could result in our loss of exclusive rights to the related product candidate and may lead to a complete termination of our product development efforts for such product candidate.

Due to the significant resources required for the development of our product candidates, we must prioritize development of certain product candidates and/or the pursuit of treatments for certain indications. We may expend our limited resources to pursue a particular product candidate or indication

 

32

 

and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.

We are developing therapies for patients with genetically defined cancers with unmet needs. We apply a tumor-agnostic development approach to the essential biological pathways and molecular machinery of cancer. Our lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, may be oncogenic in numerous cancers. Our decisions concerning the allocation of research, development, collaboration, management and financial resources toward particular product candidates or indications may not lead to the development of any viable commercial product and may divert resources away from better opportunities with other product candidates or for other indications that later prove to have greater commercial potential or a greater likelihood of success. For example, even if milademetan receives marketing approval, it may not achieve commercial success, including as a result of the gravity of the patients’ illnesses in our target market. The primary endpoint for the pivotal Phase 3 trial for milademetan that we commenced in WD/DD LPS is progression-free survival (PFS) evaluated by Response Evaluation Criteria in Solid Tumors. Even if the primary endpoint of such trial is met and milademetan demonstrates meaningful increases in PFS, there is no guarantee that such increases in PFS will lead to the market acceptance or commercial success of milademetan, if approved. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through future collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights. We may make incorrect determinations regarding the viability or market potential of any of our programs or product candidates or misread trends in our industry.

Risks Related to Product Development

We are substantially dependent on the success of our lead product candidate, milademetan, and our anticipated clinical trials of milademetan may not be successful.

Our future success is substantially dependent on our ability to timely obtain marketing approval for, and then successfully commercialize, milademetan, our lead product candidate. We are investing a majority of our efforts and financial resources into the research and development of milademetan. Our other product candidates are in earlier stages of development. We commenced a pivotal Phase 3 trial for milademetan in WD/DD LPS in the July 2021. We commenced an open-label Phase 2 MDM2-amplified tumor-agnostic basket trial for milademetan across solid tumors in patients with pre-specified MDM2 amplification levels and WT p53 in November 2021.

Milademetan will require additional clinical development, evaluation of clinical, preclinical and manufacturing activities, marketing approval in multiple jurisdictions, substantial investment and significant marketing efforts before we generate any revenues from product sales. We are not permitted to market or promote milademetan, or any other product candidates, before we receive marketing approval from the FDA and comparable foreign regulatory authorities, and we may never receive such marketing approvals.

The success of milademetan will depend on a variety of factors. We do not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to our intellectual property rights and the manufacturing, marketing, distribution and sales efforts of any future collaborator. Accordingly, we cannot assure you that we will ever be able to generate revenue through the sale of milademetan, even if approved. If we are not successful in commercializing milademetan, or are significantly delayed in doing so, our business will be materially harmed.

We may find it difficult to enroll patients in our clinical trials given the relatively small patient populations with the indications for which our product candidates are being developed. If we experience delays or difficulties in the enrollment of patients in clinical trials, including failure to develop or use existing companion diagnostic tests, our successful completion of clinical trials or receipt of marketing approvals could be delayed or prevented.

We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials. Because our product candidates are focused on indications with relatively small patient populations, our ability to enroll eligible patients in our clinical trials may be limited or may result in slower enrollment than we anticipate. Moreover, because specific genetic mutations will be used to identify the appropriate patients for our programs and our current or future product candidates, successful enrollment of eligible patients to these trials may depend, in part, on our

 

33

 

ability to use existing companion diagnostic tests and genetic sequencing, or to develop novel companion diagnostics in collaboration with partners. Patient enrollment may be affected by various factors, including if our competitors have ongoing clinical trials for product candidates that are under development for the same indications as our product candidates, and patients instead enroll in such other clinical trials. In addition, we have clinical trial sites in Russia, Georgia and surrounding countries, which may be impacted by the current situation with Ukraine and Russia and could result in difficulties enrolling or completing our clinical trials on schedule. Our inability to enroll a sufficient number of patients or a delay in enrolling such patients, could result in significant delays in completing clinical trials, increased development costs, or a delay or inability to receive marketing approvals and may require us to abandon one or more clinical trials altogether.

The results of our preclinical testing and early clinical trials may not be predictive of the success of our later clinical trials, and the results of any of our clinical trials may not satisfy the requirements of the FDA or other comparable foreign regulatory authorities.

We will be required to demonstrate with substantial evidence through well-controlled clinical trials that our product candidates are safe and effective before we can seek marketing approvals for their commercial sale. Demonstrations of efficacy or an acceptable safety profile in our prior preclinical studies does not mean that future clinical trials will yield the same results. For instance, we do not know whether milademetan will perform in future clinical trials as milademetan has performed in preclinical studies and early clinical trials conducted by Daiichi Sankyo, and, despite decades of research on p53 as a target for precision medicines, prior product development efforts have been unsuccessful. Product candidates, including milademetan, may fail to demonstrate in later-stage clinical trials sufficient safety and efficacy to the satisfaction of the FDA and other comparable foreign regulatory authorities despite having progressed through preclinical studies and earlier stage clinical trials. Regulatory authorities may also limit the scope of later-stage trials until we have demonstrated satisfactory safety or efficacy results in preclinical studies or earlier-stage trials, which could prevent us from conducting the clinical trials we currently anticipate. For example, our open-label Phase 2 basket trial evaluating milademetan across solid tumors in patients with pre-specified MDM2 amplification levels may not meet the primary endpoint of an objective response rate as measured by RECIST criteria. We may not meet the secondary endpoints, including duration of response, disease control rate progression-free survival by investigator assessment, overall survival, and growth modulation index. Even if we are able to initiate our planned clinical trials on schedule, there is no guarantee that we will be able to complete such trials on the timelines we anticipate, that such trials will produce positive results, or that positive results will result in FDA approval or the commercial sale of any product candidate. Any limitation on our ability to conduct clinical trials could delay or prevent regulatory approval or limit the size of the patient population to which we may market our product candidates, if approved.

Preclinical and clinical development involves a lengthy and expensive process with uncertain outcomes, and results of earlier studies and trials may not be predictive of future clinical trial results. If our preclinical studies and clinical trials are not sufficient to support regulatory approval of any of our product candidates, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development of such product candidates.

Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical studies and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Our clinical trials may not be conducted as planned or completed on schedule, if at all, and a failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical studies and early-stage clinical trials may not be predictive of the success of later clinical trials. In particular, we initiated a pivotal Phase 3 trial for milademetan in WD/DD LPS patients in July 2021. Although data from WD/DD LPS patients in our Phase 1 clinical trial demonstrated median PFS approximately three to four times greater than the current SOC, the efficacy of the SOC in prior preclinical studies does not mean that future clinical trials will yield the same results. Unexpectedly favorable results of the SOC in our Phase 3 trial could lead to unfavorable comparisons to milademetan. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their product candidates.

We cannot guarantee that any clinical trials will be initiated or conducted as planned or completed on schedule, if at all. We also cannot be sure that submission of an investigational new drug application (IND) or similar application will result in the FDA or other regulatory authority, as applicable, allowing clinical trials to begin in a timely manner, if at all. Moreover, even if these trials begin, issues may arise that could cause regulatory

 

34

 

authorities to suspend or terminate such clinical trials. Events that may prevent successful or timely initiation or completion of clinical trials include: inability to generate sufficient preclinical, toxicology or other in vivo or in vitro data to support the initiation or continuation of clinical trials; delays in reaching a consensus with regulatory authorities on study design or implementation of the clinical trials; delays or failure in obtaining regulatory authorization to commence a trial; delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; delays in identifying, recruiting and training suitable clinical investigators; delays in obtaining required institutional review board (IRB) approval at each clinical trial site; delays in manufacturing, testing, releasing, validating or importing/exporting sufficient stable quantities of our product candidates for use in clinical trials or the inability to do any of the foregoing; failure by our CROs, other third parties or us to adhere to clinical trial protocols; failure to perform in accordance with the FDA’s or any other regulatory authority’s good clinical practice requirements (GCPs) or applicable regulatory guidelines in other countries; changes to the clinical trial protocols; clinical sites deviating from trial protocol or dropping out of a trial; changes in regulatory requirements and guidance that require amending or submitting new clinical protocols; selection of clinical endpoints that require prolonged periods of observation or analyses of resulting data; transfer of manufacturing processes to larger-scale facilities operated by a contract manufacturing organization (CMO) and delays or failure by our CMOs or us to make any necessary changes to such manufacturing process; and third parties being unwilling or unable to satisfy their contractual obligations to us. In addition, disruptions caused by the COVID-19 pandemic may increase the likelihood that we encounter such difficulties or delays in initiating, enrolling, conducting or completing our planned and ongoing clinical trials.

We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such clinical trials are being conducted, by the Data Safety Monitoring Board, if any, for such clinical trial or by the FDA or other regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical trial protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from the product candidates, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates, if the results of these trials are not positive or are only moderately positive or if there are safety concerns, our business and results of operations may be adversely affected, and we may incur significant additional costs.

Preliminary, “top-line” or interim data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures.

From time to time, we may publicly disclose preliminary or top-line data from our preclinical studies and clinical trials, which are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data. We also make assumptions, estimations, calculations and conclusions as part of our analyses of these data without the opportunity to fully and carefully evaluate complete data. As a result, the preliminary or top-line results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results once additional data have been received and fully evaluated or subsequently made subject to audit and verification procedures. Any preliminary or top-line data should be viewed with caution until the final data are available. From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available or as patients from our clinical trials continue other treatments. Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate and our Company in general. In addition, the information we choose to publicly disclose regarding a particular preclinical study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. If the preliminary, top-line or interim data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.

 

35

 

Public health crises such as pandemics or similar outbreaks have affected and could continue to seriously and adversely affect our preclinical studies and anticipated clinical trials, business, financial condition and results of operations.

The ongoing COVID-19 pandemic continues to rapidly evolve, and we will continue to monitor the COVID-19 situation closely. The extent of the impact of the COVID-19 pandemic on our business, operations and clinical development timelines and plans remains uncertain, and will depend on certain developments, including the duration and spread of the outbreak and its impact on our clinical trial enrollment, clinical trial sites, contract research organizations (CROs), third-party manufacturers and other third parties with whom we do business, as well as its impact on regulatory authorities and our key scientific and management personnel. To the extent possible, we are conducting business as usual, with necessary or advisable modifications, and most of our employees are working remotely. We will continue to monitor the evolving situation related to the COVID-19 pandemic and may take further actions that alter our operations, including those that may be required by federal, state or local authorities, or that we determine are in the best interests of our employees and other third parties with whom we do business. Our increased reliance on personnel working from home may negatively impact productivity, or disrupt, delay or otherwise seriously harm our business.

As a result of the COVID-19 pandemic, or similar pandemics, and related “shelter in place” orders and other public health guidance measures, we have, and may in the future, experience disruptions that could seriously harm our business. Potential disruptions include but are not limited to: delays or difficulties in enrolling patients in, initiating or expanding our clinical trials, including delays or difficulties with clinical site initiation and recruiting clinical site investigators and clinical site staff; increased rates of patients withdrawing from our clinical trials following enrollment as a result of contracting COVID-19 or other health conditions or being forced to quarantine; interruption of key clinical trial activities, such as clinical trial site data monitoring and efficacy, safety and translational data collection, processing and analyses, due to limitations on travel imposed; recommendations by federal, state or local governments, employers and others or interruptions of clinical trial subject visits, which may impact the collection and integrity of subject data and clinical trial endpoints; diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; delays or disruptions in preclinical experiments and IND-enabling studies due to restrictions of on-site staff and unforeseen circumstances at CROs and vendors; interruption or delays in the operations of the FDA and comparable foreign regulatory authorities including delays in receiving approval from local regulatory authorities to initiate our planned clinical trials; interruption of, or delays in receiving, supplies of our product candidates from our CMOs due to staffing shortages, raw materials shortages, production slowdowns or stoppages and disruptions in delivery systems; and limitations on employee or other resources that would otherwise be focused on the conduct of our clinical trials and preclinical work, including because of sickness of employees or their families, the desire of employees to avoid travel or contact with large groups of people, an increased reliance on working from home, school closures or mass transit disruptions.

The COVID-19 pandemic may also affect the ability of the FDA and other regulatory authorities to perform routine functions. If global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.

The COVID-19 pandemic continues to rapidly evolve. The extent to which the COVID-19 pandemic may affect our clinical trials, business, financial condition and results of operations will depend on future developments, which are highly uncertain and cannot be predicted at this time, such as the ultimate geographic spread of the disease, the duration of the pandemic, travel restrictions and actions to contain the outbreak or treat its impact, such as social distancing and quarantines or lock-downs in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. Future developments in these and other areas present material uncertainty and risk with respect to our clinical trials, business, financial condition and results of operations.

A variety of risks associated with marketing our product candidates internationally may materially adversely affect our business.

We plan to eventually seek regulatory approval of our product candidates outside of the United States and, accordingly, we expect that we will be subject to additional risks related to operating in foreign countries and

 

36

 

meeting differing regulatory requirements in foreign countries. Risks associated with international operations may materially adversely affect our business, financial condition and results of operations.

We face substantial competition, which may result in others discovering, developing, licensing or commercializing products before or more successfully than we do.

We face substantial competition from major pharmaceutical companies and biotechnology companies worldwide. Many of our competitors have significantly greater financial, technical and human resources. Smaller and early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. As a result, our competitors may discover, develop, license or commercialize products before or more successfully than we do.

In particular, we are aware of molecules that also are being explored for p53 upregulation and activation in various stages of clinical development by Actavalon, Aprea Therapeutics, CDG Therapeutics, Cotinga Pharmaceuticals, Innovation Pharmaceuticals, PMV Pharmaceuticals and Senhwa Biosciences, among others. We are also aware of selective small molecule inhibitors that are designed to target WT p53 containing tumors through the p53-MDM2 interaction, which are in various stages of clinical development by Aileron Therapeutics, Ascentage Pharma, Boehringer Ingelheim, Kartos Therapeutics, Novartis, and Roche, including testing MDM2 inhibitors in combination with a variety of other anti-cancer agents.

We face competition with respect to our current product candidates and will face competition with respect to any future product candidates from segments of the pharmaceutical, biotechnology and other related industries that pursue targeted therapies for patients with genetically defined cancers. If milademetan or our future product candidates do not offer sustainable advantages over competing products, we may otherwise not be able to successfully compete against current and future competitors.

Our competitors may obtain regulatory approval of their products more rapidly than we may or may obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize our product candidates. Our competitors may also develop drugs that are more effective, more convenient, more widely used and less costly or have a better safety profile than our products and these competitors may also be more successful than us in manufacturing and marketing their products. In addition, we will likely need to develop our product candidates in collaboration with companion diagnostic companies, and we will face competition from other companies in establishing these future collaborations.

Furthermore, we also face competition more broadly across the market for existing cost-effective and reimbursable cancer treatments. Our product candidates, if any are approved, may compete with these existing drug and other therapies but may not be competitive with them in price. We expect that if our product candidates are approved, they will be priced at a significant premium over competitive generic, including branded generic, products. As a result, obtaining market acceptance of, and gaining significant share of the market for, any of our product candidates that we successfully introduce to the market will pose challenges.

Our product candidates may cause significant adverse events, toxicities or other undesirable side effects that may result in a safety profile that could prevent regulatory approval, marketing approval or market acceptance, or limit their commercial potential.

If our product candidates are associated with undesirable side effects or have unexpected characteristics in preclinical studies or clinical trials when used alone or in combination with other approved products or INDs, we may need to interrupt, delay or abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may prevent us from achieving or maintaining market acceptance of the affected product candidate and may adversely affect our business, financial condition and prospects significantly.

In general, the anticipated clinical trials of milademetan will include cancer patients who are very sick and whose health is deteriorating, and we expect that additional clinical trials of milademetan and our other product candidates will include similar patients with deteriorating health. A number of patients in milademetan trials have experienced adverse events, including blood and lymphatic disorders and gastrointestinal disorders.

The inclusion of critically ill patients in our clinical trials may result in deaths or other adverse medical events due to other therapies or medications that such patients may be using or due to the gravity of such

 

37

 

patients’ illnesses. For example, it is expected that many of the patients enrolled in our milademetan clinical trials will die or experience major clinical events either during the course of our clinical trials or after participating in such trials. Such outcomes may make it more difficult for us to identify a clinical benefit in our targeted patient populations, and could ultimately prevent us from obtaining regulatory approval for milademetan in such critically ill populations, including WD/DD LPS. Additionally, such adverse events or deaths in clinical trials involving our product candidates, even if not ultimately attributable to our product or product candidates, could result in increased government regulation, unfavorable public perception and publicity, potential regulatory delays in the testing or licensing of our product candidates, stricter labeling requirements for those product candidates that are licensed and a decrease in demand for any such product candidates.

Additionally, if one or more of our product candidates receives marketing approval and we or others later identify undesirable side effects or adverse events caused by such products, a number of potentially significant negative consequences could result. For example, regulatory authorities may suspend, limit or withdraw approvals of such product or seek an injunction against its manufacture or distribution, require additional warnings on the label, including “boxed” warnings, or issue safety alerts, require press releases or other communications containing warnings or other safety information about the product, require us to change the way the product is administered or conduct additional clinical trials or post-approval studies, require us to create a risk evaluation and mitigation strategy (REMS) which could include a medication guide outlining the risks of such side effects for distribution to patients, impose fines, injunctions or criminal penalties. We could also be sued and held liable for harm caused to patients, and our reputation may suffer. Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could seriously harm our business.

Risks Related to Regulatory Process and Other Legal Compliance Matters

The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired.

The process of obtaining regulatory approvals, both in the United States and abroad, is unpredictable, expensive and typically takes many years following commencement of clinical trials, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. We cannot commercialize product candidates in the United States without first obtaining regulatory approval from the FDA. Similarly, we cannot commercialize product candidates outside of the United States without obtaining regulatory approval from comparable foreign regulatory authorities. Before obtaining regulatory approvals for the commercial sale of our product candidates, including our lead product candidate milademetan, we must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that our product candidates are both safe and effective for each targeted indication. Securing regulatory approval also requires the submission of information about the drug manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Further, our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval. The FDA and comparable foreign regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other data. Our product candidates could be delayed in receiving, or fail to receive, regulatory approval for many reasons, including: the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication; the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; serious and unexpected drug-related side effects may be experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates; we may be unable to demonstrate that a product candidate’s clinical and other benefits outweigh its safety risks; the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; the data collected from clinical trials of our product candidates may not be acceptable or sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere, and we may be required to conduct additional clinical trials; the FDA or the applicable foreign regulatory authority may disagree regarding the formulation, labeling and/or the specifications of our product

 

38

 

candidates; the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. Thus, the approval requirements for our product candidates are likely to vary by jurisdiction such that success in one jurisdiction is not necessarily predicative of success elsewhere.

Of the large number of drugs in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, results of operations and prospects.

If we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, including failing to approve the most commercially promising indications, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize, or will be delayed in commercializing, our product candidates and our ability to generate revenue will be materially impaired.

If we are required by the FDA to obtain approval of a companion diagnostic test in connection with approval of any of our product candidates and we fail to obtain or face delays in obtaining FDA approval of a diagnostic device, we could be delayed or may not be able to commercialize such product candidate and our ability to generate revenue will be materially impaired.

If safe and effective use of any of our product candidates depends on an in vitro diagnostic that is not otherwise commercially available, then the FDA generally will require approval or clearance of that diagnostic, known as a companion diagnostic, at the same time that the FDA approves our product candidates, if at all. Companion diagnostics are developed in conjunction with clinical programs for the associated product and are subject to regulation as medical devices by the FDA and comparable regulatory authorities, and, to date, the FDA has required premarket approval of all companion diagnostics for cancer therapies, such as those we are developing. The approval of a companion diagnostic as part of the therapeutic product’s labeling limits the use of the therapeutic product to only those patients who express the specific genetic alteration that the companion diagnostic was developed to detect.

According to FDA guidance, if the FDA determines that a companion diagnostic device is essential to the safe and effective use of a novel therapeutic product or indication, the FDA generally will not approve the therapeutic product or new therapeutic product indication if the companion diagnostic is not also approved or cleared for that indication. If a satisfactory companion diagnostic is not commercially available, we may be required to develop or obtain one that would be subject to regulatory approval requirements. The process of obtaining or creating such diagnostics is time-consuming and costly. If the FDA or a comparable foreign regulatory authority requires approval of a companion diagnostic for any of our product candidates, whether before or after it obtains marketing approval, we, and/or future collaborators, may encounter difficulties in developing and obtaining approval for such product candidate. Any delay or failure by us or third-party collaborators to develop or obtain regulatory approval of a companion diagnostic could delay or prevent approval or continued marketing of such product candidate. We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process for the companion diagnostic or in transferring that process to commercial partners or negotiating insurance reimbursement plans, all of which may prevent us from completing our clinical trials or commercializing our product candidates, if approved, on a timely or profitable basis, if at all.

We may seek orphan drug designation for our product candidates, but we may be unable to obtain such designation or to obtain or maintain the benefits associated with orphan drug designation, including market exclusivity, which may cause our product revenue, if any, to be reduced.

We have obtained orphan drug designation in the United States for milademetan for the treatment of LPS and we may seek additional orphan drug designations for milademetan or our other product candidates; however,

 

39

 

we may never receive such designations. See the section titled “Business—Government Regulation—Review and Approval of Drugs in the United States—Orphan Drug Designation” in this Annual Report on Form 10-K.

Exclusive marketing rights in the United States may be unavailable if we or our collaborators seek approval for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective. Even if we obtain orphan drug designation, we may not be the first to obtain marketing approval for any particular orphan indication due to the uncertainties associated with developing pharmaceutical products. Further, even if we obtain orphan drug exclusivity for a product candidate, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is safer, is more effective, or makes a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process.

Even if we receive regulatory approval of our product candidates, we will be subject to extensive ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.

Any regulatory approvals that we may receive for our product candidates will require the submission of reports to regulatory authorities and surveillance to monitor the safety and efficacy of the product candidate, may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA may require a REMS in order to approve our product candidates, which could entail requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or comparable foreign regulatory authorities approve our product candidates, our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export will be subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by comparable foreign regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as on-going compliance with current good manufacturing practices (cGMPs) and GCPs for any clinical trials that we conduct following approval. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with cGMPs.

If we or a regulatory authority discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a regulatory authority may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials, restrictions on the manufacturing process, warning or untitled letters, civil and criminal penalties, injunctions, product seizures, detentions or import bans, voluntary or mandatory publicity requirements and imposition of restrictions on operations, including costly new manufacturing requirements. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity.

Even if we are able to commercialize any product candidates, due to unfavorable pricing regulations and/or third-party coverage and reimbursement policies, we may not be able to offer such products at competitive prices which would seriously harm our business.

Our ability to successfully commercialize any products that we may develop also will depend in part on the extent to which reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. See the sections titled “Business—Government Regulation—Review and Approval of Drug Products

 

40

 

in the European Union,” “Business—Government Regulation—Review and Approval of Drug Products in the United States—New Legislation and Regulations,” “Business—Government Regulation—U.S. Pharmaceutical Coverage, Pricing and Reimbursement” and “Business—Government Regulation—U.S. Healthcare Reform” in this Annual Report on Form 10-K.

The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses and any infraction could subject us to liability.

If any of our product candidates are approved and we are found to have improperly promoted off-label uses of those products, we may become subject to significant liability. See the section titled “Business—Government Regulation—Review and Approval of Drugs in the United States—Post-approval Requirements” in this Annual Report on Form 10-K. If we do not appropriately manage the promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.

Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.

We are exposed to the risk that our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors acting for or on our behalf may engage in misconduct or other improper activities. We have adopted a code of conduct, but it is not always possible to identify and deter misconduct by these parties and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations.

Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.

Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved. See the section titled “Business—Government Regulation—Healthcare Laws and Regulations” in this Annual Report on Form 10-K for a more detailed description of the laws that may affect our ability to operate.

Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. If our operations, including certain arrangements we have with physicians who are compensated in the form of stock or stock options for services provided to us, are found to be in violation of any of these laws or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. Further, defending against any such actions can be costly and time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.

If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.

We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations may involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may

 

41

 

impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.

Risks Related to Employee Matters, Managing Our Growth and Other Risks Related to Our Business

We are highly dependent on our key personnel and anticipate hiring new key personnel. If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.

Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our managerial, scientific and medical personnel, including our Chief Executive Officer and our Chief Scientific Officer. If we do not succeed in attracting and retaining qualified personnel, it could materially adversely affect our business, financial condition and results of operations. We could in the future have difficulty attracting and retaining experienced personnel and may be required to expend significant financial resources in our employee recruitment and retention efforts.

In order to successfully implement our plans and strategies, we will need to grow the size of our organization and we may experience difficulties in managing this growth.

We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug development, clinical operations, regulatory affairs and, potentially, sales and marketing. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. We are dependent on our limited financial resources and the experience of our management team in managing a company with such anticipated growth, and we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel.

Our internal computer systems, or those of any of our CROs, manufacturers, other contractors or consultants or potential future collaborators, may fail or suffer security or data privacy breaches or other unauthorized or improper access to, use of, or destruction of our proprietary or confidential data, employee data or personal data, which could result in additional costs, loss of revenue, significant liabilities, harm to our brand and material disruption of our operations.

Despite the implementation of security measures in an effort to protect systems that store our information, given their size and complexity and the increasing amounts of information maintained on our internal information technology systems and those of our third-party CROs, other contractors (including sites performing our clinical trials) and consultants, these systems are potentially vulnerable to breakdown or other damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by our employees, contractors, consultants, business partners and/or other third parties, or from cyber-attacks by malicious third parties, which may compromise our system infrastructure or lead to the loss, destruction, alteration or dissemination of, or damage to, our data. To the extent that any disruption or security breach were to result in a loss, destruction, unavailability, alteration or dissemination of, or damage to, our data or applications, or for it to be believed or reported that any of these occurred, we could incur liability and reputational damage and the development and commercialization of our product candidates could be delayed. Further, our insurance policies may not be adequate to compensate us for the potential losses arising from any such disruption in, or failure or security breach of, our systems or third-party systems where information important to our business operations or commercial development is stored.

Risks Related to Reliance on Third Parties

We currently rely, and plan to rely in the future, on third parties to conduct and support our preclinical studies and clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates.

We have utilized and plan to continue to utilize and depend upon independent investigators and collaborators, such as medical institutions, CROs, CMOs and strategic partners, to conduct and support our

 

42

 

preclinical studies and clinical trials under agreements with us. We will rely heavily on these third parties over the course of our preclinical studies and clinical trials, and we control only certain aspects of their activities. As a result, we will have less direct control over the conduct, timing and completion of these preclinical studies and clinical trials and the management of data developed through preclinical studies and clinical trials than would be the case if we were relying entirely upon our own staff. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our third-party contractors and CROs are required to comply with GCP regulations, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our products candidates in clinical development. If we or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.

Any third parties conducting our clinical trials will not be our employees and, except for remedies available to us under our agreements with such third parties, we cannot control whether they devote sufficient time and resources to our product candidates. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other product development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our product candidates.

We currently rely and expect to rely in the future on the use of manufacturing suites in third-party facilities or on third parties to manufacture our product candidates, and we may rely on third parties to produce and process our products, if approved. Our business could be adversely affected if we are unable to use third-party manufacturing suites or if the third-party manufacturers fail to provide us with sufficient quantities of our product candidates or fail to do so at acceptable quality levels or prices.

We do not currently own any facility that may be used as our clinical-scale manufacturing and processing facility and must currently rely on CMOs to manufacture our product candidates. We have not yet caused our product candidates to be manufactured on a commercial scale and may not be able to do so for any of our product candidates, if approved. We received a batch of our product candidate that we believe is representative of our anticipated early commercial batch requirements. However, as a clinical-stage company with no prior history of product sales or commercialization of products, representative batches of our product candidate received to date may not represent what will be required to meet our future commercial requirements or be manufactured at scale. We may not control the manufacturing process of, and may be completely dependent on, our contract manufacturing partners for compliance with cGMP requirements and any other regulatory requirements of the FDA or other regulatory authorities for the manufacture of our product candidates. Beyond periodic audits, we have no control over the ability of our CMOs to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any approval in the future, we may need to find alternative manufacturing facilities, which would require the incurrence of significant additional costs and materially adversely affect our ability to develop, obtain regulatory approval for or market our product candidates, if approved. Similarly, our failure, or the failure of our CMOs, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates or drugs and harm our business and results of operations.

Moreover, if any CMOs on which we will rely fail to manufacture quantities of our product candidates at quality levels necessary to meet regulatory requirements and at a scale sufficient to meet anticipated demand at a

 

43

 

cost that allows us to achieve profitability, our business, financial condition and prospects could be materially and adversely affected. Our business could be materially adversely affected by business disruptions to our third-party providers that could materially adversely affect our potential future revenue and financial condition and increase our costs and expenses. Each of these risks could delay or prevent the completion of our clinical trials or the approval of any of our product candidates by the FDA, result in higher costs or adversely impact commercialization of our product candidates.

We may, in the future, form or seek collaborations or strategic alliances or enter into licensing arrangements, and we may not realize the benefits of such collaborations, alliances or licensing arrangements.

We may, in the future, form or seek strategic alliances, create joint ventures or collaborations, or enter into licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates and any future product candidates that we may develop. Any of these relationships may require us to increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business.

Risks Related to Our Intellectual Property

Our ability to protect our patents and other proprietary rights is uncertain, exposing us to the possible loss of competitive advantage.

We rely upon a combination of patents, trademarks, trade secret protection and confidentiality agreements to protect the intellectual property related to our products and technologies and to prevent third parties from copying and surpassing our achievements, thus eroding our competitive position in our market. Our success depends in large part on our ability to obtain and maintain patent protection for our platform technologies, product candidates and their uses, as well as our ability to operate without infringing on or violating the proprietary rights of others. We own and have licensed rights to pending patent applications and expect to continue to file patent applications in the United States and abroad related to our novel discoveries and technologies that are important to our business. However, we may not be able to protect our intellectual property rights throughout the world and the legal systems in certain countries may not favor enforcement or protection of patents, trade secrets and other intellectual property. Filing, prosecuting and defending patents on product candidates worldwide would be prohibitively expensive and our intellectual property rights in some foreign jurisdictions can be less extensive than those in the United States. As such, we do not have patents in all countries or all major markets and may not be able to obtain patents in all jurisdictions even if we apply for them. Our competitors may operate in countries where we do not have patent protection and can freely use our technologies and discoveries in such countries to the extent such technologies and discoveries are publicly known or disclosed in countries where we do have patent protection or pending patent applications. Our pending and future patent applications may not result in patents being issued. Any issued patents may not afford sufficient protection of our product candidates or their intended uses against competitors, nor can there be any assurance that the patents issued will not be infringed, designed around, invalidated by third parties, or effectively prevent others from commercializing competitive technologies, products or product candidates. Further, even if these patents are granted, they may be difficult to enforce. Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated if we fail to comply with these requirements. Further, any issued patents that we may license or own covering our product candidates could be narrowed or found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad, including the United States Patent and Trademark Office (USPTO). Also, patent terms, including any extensions or adjustments that may or may not be available to us, may be inadequate to protect our competitive position on our product candidates for an adequate amount of time, and we may be subject to claims challenging the inventorship, validity, enforceability of our patents and/or other intellectual property. Finally, changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect our product candidates. Further, if we encounter delays in our clinical trials or delays in obtaining regulatory approval, the period of time during which we could market our product candidates under patent protection would be reduced. Thus, the patents that we own, and license may not afford us any meaningful competitive advantage.

Moreover, we or our licensors may be subject to a third-party preissuance submission of prior art to the USPTO or become involved in opposition, derivation, revocation, reexamination, inter partes review, post-grant

 

44

 

review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize drugs without infringing third-party patent rights. If the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. In addition to seeking patents for some of our technology and product candidates, we may also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. Any disclosure, either intentional or unintentional, by our employees, the employees of third parties with whom we share our facilities or third-party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market. In order to protect our proprietary technology and processes, we rely in part on confidentiality agreements with our collaborators, employees, consultants, outside scientific collaborators and sponsored researchers and other advisors. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. We may need to share our proprietary information, including trade secrets, with future business partners, collaborators, contractors and others located in countries at heightened risk of theft of trade secrets, including through direct intrusion by private parties or foreign actors and those affiliated with or controlled by state actors. In addition, while we undertake efforts to protect our trade secrets and other confidential information from disclosure, others may independently discover trade secrets and proprietary information, and in such cases, we may not be able to assert any trade secret rights against such party. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.

As is common in the biotechnology and pharmaceutical industries, we employ individuals and engage the services of consultants who previously worked for other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers, or that our consultants have used or disclosed trade secrets or other proprietary information of their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. This type of litigation or proceeding could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other intellectual property related proceedings could adversely affect our ability to compete in the marketplace.

Lastly, if our trademarks and trade names are not registered or adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.

Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.

Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.

 

45

 

If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of our marketing exclusivity for any product candidates we may develop, our business may be materially harmed.

In the United States, the patent term of a patent that covers an FDA-approved drug may be eligible for limited patent term extension, which permits patent term restoration as compensation for the patent term lost during the FDA regulatory review process. The Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Act, permits a patent term extension of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory review. Patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, and only one patent applicable to an approved drug may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar provisions are available in Europe and certain other non-United States jurisdictions to extend the term of a patent that covers an approved drug. While, in the future, if and when our product candidates receive FDA approval, we expect to apply for patent term extensions on patents covering those product candidates, there is no guarantee that the applicable authorities will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions. We may not be granted patent term extension either in the United States or in any foreign country because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the term of extension, as well as the scope of patent protection during any such extension, afforded by the governmental authority could be less than we request. If we are unable to obtain any patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products following the expiration of our patent rights, and our business, financial condition, results of operations and prospects could be materially harmed.

It is possible that we will not obtain patent term extension under the Hatch-Waxman Act for a U.S. patent covering any of our product candidates that we may identify even where that patent is eligible for patent term extension, or if we obtain such an extension, it may be for a shorter period than we had sought. Further, for our licensed patents, we may not have the right to control prosecution, including filing with the USPTO, a petition for patent term extension under the Hatch-Waxman Act. Thus, if one of our licensed patents is eligible for patent term extension under the Hatch-Waxman Act, we may not be able to control whether a petition to obtain a patent term extension is filed, or obtained, from the USPTO.

Also, there are detailed rules and requirements regarding the patents that may be submitted to the FDA for listing in the Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book). We may be unable to obtain patents covering our product candidates that contain one or more claims that satisfy the requirements for listing in the Orange Book. Even if we submit a patent for listing in the Orange Book, the FDA may decline to list the patent, or a manufacturer of generic drugs may challenge the listing. If one of our product candidates is approved and a patent covering that product candidate is not listed in the Orange Book, a manufacturer of generic drugs would not have to provide advance notice to us of any abbreviated new drug application filed with the FDA to obtain permission to sell a generic version of such product candidate.

Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.

Changes in either the patent laws or interpretation of patent laws in the United States, including patent reform legislation such as the Leahy-Smith America Invents Act (the Leahy-Smith Act) could increase the uncertainties and costs surrounding the prosecution of our owned and in-licensed patent applications and the maintenance, enforcement or defense of our owned and in-licensed issued patents. The Leahy-Smith Act includes a number of significant changes to United States patent law. These changes include provisions that affect the way patent applications are prosecuted, redefine prior art, provide more efficient and cost-effective avenues for competitors to challenge the validity of patents, and enable third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent at USPTO-administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. Assuming that other requirements for patentability are met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith Act, the United States transitioned to a first-to-file system in which, assuming that the other statutory requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. As such, the Leahy-Smith Act and its implementation

 

46

 

could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.

In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future actions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our patent rights and our ability to protect, defend and enforce our patent rights in the future.

We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products.

We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent’s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect. For example, we may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict whether a third-party’s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products.

In addition, because some patent applications in the United States may be maintained in secrecy until the patents are issued, patent applications in the United States and many foreign jurisdictions are typically not published until 18 months after filing, and publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications for technology covered by our issued patents or our pending applications, or that we were the first to invent the technology. Our competitors may have filed, and may in the future file, patent applications covering our products or technology similar to ours. Any such patent application may have priority over our patent applications or patents, which could require us to obtain rights to issued patents covering such technologies.

We may be subject to claims challenging the inventorship of our patents and other intellectual property.

We may be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our product candidates or as a result of questions regarding co-ownership of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.

We may be subject to patent infringement claims or may need to file claims to protect our intellectual property, which could result in substantial costs and liability and prevent us from commercializing our potential products.

Because the intellectual property landscape in the biotechnology industry is rapidly evolving and interdisciplinary, it is difficult to conclusively assess our freedom to operate without infringing on or violating third

 

47

 

party rights. However, if certain of our product candidates are ultimately granted regulatory approval, we are currently aware of certain patent rights held by third parties that, if found to be valid and enforceable, could be alleged to render one or more of our product candidates infringing. If a third party successfully brings a claim against us, we may be required to pay substantial damages, be forced to abandon any affected product and/or seek a license from the patent holder. In addition, any intellectual property claims (e.g., patent infringement or trade secret theft) brought against us, whether or not successful, may cause us to incur significant legal expenses and divert the attention of our management and key personnel from other business concerns. We cannot be certain that patents owned or licensed by us will not be challenged by others in the course of litigation. Some of our competitors may be able to sustain the costs of complex intellectual property litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise funds and on the market price of our common stock.

Competitors may infringe or otherwise violate our patents, trademarks, copyrights or other intellectual property. To counter infringement or other violations, we may be required to file claims, which can be expensive and time-consuming. Any such claims could provoke these parties to assert counterclaims against us, including claims alleging that we infringe their patents or other intellectual property rights. In addition, in a patent infringement proceeding, a court or administrative body may decide that one or more of the patents we assert is invalid or unenforceable, in whole or in part, construe the patent’s claims narrowly or refuse to prevent the other party from using the technology at issue on the grounds that our patents do not cover the technology. Similarly, if we assert trademark infringement claims, a court or administrative body may determine that the marks we have asserted are invalid or unenforceable or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In such a case, we could ultimately be forced to cease use of such marks. In any intellectual property litigation, even if we are successful, any award of monetary damages or other remedy we receive may not be commercially valuable.

Further, we may be required to protect our patents through procedures created to attack the validity of a patent at the USPTO. An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action.

In addition, if our product candidates are found to infringe the intellectual property rights of third parties, these third parties may assert infringement claims against our future licensees and other parties with whom we have business relationships and we may be required to indemnify those parties for any damages they suffer as a result of these claims, which may require us to initiate or defend protracted and costly litigation on behalf of licensees and other parties regardless of the merits of such claims. If any of these claims succeed, we may be forced to pay damages on behalf of those parties or may be required to obtain licenses for the products they use.

Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings relating to our intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings.

We license patent rights from third-party owners, and we rely on such owners to obtain, maintain and enforce the patents underlying such licenses.

We are a party to certain licenses, including with our licensors Daiichi Sankyo and Drexel University, that provide us rights to intellectual property that are necessary or useful for our product candidates, milademetan and RAD52, and their respective components, formulations, methods of manufacturing and methods of treatment. These license agreements require us to satisfy certain obligations and, if these agreements are terminated (e.g., as a result of our failure to satisfy such obligations), our technology and our business could be adversely affected. We also expect to enter into additional licenses to third-party intellectual property in the future; however, we may not be able to obtain such licenses on economically feasible terms or other reasonable terms and conditions, or at all.

Our licensors may not successfully prosecute the patent applications that we are licensed. Even if patents are issued in respect of these patent applications, our licensors may fail to maintain these patents, may determine not to pursue litigation against other companies that are infringing these patents, or may pursue such litigation less aggressively than we would. Without protection for the intellectual property we license, other companies

 

48

 

might be able to offer substantially identical products for sale, which could adversely affect our competitive business position and harm our business prospects.

Additionally, we may sometimes collaborate with academic institutions to accelerate our preclinical research or development under written agreements with these institutions. These institutions may provide us with an option to negotiate a license to any of the institution’s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to others, potentially blocking our ability to pursue our program.

We have limited, if any, control over the amount or timing of resources that our licensors devote on our behalf or the priority they place on maintaining these patent rights and prosecuting these patent applications to our advantage. For example, should Daiichi Sankyo decide it no longer wants to maintain any of the patents licensed to us, Daiichi Sankyo is required to afford us the opportunity to do so at our expense. However, we cannot be sure that Daiichi Sankyo will perform as required. If Daiichi Sankyo does not perform, and if we do not assume the maintenance of the licensed patents in sufficient time to make required payments or filings with the appropriate governmental agencies, we risk losing the benefit of all or some of those patent rights. In the event our licensors fail to adequately pursue and maintain patent protection for patents and applications they control, and to timely cede control of such prosecution to us, our competitors might be able to enter the market, which would have a material adverse effect on our business.

Our technology licensed from various third parties may be subject to retained rights.

Our licensors often retain certain rights under their agreements with us, including the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether our licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse. Further, the U.S. government may retain certain rights under the Bayh-Dole Act for research funded by the Federal Government.

We may not be able to effectively secure first-tier technologies when competing against other companies or investors.

Our future success may require that we acquire patent rights and know-how to new or complimentary technologies. However, we compete with a substantial number of other companies that may also compete for technologies we desire. In addition, many venture capital firms and other institutional investors, as well as other biotechnology companies, invest in companies seeking to commercialize various types of emerging technologies. Many of these companies have greater financial, scientific and commercial resources than us. Therefore, we may not be able to secure the technologies we desire. Furthermore, should any commercial undertaking by us prove to be successful, there can be no assurance competitors with greater financial resources will not offer competitive products and/or technologies.

Risks Related to Our Common Stock

The price of our stock may be volatile, and you could lose all or part of your investment.

The trading price of our common stock is likely to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including the factors discussed in this “Risk Factors” section and elsewhere in this Annual Report on Form 10-K. The realization of any of these factors could have a dramatic and adverse impact on the market price of our common stock.

In addition, the stock market in general, and the market for biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. In particular, the trading prices for biotechnology companies have been highly volatile as a result of the COVID-19 pandemic. In addition, broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company’s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management’s attention and resources, which would materially adversely affect our business, financial condition and results of operation.

 

49

 

Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant influence over matters subject to stockholder approval.

As of December 31, 2021, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned a significant portion of our outstanding voting common stock. These stockholders, acting together, may be able to impact matters requiring stockholder approval. For example, they may be able to impact elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders. The interests of this group of stockholders may not always coincide with your interests or the interests of other stockholders and they may act in a manner that advances their best interests and not necessarily those of other stockholders, including seeking a premium value for their common stock, and might affect the prevailing market price for our common stock.

General Risk Factors

Provisions in our amended and restated certificate of incorporation and amended and restated bylaws and Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the market price of our common stock.

Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could delay or prevent a change of control of our Company or changes in our board of directors that our stockholders might consider favorable. In addition, Section 203 of the General Corporation Law of the State of Delaware (DGCL) prohibits a publicly held Delaware corporation from engaging in a business combination with an interested stockholder for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. Any provision of our amended and restated certificate of incorporation, amended and restated bylaws or Delaware law that has the effect of delaying or preventing a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our capital stock and could also affect the price that some investors are willing to pay for our common stock.

Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware and the federal district courts of the United States will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes.

Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another State court in Delaware or the federal district court for the District of Delaware) is the exclusive forum for certain actions, in all cases subject to the court’s having jurisdiction over indispensable parties named as defendants. In addition, our amended and restated certificate of incorporation provides that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act but that the forum selection provision will not apply to claims brought to enforce a duty or liability created by the Exchange Act. These exclusive forum provisions may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes, which may discourage lawsuits. There is uncertainty as to whether a court would enforce such provisions. If a court were to find these types of provisions to be inapplicable or unenforceable, and if a court were to find the exclusive forum provision in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could materially adversely affect our business.

The dual class structure of our common stock may limit your ability to influence corporate matters and may limit your visibility with respect to certain transactions.

The dual class structure of our common stock may limit your ability to influence corporate matters. Holders of our common stock are entitled to one vote per share, while holders of our non-voting common stock are not entitled to any votes. Nonetheless, each share of our non-voting common stock may be converted at any time into one share of our common stock at the option of its holder by providing written notice to us, subject to the limitations provided for in our amended and restated certificate of incorporation. Consequently, if holders of our non-voting common stock exercise their option to make this conversion, this will have the effect of increasing the

 

50

 

relative voting power of those prior holders of our non-voting common stock, and correspondingly decreasing the voting power of the holders of our common stock, which may limit your ability to influence corporate matters. Additionally, stockholders who hold, in the aggregate, more than 10% of our common stock and non-voting common stock, but 10% or less of our common stock, and are not otherwise an insider, may not be required to report changes in their ownership due to transactions in our non-voting common stock pursuant to Section 16(a) of the Exchange Act, and may not be subject to the short-swing profit provisions of Section 16(b) of the Exchange Act.

Item 1B. Unresolved Staff Comments.

None

Item 2. Properties.

Our corporate headquarters are located in Newark, California where we occupy approximately 3,900 square feet of office space under a lease that expires on September 30, 2024. We use this facility for administrative purposes. We believe that our facility is sufficient to meet our current needs. We also believe we will be able to obtain additional space, as needed, on commercially reasonable terms.

We are currently not a party to any material legal proceedings. From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors, and there can be no assurances that favorable outcomes will be obtained.

Item 4. Mine Safety Disclosures.

Not applicable.

 

 

51

 

 

PART II

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

Market Information

Our common stock is traded on The Nasdaq Global Select Market under the symbol “RAIN.”

Holders

As of February 17, 2022, we had 32 holders of record of our common stock.

Dividend Policy

We have never declared or paid dividends on our capital stock. We currently intend to retain any future earnings and do not anticipate paying dividends in the foreseeable future. Any future determination to pay dividends will be at the discretion of our Board of Directors and will be dependent on a number of factors, including our financial condition, results of operations, capital requirements, contractual restrictions, general business conditions, and any other factors that our board may deem relevant.

Use of Proceeds from our Initial Public Offering

On April 27, 2021, we completed our IPO, in which we issued and sold 7,352,941 shares of our common stock, $0.001 par value per share, at the public offering price of $17.00 per share. On May 7, 2021, the underwriters exercised their option to purchase 492,070 additional shares our common stock at the public offering price (the Overallotment) and the Overallotment closed on May 11, 2021.

The offer and sale of all of the shares of our common stock in the IPO were registered under the Securities Act pursuant to our Registration Statement on Form S-1, as amended (File No. 333-254998), which was declared effective on April 22, 2021. Goldman Sachs & Co. LLC, Citigroup, Global Markets, Inc., Piper, Sandler & Co., and Guggenheim Securities LLC acted as joint book-running managers for the IPO.

We received net proceeds from our IPO of approximately $121.5 million, after deducting underwriting discounts and commissions, and other offering fees, inclusive of the Overallotment. None of the underwriting discounts and commissions or other offering expenses were incurred or paid, directly or indirectly, to any of our directors or officers or their associates or to persons owning 10% or more of our common stock or to any of our affiliates.

The net proceeds from the IPO (including the Overallotment) have been used and will be used, to fund a pivotal Phase 3 trial in LPS, a Phase 2 tumor-agnostic basket trial in certain solid tumors and a Phase 2 trial in Merkel cell carcinoma, in each case, for our lead product candidate, milademetan, to fund the purchase of raw materials and drug substance and drug product manufacturing for our milademetan program and to fund various clinical pharmacology, biomarker and translational studies for our milademetan program, and for working capital, including continuing to advance our pipeline through preclinical studies and clinical trials, and general corporate purposes. This use of proceeds represents a change from our intended use of proceeds from our IPO as described in the prospectus filed with the SEC pursuant to Rule 424(b)(4) on April 23, 2021, as the Phase 2 clinical trial of milademetan in Merkel cell carcinoma will replace the previously planned Phase 2 clinical trial of milademetan in intimal sarcoma.

Item 6. Reserved.

 

 

52

 

 

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes and other financial information included elsewhere in this Annual Report on Form 10-K. This discussion and analysis contain forward-looking statements based upon our current plans and expectations that involve risks, uncertainties and assumptions, such as statements regarding our plans, objectives, expectations, intentions and beliefs. Our actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under the section titled “Risk Factors” and included elsewhere in this Annual Report on Form 10-K. You should carefully read the sections titled “Note Regarding Forward-Looking Statements” and “Risk Factors” to gain an understanding of the important factors that could cause actual results to differ materially from the results described below.

 

Overview

We are a late-stage precision oncology company developing therapies that target oncogenic drivers for which we are able to genetically select patients we believe will be most likely to benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. We have in-licensed product candidates, each with a differentiated profile relative to available therapies, and we intend to continue strengthening our pipeline through focused business development and internal research efforts.

Our lead product candidate, milademetan (also known as RAIN-32) is a small molecule, oral inhibitor of mouse double minute 2 (MDM2), which may be oncogenic in numerous cancers. We in-licensed milademetan from Daiichi Sankyo in September 2020 based on the results of a Phase 1 clinical trial, which demonstrated meaningful antitumor activity in an MDM2-amplified subtype of liposarcoma (LPS) and other solid tumors. Data from well-differentiated/de-differentiated (WD/DD) liposarcoma LPS patients in the Phase 1 clinical trial of milademetan demonstrated median progression-free survival (mPFS) of approximately seven to eight months. Importantly, this result was accomplished with a rationally designed dosing schedule designed to mitigate safety concerns and widen the therapeutic window of MDM2 inhibition unlocking the potential for milademetan in a broad range of MDM2-dependent cancers. Based on these data, we commenced a pivotal Phase 3 trial in LPS (MANTRA) in July 2021. We also commenced a Phase 2 tumor-agnostic basket trial in certain solid tumors (MANTRA-2) in November 2021. We anticipate commencing a Phase 2 clinical trial in Merkel cell carcinoma (MCC) (MANTRA-3) in the second half of 2022 and a Phase 1 clinical trial to evaluate the safety, tolerability and efficacy of milademetan in combination with atezolizumab in patients with loss of cyclin-dependent kinase inhibitor 2A (CDKN2A) and wildtype p53 advanced solid tumors (MANTRA-4) in the second half of 2022. In addition to milademetan, we are also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Since our inception in 2017, we have incurred significant operating losses and have utilized substantially all of our resources to date in-licensing and developing our product candidates, organizing and staffing our Company and providing other general and administrative support for our operations. As of December 31, 2021, we had an accumulated deficit of $90.0 million and we incurred net losses of approximately $51.4 million and $21.1 million for the years ended December 31, 2021 and 2020, respectively. Our operations to date have been funded primarily through the issuance of convertible promissory notes, the issuance of convertible preferred stock, as well as issuance and sale of common stock through our initial public offering (IPO). From our inception through December 31, 2021, we have raised aggregate gross proceeds of $9.9 million from the issuance of convertible promissory notes and $81.9 million from the issuance of convertible preferred stock. On April 27, 2021, we completed our IPO in which we issued and sold 7,352,941 shares of common stock at a public offering price of $17.00 per share. On May 11, 2021, we issued an additional 492,070 shares of common stock in connection with the exercise of the underwriters’ option to purchase additional shares at the public offering price. Our net proceeds from the sale of shares in the IPO, including the sale of shares pursuant to the exercise of the underwriters’ option to purchase additional shares, was $121.5 million, net of underwriting discounts and commissions, and other offering fees. As of December 31, 2021, we had cash, cash equivalents and short-term investments of $140.2 million. Although we believe, based on our current business plans, that our existing cash, cash equivalents and short-term investments will be sufficient to meet our obligations for at least the next twelve months, we anticipate that we will require additional capital in the future in order to continue the research and development of our drug candidates. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our product

 

53

 

candidates. We expect to continue to incur significant expenses and increasing operating losses for at least the next several years as we continue our development of, and seek regulatory approvals for, our product candidates and begin to commercialize any approved products, seek to expand our product pipeline, invest in our organization, as well as incur expenses associated with operating as a public company.

We do not expect to generate any revenue from product sales unless and until we successfully complete development and obtain regulatory approval for one or more product candidates, which will not be for many years, if ever. Accordingly, until such time as we can generate significant revenue from sales of our product candidates, if ever, we expect to finance our cash needs through public or private equity offerings, debt financings or other capital sources which may include strategic collaborations, licensing arrangements or other arrangements with third parties. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms or at all. If we raise funds through strategic collaborations or other similar arrangements with third parties, we may have to relinquish valuable rights to our platform technology, future revenue streams, research programs or product candidates or we may have to grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts. Our ability to raise additional funds may be adversely impacted by potential worsening of global economic conditions and disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic or otherwise. Because of the numerous risks and uncertainties associated with our product development, we cannot predict the timing or amount of increased expenses and cannot assure you that we will ever be profitable or generate positive cash flow from operating activities. Based upon our current operating plan, we estimate that our cash, cash equivalents and short-term investments as of December 31, 2021 will be sufficient to fund our pivotal Phase 3 data timelines in LPS, Phase 2 tumor-agnostic basket trial in certain solid tumors, a Phase 2 trial in MCC, and a Phase 1 clinical trial to evaluate the safety, tolerability and efficacy of milademetan in combination with atezolizumab in patients with loss of CDKN2A and wildtype p53 advanced solid tumors, including continuing to advance our pipeline through additional preclinical studies and clinical trials.

We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We currently rely and expect to continue to rely for the foreseeable future, on third parties for the manufacture of our drug candidates for preclinical and clinical testing, as well as for commercial manufacture of any drugs that we may commercialize. We expect to continue to develop drug candidates that can be produced cost-effectively at contract manufacturing facilities. For the milademetan program, we have transferred Daiichi Sankyo Company, Limited (Daiichi Sankyo) processes to suitable contract manufacturing organizations to supply active pharmaceutical ingredients and clinical drug product for our clinical trials and in preparation for submission of marketing applications and potential future commercial supplies.

 

COVID-19

The ongoing COVID-19 pandemic continues to rapidly evolve, and we will continue to monitor the COVID-19 situation closely. The extent of the impact of the COVID-19 pandemic on our business, operations and clinical development timelines and plans remains uncertain, and will depend on certain developments, including the duration and spread of the outbreak and its impact on our clinical trial enrollment, clinical trial sites, contract research organizations (CROs), third-party manufacturers and other third parties with whom we do business, as well as its impact on regulatory authorities and our key scientific and management personnel. Our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic. To the extent possible, we are conducting business as usual, with necessary or advisable modifications, and most of our employees are working remotely. The increased reliance on our personnel working from home has not negatively impacted productivity, or disrupted, delayed or otherwise seriously harmed our business. The collection and integrity of subject data and clinical trial endpoints have not been negatively impacted by the COVID-19 pandemic. We will continue to monitor the evolving situation related to the COVID-19 pandemic and may take further actions that alter our operations, including those that may be required by federal, state or local authorities, including the ability of the FDA and other regulatory authorities to perform routine functions or that we determine are in the best interests of our employees and other third parties with whom we do business. If global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. At this point, the extent to which the COVID-19 pandemic may affect

 

54

 

our business, operations and clinical development timelines and plans, including the resulting impact on our expenditures and capital needs, remains uncertain and is subject to change.

 

Recent Developments

In January 2022, we announced a clinical supply agreement with Roche for the supply of the anti-Programmed Death Ligand-1 (PD-L1) monoclonal antibody, atezolizumab. Clinical trials are planned to evaluate milademetan in combination with atezolizumab for the treatment of patients in genetically selected populations (MANTRA-4). Under this agreement, Rain is the sponsor of the anticipated clinical trials, and Roche will supply atezolizumab.

In November 2021, the first patient was dosed in the multicenter, single arm, open-label, Phase 2 basket trial evaluating Milademetan for the treatment of MDM2-amplified advanced solid (MANTRA-2).

In November 2021, we announced our plan to commence a Phase 2 clinical trial, named MANTRA-3, evaluating the efficacy of milademetan as a monotherapy for the treatment of patients with MCC refractory to immune checkpoint inhibition (ICI) in the second half of 2022.

We hosted an R&D day webinar on November 9, 2021, which featuring several key opinion leaders in oncology, along with members of Rain’s management team, who discussed our R&D program, as well as select clinical and preclinical data.

We, in collaboration with certain research partners, presented non-clinical data on milademetan at the IASLC 2021 World Conference of Lung Cancer hosted by the International Association for the Study of Lung Cancer (Sept. 8-14, 2021) and at the AACR-NCI-EORTC (Triple Cancer Conference) 2021 on Molecular Targets and Cancer Therapeutics virtual conference (Oct. 7-10, 2021), highlighting non-clinical data in MDM2-amplified tumors, MCC, GATA3-mutant ER+ breast cancer, and mesothelioma models. On the strength of recent non-clinical data from Dana-Farber Cancer Institute presented at the Triple Cancer Conference, we are now prioritizing our financial resources towards a Phase 2 clinical trial of milademetan as monotherapy in MCC patients failing first-line checkpoint inhibitors, with a clinical trial commencement expected in the second half of 2022. The Phase 2 clinical trial of milademetan in MCC (MANTRA-3) will replace the previously planned Phase 2 clinical trial of milademetan in intimal sarcoma. We do not expect the new planned MCC trial to have significant net impact on our financial condition, cash flow or results of operations.

In July 2021, we announced that the first patient has been randomized in the multicenter, open-label, Phase 3 registrational trial (MANTRA) evaluating milademetan for the treatment of DD LPS.

In June 2021, we announced a patient referral partnership with Caris Life Sciences (Caris). Under the terms of the partnership, Caris will provide patient referral services using their molecular intelligence trials platform for our Phase 2 MDM2-amplified tumor-agnostic basket trial for milademetan (MANTRA-2).

Also in June 2021, we announced a master program and a genomic analysis platform agreement for comprehensive genomic profiling tests utilizing the genomic analysis platform of Tempus, an artificial intelligence and precision medicine company. Under the terms of the agreement, Tempus will provide both centralized tumor testing and patient matching services using their Connect & TIME Trial® Network for the Phase 2 MDM2-amplified tumor-agnostic basket trial for milademetan (MANTRA-2).

 

Our Development Pipeline

Our development pipeline is unified by a strategy to target oncogenic drivers through differentiated therapies for which we are able to genetically select the patients we believe will be most likely to benefit from treatment. We currently retain global development and commercialization rights to all of our product candidates. See Part 1, Item 1. “Business – Our Development Pipeline”.

 

Collaboration and License Agreements

We are party to a number of license agreements for the in-license of our product candidates and development programs. See Note 9 to the Financial Statements.

 

 

55

 

 

Components of Our Results of Operations

 

Revenue

To date, we have not generated any revenue from product sales, licenses or collaborations and do not expect to generate any revenue from the sale of products in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval, we may generate revenue from future product sales. If we enter into license or collaboration agreements for any of our product candidates or intellectual property, we may generate revenue in the future from payments as a result of such license or collaboration agreements. We cannot predict if, when, or to what extent we will generate revenue from the commercialization and sale of our product candidates or from license or collaboration agreements. We may never succeed in obtaining regulatory approval for any of our product candidates.

 

Operating Expenses

Our operating expenses since inception have consisted solely of research and development costs, including acquisition of in-process research and development, and general and administrative costs.

 

Research and Development Expenses

To date, our research and development expenses have related to the discovery and clinical development of our product candidates, including acquisition of in-process research and development. Research and development expenses are recognized as incurred and payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.

Research and development expenses include:

 

•

salaries, payroll taxes, employee benefits and stock-based compensation charges for those individuals involved in research and development efforts;

 

•

expenses incurred in connection with research, laboratory consumables and preclinical studies;

 

•

external research and development expenses incurred under agreements with CROs and consultants to conduct and support our planned clinical trials of our product candidates;

 

•

the cost of consultants engaged in research and development-related services and the cost to manufacture drug product for use in our preclinical studies and clinical trials;

 

•

costs related to regulatory compliance;

 

•

the cost of annual license fees and the cost of acquiring in-process research and development, including upfront license payments; and

 

•

any development milestone payments that we may make under our license agreements.

We track external development costs by product candidate or development program, but we do not allocate personnel costs or other internal costs to specific development programs or product candidates as our personnel works across multiple development programs and product candidates. These costs are included in unallocated research and development expenses in the table below.

The following table summarizes our research and development expenses by product candidate or development program:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

 

(in thousands)

 

Milademetan

 

$

23,261

 

 

$

6,639

 

Other research and clinical candidates

 

 

1,761

 

 

 

7,286

 

Unallocated internal research and development costs

 

 

15,751

 

 

 

1,442

 

Total research and development expenses

 

$

40,773

 

 

$

15,367

 

 

We plan to substantially increase our research and development expenses for the foreseeable future as we continue to expand the development of our product candidates. The clinical development timeline, probability

 

56

 

of success of clinical trials and development costs can differ materially from expectations. In addition, we cannot forecast which product candidates may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements.

Our future clinical development costs may vary significantly. See the section titled “Risk Factors—Risks Related to Product Development— Preclinical and clinical development involves a lengthy and expensive process with uncertain outcomes, and results of earlier studies and trials may not be predictive of future clinical trial results. If our preclinical studies and clinical trials are not sufficient to support regulatory approval of any of our product candidates, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development of such product candidates”.

 

General and Administrative Expenses

General and administrative expenses consist of salaries and employee-related costs, including stock-based compensation, for personnel in executive, finance and other administrative functions, legal fees relating to intellectual property and corporate matters, professional fees for accounting and consulting services and facility-related costs. We anticipate that our general and administrative expenses will continue to increase in the future to support our continued research and development activities, pre-commercial preparation activities for our product candidates and, if any product candidate receives marketing approval, commercialization activities. We also anticipate increased expenses related to audit, legal, regulatory and tax-related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums and investor relations costs associated with operating as a public company.

 

Interest Income

Interest income consists of interest on our available-for-sale (AFS) securities.

 

Interest Expense

We did not have interest expense for the year ended December 31, 2021. Interest expense for year ended December 31, 2020 consisted of interest on the outstanding convertible promissory notes.

 

Change in Fair Value of Convertible Promissory Notes

We issued convertible promissory notes in October 2019 (the 2019 Notes) and June 2020 (the 2020 Notes) for which we had elected the fair value option. We adjusted the carrying value of our convertible promissory notes to their estimated fair value at each reporting date, with any change in fair value of the convertible promissory notes recorded as an increase or decrease to change in fair value of convertible promissory notes in our statements of operations and comprehensive loss.

The fair value of the 2019 Notes and the 2020 Notes were estimated using a scenario-based analysis that estimated the fair value of the convertible promissory notes based on the probability-weighted present value of expected future investment returns, considering possible outcomes available to the noteholders, including conversions in subsequent equity financings, settlement and dissolution.

On September 2, 2020, upon consummation of our Series B convertible preferred stock financing, the principal balance plus accrued interest earned on the 2019 Notes and the 2020 Notes automatically converted into 1,905,688 shares of Series B convertible preferred stock. Upon conversion, we no longer are required to adjust the carrying value of the convertible promissory notes at each reporting date.

 

Income Taxes

We are subject to corporate U.S. federal and state income taxation. As of December 31, 2021, we had federal and state net operating loss carryforwards of approximately $69.2 million and $27.8 million respectively. $0.2 million of the $69.2 million of federal net operating loss carryforwards will begin expiring in 2037 and the remaining $69.0 million can be carried forward indefinitely. The yearly utilization of such federal net operating loss carryforwards is limited to 80 percent of taxable income. On March 27, 2020, Congress enacted the Coronavirus Aid, Relief and Economic Security Act (the CARES Act), which may provide some relief from such limitations. The state tax loss carryforwards will begin expiring in 2031, if not utilized. As of December 31, 2021, we had federal

 

57

 

and state research and development tax credits of approximately $3.1 million and $0.9 million, respectively. If not utilized, the federal research tax credit will begin to expire in 2039. The California research tax credit can be carried forward indefinitely.

Utilization of the net operating loss carryforwards and other tax attributes may be subject to a substantial annual limitation due to the ownership change limitations provided by Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the Code), and similar state provisions. Specifically, under Sections 382 and 383 of the Code, if a corporation undergoes an “ownership change” (generally defined as a greater than 50% change (by value) in its equity ownership by 5% stockholders over a three-year period), our ability to use such pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-change taxable income may be limited. As a result of our most recent private placements and other transactions that have occurred over the past three years, we may have experienced, and, upon the closing of this offering, may experience, an “ownership change.” We may also experience ownership changes in the future as a result of subsequent shifts in our stock ownership.

We estimate our income tax provision, including deferred tax assets and liabilities, based on management’s judgment. We record a valuation allowance to reduce our deferred tax assets to the amounts that are more likely than not to be realized. We consider future taxable income, ongoing tax planning strategies and our historical financial performance in assessing the need for a valuation allowance. If we expect to realize deferred tax assets for which we have previously recorded a valuation allowance, we will reduce the valuation allowance in the period in which such determination is first made.

We record liabilities related to uncertain tax positions in accordance with the guidance that clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.

 

Results of Operations

 

Comparison of Years Ended December 31, 2021 and 2020

The following table summarizes our results of operations for the years ended December 31, 2021 and 2020, together with the changes in those items in dollars:

 

 

 

Year Ended December 31,

 

 

 

 

 

 

 

2021

 

 

2020

 

 

Change

 

 

 

(in thousands)

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

40,773

 

 

$

15,367

 

 

$

25,406

 

General and administrative

 

 

10,739

 

 

 

3,591

 

 

 

7,148

 

Total operating expenses

 

 

51,512

 

 

 

18,958

 

 

 

32,554

 

Loss from operations

 

 

(51,512

)

 

 

(18,958

)

 

 

(32,554

)

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

119

 

 

 

32

 

 

 

87

 

Interest expense, related party

 

 

—

 

 

 

(135

)

 

 

135

 

Change in fair value of convertible promissory notes, related party

 

 

—

 

 

 

(2,024

)

 

 

2,024

 

Other income

 

 

1

 

 

 

2

 

 

 

(1

)

Total other income (expense), net

 

 

120

 

 

 

(2,125

)

 

 

2,245

 

Net loss before income tax expense

 

$

(51,392

)

 

$

(21,083

)

 

$

30,309

 

 

Research and Development Expenses

Research and development (R&D) expenses were $40.8 million and $15.4 million for the years ended December 31, 2021 and 2020, respectively. The increase in R&D expenses was primarily related to milademetan and other research costs, including the milestone fees payable to Daiichi Sankyo of $5.5 million. Non-cash stock-based compensation expenses, included as part of personnel costs, were $2.5 million and $0.6 million for the years ended December 31, 2021 and 2020, respectively. We expect our R&D costs to continue to increase in 2022 as we continue our Phase 3 trial in LPS and our Phase 2 tumor-agnostic basket trial for milademetan.

 

58

 

 

General and Administrative Expenses

General and administrative (G&A) expenses were $10.7 million and $3.6 million for the years ended December 31, 2021 and 2020, respectively. The increase in G&A expenses was primarily due to director and officer insurance of $2.4 million, payroll-related costs of $2.3 million and various third-party G&A costs of $2.4 million. Non-cash stock-based compensation expense included in G&A expenses was $0.6 million and $0.3 million for the years ended December 31, 2021 and 2020, respectively. We have incurred and expect to continue incur additional expenses as a result of being a public company following the completion of our IPO in April 2021, including costs associated with maintaining compliance with exchange listing and SEC requirements as a public company. In addition, we expect our general and administrative expenses to continue to increase in 2022 as we continue to add personnel and build out systems and infrastructure to support our operations as a public company.

 

Other (Income) Expense

Other (income) expense, net with nominal amounts for the years ended December 31, 2021 and 2020 represents interest income, interest expense on the outstanding convertible promissory notes and change in the fair value of our convertible promissory notes recorded in 2020.

 

Liquidity and Capital Resources

Since our inception, we have incurred significant operating losses. We expect to continue to incur significant expenses and operating losses for the foreseeable future as we advance the preclinical and clinical development of our research programs and product candidates. We expect that our research and development and general and administrative costs will increase in connection with conducting additional preclinical studies and clinical trials, expanding our intellectual property portfolio and providing general and administrative support for our operations. As a result, we will need additional capital to fund our operations, which we may obtain from additional equity or debt financings, collaborations, licensing arrangements or other sources.

We do not currently have any approved products and have not generated any revenue from product sales since inception. To date, we have financed our operations through the issuance of convertible promissory notes and the issuance of convertible preferred stock and common stock. From our inception through December 31, 2021, we have raised aggregate gross proceeds of $9.9 million from the issuance of convertible promissory notes and $81.9 million from the issuance of convertible preferred stock. On April 27, 2021, we completed our IPO in which we issued and sold 7,352,941 shares of common stock at a public offering price of $17.00 per share. On May 11, 2021, we issued an additional 492,070 shares of common stock in connection with the exercise of the underwriters’ option to purchase additional shares at the public offering price. Our net proceeds from the sale of shares in the IPO, including the sale of shares pursuant to the exercise of the underwriters’ option to purchase additional shares, was $121.5 million, net of underwriting discounts and commissions, and other offering fees. As of December 31, 2021, we had cash, cash equivalents and short-term investments of $140.2 million. Although we believe, based on our current business plans, that our existing cash, cash equivalents and short-term investments will be sufficient to meet our obligations for at least the next twelve months, we anticipate that we will require additional capital in the future in order to continue the research and development of our drug candidates. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect.

 

Future Funding Requirements

We expect our expenses to increase substantially in connection with our ongoing development activities related to milademetan and other product candidates and programs, which are still in the early stages of development. In addition, following the IPO, we expect to incur additional costs associated with operating as a public company. We expect that our expenses will increase substantially if and as we:

 

•

continue our on-going clinical trials, initiate new clinical trials for our milademetan program and incur additional preclinical research costs for our RAD52 program;

 

•

initiate and continue research and preclinical and clinical development of our product candidates;

 

•

seek to identify and develop additional product candidates;

 

59

 

 

 

•

seek marketing approvals for any of our product candidates that successfully complete clinical trials, if any;

 

•

establish a sales, marketing, manufacturing and distribution infrastructure to commercialize any products for which we may obtain marketing approval;

 

•

require the manufacture of larger quantities of our product candidates for clinical development and potentially commercialization;

 

•

maintain, expand, protect and enforce our intellectual property portfolio;

 

•

acquire or in-license other drugs and technologies;

 

•

defend against any claims of infringement, misappropriation or other violation of third-party intellectual property;

 

•

hire and retain additional clinical, quality control and scientific personnel;

 

•

build out new facilities or expand existing facilities to support our ongoing development activity;

 

•

add operational, financial and management information systems and personnel, including personnel to support our drug development, any future commercialization efforts and our transition to a public company;

 

•

potentially experience the effects of the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide from the ongoing COVID-19 pandemic; and

 

•

operate as a public company.

Because of the numerous risks and uncertainties associated with the development of milademetan and other product candidates and programs and because the extent to which we may enter into collaborations with third parties for development of our product candidates is unknown, we are unable to estimate the timing and amounts of increased capital outlays and operating expenses associated with completing the research and development of our product candidates and programs. Our future capital requirements will depend on many factors, including:

 

•

the scope, progress, results and costs of our current and future clinical trials of milademetan for our current targeted indications;

 

•

the scope, progress, results and costs of drug discovery, preclinical research and clinical trials for RAD52 and other product candidates;

 

•

the number of future product candidates that we pursue and their development requirements;

 

•

the costs, timing and outcome of regulatory review of our product candidates;

 

•

the extent to which we acquire or invest in businesses, products and technologies, including entering into or maintaining licensing or collaboration arrangements for product candidates on favorable terms, although we currently have no commitments or agreements to complete any such transactions;

 

•

the costs of preparing, filing and prosecuting patent applications, maintaining, protecting and enforcing our intellectual property rights and defending intellectual property-related claims;

 

•

our headcount growth and associated costs as we expand our business operations and our research and development activities;

 

•

our ability to successfully acquire or in-license other drugs and technologies;

 

•

the costs and timing of future commercialization activities, including drug sales, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval, to the extent that such sales, marketing, manufacturing and distribution are not the responsibility of any collaborator that we may have at such time;

 

•

the amount of revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval; and

 

•

the costs of operating as a public company.

Developing drug products, including conducting preclinical studies and clinical trials, is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or

 

60

 

results required to obtain marketing approval for any product candidates or generate revenue from the sale of any products for which we may obtain marketing approval. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of drugs that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to obtain substantial additional funds to achieve our business objectives.

Until such time, if ever, as we can generate product revenues to support our cost structure, we expect to finance our cash needs through public or private equity offerings, debt financings or other capital sources which may include strategic collaborations, licensing arrangements or other arrangements with third parties. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through strategic collaborations or other similar arrangements with third parties, we may have to relinquish valuable rights to our technology, future revenue streams, research programs or product candidates or may have to grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic or otherwise. Because of the numerous risks and uncertainties associated with product development, we cannot predict the timing or amount of increased expenses and cannot assure you that we will ever be profitable or generate positive cash flow from operating activities.

 

Cash Flows

The following table summarizes our sources and uses of cash for the years ended December 31, 2021 and 2020:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

 

(in thousands)

 

Net cash provided by (used in):

 

 

 

 

 

 

 

 

Operating activities

 

$

(37,463

)

 

$

(11,231

)

Investing activities

 

 

(118,235

)

 

 

(5,191

)

Financing activities

 

 

121,615

 

 

 

69,491

 

Net (decrease) increase in cash and cash equivalents

 

$

(34,083

)

 

$

53,069

 

 

Operating Activities

We have incurred losses since inception. Net cash used in operating activities for the year ended December 31, 2021 was $37.5 million, consisting primarily of net loss of $51.4 million resulting from expenses associated with research and development activities for our lead product candidate and general and administrative expenses, partially offset by a net decrease in changes in operating assets and liabilities of $5.2 million and non-cash adjustments of $8.7 million.

Net cash used in operating activities for the year ended December 31, 2020 was $11.2 million, consisting primarily of net loss of $21.1 million offset by a net decrease from changes in operating assets and liabilities of $1.6 million and non-cash adjustments of $8.2 million.

 

Investing Activities

Net cash used in investing activities for the year ended December 31, 2021 was $118.2 million, which was primarily related to purchases of available for sale securities of $163.6 million, and payment of $2.5 million to Daiichi Sankyo for in-process research and development expense, partially offset by maturities of available for sale securities of $48.0 million.

 

61

 

Net cash used in investing activities for the year ended December 31, 2020 was $5.2 million, which was primarily for payment to Daiichi Sankyo for in-process research and development expense.

 

Financing Activities

Net cash provided by financing activities for the year ended December 31, 2021 was $121.6 million, which primarily relates to the net proceeds from IPO, after deducting underwriting discounts and commissions, and other offering fees.

Net cash provided by financing activities in the year ended December 31, 2020 was $69.5 million primarily relates to proceeds of $6.4 million from issuance of convertible promissory notes and proceeds of $63.2 million from issuance of convertible preferred stock, net of issuance costs.

 

Obligations and other Commitments

As discussed in Note 9 to the financial statements appearing elsewhere in this Annual Report on Form 10-K, we are party to agreements to license intellectual property. The license agreements may require us to pay future milestones if certain developmental, regulatory and commercial milestones are achieved, as well as to pay royalties on net sales of products applicable to the license agreements. We cannot estimate if milestone and/or royalty payments will occur in future periods and the agreements are cancelable by us at any time upon prior written notice to the licensor.

In the normal course of business, we enter into contracts with CROs and other vendors for preclinical studies and clinical trials, research and development supplies and other testing and manufacturing services. These contracts generally do not contain minimum purchase commitments and are cancelable by either party at any time upon prior written notice.

Our incurred and accrued research and development obligations as of December 31, 2021 and 2020 were $4.3 million and $1.5 million, respectively.

We pay the office operating lease obligation at the beginning of each month. Under our office operating leases as noted in Note 10 to the financial statements appearing elsewhere in this Annual Report on Form 10-K, our obligation as of December 31, 2021 and 2020 were $0.4 million and $0.5 million, respectively.

 

Critical Accounting Estimates

The discussion and analysis of our financial condition and results of operations is based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates and base our estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions and could have a material impact on our reported results. While our significant accounting policies are more fully described in the notes to our financial statements included elsewhere in this Report, we believe the following accounting policies to be the most critical in understanding the judgments and estimates we use in preparing our financial statements.

 

Accrued Liabilities

We are required to estimate our expenses resulting from our obligations under contracts with vendors, consultants, CROs and clinical site agreements in connection with conducting preclinical activities and clinical trials. The financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. However, some payments are made in arrears and expenditures are accrued for the time periods which services are performed on a pre-determined schedule or when contractual milestones are met. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones.

This process involves reviewing open contracts and purchase orders, communicating with our applicable personnel to identify services that have been performed on our behalf and estimating the level of service

 

62

 

performed and the associated cost incurred when we have not yet been invoiced or otherwise notified of actual costs. During the course of a preclinical study or clinical trial, we adjust our prepaid and expense recognition if actual results differ from our estimates. To date, we have not experienced any material differences between accrued costs and actual costs incurred. The accrued research and development balances were $4.3 million and $1.5 million as of December 31, 2021 and 2020, respectively. The other accrued liabilities balances were $5.7 million and $0.9 million as of December 31, 2021 and 2020, respectively.

 

Stock-Based Compensation

We follow the provision of the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 718, “Compensation – Stock Compensation” (ASC 718), which requires the measurement and recognition of compensation expense for all stock-based payment awards. We determine the fair value of restricted stock units based on the fair value of our common stock on the date of grant.

We estimate the fair value of our stock options using the Black-Scholes option pricing model, which requires us to develop subjective estimates to be used in calculating the fair value of stock options. The use of the model requires us to make estimates of subjective assumptions, such as expected stock price volatility and the estimated expected term of each award.

Stock-based compensation expense based on the fair value estimated is recognized over the requisite service period of the awards (generally the vesting period) on a straight-line basis. Prior to the IPO, the estimated fair value of the underlying common stock as determined on the date of grant by our Board of Directors. For the year ended December 31, 2021 and 2020, stock-based compensation expense was $3.1 million and $0.9 million, respectively. The following table summarizes unvested equity compensation costs not yet recognized as of the years ended December 31, 2021 and 2020.

 

 

 

As of December 31,

 

 

 

2021

 

 

2020

 

Unvested equity compensation costs not yet recognized

   (in millions)

 

$

9.8

 

 

$

1.4

 

Weighted average period over which the unvested awards are expected to be recognized (in years)

 

 

3.1

 

 

 

2.3

 

 

Recent Accounting Pronouncements

A description of recent accounting pronouncements that may potentially impact our financial position, results of operations or cash flows is disclosed in Note 2 to our audited financial statements for the year ended December 31, 2021, included elsewhere in this Annual Report on Form 10-K.

 

Item 7A. Quantitative and Qualitative Disclosures About Market Risk.

We are a smaller reporting company, as defined by Rule 12b-2 under the Securities and Exchange Act of 1934 and in Item 10(f)(1) of Regulation S-K, and are not required to provide the information under this item.

 

63

 

Item 8. Financial Statements and Supplementary Data.

 

Index to Financial Statements

 

 

 

64

 

 

Report of Independent Registered Public Accounting Firm

To the Stockholders and the Board of Directors of Rain Therapeutics Inc.

Opinion on the Financial Statements

We have audited the accompanying balance sheets of Rain Therapeutics Inc. (the Company) as of December 31, 2021 and 2020, the related statements of operations and comprehensive loss, convertible preferred stock and stockholders’ equity (deficit) and cash flows for the years then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

/s/ Ernst & Young LLP

We have served as the Company’s auditor since 2019.

San Diego, California

March 3, 2022

 

 

65

 

 

Rain Therapeutics Inc.

Balance Sheets

(In thousands, except share and per share data)

 

 

 

December 31,

 

 

 

2021

 

 

2020

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

24,780

 

 

$

58,863

 

Short-term investments

 

 

115,438

 

 

 

—

 

Prepaid and other current assets

 

 

5,928

 

 

 

662

 

Total current assets

 

 

146,146

 

 

 

59,525

 

Property and equipment, net

 

 

165

 

 

 

99

 

Operating lease right-of-use asset

 

 

386

 

 

 

447

 

Deferred offering costs

 

 

—

 

 

 

385

 

Other assets

 

 

443

 

 

 

624

 

Total assets

 

$

147,140

 

 

$

61,080

 

Liabilities, convertible preferred stock, and stockholders’ equity

   (deficit)

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

6,112

 

 

$

816

 

Accrued research and development

 

 

4,349

 

 

 

1,527

 

Other accrued liabilities

 

 

5,694

 

 

 

935

 

Operating lease liability, current portion

 

 

160

 

 

 

141

 

Total current liabilities

 

 

16,315

 

 

 

3,419

 

Operating lease liability, net of current portion

 

 

252

 

 

 

312

 

Other long-term liabilities

 

 

69

 

 

 

69

 

Total liabilities

 

 

16,636

 

 

 

3,800

 

Commitments and contingencies

 

 

 

 

 

 

 

 

Series A convertible preferred stock, $0.001 par value; no shares

   and 3,731,208 shares authorized, issued and outstanding as

   of December 31, 2021 and December 31, 2020, respectively

 

 

—

 

 

 

20,147

 

Series B convertible preferred stock, $0.001 par value; no shares

   and 12,542,198 shares authorized, issued and outstanding as

   of December 31, 2021 and December 31, 2020, respectively

 

 

—

 

 

 

74,550

 

Total convertible preferred stock

 

 

—

 

 

 

94,697

 

Stockholders’ equity (deficit):

 

 

 

 

 

 

 

 

Common Stock, $0.001 par value; 250,000,000 and 24,000,000

   shares authorized as of December 31, 2021 and December

   31, 2020, respectively; 26,475,812 shares (comprised of

   18,748,342 shares of common stock and 7,727,470

   shares of non-voting common stock) and 3,530,975 shares

   issued and outstanding as of December 31, 2021 and

   December 31, 2020, respectively

 

 

27

 

 

 

4

 

Additional paid-in capital

 

 

220,530

 

 

 

1,149

 

Accumulated other comprehensive loss

 

 

(89

)

 

 

—

 

Accumulated deficit

 

 

(89,964

)

 

 

(38,570

)

Total stockholders' equity (deficit)

 

 

130,504

 

 

 

(37,417

)

Total liabilities, convertible preferred stock, and stockholders’ equity (deficit)

 

$

147,140

 

 

$

61,080

 

The accompanying notes are an integral part of these financial statements.

 

66

 

Rain Therapeutics Inc.

Statements of Operations and Comprehensive Loss

(In thousands, except share and per share data)

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Operating expenses:

 

 

 

 

 

 

 

 

Research and development

 

$

40,773

 

 

$

15,367

 

General and administrative

 

 

10,739

 

 

 

3,591

 

Total operating expenses

 

 

51,512

 

 

 

18,958

 

Loss from operations

 

 

(51,512

)

 

 

(18,958

)

Other income (expense):

 

 

 

 

 

 

 

 

Interest income

 

 

119

 

 

 

32

 

Interest expense, related party

 

 

—

 

 

 

(135

)

Change in fair value of convertible promissory notes, related party

 

 

—

 

 

 

(2,024

)

Other income

 

 

1

 

 

 

2

 

Total other income (expense), net

 

 

120

 

 

 

(2,125

)

Net loss before income tax expense

 

 

(51,392

)

 

 

(21,083

)

Income tax expense

 

 

(2

)

 

 

—

 

Net loss

 

$

(51,394

)

 

$

(21,083

)

Net loss per share, basic and diluted

 

$

(2.65

)

 

$

(6.29

)

Weighted-average shares used to compute net loss per share, basic

   and diluted

 

 

19,405,833

 

 

 

3,351,850

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(51,394

)

 

$

(21,083

)

Other comprehensive income:

 

 

 

 

 

 

 

 

Unrealized loss on investments

 

 

(89

)

 

 

—

 

Comprehensive loss

 

$

(51,483

)

 

$

(21,083

)

 

The accompanying notes are an integral part of these financial statements.

 

 

 

67

 

 

Rain Therapeutics Inc.

Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit)

(In thousands, except share amounts)

 

 

 

Series A

 

 

Series B

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Convertible Preferred

Stock

 

 

Convertible Preferred

Stock

 

 

 

Common Stock

 

 

Additional

Paid-in

 

 

Accumulated

 

 

Accumulated

Other

Comprehensive

 

 

Total

Stockholders’

 

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Deficit

 

 

Loss

 

 

Equity (Deficit)

 

Balance as of December 31, 2019

 

 

3,731,208

 

 

$

20,147

 

 

 

—

 

 

$

—

 

 

 

 

2,986,385

 

 

$

3

 

 

$

236

 

 

$

(17,487

)

 

$

—

 

 

$

(17,248

)

Issuance of Series B convertible

   preferred stock, net of issuance

   costs of $327

 

 

—

 

 

 

—

 

 

 

10,636,510

 

 

 

63,173

 

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Conversion of convertible

   promissory notes into Series

   B convertible preferred stock

 

 

—

 

 

 

—

 

 

 

1,905,688

 

 

 

11,377

 

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Vesting of restricted shares

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

532,455

 

 

 

1

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

1

 

Exercise of stock options

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

 

12,135

 

 

 

—

 

 

 

48

 

 

 

—

 

 

 

—

 

 

 

48

 

Stock-based compensation

   expense

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

865

 

 

 

—

 

 

 

—

 

 

 

865

 

Net loss

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(21,083

)

 

 

—

 

 

 

(21,083

)

Balance as of December 31, 2020

 

 

3,731,208

 

 

$

20,147

 

 

 

12,542,198

 

 

$

74,550

 

 

 

 

3,530,975

 

 

$

4

 

 

$

1,149

 

 

$

(38,570

)

 

$

—

 

 

$

(37,417

)

Conversion of convertible preferred

   stock to common stock

 

 

(3,731,208

)

 

 

(20,147

)

 

 

(12,542,198

)

 

 

(74,550

)

 

 

 

15,069,330

 

 

 

15

 

 

 

94,682

 

 

 

—

 

 

 

—

 

 

 

94,697

 

Issuance of common stock upon

   IPO, net of issuance cost

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

 

7,845,011

 

 

 

8

 

 

 

121,486

 

 

 

—

 

 

 

—

 

 

 

121,494

 

Exercise of stock options

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

 

30,496

 

 

 

—

 

 

 

121

 

 

 

—

 

 

 

—

 

 

 

121

 

Stock-based compensation

   expense

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

3,092

 

 

 

—

 

 

 

—

 

 

 

3,092

 

Unrealized loss on investments

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(89

)

 

 

(89

)

Net loss

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(51,394

)

 

 

—

 

 

 

(51,394

)

Balance as of December 31, 2021

 

 

—

 

 

 

—

 

 

 

—

 

 

$

—

 

 

 

 

26,475,812

 

 

$

27

 

 

$

220,530

 

 

$

(89,964

)

 

$

(89

)

 

$

130,504

 

 

The accompanying notes are an integral part of these financial statements.

 

 

 

68

 

 

Rain Therapeutics Inc.

Statements of Cash Flows

(In thousands)

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Operating activities

 

 

 

 

 

 

 

 

Net loss

 

$

(51,394

)

 

$

(21,083

)

Adjustments to reconcile net loss to cash used in operating activities:

 

 

 

 

 

 

 

 

In-process research and development expense

 

 

5,500

 

 

 

5,167

 

Depreciation and amortization expense

 

 

71

 

 

 

52

 

Stock-based compensation expense

 

 

3,092

 

 

 

865

 

Non-cash interest expense, related party

 

 

—

 

 

 

135

 

Change in fair value of convertible promissory notes, related party

 

 

—

 

 

 

2,024

 

Amortization of premium and accretion of discounts on short-term investments, net

 

 

81

 

 

 

—

 

Fair value loss/(gain) on investments

 

 

(1

)

 

 

—

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Prepaid and other current assets

 

 

(5,266

)

 

 

(182

)

Operating lease right-of-use asset and liability, net

 

 

19

 

 

 

10

 

Other assets

 

 

181

 

 

 

(195

)

Accounts payable

 

 

5,288

 

 

 

555

 

Accrued research and development

 

 

2,822

 

 

 

1,417

 

Other accrued liabilities

 

 

2,144

 

 

 

—

 

Other long-term liabilities

 

 

—

 

 

 

4

 

Net cash used in operating activities

 

 

(37,463

)

 

 

(11,231

)

 

 

 

 

 

 

 

 

 

Investing activities

 

 

 

 

 

 

 

 

Purchases of short-term investments

 

 

(163,557

)

 

 

—

 

Purchases of property and equipment

 

 

(128

)

 

 

(24

)

Payment of in-process research and development expense

 

 

(2,500

)

 

 

(5,167

)

Maturities of available for sale investments

 

 

47,950

 

 

 

—

 

Net cash used in investing activities

 

 

(118,235

)

 

 

(5,191

)

 

 

 

 

 

 

 

 

 

Financing Activities

 

 

 

 

 

 

 

 

Proceeds from initial public offering

 

 

133,366

 

 

 

—

 

Proceeds from stock option exercises

 

 

121

 

 

 

48

 

Issuance of common stock for vesting of restricted shares

 

 

—

 

 

 

1

 

Proceeds from issuance of convertible preferred stock, net of

   issuance costs

 

 

—

 

 

 

63,173

 

Proceeds from issuance of convertible promissory notes

 

 

—

 

 

 

6,435

 

Payments of issuance costs related to the initial public offering

 

 

(11,872

)

 

 

(166

)

Net cash provided by financing activities

 

 

121,615

 

 

 

69,491

 

Net (decrease) increase in cash and cash equivalents

 

 

(34,083

)

 

 

53,069

 

Cash and cash equivalents at beginning of period

 

 

58,863

 

 

 

5,794

 

Cash and cash equivalents at end of period

 

$

24,780

 

 

$

58,863

 

 

 

 

 

 

 

 

 

 

Supplemental schedule of non-cash investing and financing

   activities:

 

 

 

 

 

 

 

 

Conversion of convertible preferred stock to common stock

 

$

94,697

 

 

$

—

 

Non-cash in-process research and development accrual

 

$

3,000

 

 

$

—

 

Non-cash additions to property and equipment

 

$

9

 

 

$

—

 

Conversion of convertible promissory notes and interest into

   Series B convertible preferred stock

 

$

—

 

 

$

11,377

 

Accruals for unbilled professional fees related to the IPO

 

$

—

 

 

$

219

 

 

The accompanying notes are an integral part of these financial statements.

 

69

 

Rain Therapeutics Inc.

Notes to Financial Statements

 

Note 1 – Organization and Nature of Operations

Description of Business

Rain Therapeutics Inc. (“Rain” or the “Company”) was incorporated in the state of Delaware in April 2017. Rain is a late-stage precision oncology company developing therapies that target oncogenic drivers for which the Company is able to genetically select patients most likely to benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of mouse double minute 2, which may be oncogenic in numerous cancers. In addition to milademetan, the Company is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52. The Company operates in one business segment and its principal operations are in the United States, with its headquarters in Newark, California.

Reverse Stock Split

On April 15, 2021 and April 16, 2021, the Company’s board of directors (the “Board of Directors”) and stockholders, respectively, approved an amended and restated certificate of incorporation of the Company to effect a 1-for-1.0799 reverse stock split of the Company’s common stock. The reverse stock split was effected on April 16, 2021. The Company’s outstanding stock options were also adjusted to reflect the 1-for-1.0799 reverse stock split of the Company’s common stock. Accordingly, all common stock and stock options and related per share amounts in these financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock split. Outstanding stock options were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased. The reverse stock split resulted in an adjustment to the Series A and Series B convertible preferred stock conversion prices to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion.

Initial Public Offering

On April 27, 2021, the Company completed its initial public offering (“IPO”) in which the Company issued and sold 7,352,941 shares of common stock at a public offering price of $17.00 per share. On May 11, 2021, the Company issued an additional 492,070 shares of common stock in connection with the exercise of the underwriters’ option to purchase additional shares at the public offering price. The Company’s net proceeds from the sale of shares in the IPO, including the sale of shares pursuant to the exercise of the underwriters’ option to purchase additional shares, was $121.5 million, net of underwriting discounts and commissions, and other offering fees.

Immediately prior to the closing of the IPO, 8,344,905 shares of the Company’s convertible preferred stock were exchanged for 7,727,470 shares of non-voting common stock. Upon the closing of the IPO, 7,928,501 shares of the Company’s convertible preferred stock were automatically converted into 7,341,860 shares of common stock. Following the IPO, there were no shares of convertible preferred stock outstanding.

Basis of Presentation

The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) promulgated by the Financial Accounting Standards Board (“FASB”).

Liquidity and Capital Resources

The Company has devoted substantially all of its efforts to drug discovery and development, raising capital and building operations. The Company has a limited operating history and has not generated any revenue since its inception, and the sales and income potential of the Company’s business is unproven. The Company has incurred net losses and negative cash flows from operating activities since its inception and expects to continue to incur net losses into the foreseeable future as it continues the development of its product candidates. From

 

70

 

inception through December 31, 2021, the Company has funded its operations through net proceeds from its IPO in April 2021, and the issuance of convertible promissory notes and convertible preferred stock.

The accompanying financial statements have been prepared assuming the Company will continue as a going concern. Management believes that the Company’s current cash, cash equivalents and short-term investments will provide sufficient funds to enable the Company to meet its obligations for at least twelve months from the filing date of this report.

Note 2 – Summary of Significant Accounting Policies

Use of Estimates

The preparation of the Company’s financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent liabilities in the Company’s financial statements and accompanying notes. The most significant estimate in the Company’s financial statements relates to the clinical trial expense accruals. Management evaluates its estimates on an ongoing basis. Although these estimates are based on the Company’s historical experience, knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents include commercial paper, readily available money market and checking accounts.

Available-for-Sale Investments

The Company holds investment grade securities consisting of money market funds, commercial paper, corporate debt securities, U.S. government securities and U.S. agency bonds, classified as available-for-sale (“AFS”) securities at the time of purchase, since it is the Company’s intent that these investments be available for current operations. The Company has classified all of its AFS securities as current assets on the balance sheets even though the stated maturity date may be one year or more beyond the current balance sheet date, which reflects management’s intention to use the proceeds from sales of these securities to fund its operations, as necessary.

The Company carries these securities at fair value and reports unrealized gains and losses, if any, as a separate component of accumulated other comprehensive loss. The cost of debt securities is adjusted for amortization of purchase premiums and accretion of discounts to maturity. Such amortization and accretion are included in interest income in the statements of operations and comprehensive loss. Realized gains and losses on sales of securities are determined using the specific identification method and recorded in other income (expense), net in the statement of operations and comprehensive loss.

Investments are considered to be impaired when a decline in fair value is judged to be other-than-temporary. The Company consults with its investment managers and considers available quantitative and qualitative evidence in evaluating potential impairment of its investments on a quarterly basis. If the cost of an individual investment exceeds its fair value, the Company evaluates among other factors, general market conditions, the duration and extent to which the fair value is less than cost, and the Company’s intent and ability to hold the investment. Once an impairment is determined to be other-than-temporary, an impairment charge is recorded and a new cost basis in the investment is established. Declines in the value of AFS securities determined to be other than temporary are included in other income (expense), net.

Fair Value Option

 

As permitted under ASC 825, Financial Instruments (“ASC 825”), the Company has elected the fair value option to account for the convertible promissory notes issued in 2019 (the “2019 Notes”) and 2020 (the “2020 Notes”). In accordance with ASC 825, the Company records these convertible promissory notes at fair value and records changes in fair value as a line item within other income (expense) in the accompanying statements

 

71

 

of operations and comprehensive loss. As a result of applying the fair value option, direct costs and fees related to the 2019 Notes and 2020 Notes were recognized in net loss as incurred and not deferred.

Fair Value of Financial Instruments

 

The carrying amounts of all cash equivalents, prepaid expenses and other assets, accounts payable and accrued and other current liabilities are reasonable estimates of their fair value because of the short-term nature of these items.

Concentration of Credit Risk

 

Financial instruments, which potentially subject the Company to significant concentration of credit risk, consist primarily of cash, cash equivalents and short-term investments. The Company maintains cash and money market deposits in a federally insured major financial institution in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institution in which those deposits are held.

Deferred Offering Costs

The Company capitalized offering costs consisting of all direct and incremental legal, professional, accounting and other third-party fees incurred in connection with the Company’s IPO. Upon the completion of the IPO in April 2021, the total deferred offering costs of $2.5 million were reclassified to additional paid-in capital on the balance sheets.

Research and Development Costs

Research and development costs primarily consist of costs associated with the Company’s research and development activities, including its drug discovery efforts, and the preclinical and clinical development of its product candidates. Research and development costs are expensed as incurred.

Property and Equipment

Property and equipment, net consists of computer equipment, furniture and equipment and leasehold improvements. Leasehold improvements are amortized over the remainder of the lease term. Computer equipment and furniture and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally two to three years). Repairs and maintenance costs are charged to expense as incurred.

Long-Lived Assets

The Company regularly reviews the carrying value and estimated lives of all of its long-lived assets, including property and equipment, to determine whether indicators of impairment may exist which warrant adjustments to carrying values or estimated useful lives. Should an impairment exist, the impairment loss would be measured based on the excess over the carrying amount of the asset’s fair value. The Company has not recognized any impairment losses from inception through December 31, 2021.

Commitments

The Company recognizes a liability with regard to loss contingencies when it believes it is probable that a liability has occurred, and the amount can be reasonably estimated. If some amount within a range of loss appears at the time to be a better estimate than any other amount within the range, the Company accrues that amount. When no amount within the range is a better estimate than any other amount, the Company accrues the minimum amount in the range. The Company has not recorded any such liabilities as of December 31, 2021.

Leases

At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company records the associated lease liability and corresponding right-of-use asset upon commencement of the lease using the implicit rate or a discount rate based on a credit- adjusted secured borrowing rate commensurate

 

72

 

with the term of the lease. The Company additionally evaluates leases at their inception to determine if they are to be accounted for as an operating lease or a finance lease. Operating lease assets represent a right to use an underlying asset for the lease term and operating lease liabilities represent an obligation to make lease payments arising from the lease. Operating lease liabilities with a term greater than one year and their corresponding right-of-use assets are recognized on the balance sheet at the commencement date of the lease based on the present value of lease payments over the expected lease term. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. As the Company’s leases do not typically provide an implicit rate, the Company utilizes the appropriate incremental borrowing rate, determined as the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and in a similar economic environment. Lease cost is recognized on a straight-line basis over the lease term and variable lease payments are recognized as operating expenses in the period in which the obligation for those payments is incurred. Variable lease payments primarily include common area maintenance, utilities, real estate taxes, insurance and other operating costs that are passed on from the lessor in proportion to the space leased by the Company. The Company has elected the practical expedient to not separate lease and non-lease components.

Preclinical Studies and Clinical Trial Accruals

The Company is required to estimate its expenses resulting from its obligations under contracts with vendors, consultants, clinical research organizations and clinical site agreements in connection with conducting preclinical activities and clinical trials. The financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company reflects preclinical study and clinical trial expenses in its financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of the preclinical study or clinical trial as measured by the timing of various aspects of the preclinical study, clinical trial or related activities. The Company determines accrual and prepaid estimates through review of the underlying contracts along with preparation of financial models taking into account correspondence with clinical and other key personnel and third- party service providers as to the progress of preclinical studies, clinical trials or other services being conducted. During the course of a preclinical study or clinical trial, the Company adjusts its expense recognition if actual results differ from its estimates. To date, the Company has not experienced any material differences between accrued costs and actual costs incurred.

In-Process Research and Development

The Company evaluates whether acquired intangible assets are a business under applicable accounting standards. Additionally, the Company evaluates whether the acquired assets have a future alternative use. Intangible assets that do not have future alternative use, such as the license the Company acquired from Daiichi, are considered acquired in-process research and development. When the acquired in-process research and development assets are not part of a business combination, the value of the consideration paid is expensed on the acquisition date. Future costs to develop these assets are recorded to research and development expenses as they are incurred.

Patent Costs

Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.

General and Administrative Expenses

General and administrative expenses consist of salaries, stock-based compensation, facilities and third-party expenses. General and administrative expenses are associated with the activities of the executive, finance, accounting, information technology, legal and human resource functions.

Stock-Based Compensation

Stock-based compensation expense represents the grant date fair value of equity awards recognized over the requisite service period of the awards (generally the vesting period) on a straight-line basis. The Company recognizes forfeitures as they occur. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model. Prior to the IPO, the exercise price for all stock options granted was at the estimated fair value of the underlying common stock as determined on the date of grant by the Company’s Board of Directors.

 

73

 

Income Taxes

The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

The Company recognizes deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.

The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more likely than not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.

Comprehensive Loss

Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company’s comprehensive loss includes unrealized gains / losses from short-term investments.

Net Loss Per Share

Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the sum of the weighted-average number of shares of common stock plus the potential dilutive effects of potential dilutive securities outstanding during the period. Potential dilutive securities are excluded from diluted earnings or loss per share if the effect of such inclusion is antidilutive. The Company’s potentially dilutive securities, which include convertible preferred stock, ESPP shares, and outstanding stock options under the Company’s equity incentive plan, have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For the periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position.

Recent Developments Regarding the COVID-19 Pandemic

Efforts to control the outbreak of COVID-19 have resulted in challenges to businesses and facilities in various industries around the world, including disruptions to the global economy and supply chains. To date, COVID-19 has not had a material impact on the Company’s expenditures.

The Company is unable to predict the ultimate effects of COVID-19 on the U.S. or global economy or its operations. The Company continues to monitor developments affecting its workforce, suppliers, and operations. The extent of the impact of COVID-19 will depend on its duration, actions by government authorities, and impacts on the Company’s customers, employees, or vendors. These developments are continuously evolving, and the Company cannot predict whether COVID-19 will have a material impact on its financial condition, results of operations or cash flows.

Recent Accounting Pronouncements

Financial Instruments. In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The objective of the standard is to provide information about expected credit losses on financial instruments at each reporting date and to change

 

74

 

how other-than temporary impairments on investment securities are recorded. The guidance is effective for the Company beginning on January 1, 2023, with early adoption permitted. The Company does not anticipate that the adoption of ASU 2016-13 will have a significant impact on its financial statements or the related disclosures.

Income Taxes. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which simplifies the accounting for income taxes. ASU 2019-12 is effective for the Company for the fiscal year beginning after December 15, 2021 and early adoption is permitted. The Company does not anticipate that the adoption of ASU 2019-12 will have a significant impact on its financial statements or the related disclosures.

Debt and Equity Instruments. In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40), which addresses the complexity associated with applying generally accepted accounting principles for certain financial instruments with characteristics of liabilities and equity. The guidance is effective for the Company beginning on January 1, 2024, with early adoption permitted. The Company elected to adopt this standard on January 1, 2020 under the modified retrospective transition method with no material impact on its financial statements or the related disclosures.

There were no other significant updates to the recently issued accounting standards other than as disclosed herein for the year ended December 31, 2021. Although there are several other new accounting pronouncements issued or proposed by the FASB, based on the Company’s preliminary assessment, the Company does not believe any of those accounting pronouncements have had or will have a material impact on its financial position or operating results.

Note 3 – Fair Value Measurements

The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

The carrying amounts of cash, prepaid expenses and other current assets, deferred offering costs, other assets, accounts payable, accrued research and development, other current liabilities and other long-term liabilities are reasonable estimates of their fair value due to the short-term nature of these accounts.

The Company’s money market funds under cash and cash equivalents are classified using Level 1 inputs within the fair value hierarchy because they are valued using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. There were no transfers between levels of the fair value hierarchy during the years ended December 31, 2021 and 2020, respectively.

 

75

 

The following table summarizes financial assets that the Company measured at fair value on a recurring basis, classified in accordance with the fair value hierarchy (in thousands):

 

 

 

Fair Value Measurements at Reporting Date Using:

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

As of December 31, 2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

10,585

 

 

$

—

 

 

$

—

 

 

$

10,585

 

Commercial paper

 

 

—

 

 

 

84,616

 

 

 

—

 

 

 

84,616

 

U.S. government securities

 

 

27,824

 

 

 

 

 

 

 

—

 

 

 

27,824

 

U.S. agency bonds

 

 

—

 

 

 

8,531

 

 

 

—

 

 

 

8,531

 

Corporate debt securities

 

 

—

 

 

 

8,265

 

 

 

—

 

 

 

8,265

 

Total cash equivalents and short-term investments

 

$

38,409

 

 

$

101,412

 

 

$

—

 

 

$

139,821

 

Reported as:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents (includes cash of $397)

 

 

 

 

 

 

 

 

 

 

 

 

 

$

24,780

 

Short-term investments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

115,438

 

Total cash, cash equivalents and short-term investments

 

 

 

 

 

 

 

 

 

 

 

 

 

$

140,218

 

 

 

 

Fair Value Measurements at Reporting Date Using:

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

As of December 31, 2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents

 

$

19,257

 

 

$

—

 

 

$

—

 

 

$

19,257

 

 

There were no liabilities measured at fair value on a recurring basis as of December 31, 2021 and 2020.

The following table provides a reconciliation of all liabilities measured at fair value using Level 3 significant unobservable inputs (in thousands) during the year ended December 31, 2020.

 

 

 

Convertible

Promissory

Notes

 

Fair value as of December 31, 2019

 

$

2,751

 

Issuance of convertible promissory notes

 

 

6,435

 

Conversion to convertible preferred stock (excluding interest expense)

 

 

(11,210

)

Change in fair value of convertible promissory notes (Note 7)

 

 

2,024

 

Fair value as of December 31, 2020

 

$

—

 

 

Convertible Promissory Notes

As further described in Note 7, the Company issued convertible promissory notes in October 2019 (the “2019 Notes”) and in June 2020 (the “2020 Notes”) to investors. The Company elected the ASC 825, Financial Instruments, fair value option for the convertible promissory notes. The fair value of the convertible promissory notes was determined using a scenario-based analysis that estimated the fair value of the convertible promissory notes based on the probability-weighted present value of expected future investment returns, considering possible outcomes available to the noteholders, including conversions in subsequent equity financings. The 2019 Notes and 2020 Notes were valued upon issuance, remeasured to fair value each reporting period and remeasured immediately prior to conversion into Series B convertible preferred stock based on changes in the expected time to closing ranging from 0 to 0.67 years and the relevant discount rate of 25% during the period. In September 2020, the 2019 Notes and 2020 Notes were converted to 1,905,688 shares of Series B convertible preferred stock.

In September 2020, all outstanding convertible promissory notes with a total fair value of $11.2 million and accrued interest of $167,000 were converted to 1,905,688 shares of Series B convertible preferred stock. Upon conversion, the Company no longer is required to adjust the carrying value of the convertible promissory notes at each reporting date.

 

76

 

Note 4 – Investments

Financial assets measured at fair value on a recurring basis consist of the Company’s cash equivalents and AFS securities. The Company obtains pricing information from its investment manager and generally determines the fair value of investment securities using standard observable inputs, including reported trades, broker/dealer quotes, and bids and/or offers.

Investments are classified as Level 1 within the fair value hierarchy if their quoted prices are available in active markets for identical securities. Investments in money market funds and U.S. government securities were classified as Level 1 instruments.

Investments in commercial paper, corporate debt securities and U.S. agency bonds are valued using Level 2 inputs. The Company classifies investments within Level 2 if the investments are valued using model driven valuations using observable inputs such as quoted market prices, benchmark yields, reported trades, broker/dealer quotes or alternative pricing sources with reasonable levels of price transparency. Investments are held by custodians who obtain investment prices from a third-party pricing provider that incorporates standard inputs in various asset price models.

The following table summarizes, by major types of cash equivalents, and investments that are measured at fair value on a recurring basis (in thousands):

 

 

 

December 31, 2021

 

 

 

Amortized

Cost

 

 

Unrealized

Gains

 

 

Unrealized

Losses

 

 

Estimated

Fair Value

 

Money market funds

 

$

10,585

 

 

 

—

 

 

 

—

 

 

$

10,585

 

Commercial paper

 

 

84,642

 

 

 

2

 

 

 

(28

)

 

 

84,616

 

U.S. government securities

 

 

27,870

 

 

 

—

 

 

 

(46

)

 

 

27,824

 

U.S. agency bonds

 

 

8,546

 

 

 

—

 

 

 

(15

)

 

 

8,531

 

Corporate debt securities

 

 

8,267

 

 

 

—

 

 

 

(2

)

 

 

8,265

 

Cash equivalents and investments

 

$

139,910

 

 

$

2

 

 

$

(91

)

 

$

139,821

 

 

The contractual maturities of the Company’s AFS securities were as follows (in thousands):

 

 

 

December 31,

2021

 

Due within one year

 

$

105,173

 

Due within one to two years

 

 

10,265

 

Available-for-Sale Investments

 

$

115,438

 

 

The available-for-sale investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date, which reflects management’s intention to use the proceeds from sales of these securities to fund the Company’s operations, as necessary. As of December 31, 2020, the Company did not own any investments. There were no realized gains or losses due to investment sales for the year ended December 31, 2021. As of December 31, 2021, $129.2 million of the Company’s marketable securities were in gross unrealized loss positions, of which none had been in such position for greater than 12 months and $23.8 million will mature within three months of December 31, 2021.

At each reporting date, the Company performs an evaluation of its marketable securities to determine if any unrealized losses are other-than-temporary. Factors considered in determining whether a loss is other-than-temporary include (i) the financial strength of the issuing institution, (ii) the length of time and extent for which fair value has been less than the cost basis and (iii) the Company’s intent and ability to hold its investments in unrealized loss positions until their amortized cost basis has been recovered. Based on the Company’s evaluation, it determined that its unrealized losses were not other-than-temporary at December 31, 2021. The Company does not intend to sell the investments before maturity and it is unlikely that the Company will be required to sell the investments before recovery of their amortized cost bases.

 

 

77

 

 

Note 5 - Balance Sheet Details

Prepaid and Other Current Assets

Prepaid and other current assets consist of the following (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Prepaid insurance

 

$

827

 

 

$

—

 

Prepaid research

 

 

4,329

 

 

 

371

 

Prepaid other

 

 

96

 

 

 

159

 

FICA tax credit receivable

 

 

452

 

 

 

110

 

Deposits

 

 

19

 

 

 

22

 

Other current assets

 

 

205

 

 

 

—

 

Prepaid and Other Current Assets

 

$

5,928

 

 

$

662

 

 

Property and equipment, net, consist of the following (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Computer equipment

 

$

50

 

 

$

45

 

Furniture and equipment

 

 

204

 

 

 

72

 

Leasehold improvements

 

 

67

 

 

 

67

 

 

 

$

321

 

 

$

184

 

Less: accumulated depreciation and amortization expense

 

$

(156

)

 

 

(85

)

Property and Equipment, net

 

$

165

 

 

$

99

 

Depreciation expense for years ended December 31, 2021 and 2020 were $0.1 million, respectively.

Other Non-Current Assets

Other non-current assets consist of the following (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

FICA tax credit receivable

 

$

298

 

 

$

549

 

Deposits

 

 

75

 

 

 

75

 

Other

 

 

70

 

 

 

—

 

Other non-current assets

 

$

443

 

 

$

624

 

 

Note 6 – Related Party Transactions

As further described in Note 7, the Company issued the 2019 Notes in October 2019 to certain holders of convertible preferred stock, for an aggregate purchase price of $2.5 million and the 2020 Notes in June 2020 to certain holders of convertible preferred stock, for an aggregate purchase price of $6.4 million. In September 2020, all outstanding convertible promissory notes with a total fair value of $11.2 million and accrued interest of $167,000 were converted to 1,905,688 shares of Series B convertible preferred stock. The change in fair value of the convertible promissory notes for the year ended December 31, 2020 was $2.0 million.

 

78

 

Note 7 – Convertible Promissory Notes

In October 2019, the Company entered into a convertible note purchase agreement with certain holders of preferred stock and issued the 2019 Notes for an aggregate purchase price of $2.5 million. The 2019 Notes bore an interest rate of the lesser of (a) 5% per annum and (b) the maximum rate permissible by law. The 2019 Notes were due and payable on demand from the holders on or after 18 months after the date of issuance (“2019 Notes Maturity Date”), unless repaid in full or automatically converted per the Automatic Conversion feature. Under the Automatic Conversion feature, the 2019 Notes were to automatically convert to convertible preferred stock, upon the closing of the Company’s next issuance of preferred stock for capital-raising purposes resulting in net proceeds to the Company of at least $10.0 million (excluding any amounts received in connection with the conversion of the 2019 Notes) (“Future Qualifying Financing”). The 2019 Notes would convert into that whole number of shares of the securities equal to the number obtained by dividing the principal plus accrued interest of the 2019 Notes by 80% of the price per share paid by cash investors in the Future Qualifying Financing. The convertible notes included other optional redemption features as follows (i) optionally converted upon a non-qualified equity financing with a conversion price of 80% of the price paid per share in such financing, (ii) any time after the 2019 Notes Maturity Date, demand immediate repayment of an amount equal to the then-outstanding loan balance, or convert the outstanding loan balance into shares of common stock of the Company in an amount equal to the ratio of the then-outstanding loan balance over the ratio of $38.4 million divided by the number of shares of capital stock of the Company outstanding, (iii) automatically upon the occurrence of change in control or an IPO with a conversion of the loan balance into shares of common stock in an amount equal to the ratio of the then-outstanding loan balance over the ratio of $76.8 million divided by the fully diluted capitalization prior to the change in control or IPO, or demand immediate repayment of two times the outstanding loan balance, and (iv) upon certain events of default, immediately due and payable in full.

In June 2020, the Company entered into a convertible note purchase agreement with certain holders of preferred stock and issued the 2020 Notes for an aggregate purchase price of $6.4 million. The 2020 Notes bore an interest rate of the lesser of (a) 5% per annum and (b) the maximum rate permissible by law. The 2020 Notes were due and payable on demand from the holders on or after 18 months after the date of issuance (“2020 Notes Maturity Date”), unless repaid in full or automatically converted per the Automatic Conversion feature. Under the Automatic Conversion feature, the 2020 Notes were to automatically convert to convertible preferred stock, upon the closing of the Company’s next issuance of preferred stock for capital-raising purposes resulting in net proceeds to the Company of at least $10.0 million (excluding any amounts received in connection with the conversion of the 2020 Notes) (“Qualifying Financing”). The 2020 Notes would convert into that whole number of shares of the securities equal to the number obtained by dividing the principal plus accrued interest of the 2020 Notes by 80% of the price per share paid by cash investors in the Qualifying Financing. The convertible notes included other optional redemption features as follows (i) optionally converted upon a non-qualified equity financing with a conversion price of 80% of the price paid per share in such financing, (ii) any time after the 2020 Notes Maturity Date, demand immediate repayment of an amount equal to the then-outstanding loan balance, or convert the outstanding loan balance into shares of common stock of the Company in an amount equal to the ratio of the then-outstanding loan balance over the ratio of $38.4 million divided by the number of shares of capital stock of the Company outstanding, (iii) automatically upon the occurrence of change in control or an IPO with a conversion of the loan balance into shares of common stock in an amount equal to the ratio of the then-outstanding loan balance over the ratio of $76.8 million divided by the fully diluted capitalization prior to the change in control or IPO, or demand immediate repayment of two times the outstanding loan balance, (iv) automatically upon the consummation of a transaction in which the Company merges with a public company and (v) upon certain events of default, immediately due and payable in full.

For the year ended December 31, 2020, the Company recognized interest expense of $135,000 in connection with the 2019 Notes and 2020 Notes. In September 2020, all outstanding convertible promissory notes with a total fair value of $11.2 million and accrued interest of $167,000 were converted to 1,905,688 shares of Series B convertible preferred stock.

 

Note 8 – Convertible Preferred Stock and Stockholders’ Equity (Deficit)

In 2020, the Company amended its Certificate of Incorporation to authorize the issuance of 24,000,000 shares of common stock, par value $0.001 per share, and 16,273,406 shares of preferred stock, par value $0.001 per share, of which 3,731,208 shares were designated Series A convertible preferred stock and 12,542,198 shares were designated Series B convertible preferred stock.

 

79

 

In connection with the reverse stock split on April 16, 2021, the Company filed a certificate of amendment to its certificate of incorporation, which authorized 260,000,000 shares of capital stock, consisting of 250,000,000 shares of common stock, par value $0.001 per share, and 10,000,000 shares of undesignated preferred stock, par value $0.001 per share that may be issued from time to time by the Company’s Board of Directors in one or more series. Of the 250,000,000 shares of common stock, 200,000,000 shares were designated as “Common Stock” and 50,000,000 shares were designated as “Non-Voting Common Stock”.

Rights, preferences, powers, privileges and restrictions, qualifications and limitations for holders of the Company’s Common Stock and Non-Voting Common Stock are:

 

a)

Voting Common Stock Voting Rights. Each holder of Voting Common Stock, as such, shall be entitled to one vote for each share of Voting Common Stock held of record by such holder on all matters on which stockholders generally are entitled to vote; provided, however, that, except as otherwise required by law, holders of Voting Common Stock, as such, shall not be entitled to vote on any amendment to the Certificate of Incorporation, including any certificate of designations relating to any series of Preferred Stock (each hereinafter referred to as a “Preferred Stock Designation”), that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together with the holders of one or more other such series, to vote thereon pursuant to the Certificate of Incorporation (including any Preferred Stock Designation).

 

b)

Non-Voting Common Stock Voting Rights. Non-Voting Common Stock (i) shall be non-voting except as may be required by law and (ii) shall not entitle the holder thereof to vote on the election of directors at any time.

 

c)

Non-Voting Common Stock Conversion. Each holder of shares of Non-Voting Common Stock shall have the right to convert each share of Non-Voting Common Stock held by such holder into one share (subject to appropriate adjustment in the event of any stock dividend, stock split, reverse stock split, combination or other similar recapitalization with respect to the Voting Common Stock) of Voting Common Stock at such holder’s election by providing written notice to the Corporation; provided, however, that such shares of Non-Voting Common Stock may only be converted into shares of Voting Common Stock during such time or times as immediately prior to or as a result of such conversion would not result in the holder(s) thereof beneficially owning (for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended and the rules and regulations promulgated thereunder (collectively, the “Exchange Act”)), when aggregated with affiliates with whom such holder is required to aggregate beneficial ownership for purposes of Section 13(d) of the Exchange Act, in excess of the Beneficial Ownership Limitation. The “Beneficial Ownership Limitation” means initially 9.99% of the Voting Common Stock. Any holder of Non-Voting Common Stock may increase the Beneficial Ownership Limitation with respect to such holder, not to exceed 19.99% of the Voting Common Stock, upon 61 days’ prior written notice to the Corporation and may decrease the Beneficial Ownership Limitation at any time upon providing written notice of such election to the Corporation; provided, however, that no holder may make such an election to change the percentage with respect to such holder unless all holders managed by the same investment advisor as such electing holder make the same election. Before any holder of Non-Voting Common Stock shall be entitled to convert any shares of Non-Voting Common Stock into shares of Voting Common Stock, such holder shall (A) surrender the certificate or certificates therefor (if any), duly endorsed, at the principal corporate office of the Corporation or of any transfer agent for the Non-Voting Common Stock, and (B) provide written notice to the Corporation, during regular business hours at its principal corporate office, of such conversion election (in form satisfactory to the Corporation) and shall state therein the name or names (i) in which the certificate or certificates representing the shares of Voting Common Stock into which the shares of Non-Voting Common Stock are so converted are to be issued (if such shares of Voting Common Stock are certificated) or (ii) in which such shares of Voting Common Stock are to be registered in book-entry form (if such shares of Voting Common Stock are uncertificated). If the shares of Voting Common Stock into which the shares of Non-Voting Common Stock are to be converted are to be issued in a name or names other than the name of the holder of the shares of Non-Voting Common Stock being converted, such notice shall be accompanied by a written instrument or instruments of transfer, in form satisfactory to the Corporation, duly executed by the holder. The Corporation shall, as soon as practicable thereafter, issue and deliver at such office to such holder, or to the nominee or nominees of such holder, a certificate or certificates representing the number of shares of Voting Common Stock to which such holder shall be entitled upon such

 

80

 

 

conversion (if such shares of Voting Common Stock are certificated) or shall register such shares of Voting Common Stock in book-entry form (if such shares of Voting Common Stock are uncertificated). Such conversion shall be deemed to be effective immediately prior to the close of business on the date of such surrender of the shares of Non-Voting Common Stock to be converted following or contemporaneously with the provision of written notice of such conversion election as required by this section, the shares of Voting Common Stock issuable upon such conversion shall be deemed to be outstanding as of such time, and the person or persons entitled to receive the shares of Voting Common Stock issuable upon such conversion shall be deemed to be the record holder or holders of such shares of Voting Common Stock as of such time. Notwithstanding anything herein to the contrary, shares of Non-Voting Common Stock represented by a lost, stolen or destroyed stock certificate may be converted if the holder thereof notifies the Corporation or its transfer agent that such certificate has been lost, stolen or destroyed and makes an affidavit of that fact acceptable to the Corporation and executes an agreement acceptable to the Corporation to indemnify the Corporation from any loss incurred by it in connection with such certificate. The effectiveness of any conversion of any shares of Non-Voting Common Stock into shares of Voting Common Stock is subject to the expiration or early termination of any applicable premerger notification and waiting period requirements of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules and regulations promulgated thereunder.

 

d)

Dividends. Subject to the rights of the holders of any outstanding series of Preferred Stock, the holders of shares of Common Stock shall be entitled to receive any dividends to the extent permitted by law when, as and if declared by the board of directors of the Corporation (the “Board”).

 

e)

Liquidation. Upon the dissolution, liquidation or winding up of the Corporation, subject to the rights of the holders of any outstanding series of Preferred Stock, the holders of shares of Common Stock shall be entitled to receive the assets of the Corporation available for distribution to its stockholders ratably in proportion to the number of shares held by them. The Non-Voting Common Stock shall rank on parity with the Voting Common Stock as to distributions of assets upon dissolution, liquidation or winding up of the Corporation, whether voluntary or involuntary.

Convertible Preferred Stock

Series A Convertible Preferred Stock. In April 2018, the Company entered into a Series A convertible preferred stock purchase agreement, pursuant to which the Company issued 2,098,269 shares of Series A convertible preferred stock for an aggregate purchase price of $11.0 million, net of issuance costs. In December 2018, the Company issued an additional 1,390,788 shares of Series A convertible preferred stock for an aggregate purchase price of $7.3 million, net of issuance costs.

Series B Convertible Preferred Stock. In September 2020, the Company entered into a Series B convertible preferred stock purchase agreement, pursuant to which the Company issued 10,636,510 shares of Series B convertible preferred stock for an aggregate purchase price of $63.2 million, net of issuance costs.

Rights, preferences, powers, privileges and restrictions, qualifications and limitations for holders of the Company’s Series A convertible preferred stock and Series B convertible preferred stock are:

 

•

Dividends: Each holder of the Company’s Series A and Series B convertible preferred stock is entitled to receive non-cumulative dividends, when and if declared by the Company’s Board of Directors. No dividends have been declared to date.

 

•

Liquidation Preferences: In the event of any liquidation, dissolution or winding up of the Company, the holders of the Series A and Series B convertible preferred stock shall be entitled to receive, prior and in preference to any distribution of any of the assets of the Company to the holders of common stock, an amount per share equal to the original issue price plus declared but unpaid dividends.

 

•

Conversion: Each share of Series A and Series B convertible preferred stock is convertible at the option of the holder, at any time, into the number of shares of common stock determined by dividing the applicable purchase price by the applicable conversion price at the time of conversion. Each share of Series A and Series B convertible preferred stock will be automatically converted into common stock immediately upon (i) the closing of a firm commitment underwritten IPO resulting in at least $50.0 million of gross proceeds to the Company or (ii) the receipt by the Company of a written request for automatic conversion from the holders of a majority of the outstanding shares of Series A and Series B convertible preferred stock.

 

81

 

 

•

Voting: The holders of the Series A and Series B convertible preferred stock are entitled to one vote for each share of common stock into which such shares of Series A and Series B convertible preferred stock could then be converted; and with respect to such vote, such holders shall have full voting rights and powers equal to the voting rights and powers of the holders of the common stock.

 

•

Redemption: The Series A and Series B convertible preferred stock are not explicitly redeemable at the option of the holder at a specified date in the future or at the option of the Company.

Prior to the IPO, the Company’s Series A and Series B convertible preferred stock were classified as temporary equity on the accompanying balance sheet instead of in stockholders’ equity (deficit) as events triggering redemption that were not solely within the Company’s control because the preferred stockholders had the ability to effect a liquidation event. The Company determined not to adjust the carrying values of the Series A and Series B convertible preferred stock to the liquidation preferences of such shares because of the uncertainty of whether or when such liquidation events would occur.

On April 27, 2021, immediately prior to the closing of the IPO, 8,344,905 shares of the Company’s convertible preferred stock were exchanged for 7,727,470 shares of Non-Voting common stock and 7,928,501 shares of the Company’s convertible preferred stock converted into 7,341,860 shares of common stock. There were no outstanding shares of the Company’s convertible preferred stock as of December 31, 2021.

Equity Incentive Plan

In August 2020, the Company’s Board of Directors amended the Amended and Restated 2018 Stock Option—Stock Issuance Plan (the “2018 Plan”) to increase the maximum number of shares of common stock that may be issued over the term of the plan. The 2018 Plan provides for the grant of stock options, non-statutory stock options, incentive stock options and stock issuances to employees, nonemployees and consultants of the Company.

In April 2021, the Company’s 2021 Equity Incentive Plan (the “2021 Plan”) was approved by the Company’s Board of Directors and became effective on April 15, 2021. Upon the effectiveness of the 2021 Plan, no further grants may be made under the Company’s 2018 Plan.

The 2021 Plan allows the Company to grant equity-based awards to its officers, employees, directors and other key persons (including consultants). The Company initially reserved up to 3,246,120 shares of common stock for issuance under the 2021 Plan, plus (i) 1,722 shares that remained available for the issuance of awards under the 2018 Plan at the time the 2021 Plan became effective, and (ii) any shares subject to outstanding options or other share awards that were granted under the 2018 Plan that terminate or expire prior to exercise or settlement; are forfeited because of the failure to vest; or are reacquired or withheld (or not issued) to satisfy a tax withholding obligation or the purchase or exercise price. The 2021 Plan provides that the number of shares reserved and available for issuance under the plan will automatically increase each January 1, beginning on January 1, 2022 and each January 1 thereafter through January 31, 2032, by 4.0% of the outstanding number of shares of common stock on the immediately preceding December 31, or such lesser number of shares as determined by the Company’s Board of Directors.

A summary of the Company’s stock option activities during the year ended December 31, 2021 are as follows (in thousands, except share and per share amounts and years):

 

 

 

Total

Options

 

 

Weighted-

Average

Exercise

Price Per

Share

 

 

Weighted-

Average

Remaining

Contract

Term

 

 

Aggregate

Intrinsic

Value

 

Outstanding as of December 31, 2020

 

 

882,942

 

 

$

3.72

 

 

 

9.0

 

 

$

1,263

 

Granted

 

 

932,296

 

 

$

12.80

 

 

 

 

 

 

 

 

 

Exercised

 

 

(30,496

)

 

$

3.96

 

 

 

 

 

 

$

171

 

Forfeited or cancelled

 

 

(50,046

)

 

$

7.00

 

 

 

 

 

 

 

 

 

Outstanding as of December 31, 2021

 

 

1,734,696

 

 

$

8.50

 

 

 

8.8

 

 

$

7,594

 

Vested and expected to vest as of December 31, 2021

 

 

1,734,696

 

 

$

8.50

 

 

 

8.8

 

 

$

7,594

 

Vested and exercisable as of December 31, 2021

 

 

621,869

 

 

$

4.15

 

 

 

8.2

 

 

$

5,429

 

 

82

 

 

 

The weighted-average grant date fair values of option grants during the years ended December 31, 2021 and 2020 were $12.14 and $2.74 per share, respectively. The weighted-average grant date fair values of options forfeited during the years ended December 31, 2021 and 2020 were $6.08 and $2.82 per share, respectively.

Employee Stock Purchase Plan

The 2021 Employee Share Purchase Plan (the “ESPP”) was approved by the Board of Directors and became effective on April 15, 2021. The ESPP initially reserved and authorized the issuance of up to 259,689 shares of common stock to participating employees. Under the ESPP, eligible employees can contribute up to 15% of their eligible compensation, as defined in the ESPP, towards the purchase of the Company’s common stock at a price of 85% of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the last trading day of the offering period. The ESPP provides for twenty-four-month offering periods with four six-month purchase periods in each offering period. The ESPP provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2022 and each January 1 thereafter through January 31, 2032, by 1.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year. As of December 31, 2021, no shares had been issued under the ESPP, and 259,689 shares authorized under the ESPP were available for issuance. In January 2022, the Company issued 26,804 shares under the ESPP.

Liability for Restricted Stock

In 2017, the Company entered into restricted stock purchase agreements with various employees for 3,518,842 shares of common stock, which are subject to time-based vesting. The Company had the option to repurchase any unvested shares at the original purchase price upon any voluntary or involuntary separation of an employee from the Company. The shares purchased pursuant to the restricted stock purchase agreements were not deemed, for accounting purposes, to be outstanding until those shares vest. The cash received in exchange for unvested shares of the restricted stock granted were recorded as a liability on the accompanying balance sheet and were transferred into common stock and additional paid-in capital as the restricted stock vested.

The Company issued 532,455 shares in 2020 in connection with the vesting of the restricted stock. As of December 31, 2020, no shares remained subject to repurchase by the Company.

Stock-Based Compensation Expense

The Company recognized stock-based compensation expense as follows (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Research and development

 

$

2,486

 

 

$

581

 

General and administrative

 

 

606

 

 

 

284

 

Stock-based compensation expense

 

$

3,092

 

 

$

865

 

 

The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the stock option grants were as follows:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Risk-free interest rate

 

0.8% - 1.3%

 

 

0.2% - 0.9%

 

Expected volatility

 

113.2% - 118.7%

 

 

96.9% - 116.2%

 

Expected term (in years)

 

5.0 – 6.1

 

 

1.5 – 6.1

 

Expected dividend yield

 

0%

 

 

0%

 

 

As of December 31, 2021, the unrecognized compensation cost related to outstanding options was $9.8 million and is expected to be recognized as expense over approximately 3.1 years.

 

83

 

The weighted average assumptions used in Black-Scholes option pricing model to estimate the fair value of purchase rights granted under the ESPP were as follows:

 

 

 

Year Ended December 31,

 

 

 

2021

 

Risk-free interest rate

 

0.1%

 

Expected volatility

 

127.8%

 

Expected term (in years)

 

1.4

 

Expected dividend yield

 

0%

 

 

As of December 31, 2021, there was $0.5 million of unrecognized compensation cost related to the ESPP and is expected to be recognized over approximately 1.5 years.

The determination of the fair value of share-based payment awards utilizing the Black-Scholes option-pricing model is affected by the Company’s stock price and the following assumptions:

Risk-free interest rate. The risk-free interest rate assumption is based on the U.S. Treasury instruments, the terms of which were consistent with the expected term of the Company’s stock-based awards.

Expected volatility. Due to the Company’s limited operating history and lack of company-specific historical or implied volatility, the expected volatility assumption was determined by examining the historical volatilities of a group of industry peers whose share prices are publicly available.

Expected term. The expected term represents the weighted-average period the stock-based awards are expected to be outstanding. The Company uses the simplified method for estimating the expected term. The simplified method calculates the expected term as the average of the time-to-vesting and the contractual life of the stock-based awards.

Expected dividend yield. The expected dividend assumption is based on the Company’s history and expectation of dividend payouts. The Company has not paid and does not intend to pay dividends.

Forfeitures. The Company reduces stock-based compensation expense for actual forfeitures during the period.

Common Stock Reserved for Future Issuance

Common stock reserved for future issuance consist of the following:

 

 

 

As of December 31,

 

 

 

2021

 

 

2020

 

Stock options

 

 

1,734,696

 

 

 

882,942

 

Reserved for future equity award grants

 

 

2,933,930

 

 

 

582,203

 

Reserved for future ESPP issuances

 

 

259,689

 

 

 

—

 

Convertible preferred stock

 

 

—

 

 

 

15,069,330

 

Common stock reserved for future issuance

 

 

4,928,315

 

 

 

16,534,475

 

 

Note 9 – License and Clinical Supply Agreements

The Company has entered into license agreements, accounted for as asset acquisitions, under which the Company is required to use commercially reasonable efforts to meet certain specified development and regulatory milestones related to the licensed technologies within specified time periods. In consideration of the rights granted to the Company under the agreements, the Company is required to make cash milestone payments to the licensors upon the completion of certain development, regulatory and commercial milestones. For the arrangements that the Company accounted for as asset acquisitions, contingent consideration liabilities are recorded as an additional cost of the acquired assets when the contingency is resolved, and the consideration is paid or becomes payable. Additionally, the Company has agreed to pay royalties on net sales of products applicable to the license agreements. The Company may terminate the agreements upon written notice to the licensors.

 

84

 

Daiichi Sankyo License Agreement

On September 2, 2020, the Company licensed the rights to milademetan (DS-3032b) for all human prophylactic or therapeutic uses in all countries and territories of the world from Daiichi Sankyo Company, Limited, (“Daiichi Sankyo”), a Japanese corporation (the “Daiichi Sankyo License Agreement”). Daiichi Sankyo conducted clinical studies of milademetan prior to the Company’s licensing the rights to this product. The Company refers to this product candidate as milademetan.

In accordance with the terms of the Daiichi Sankyo License Agreement, the Company paid Daiichi Sankyo an initial upfront payment of $5.0 million during the year ended December 31, 2020.

Under the Daiichi Sankyo License Agreement, the Company obtained worldwide, sublicensable exclusive rights to seven families of patents with respect to milademetan. The Company is solely responsible under the Daiichi Sankyo License Agreement for the research, development and registration of milademetan. Pursuant to the Daiichi Sankyo License Agreement, Daiichi Sankyo had the right to continue to conduct three clinical trials and prepare final reports with respect to these clinical trials, and such right expires upon all subjects completing the study treatment. The Company has agreed to reimburse Daiichi Sankyo certain third-party expenses incurred while conducting such trials. The Company made clinical trials payments of $0.2 million under the Daiichi Sankyo License Agreement for the year ended December 31, 2021. The Company made no clinical trials payments to Daiichi Sankyo for the year ended December 31, 2020. As of December 31, 2021, the accrued Daiichi Sankyo reimbursable clinical trials costs were $2.0 million, which was recorded in accrued research and development in the balance sheet.

The Company is required to make aggregate future milestone payments of up to $222.5 million, contingent on the attainment of certain development, regulatory and sales milestones. On July 20, 2021, the Company announced that the first patient has been randomized in the multicenter, open-label, Phase 3 registrational trial (MANTRA) evaluating milademetan for the treatment of de-differentiated liposarcoma. Accordingly, pursuant to the Daiichi Sankyo License Agreement, the Company recorded $5.5 million in milestone fees as research and development expense in the statement of operations. Of the $5.5 million milestone fees, $2.5 million was paid in the third quarter of 2021 and $3.0 million was accrued as part of accrued research and development in the balance sheet as of December 31, 2021.

Additionally, the Company is required to pay Daiichi Sankyo a high single digit royalty based on the annual net sales of the Products, subject to reduction at an agreed rate upon the expiration of the licensed patent in the particular country where the Products are sold. To date, no royalty payments have been made to Daiichi Sankyo under the Daiichi Sankyo License Agreement. The royalty obligation terminates on a country-by-country and Product-by-Product basis on the later of: (i) loss of all market exclusivity for such Product in such country, (ii) the last-to-expire patent that covers the Licensed Compound or the Product in such country and (iii) twelve years from launch of the first Product sold by the Company in such country.

Unless sooner terminated or extended, the Daiichi Sankyo License Agreement will remain in full force and effect until the Company, its affiliates and its sublicensees cease all development and commercial activity related to milademetan. Either party may terminate the Daiichi Sankyo License Agreement for cause in the event of an uncured material breach (subject to a 90-day cure period). However, the Company may only terminate the Daiichi Sankyo License Agreement with respect to the countries affected by such uncured material breach. Daiichi Sankyo may also terminate the Daiichi Sankyo License Agreement in the event of Rain’s bankruptcy or insolvency. Additionally, Daiichi Sankyo may terminate the Daiichi Sankyo License Agreement immediately upon written notice if the Company, its affiliates or its sublicensors initiate or join any challenge to the validity or enforceability of a licensed patent, subject to certain exclusions. Furthermore, the Company may terminate the Daiichi Sankyo License Agreement in its entirety or on a country-by-country basis for bona fide material concerns regarding the (i) lack of safety for human use arising from toxicity of the Licensed Compound or Product(s), (ii) lack of efficacy of the Licensed Compound or Product(s) or (iii) adverse economic impact to the Company in connection with its continued development of the Products, in each case, upon six months’ prior written notice to Daiichi Sankyo. In addition, if the Company is acquired by a third party that is developing and commercializing a competing compound and the acquiring party decides not to discontinue the development or commercialization of such competing compound, such third party must terminate the Daiichi Sankyo License Agreement within 30 days of such acquisition if it does not discontinue such development or commercialization. Upon termination of the Daiichi Sankyo License Agreement by Daiichi Sankyo for the Company’s uncured material breach or by the Company for its bona fide material concerns regarding the safety, efficacy or adverse economic impacts relating to the Licensed Compound or Products, or its development thereof, the Company is required to, among other actions, if requested by Daiichi Sankyo (i) transfer to Daiichi Sankyo ongoing clinical trials, data, reports, records

 

85

 

and materials, (ii) grant to Daiichi Sankyo an exclusive, irrevocable, sublicensable, fully paid-up license under any patents and know-how that are controlled and actually used by the Company at the time of termination in connection with the Products to allow Daiichi Sankyo exploit the Licensed Compound or Products in countries that are affected by the termination, (iii) grant to Daiichi Sankyo an exclusive, irrevocable, sublicensable, fully paid up license to use trademarks that are specific to the Products and (iv) assign any applicable sublicenses.

Drexel License Agreement and Sponsored Research Agreement

On July 30, 2020 (the “Effective Date”), the Company entered into an intellectual property license agreement (the “Drexel License Agreement”) with Drexel University (“Drexel”). Pursuant to the Drexel License Agreement, Drexel granted to the Company (i) a worldwide, exclusive license to make and commercialize products under a single issued patent and two patent applications related to RAD52 inhibitors for the treatment of cancer (the “Patent Rights”) and (ii) a worldwide, nonexclusive license to make, use and commercialize certain technical information and know-how related to the Patent Rights. The license grant includes the right to sublicense after the first anniversary of the Effective Date, subject to express conditions set forth in the Drexel License Agreement.

The Company is obligated to use commercially reasonable efforts to (i) develop, commercialize, market and sell licensed products in a manner consistent with a development plan and (ii) achieve certain milestone events, including, among other things, receiving investigational new drug application (“IND”) approval for a licensed product by the fourth anniversary of the Effective Date. Under the Drexel License Agreement, for a period of five years from the Effective Date, the Company is granted a first option to license Drexel’s rights in certain improvements, developments or inventions developed by Drexel (or jointly by the parties) during the five-year period that are directly related to the licensed products or to RAD52 or compounds that have been generated to specifically target RAD52.

In addition to a one-time, non-refundable initiation fee of $20,000 paid in four equal installments of $5,000 each within ten days after the Effective Date and six, twelve and eighteen months after the Effective Date, the Drexel License Agreement requires the Company to make further payments to Drexel of up to an aggregate of $6.25 million, for the achievement of specified development milestones for certain licensed products. The Company is also required to reimburse Drexel (i) after the filing of the first IND for the first licensed product, for all costs related to the filing, prosecution and maintenance of the Patent Rights accumulated prior to the Effective Date, and (ii) for all reasonable costs related to the filing, prosecution and maintenance of the Patent Rights after the Effective Date. In addition, the Company is also required to pay Drexel, on a quarterly basis, a low single digit royalty on net sales by the Company, its affiliates and sublicensees of certain licensed products, subject to specified reductions and a minimum quarterly royalty payment of up to $6,250.

Lastly, the Company is also obligated to pay Drexel (i) an annual license maintenance fee of $15,000 commencing upon filing of the first IND for a licensed product until the first sale of the first licensed product, (ii) a sublicense fee of low double digits percentage on all consideration received by the Company from its sublicensees, subject to certain reductions and (iii) a one-time transaction fee equal to the actual amount of Drexel’s licensing and legal expenses in connection with the Drexel License Agreement and the Sponsored Research Agreement the parties simultaneously entered into with the Drexel License Agreement (the Sponsored Research Agreement).

The Company made payments of $34,387 and $11,720 under the Drexel License Agreement for the years ended December 31, 2021 and 2020, respectively.

Unless sooner terminated or extended, the term of the Drexel License Agreement with respect to any licensed product and country continues until the later of (i) the expiration or abandonment of the last-to-expire valid claim of the Patent Rights that covers the sale of such licensed product in such country, (ii) the expiration of any granted statutory period of marketing and/or data exclusivity for such licensed product that confers upon the Company exclusive commercialization, (iii) the month of the first sale of a generic equivalent of such licensed product in such country and (iv) ten years after the first sale of the first licensed product.

The Company may terminate the Drexel License Agreement at any time by providing 60 days’ prior written notice to Drexel, in which case the Company will be required to cease exploitation of all licensed products, terminate all permitted sublicenses and pay all amounts owed to Drexel under the Drexel License Agreement and the Sponsored Research Agreement through the effective date of termination. Drexel may terminate the Drexel License Agreement for the Company’s uncured material breach (with 30-135 day cure periods), for the

 

86

 

Company’s bankruptcy or insolvency, for the Company’s uncured material default under the Sponsored Research Agreement, or if the Company challenges the validity or enforceability of the licensed patent rights.

Roche Clinical Supply Agreement

In December 2021, the Company entered into a clinical supply agreement with Roche for the supply of the anti-Programmed Death Ligand-1 (PD-L1) monoclonal antibody, atezolizumab. Clinical trials are planned to evaluate milademetan, in combination with atezolizumab for the treatment of patients in genetically selected populations. Under this agreement, Rain is the sponsor of the anticipated clinical trials, and Roche will supply atezolizumab. The Company does not have any financial commitments to Roche under this agreement.

Note 10 – Commitments and Contingencies

Leases

In September 2018, the Company entered into a noncancelable operating lease agreement for office space for its corporate headquarters in Newark, California with an initial term of 5.25 years. The lease commenced in January 2019 and ends March 2024. Under the terms of the lease, the Company pays annual base rent, subject to an annual fixed percentage increase of 3% on March 1st of each year. The Company is obligated to pay for its share of direct expenses including operating expense and taxes, which are considered variable lease costs and are expensed as incurred.

In March 2020, Governor Newsom issued State of California Executive Order No. N-33-20 instructing all individuals in California to stay at home due to the COVID-19 pandemic. In connection with such order, the Company entered into an amendment to the noncancelable operating lease agreement in June 2020. The amendment provided the Company rent relief for three months in 2020. In consideration of the rent relief, the Company agreed to adjust the base rent annual fixed percentage increase of 3% on February 1st of each year and extend the lease until September 2024. The amendment was determined to be a lease modification that qualified as a change of accounting on the existing lease and not a separate contract. Remeasurement of the right-of-use asset and operating lease liabilities at the date of modification did not result in a material increase of the right-of-use asset and operating lease liabilities.

The future minimum lease payments required under the operating lease are summarized as follows (in thousands):

 

 

 

As of December 31,

 

 

 

2021

 

2022

 

 

167

 

2023

 

 

171

 

2024

 

 

129

 

Total minimum lease payments

 

$

467

 

Less: amount representing interest

 

 

(55

)

Present value of operating lease liabilities

 

$

412

 

Operating lease liabilities, current

 

 

160

 

Operating lease liabilities, non-current

 

 

252

 

Total operating lease liabilities

 

$

412

 

 

 

 

 

 

Weighted-average remaining lease term (in years)

 

 

2.7

 

Weighted-average incremental borrowing rate

 

 

10.0

%

 

The table below summarizes the Company’s lease costs and cash payments in connection with operating lease obligations (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Total operating lease expense

 

$

160

 

 

$

130

 

Operating cash flows used for operating lease

 

$

162

 

 

$

130

 

 

 

87

 

 

Contingencies

In the event the Company becomes subject to claims or suits arising in the ordinary course of business, the Company would accrue a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated.

Note 11 – Employee Benefits

The Company has a defined contribution 401(k) plan available to eligible employees. Under the terms of the plan, employees may make voluntary contributions as a percent of compensation, limited to the maximum amount allowable under federal tax regulations. The Company, at its discretion, may make certain contributions to the 401(k) plan. The Company made matching contributions of $233,831 and $79,000 for the years ended December 31, 2021 and 2020, respectively.

Note 12 – Income Taxes

The Company recorded de minimis state income tax expense for the years ended December 31, 2021 and 2020 primarily as a result of the Company maintaining a full valuation allowance against its loss from operations for tax purposes. The net losses for the years ended December 31, 2021 and 2020 were generated solely in the United States.

The provision for income taxes is comprised of the following (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Current:

 

 

 

 

 

 

 

 

State

 

$

2

 

 

$

—

 

Provision for income taxes

 

$

2

 

 

$

—

 

 

The provision for income taxes differs from the amount computed by applying the federal statutory income tax rate to income before taxes as follows (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Federal tax benefit at statutory rate

 

$

(10,792

)

 

$

(4,426

)

State taxes

 

 

604

 

 

 

(1,640

)

Change in fair value of convertible promissory notes

 

 

—

 

 

 

425

 

Non-deductible expenses

 

 

490

 

 

 

(11

)

Convertible note interest

 

 

—

 

 

 

28

 

R&D credits

 

 

(2,177

)

 

 

(187

)

Change in valuation allowance

 

 

11,870

 

 

 

5,797

 

Other

 

 

7

 

 

 

14

 

Provision for income taxes

 

$

2

 

 

$

—

 

 

 

88

 

 

Deferred income taxes reflect the tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The components of deferred income tax assets and liabilities are as follows (in thousands):

 

 

 

As of December 31,

 

 

 

2021

 

 

2020

 

Deferred tax assets:

 

 

 

 

 

 

 

 

Accrued expenses and other

 

$

407

 

 

$

188

 

Fixed assets

 

 

10

 

 

 

11

 

Intangibles

 

 

2,378

 

 

 

1,698

 

Net operating losses

 

 

16,993

 

 

 

8,254

 

R&D and Orphan Drug credits

 

 

2,615

 

 

 

438

 

Stock-based compensation

 

 

287

 

 

 

236

 

Lease liability

 

 

87

 

 

 

135

 

Other

 

 

2

 

 

 

—

 

Total deferred tax assets

 

$

22,779

 

 

$

10,960

 

Valuation allowance

 

 

(22,698

)

 

 

(10,827

)

Total net deferred tax assets

 

$

81

 

 

$

133

 

Deferred tax liabilities:

 

 

 

 

 

 

 

 

Right-of-use asset

 

$

(81

)

 

 

(133

)

Total deferred tax liabilities

 

$

(81

)

 

$

(133

)

Net deferred tax assets

 

$

—

 

 

$

—

 

 

Realization of deferred tax assets is dependent upon the Company’s ability to generate sufficient taxable income within the carryforward period. In assessing the realizability of some portion or all of the deferred tax assets, the Company evaluated both positive and negative evidence to determine if some or all of its deferred tax assets should be recognized. Based on the available objective evidence, the Company has concluded it is not more likely than not that its deferred tax assets will be realized.

Therefore, a valuation allowance in the amount of $22.7 million has been recorded for 2021 against the Company’s deferred tax assets.

The net valuation allowance increased by $11.9 million and $5.8 million during the years ended December 31, 2021 and 2020, respectively.

The following table sets forth the Company’s federal and state net operating loss carryforwards as of December 31, 2021 (in thousands):

 

 

 

Amount

 

 

Expiration Years

Net operating losses, Federal—pre TCJA

 

$

159

 

 

2037

Net operating losses, Federal—post TCJA

 

$

69,085

 

 

N/A

Net operating losses, state

 

$

27,801

 

 

2031-2041

R&D and Orphan Drug credits, Federal

 

$

3,110

 

 

2039-2041

R&D credits, California

 

$

948

 

 

N/A

 

Utilization of the Company’s net operating loss and R&D credits may be subject to substantial limitations due to the ownership changes limitations provided by the Internal Revenue Code and similar state provisions. Such annual limitations could result in the expiration of the net operating loss before their utilization. Sections 382 and 383 of the Internal Revenue Code (“IRC Sections 382 and 383”) impose limitations on a corporation’s ability to utilize its net operating losses and credit carryforwards if it experiences an “ownership change” as defined by IRC Sections 382 and 383. The Company has performed an analysis under Section 382 of the Internal Revenue Code which subjects the amount of pre-change net operating losses and certain other tax attributes that can be utilized to an annual limitation. Based on the analysis, ownership changes have occurred in 2018 and 2021.

The Company is required to recognize in the financial statements the impact of a tax position, if that position is more likely than not of being sustained on audit, based on the technical merits of the position.

 

89

 

The following table reflects changes in the gross unrecognized tax benefits (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Balance at beginning of year

 

$

402

 

 

$

215

 

Additions based on tax positions related to

   current year

 

 

1,040

 

 

 

187

 

Balance at end of year

 

$

1,442

 

 

$

402

 

 

The Company recognizes interest and penalties as a component of income tax expense. There were no interest or penalties recognized in the statements of operations and comprehensive loss. The total unrecognized tax benefits of $1.4 million and $0.4 million were recorded as of December 31, 2021 and 2020, respectively, which, if recognized currently, should not impact the effective tax rate due to the Company maintaining a full valuation allowance. The Company expects the unrecognized tax benefits will not change significantly within the next 12 months.

The Company is subject to examination by the United States federal and state tax authorities for the tax years 2017 and later.

 

Note 13 – Net Loss Per Share

The following tables summarize the computation of the basic and diluted net loss per share (in thousands, except share and per share data):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Numerator:

 

 

 

 

 

 

 

 

Net loss

 

$

(51,394

)

 

$

(21,083

)

Denominator:

 

 

 

 

 

 

 

 

Weighted-average shares of common stock outstanding, basic and

   diluted

 

 

19,405,833

 

 

 

3,519,728

 

Less: weighted-average unvested common stock

 

 

—

 

 

 

(167,878

)

Weighted-average shares used to compute net loss per share, basic and

   diluted

 

 

19,405,833

 

 

 

3,351,850

 

Net loss per share, basic and diluted

 

$

(2.65

)

 

$

(6.29

)

 

The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their inclusion would be anti-dilutive:

 

 

 

As of December 31,

 

 

 

2021

 

 

2020

 

Stock options

 

 

1,734,696

 

 

 

882,942

 

Series A convertible preferred stock

 

 

—

 

 

 

3,731,208

 

Series B convertible preferred stock

 

 

—

 

 

 

12,542,198

 

ESPP shares

 

 

85,031

 

 

 

—

 

Total

 

 

1,819,727

 

 

 

17,156,348

 

 

 

 

90

 

 

Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.

None.

Item 9A. Controls and Procedures.

Management’s Evaluation of Disclosure Controls and Procedures

As of December 31, 2021, our management, with the participation and supervision of our principal executive officer and our principal financial officer, evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost benefit relationship of possible controls and procedures. Based on this evaluation, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures were effective as of December 31, 2021 to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and our principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Management’s Annual Report on Internal Controls over Financial Reporting

This Annual Report does not include a report of management’s assessment regarding internal control over financial reporting due to a transition period established by rule of the SEC for newly public companies.

 

Attestation Report of the Registered Public Accounting Firm

As an emerging growth company, we are not required to provide an attestation report on our internal control over financial reporting issued by the Company’s independent registered public accounting firm.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) identified in management’s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act that occurred during the quarter ended December 31, 2021, that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Item 9B. Other Information.

None.

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.

Not applicable.

 

 

91

 

 

PART III

Item 10. Directors, Executive Officers and Corporate Governance.

The information required by this Item will be set forth in the Company’s definitive proxy statement to be filed with the SEC in connection with the Company’s 2022 Annual Meeting of Stockholders (the “2022 Proxy Statement”) within 120 days of the end of the Company’s fiscal year ended December 31, 2021 and is incorporated herein by reference.

We have adopted a Code of Business Conduct and Ethics that applies to all of our directors, officers and employees, including our principal executive, principal financial and principal accounting officers, or persons performing similar functions. Our Code of Business Conduct and Ethics is posted on our website located at www.rainthera.com, under “Governance Documents.” We intend to disclose on our website any amendments to, or waivers from, the code of business conduct and ethics that are required to be disclosed pursuant to the disclosure requirements of Item 5.05 of Form 8-K within four business days following the date of the amendment or waiver.

Item 11. Executive Compensation.

The information required by this Item will be set forth in the Company’s 2022 Proxy Statement and is incorporated herein by reference.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

The information required by this Item will be set forth in the Company’s 2022 Proxy Statement and is incorporated herein by reference.

The information required by this Item will be set forth in the Company’s 2022 Proxy Statement and is incorporated herein by reference.

Item 14. Principal AccountANT Fees and Services.

The information required by this Item will be set forth in the Company’s 2022 Proxy Statement and is incorporated herein by reference.

 

92

 

PART IV

Item 15. Exhibits, Financial Statement Schedules.

The following documents are filed as part of this report on Form 10-K:

(a) Financial Statements:

Reference is made to the Index to the registrant’s Financial Statements under Item 8 in Part II of this Form 10-K.

(b) Financial Statement Schedules:

Financial statement schedules have been omitted because the required information is not present or not present in the amounts sufficient to require submission of the schedule or because the information is already included in the financial statements or notes thereto.

(c) Exhibits:

The documents listed in the following Exhibit Index are incorporated by reference or are filed with this Annual Report on Form 10-K.

 

 

93

 

 

Exhibit Index

 

Exhibit

Number

 

Description of Exhibit

3.1

 

Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference from Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on April 27, 2021 (Commission File No. 001-40356)).

 

 

 

3.2

 

Bylaws of the Registrant (incorporated by reference from Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed on April 27, 2021 (Commission File No. 001-40356)).

 

 

 

4.1

 

Form of Common Stock Certificate of the Registrant (incorporated by reference from Exhibit 4.1 of the Registrant’s Amendment No. 1 to Registration Statement on Form S-1 filed on April 9, 2021 (Commission File No. 333-254998)).

 

 

 

4.2

 

Amended and Restated Investors’ Rights Agreement, dated September 2, 2020, by and among the Registrant and certain of its stockholders (incorporated by reference from Exhibit 4.2 of the Registrant’s Registration Statement on Form S-1 filed on April 2, 2021 (Commission File No. 333-254998)).

 

 

 

4.3*

 

Description of Securities.

 

 

 

10.1

 

Form of Indemnification Agreement for directors and executive officers (incorporated by reference from Exhibit 10.1 of the Registrant’s Registration Statement on Form S-1 filed on April 2, 2021 (Commission File No. 333-254998)).

 

 

 

10.2+

 

Amended and Restated 2018 Stock Option/Stock Issuance Plan and form of award agreement thereunder (incorporated by reference from Exhibit 10.2 of the Registrant’s Registration Statement on Form S-1 filed on April 2, 2021 (Commission File No. 333-254998)).

 

 

 

10.3+

 

2021 Equity Incentive Plan (incorporated by reference from Exhibit 10.3 of the Registrant’s Amendment No. 2 to Registration Statement on Form S-1 filed on April 19, 2021 (Commission File No. 333-254998)).

 

 

 

10.4+

 

2021 Employee Stock Purchase Plan (incorporated by reference from Exhibit 10.4 of the Registrant’s Amendment No. 2 to Registration Statement on Form S-1 filed on April 19, 2021 (Commission File No. 333-254998)).

 

 

 

10.5+

 

Director Offer Letter, dated March 19, 2018, by and between the Registrant and Tran Nguyen (incorporated by reference from Exhibit 10.5 of the Registrant’s Registration Statement on Form S-1 filed on April 2, 2021 (Commission File No. 333-254998)).

 

 

 

10.6+

 

Director Offer Letter, dated March 19, 2018, by and between the Registrant and Peter Radovich (incorporated by reference from Exhibit 10.6 of the Registrant’s Registration Statement on Form S-1 filed on April 2, 2021 (Commission File No. 333-254998)).

 

 

 

10.7+

 

Employment Agreement, dated September 10, 2020, by and between the Registrant and Avanish Vellanki (incorporated by reference from Exhibit 10.7 of the Registrant’s Registration Statement on Form S-1 filed on April 2, 2021 (Commission File No. 333-254998)).

 

 

 

10.8+

 

Employment Agreement, dated September 10, 2020, by and between the Registrant and Robert Doebele (incorporated by reference from Exhibit 10.8 of the Registrant’s Registration Statement on Form S-1 filed on April 2, 2021 (Commission File No. 333-254998)).

 

 

 

10.9+

 

Offer Letter, dated October 1, 2020, by and between the Registrant and Nelson Cabatuan (incorporated by reference from Exhibit 10.9 of the Registrant’s Registration Statement on Form S-1 filed on April 2, 2021 (Commission File No. 333-254998)).

 

 

 

 

94

 

10.10#

 

License Agreement, dated September 2, 2020, between the Registrant and Daiichi Sankyo Company, Limited (incorporated by reference from Exhibit 10.10 of the Registrant’s Registration Statement on Form S-1 filed on April 2, 2021 (Commission File No. 333-254998)).

 

 

 

10.11#

 

Intellectual Property License Agreement, dated July 30, 2020, by and between the Registrant and Drexel University (incorporated by reference from Exhibit 10.11 of the Registrant’s Registration Statement on Form S-1 filed on April 2, 2021 (Commission File No. 333-254998)).

 

 

 

10.12

 

Office Lease Agreement, dated September 25, 2018, between the Registrant and BSP Senita 8000 Jarvis, LLC, as amended (incorporated by reference from Exhibit 10.12 of the Registrant’s Registration Statement on Form S-1 filed on April 2, 2021 (Commission File No. 333-254998)).

 

 

 

10.13

 

Exchange Agreement, dated April 17, 2021, by and among the Registrant and the stockholders listed therein (incorporated by reference from Exhibit 10.13 of the Registrant’s Amendment No. 2 to Registration Statement on Form S-1 filed on April 19, 2021 (Commission File No. 333-254998)).

 

 

 

10.14

 

Rain Therapeutics Inc. Executive Severance Plan (incorporated by reference from Exhibit 10.1 of the Registrant’s Current Report on Form 8-K filed on August 17, 2021 (Commission File No. 001-40356)).

 

 

 

23.1*

 

Consent of Independent Registered Public Accounting Firm.

 

 

 

31.1*

 

Certification of the principal executive officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934.

 

 

 

31.2*

 

Certification of the principal financial officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934.

 

 

 

32.1 (1)

 

Certification of the principal executive officer and principal financial officer pursuant to 18 U.S.C. Section 1350 and Rule 13a-14(b) under the Securities Exchange Act of 1934

 

 

 

101.INS*

 

Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.

 

 

 

101.SCH*

 

Inline XBRL Taxonomy Extension Schema Document.

 

 

 

101.CAL*

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document.

 

 

 

101.DEF*

 

Inline XBRL Taxonomy Extension Definition Linkbase Document.

 

 

 

101.LAB*

 

Inline XBRL Taxonomy Extension Label Linkbase Document.

 

 

 

101.PRE*

 

Inline XBRL Taxonomy Extension Presentation Linkbase Document.

 

 

 

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

*

Filed herewith.

+

Indicates management contract or compensatory plan.

#

Portions of the exhibit have been omitted for confidentiality purposes.

 

 

(1)

The certifications on Exhibit 32 hereto are deemed not “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that Section. Such certifications will not be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.

 

Item 16. Form 10-K Summary.

None.

 

95

 

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

Company Name

 

 

 

 

Date: March 3, 2022

 

By:

/s/ Avanish Vellanki

 

 

 

Avanish Vellanki

 

 

 

Chairman and Chief Executive Officer

(principal executive officer)

 

 

 

 

Date: March 3, 2022

 

By:

/s/ Nelson Cabatuan

 

 

 

Nelson Cabatuan

 

 

 

Senior Vice President of Finance and Administration

(principal financial and accounting officer)

 

POWER OF ATTORNEY

 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Avanish Vellanki, Nelson Cabatuan and Jamie S. Blose, and each of them, the true and lawful attorneys-in-fact and agents of the undersigned, with full power of substitution and resubstitution, for and in the name, place and stead of the undersigned, to sign in any and all capacities (including, without limitation, the capacities listed below), this Annual Report on Form 10-K, any and all amendments thereto, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, and hereby grants to such attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and anything necessary to be done to enable the registrant to comply with the provisions of the Securities Exchange Act and all the requirements of the Securities and Exchange Commission, as fully to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitute, or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

 

 

Name

 

Title

 

Date

 

 

 

 

 

/s/ Avanish Vellanki

 

Chief Executive Officer and Chairman

 

March 3, 2022

Avanish Vellanki

 

(principal executive officer)

 

 

 

 

 

 

 

/s/ Nelson Cabatuan

 

Senior Vice President of Finance and Administration

 

March 3, 2022

Nelson Cabatuan

 

(principal financial and accounting officer)

 

 

 

 

 

 

 

/s/ Franklin Berger

 

Director

 

March 3, 2022

Franklin Berger

 

 

 

 

 

 

 

 

 

/s/ Aaron Davis

 

Director

 

March 3, 2022

Aaron Davis

 

 

 

 

 

 

 

 

 

/s/ Gorjan Hrustanovic

 

Director

 

March 3, 2022

Gorjan Hrustanovic, Ph.D.

 

 

 

 

 

96

 

 

 

 

 

 

/s/ Tran Nguyen

 

Director

 

March 3, 2022

Tran Nguyen

 

 

 

 

 

 

 

 

 

/s/ Peter Radovich

 

Director

 

March 3, 2022

Peter Radovich

 

 

 

 

 

 

 

 

 

/s/ Stefani Wolff

 

Director

 

March 3, 2022

Stefani Wolff

 

 

 

 

 

 

 

 

 

 

 

 

 

97

 EX-4.3 2 rain-ex43_74.htm EX-4.3 rain-ex43_74.htm

 

Exhibit 4.3

DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934

General

The following is a summary of the material terms of our capital stock, as well as other material terms of our amended and restated certificate of incorporation and amended and restated bylaws and certain provisions of Delaware law. This summary does not purport to be complete and is qualified in its entirety by the provisions of our certificate of incorporation and bylaws, copies of which are filed as exhibits to our Annual Report on Form 10-K, to which this exhibit is also appended.

Our authorized capital stock consists of 200,000,000 shares of common stock, $0.001 par value per share, 50,000,000 shares of non-voting common stock, $0.001 par value per share, and 10,000,000 shares of “blank check” preferred stock, $0.001 par value per share.

Common Stock and Non-Voting Common Stock

Our amended and restated certificate of incorporation authorizes the issuance of up to 200,000,000 shares of our common stock and 50,000,000 shares of our non-voting common stock. All outstanding shares of our common stock and non-voting common stock are validly issued, fully paid and nonassessable.

Holders of our common stock and our non-voting common stock have identical rights, provided that, (i) except as otherwise expressly provided in our amended and restated certificate of incorporation or as required by applicable law, on any matter that is submitted to a vote by our stockholders, holders of our common stock are entitled to one vote per share of common stock, and holders of our non-voting common stock are not entitled to any votes per share of non-voting common stock, including for the election of directors, and (ii) holders of our common stock have no conversion rights, while holders of our non-voting common stock shall have the right to convert each share of our non-voting common stock into one share of common stock at such holder’s election, provided that as a result of such conversion, such holder, together with its affiliates and any members of a Schedule 13(d) group with such holder, would not beneficially own in excess of 9.99% of our common stock immediately prior to and following such conversion (the “Beneficial Ownership Limitation”), unless otherwise as expressly provided for in our amended and restated certificate of incorporation. However, the Beneficial Ownership Limitation may be increased or decreased to any other percentage (not to exceed 19.99%) designated by such holder of non-voting common stock upon 61 days’ notice to us.

        Voting Rights

 Our common stock is entitled to one vote per share on any matter that is submitted to a vote of our stockholders, and our non-voting common stock is not entitled to any votes per share. Except as otherwise expressly provided in our amended and restated certificate of incorporation or required by applicable law, all shares of common stock and non-voting common stock will have the same rights and privileges and rank equally, share ratably, and be identical in all respects for all matters, including those described below.

         Dividends   

Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of our common stock and non-voting common stock are entitled to receive dividends out of funds legally available if our board of directors, in its discretion, determines to issue dividends and then only at the times and in the amounts that our board of directors may determine.

         Liquidation Rights    

On our liquidation, dissolution, or winding-up, the holders of common stock and non-voting common stock will be entitled to share equally, identically, and ratably in all assets remaining after the payment of any liabilities, liquidation preferences and accrued or declared but unpaid dividends, if any, with respect to any outstanding

 

 

preferred stock, unless a different treatment is approved by the affirmative vote of the holders of a majority of the outstanding shares of such affected class, voting separately as a class.

Preferred Stock

Under the terms of our amended and restated certificate of incorporation, our board of directors (the “Board”) has the authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the dividend, voting and other rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon, and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding.

Our Board may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of our common stock and non-voting common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in our control and may adversely affect the market price of our common stock and non-voting common stock and the voting and other rights of the holders of our common stock and non-voting common stock. We have no current plans to issue any shares of preferred stock.

Registration Rights

We are party to the amended and restated investors’ rights agreement, effective as of September 2, 2020 (the “IRA”) which provides that certain of our stockholders have certain registration rights described below. The registration of shares of our common stock pursuant to the exercise of registration rights described below would enable holders to sell these shares without restriction under the Securities Act of 1933, as amended (the “Securities Act”) when the registration statement is declared effective. We will pay all expenses related to any demand, piggyback, or Form S-3 registration described below, with the exception of underwriting discounts and commissions.

The registration rights described below will expire upon the earliest to occur of: (i) April 27, 2024; (ii) the closing of a deemed liquidation event (as defined in our amended and restated certificate of incorporation) or (iii) with respect to any particular holder, at such time that such holder can sell its shares, under Rule 144 or another similar exemption under the Securities Act, during any three-month period without registration.

 

Demand Registration Rights

 

The holders of registrable securities are entitled to certain demand registration rights. At any time after October 19, 2021, holders who are major investors and hold a majority of the registrable securities then outstanding may request that we register at least 40% of the registrable securities then outstanding.

Piggyback Registration Rights

Subject to certain specified exceptions, if we propose to register any of our securities under the Securities Act either for our own account or for the account of other stockholders, the holders of shares having registration rights are entitled to written notice and certain “piggyback” registration rights allowing them to include their shares in our registration statement. These registration rights are subject to specified conditions and limitations, including the right of the underwriters, in their sole discretion, to limit the number of shares included in any such offering under certain circumstances, but not below 30% of the total amount of securities included in such offering.

Form S-3 Registration Rights

At any time after we are qualified to file a registration statement on Form S-3, and subject to limitations and conditions, holders who are major investors and hold at least 30% of the registrable securities then outstanding may make a written request that we prepare and file a registration statement on Form S-3 under the Securities Act covering their shares, so long as the aggregate price to the public, net of the underwriters’ discounts and commissions, is at least $5,000,000. We will prepare and file the Form S-3 registration statement as requested, unless, in the good faith judgment of our Board, such registration would be materially detrimental to the company and its stockholders and filing should be deferred. We may defer only once in any 12-month period, and such deferral shall not exceed 90 days after receipt of the request. In addition, we are not obligated to prepare or file any of these registration statements (i) within 30 days before or 90 days after the effective date of a registration

 

 

statement pursuant to demand or piggyback registration rights or (ii) if two of these registrations have been completed within any 12-month period.

Anti-Takeover Effects of Our Amended and Restated Certificate of Incorporation, Amended and Restated Bylaws and Delaware Law

Our amended and restated certificate of incorporation and our amended and restated bylaws include a number of provisions that may have the effect of delaying, deferring or preventing another party from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our Board rather than pursue non-negotiated takeover attempts.

 

 

 

 

 

 

•

Issuance of undesignated preferred stock: Under our amended and restated certificate of incorporation, our Board has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of undesignated preferred stock with rights and preferences, including voting rights, designated from time to time by our Board. The existence of authorized but unissued shares of preferred stock enables our Board to make it more difficult to attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise.

•

Classified board: Our amended and restated certificate of incorporation establishes a classified Board consisting of three classes of directors, with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders to succeed the directors of the same class whose terms are then expiring, with the other classes continuing for the remainder of their respective three-year terms. This provision may have the effect of delaying a change in control of our Board.

•

Election and removal of directors and board vacancies: Our amended and restated certificate of incorporation provides that directors will be elected by a plurality vote. Our amended and restated certificate of incorporation and amended and restated bylaws also provide that our Board has the right to increase or decrease the size of the Board and to fill vacancies on the Board. Directors may be removed only for cause by the affirmative vote of the holders of at least 66 2/3% of the votes that all our stockholders would be entitled to cast in an annual election of directors. Only our Board is authorized to fill vacant directorships. In addition, the number of directors constituting our Board may be set only by resolution adopted by a majority vote of the directors then in office. These provisions prevent stockholders from increasing the size of our Board and gaining control of our Board by filling the resulting vacancies with its own nominees.

•

Requirements for advance notification of stockholder nominations and proposals: Our amended and restated bylaws establish advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors that specify certain requirements as to the timing, form and content of a stockholder’s notice. Business that may be conducted at an annual meeting of stockholders will be limited to those matters properly brought before the meeting. These provisions may make it more difficult for our stockholders to bring matters before our annual meeting of stockholders or to nominate directors at annual meetings of stockholders.

•

No written consent of stockholders: Our amended and restated certificate of incorporation provides that all stockholder actions be taken by a vote of the stockholders at an annual or special meeting, and that stockholders may not take any action by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take stockholder actions and would prevent the amendment of our amended and restated bylaws or removal of directors by our stockholders without holding a meeting of stockholders.

•

No stockholder ability to call special meetings: Our amended and restated certificate of incorporation and amended and restated bylaws provide that only our Board may be able to call special meetings of stockholders and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders.

 

 

•

Amendments to certificate of incorporation and bylaws: Any amendment to our amended and restated certificate of incorporation must be approved by a majority of our Board as well as, if required by law or our amended and restated certificate of incorporation, a majority of the outstanding shares entitled to vote on the amendment and a majority of the outstanding shares of each class entitled to vote thereon as a class, except that the amendment of provisions to Board classification, stockholder action, certificate amendments and liability of directors must be approved by not less than 66 2/3% of the outstanding shares entitled to vote on the amendment, voting together as a single class. Any amendment to our amended and restated bylaws must be approved by either a majority of our Board or not less than 66 2/3% of the outstanding shares entitled to vote on the amendment, voting together as a single class.

 

 

 

 

 

 

 

 

 

These provisions are designed to enhance the likelihood of continued stability in the composition of our Board and its policies, to discourage certain types of transactions that may involve an actual or threatened acquisition of our company and to reduce our vulnerability to an unsolicited acquisition proposal. We also designed these provisions to discourage certain tactics that may be used in proxy fights. However, these provisions could have the effect of discouraging others from making tender offers for our shares and, as a consequence, they may also reduce fluctuations in the market price of our shares that could result from actual or rumored takeover attempts.

Delaware General Corporation Law Section 203

As a Delaware corporation, we are also subject to the anti-takeover provisions of Section 203 of the Delaware General Corporation Law, which prohibits a Delaware corporation from engaging in a business combination specified in the statute with an interested stockholder (as defined in the statute) for a period of three years after the date of the transaction in which the person first becomes an interested stockholder, unless the business combination is approved in advance by a majority of the independent directors or by the holders of at least two-thirds of the outstanding disinterested shares. The application of Section 203 of the Delaware General Corporation Law could also have the effect of delaying or preventing a change of control of us.

Exclusive Forum Selection Clause

Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the sole and exclusive forum to the fullest extent permitted by law for: (1) any derivative action or proceeding brought on our behalf; (2) any action asserting a breach of fiduciary duty owed by any director, officer or other employee to us or our stockholders; (3) any action asserting a claim against us or any director or officer or other employee arising pursuant to the Delaware General Corporation Law; (4) any action to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or bylaws; or (5) any other action asserting a claim that is governed by the internal affairs doctrine, shall be the Court of Chancery of the State of Delaware (or another state court or the federal court located within the State of Delaware if the Court of Chancery does not have or declines to accept jurisdiction), in all cases subject to the court’s having jurisdiction over indispensable parties named as defendants. Our amended and restated certificate of incorporation provides that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act but the forum selection provisions will not apply to claims brought to enforce a duty or liability created by the Exchange Act. Although we believe these provisions benefit us by providing increased consistency in the application of Delaware law for the specified types of actions and proceedings, the provisions may have the effect of discouraging lawsuits against us or our directors or officers. It is possible that a court could find that such provisions are inapplicable for a particular claim or action or that such provisions are unenforceable. In addition, under the Securities Act, federal courts have concurrent jurisdiction over all suits brought to enforce any duty or liability created by the Securities Act, and investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder.

Transfer Agent and Registrar

American Stock Transfer & Trust Company, LLC serves as the transfer agent and registrar for our common stock.

 

 

Listing

Our common stock is listed on the Nasdaq Global Select Market under the symbol “RAIN.” Our non-voting common stock is not listed on any securities exchange.

 

 

 

 EX-23.1 3 rain-ex231_75.htm EX-23.1 AUDITOR CONSENT rain-ex231_75.htm

Exhibit 23.1

 

Consent of Independent Registered Public Accounting Firm

 

We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-255548) pertaining to the Rain Therapeutics Inc. 2021 Equity Incentive Plan, the Rain Therapeutics Inc. 2021 Employee Stock Purchase Plan, and the Rain Therapeutics Inc. Amended and Restated 2018 Stock Option/Stock Issuance Plan of Rain Therapeutics Inc. of our report dated March 3, 2022, with respect to the financial statements of Rain Therapeutics Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2021.

 

/s/ Ernst & Young LLP

 

San Diego, California

March 3, 2022


 

1

 

 

 

2

 EX-31.1 4 rain-ex311_76.htm EX-31.1 CEO 302 CERTIFICATION rain-ex311_76.htm

Exhibit 31.1

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Avanish Vellanki, certify that:

1.

I have reviewed this Annual Report on Form 10-K of Rain Therapeutics Inc.;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

 

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(c)

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.

The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: March 3, 2022

 

By:

/s/ Avanish Vellanki

 

 

 

Avanish Vellanki

 

 

 

Chairman and Chief Executive Officer

(principal executive officer)

 

 

1

 EX-31.2 5 rain-ex312_77.htm EX-31.2 SENIOR VP -FINANCE 302 CERTIFICATION rain-ex312_77.htm

Exhibit 31.2

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Nelson Cabatuan, certify that:

1.

I have reviewed this Annual Report on Form 10-K of Rain Therapeutics Inc.;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

 

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(c)

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.

The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: March 3, 2022

 

By:

/s/ Nelson Cabatuan

 

 

 

Nelson Cabatuan

 

 

 

Senior Vice President of Finance and Administration

(principal financial and accounting officer)

 

 

1

 EX-32.1 6 rain-ex321_73.htm EX-32.1 rain-ex321_73.htm

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report on Form 10-K of Rain Therapeutics Inc. (the “Company”) for the year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

 

1.

The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act, and

 

2.

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: March 3, 2022

By:

/s/ Avanish Vellanki

 

 

Avanish Vellanki

 

 

Chairman and Chief Executive Officer

(principal executive officer)

 

 

 

 

Date: March 3, 2022

By:

/s/ Nelson Cabatuan

 

 

Nelson Cabatuan

 

 

Senior Vice President of Finance and Administration

(principal financial and accounting officer)

 

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

Note: A signed original of this written statement required by § 906 has been provided to Rain Therapeutics Inc. and will be retained by Rain Therapeutics Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

1

 GRAPHIC 7 gxcvxnmtxzcp000001.jpg GRAPHIC begin 644 gxcvxnmtxzcp000001.jpg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end EX-101.SCH 8 rain-20211231.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Balance Sheets link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Statements of Operations and Comprehensive Loss link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100060 - Statement - Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Organization and Nature of Operations link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Fair Value Measurements link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Investments link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Balance Sheet Details link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Related Party Transactions link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Convertible Promissory Notes link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - License and Clinical Supply Agreements link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Employee Benefits link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Net Loss Per Share link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Fair Value Measurements (Tables) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Investments (Tables) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Balance Sheet Details (Tables) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) (Tables) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Commitments and Contingencies (Tables) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Income Taxes (Tables) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Net Loss Per Share (Tables) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Organization and Nature of Operations - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Fair Value Measurements - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Details) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Parenthetical) (Details) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value Using Level 3 Significant Unobservable Inputs (Details) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Investments - Summary of Cash Equivalents and Investments Measured at Fair Value on Recurring Basis (Details) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Investments - Schedule of Contractual Maturities of AFS Securities (Details) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Investments - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100370 - Disclosure - Balance Sheet Details - Schedule of Prepaid and Other Current Assets (Details) link:calculationLink link:presentationLink link:definitionLink 100380 - Disclosure - Balance Sheet Details - Schedule of Property and Equipment, Net (Details) link:calculationLink link:presentationLink link:definitionLink 100390 - Disclosure - Balance Sheet Details - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100400 - Disclosure - Balance Sheet Details - Schedule of Other Non-Current Assets (Details) link:calculationLink link:presentationLink link:definitionLink 100410 - Disclosure - Related Party Transactions - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100420 - Disclosure - Convertible Promissory Notes - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100430 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100440 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) - Summary of Stock Option Activities (Details) link:calculationLink link:presentationLink link:definitionLink 100450 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) - Summary of Stock-Based Compensation Expense Recognized (Details) link:calculationLink link:presentationLink link:definitionLink 100460 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) - Weighted-Average Assumptions Used in Black-Scholes Option Pricing Model to Determine Fair Value of Stock Option Grants (Details) link:calculationLink link:presentationLink link:definitionLink 100470 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) - Schedule of Common Stock Reserved for Future Issuance (Details) link:calculationLink link:presentationLink link:definitionLink 100480 - Disclosure - License and Clinical Supply Agreements - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100490 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100500 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments Required under Operating Lease (Details) link:calculationLink link:presentationLink link:definitionLink 100510 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments Required under Operating Lease (Details)2 link:calculationLink link:presentationLink link:definitionLink 100520 - Disclosure - Commitments and Contingencies - Summary of Lease Costs and Cash Payments (Details) link:calculationLink link:presentationLink link:definitionLink 100530 - Disclosure - Employee Benefits - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100540 - Disclosure - Income Taxes - Components of Provision for Income Taxes (Details) link:calculationLink link:presentationLink link:definitionLink 100550 - Disclosure - Income Taxes - Computation of Provision for Income Taxes by Applying Federal Statutory Income Tax Rate to Income Before Taxes (Detail) link:calculationLink link:presentationLink link:definitionLink 100560 - Disclosure - Income Taxes - Components of Deferred Income Tax Assets and Liabilities (Detail) link:calculationLink link:presentationLink link:definitionLink 100570 - Disclosure - Income Taxes - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100580 - Disclosure - Income Taxes - Schedule of Federal and State Net Operating Loss Carryforwards (Details) link:calculationLink link:presentationLink link:definitionLink 100590 - Disclosure - Income Taxes - Changes in Gross Unrecognized Tax Benefits (Detail) link:calculationLink link:presentationLink link:definitionLink 100600 - Disclosure - Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss per Share (Details) link:calculationLink link:presentationLink link:definitionLink 100610 - Disclosure - Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 9 rain-20211231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 10 rain-20211231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 11 rain-20211231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Income tax reconciliation change in fair value of convertible promissory note. Income tax reconciliation convertible notes interest. Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Annual Report Document Annual Report Document Transition Report Document Transition Report Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Entity File Number Entity File Number Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Well-known Seasoned Issuer Entity Well Known Seasoned Issuer Entity Voluntary Filers Entity Voluntary Filers Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Entity Shell Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Entity Public Float Entity Public Float Current Fiscal Year End Date Current Fiscal Year End Date Entity Central Index Key ICFR Auditor Attestation Flag Icfr Auditor Attestation Flag Auditor Name Auditor Name Auditor Location Auditor Location Auditor Firm ID Auditor Firm Id Deferred offering cost noncurrent. Accrued research and development current. Statement Of Financial Position [Abstract] Statement [Table] Statement [Table] Class of Stock Statement Class Of Stock [Axis] Class of Stock Class Of Stock [Domain] Series A convertible preferred stock. Series A Convertible Preferred Stock Series A Convertible Preferred Stock [Member] Series B convertible preferred stock. Series B Convertible Preferred Stock Series B Convertible Preferred Stock [Member] Statement [Line Items] Statement [Line Items] Assets Assets [Abstract] Current assets: Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Short-term investments Short Term Investments Prepaid and other current assets Prepaid Expense And Other Assets Current Total current assets Assets Current Property and equipment, net Property Plant And Equipment Net Operating lease right-of-use asset Operating Lease Right Of Use Asset Deferred offering costs Deferred Offering Cost Noncurrent Other assets Other Assets Noncurrent Total assets Assets Liabilities, convertible preferred stock, and stockholders’ equity (deficit) Liabilities And Stockholders Equity [Abstract] Current liabilities: Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued research and development Accrued Research And Development Current Other accrued liabilities Other Accrued Liabilities Current Operating lease liability, current portion Operating Lease Liability Current Total current liabilities Liabilities Current Operating lease liability, net of current portion Operating Lease Liability Noncurrent Other long-term liabilities Other Liabilities Noncurrent Total liabilities Liabilities Commitments and contingencies Commitments And Contingencies Total convertible preferred stock Temporary Equity Carrying Amount Attributable To Parent Stockholders’ equity (deficit): Stockholders Equity [Abstract] Common Stock, $0.001 par value; 250,000,000 and 24,000,000 shares authorized as of December 31, 2021 and December 31, 2020, respectively; 26,475,812 shares (comprised of 18,748,342 shares of common stock and 7,727,470 shares of non-voting common stock) and 3,530,975 shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively Common Stock Value Additional paid-in capital Additional Paid In Capital Common Stock Accumulated other comprehensive loss Accumulated Other Comprehensive Income Loss Net Of Tax Accumulated deficit Retained Earnings Accumulated Deficit Total stockholders' equity (deficit) Stockholders Equity Total liabilities, convertible preferred stock, and stockholders’ equity (deficit) Liabilities And Stockholders Equity Undesignated Common Stock. Common Stock Undesignated Common Stock [Member] Non-voting Common Stock Nonvoting Common Stock [Member] Convertible preferred stock, Par value Temporary Equity Par Or Stated Value Per Share Convertible preferred stock, Shares authorized Temporary Equity Shares Authorized Convertible preferred stock, Shares issued Temporary Equity Shares Issued Convertible preferred stock, Shares outstanding Temporary Equity Shares Outstanding Common stock, Par value Common Stock Par Or Stated Value Per Share Common stock, shares authorized Common Stock Shares Authorized Common stock, shares issued Common Stock Shares Issued Common stock, shares outstanding Common Stock Shares Outstanding Change in fair value of convertible promissory notes, related party Income Statement [Abstract] Operating expenses: Operating Expenses [Abstract] Research and development Research And Development Expense General and administrative General And Administrative Expense Total operating expenses Operating Expenses Loss from operations Operating Income Loss Other income (expense): Nonoperating Income Expense [Abstract] Interest income Investment Income Interest Interest expense, related party Interest Expense Related Party Change in fair value of convertible promissory notes, related party Change In Fair Value Of Convertible Promissory Notes Related Party Other income Other Nonoperating Income Total other income (expense), net Nonoperating Income Expense Net loss before income tax expense Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest Income tax expense Income Tax Expense Benefit Net loss Net Income Loss Net loss per share, basic and diluted Earnings Per Share Basic And Diluted Weighted-average shares used to compute net loss per share, basic and diluted Weighted Average Number Of Share Outstanding Basic And Diluted Net loss Other comprehensive income: Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract] Unrealized loss on investments Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax Comprehensive loss Comprehensive Income Net Of Tax Temporary equity stock issued during period shares new issues. Temporary Equity Stock Value Conversion of Convertible Promissory Notes into Convertible Preferred Stock. Temporary equity stock shares conversion of convertible promissory notes into convertible preferred stock. Temporary equity stock issued during period shares conversion of share. Temporary equity stock issued during period value conversion of share. Statement Of Stockholders Equity [Abstract] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Common Stock Common Stock [Member] Additional Paid-in Capital Additional Paid In Capital [Member] Accumulated Deficit Retained Earnings [Member] Accumulated Other Comprehensive Loss Accumulated Other Comprehensive Income [Member] Balance Temporary equity, balance, Shares Temporary equity, balance Balance, Shares Shares Outstanding Issuance of Series B convertible preferred stock, net of issuance costs of $320 Temporary Equity Stock Issued During Period Value New Issues Issuance of Series B convertible preferred stock, net of issuance costs of $320, Shares Temporary Equity Stock Issued During Period Shares New Issues Conversion of convertible promissory notes into Series B convertible preferred stock Temporary Equity Stock Value Conversion Of Convertible Promissory Notes Into Convertible Preferred Stock Conversion of convertible promissory notes into Series B convertible preferred stock, Shares Temporary Equity Stock Shares Conversion Of Convertible Promissory Notes Into Convertible Preferred Stock Vesting of restricted shares Stock Issued During Period Value Restricted Stock Award Gross Vesting of restricted shares, Shares Stock Issued During Period Shares Restricted Stock Award Gross Conversion of convertible preferred stock to common stock Stock Issued During Period Value Conversion Of Convertible Securities Temporary equity conversion of convertible preferred stock to common stock, shares Temporary Equity Stock Issued During Period Shares Conversion Of Share Temporary equity conversion of convertible preferred stock to common stock Temporary Equity Stock Issued During Period Value Conversion Of Share Conversion of convertible preferred stock to common stock, shares Stock Issued During Period Shares Conversion Of Convertible Securities Issuance of common stock upon IPO, net of issuance cost Stock Issued During Period Value New Issues Issuance of common stock upon IPO, net of issuance cost, shares Stock Issued During Period Shares New Issues Exercise of stock options Stock Issued During Period Value Stock Options Exercised Exercise of stock options, shares Stock Issued During Period Shares Stock Options Exercised Stock-based compensation expense Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Balance Temporary equity, balance, Shares Temporary equity, balance Balance, Shares Temporary equity issuance cost. Stock issuance cost Temporary Equity Issuance Cost Increase decrease in operating lease right-of-use asset and liability net. Increase decrease in accrued research and development. Non cash in process research and development accrual. Non cash additions to property and equipment. Conversion of convertible promissory notes and interest into series b convertible preferred stock. Accruals for unbilled professional fees related to IPO. Statement Of Cash Flows [Abstract] Operating activities Net Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net loss to cash used in operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] In-process research and development expense Research And Development In Process Depreciation and amortization expense Depreciation And Amortization Stock-based compensation expense Share Based Compensation Non-cash interest expense, related party Change in fair value of convertible promissory notes, related party Amortization of premium and accretion of discounts on short-term investments, net Accretion Amortization Of Discounts And Premiums Investments Fair value loss/(gain) on investments Gain Loss On Investments Changes in operating assets and liabilities: Increase Decrease In Operating Capital [Abstract] Prepaid and other current assets Increase Decrease In Prepaid Deferred Expense And Other Assets Operating lease right-of-use asset and liability, net Increase Decrease In Operating Lease Right Of Use Asset And Liability Net Other assets Increase Decrease In Other Noncurrent Assets Accounts payable Increase Decrease In Accounts Payable Accrued research and development Increase Decrease In Accrued Research And Development Other accrued liabilities Increase Decrease In Other Accrued Liabilities Other long-term liabilities Increase Decrease In Other Noncurrent Liabilities Net cash used in operating activities Net Cash Provided By Used In Operating Activities Investing activities Net Cash Provided By Used In Investing Activities [Abstract] Purchases of short-term investments Payments To Acquire Short Term Investments Purchases of property and equipment Payments To Acquire Property Plant And Equipment Payment of in-process research and development expense Payments To Acquire In Process Research And Development Maturities of available for sale investments Proceeds From Sale And Maturity Of Available For Sale Securities Net cash used in investing activities Net Cash Provided By Used In Investing Activities Financing Activities Net Cash Provided By Used In Financing Activities [Abstract] Proceeds from initial public offering Proceeds From Issuance Initial Public Offering Proceeds from stock option exercises Proceeds From Stock Options Exercised Issuance of common stock for vesting of restricted shares Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Proceeds from issuance of convertible preferred stock, net of issuance costs Proceeds From Issuance Of Convertible Preferred Stock Proceeds from issuance of convertible promissory notes Proceeds From Convertible Debt Payments of issuance costs related to the initial public offering Payments Of Stock Issuance Costs Net cash provided by financing activities Net Cash Provided By Used In Financing Activities Net (decrease) increase in cash and cash equivalents Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Cash and cash equivalents at beginning of period Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations Cash and cash equivalents at end of period Supplemental schedule of non-cash investing and financing activities: Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract] Conversion of convertible preferred stock to common stock Conversion Of Stock Amount Converted1 Non-cash in-process research and development accrual Non Cash In Process Research And Development Accrual Non-cash additions to property and equipment Non Cash Additions To Property And Equipment Conversion of convertible promissory notes and interest into Series B convertible preferred stock Conversion Of Convertible Promissory Notes And Interest Into Series B Convertible Preferred Stock Accruals for unbilled professional fees related to the IPO Accruals For Unbilled Professional Fees Related To I P O Documents Incorporated by Reference Documents Incorporated By Reference [Text Block] Organization Consolidation And Presentation Of Financial Statements [Abstract] Organization and Nature of Operations Nature Of Operations Accounting Policies [Abstract] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Fair Value Disclosures [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Investments Debt And Equity Securities [Abstract] Investments Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block] Balance Sheet Related Disclosures [Abstract] Balance Sheet Details Supplemental Balance Sheet Disclosures [Text Block] Related Party Transactions [Abstract] Related Party Transactions Related Party Transactions Disclosure [Text Block] Convertible debt. Debt Disclosure [Abstract] Convertible Promissory Notes Convertible Debt [Text Block] Stockholders Equity Note [Abstract] Convertible Preferred Stock and Stockholders' Equity (Deficit) Stockholders Equity Note Disclosure [Text Block] License Agreements [Abstract] License and Clinical Supply Agreements License Agreements [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments And Contingencies Disclosure [Text Block] Compensation And Retirement Disclosure [Abstract] Employee Benefits Defined Contribution Plan [Text Block] Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Earnings Per Share [Abstract] Net Loss Per Share Earnings Per Share [Text Block] Use of Estimates Use Of Estimates Cash and Cash Equivalents Cash And Cash Equivalents Policy [Text Block] Available-for-Sale Investments Investment Policy [Text Block] Fair Value Option Fair Value Measurement Policy Policy [Text Block] Fair Value of Financial Instruments Fair Value Of Financial Instruments Policy Concentration of Credit Risk Concentration Risk Credit Risk Deferred offering costs. Deferred Offering Costs Deferred Offering Costs Policy [Text Block] Research and Development Costs Research And Development Expense Policy Property and Equipment Property Plant And Equipment Policy [Text Block] Long-Lived Assets Impairment Or Disposal Of Long Lived Assets Policy [Text Block] Commitments Commitments And Contingencies Policy [Text Block] Leases Lessee Leases Policy [Text Block] Preclinical studies and clinical trial accruals. Preclinical Studies and Clinical Trial Accruals Preclinical Studies And Clinical Trial Accruals Policy [Text Block] In-Process Research and Development In Process Research And Development Policy Patent Costs Intangible Assets Finite Lived Policy Costs Incurred To Renew Or Extend General and Administrative Expenses Selling General And Administrative Expenses Policy [Text Block] Stock-Based Compensation Share Based Compensation Option And Incentive Plans Policy Income Taxes Income Tax Policy [Text Block] Comprehensive Loss Comprehensive Income Policy Policy [Text Block] Net Loss Per Share Earnings Per Share Policy [Text Block] Recent developments regarding the COVID-19 pandemic. Recent Developments Regarding the COVID-19 Pandemic Recent Developments Regarding The C O V I D19 Pandemic Recent Accounting Pronouncements New Accounting Pronouncements Policy Policy [Text Block] Summary of Financial Assets Measured at Fair Value on Recurring Basis Fair Value Assets Measured On Recurring Basis [Text Block] Reconciliation of Liabilities Measured at Fair Value Using Level 3 Significant Unobservable Inputs Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block] Schedule of cash, cash equivalents and investments reconciliation. Summary of Cash Equivalents and Investments Measured at Fair Value on Recurring Basis Schedule Of Cash Cash Equivalents And Investments Reconciliation Table [Text Block] Schedule of Contractual Maturities of AFS Securities Debt Securities Available For Sale Table [Text Block] Schedule of Prepaid and Other Current Assets Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Text Block] Schedule of Property and Equipment, Net Property Plant And Equipment [Text Block] Schedule of Other Non-Current Assets Schedule Of Other Assets Noncurrent [Text Block] Plan Name Plan Name [Axis] Plan Name Plan Name [Domain] 2021 Employee Share Purchase Plan Two Thousand And Twenty One Employee Share Purchase Plan [Member] Summary of Stock Option Activities Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Summary of Stock-Based Compensation Expense Recognized Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Weighted-Average Assumptions Used in Black-Scholes Option Pricing Model to Determine Fair Value of Stock Option Grants Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block] Schedule of common stock reserved for future issuance. Schedule of Common Stock Reserved for Future Issuance Schedule Of Common Stock Reserved For Future Issuance Table [Text Block] Schedule of Future Minimum Lease Payments Required under Operating Lease Lessee Operating Lease Liability Maturity Table [Text Block] Summary of Lease Costs and Cash Payments Lease Cost Table [Text Block] Components of Provision for Income Taxes Schedule Of Components Of Income Tax Expense Benefit Table [Text Block] Computation of Provision for Income Taxes by Applying Federal Statutory Income Tax Rate to Income Before Taxes Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block] Components of Deferred Income Tax Assets and Liabilities Schedule Of Deferred Tax Assets And Liabilities Table [Text Block] Schedule of Federal and State net operating loss carryforwards. Schedule of Federal and State Net Operating Loss Carryforwards Schedule Of Federal And State Net Operating Loss Carryforwards Table [Text Block] Changes in Gross Unrecognized Tax Benefits Summary Of Income Tax Contingencies [Text Block] Schedule of Computation of Basic and Diluted Net Loss per Share Schedule Of Earnings Per Share Basic And Diluted Table [Text Block] Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block] Organization and nature of operations. Organization and nature of operations. Organization And Nature Of Operations [Table] Organization And Nature Of Operations [Table] Sale of Stock Subsidiary Sale Of Stock [Axis] Sale of Stock Sale Of Stock Name Of Transaction [Domain] IPO I P O [Member] Underwriters Option Over Allotment Option [Member] IPO and over allotment option. IPO and Over Allotment Option I P O And Over Allotment Option [Member] Organization And Nature Of Operations [Line Items] Organization And Nature Of Operations [Line Items] Entity incorporation date Entity Incorporation Date Of Incorporation Number of operating segments Number Of Operating Segments Reverse stock split description Stockholders Equity Reverse Stock Split Reverse stock split conversion ratio Stockholders Equity Note Stock Split Conversion Ratio1 Number of shares issued and sold Public offering price per share Sale Of Stock Price Per Share Proceeds from issuance of common stock Proceeds From Issuance Of Common Stock Conversion of convertible preferred stock Summary of significant accounting policies. Summary of significant accounting policies. Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Statistical Measurement Range [Axis] Statistical Measurement Range [Member] Minimum Minimum [Member] Maximum Maximum [Member] Accounting Standards Update Adjustments For New Accounting Pronouncements [Axis] Accounting Standards Update Type Of Adoption [Member] ASU 2020 - 06 Accounting Standards Update202006 [Member] Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Deferred offering costs Deferred Offering Costs Estimated useful lives of assets Property Plant And Equipment Useful Life Impairment losses on long-lived assets Tangible Asset Impairment Charges Change in accounting principle, accounting standards update, early adopted Change In Accounting Principle Accounting Standards Update Early Adoption Change in accounting principle, accounting standards update, adoption date Change In Accounting Principle Accounting Standards Update Adoption Date Change in accounting principle, accounting standards update, immaterial effect Change In Accounting Principle Accounting Standards Update Immaterial Effect Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Debt Instrument Debt Instrument [Axis] Debt Instrument, Name Debt Instrument Name [Domain] Two thousand nineteen and twenty convertible promissory notes. 2019 and 2020 Notes Two Thousand Nineteen And Twenty Convertible Promissory Notes [Member] Measurement Input Type Measurement Input Type [Axis] Measurement Input Type Measurement Input Type [Domain] Measurement Input, Expected Term Measurement Input Expected Term [Member] Measurement Input, Discount Rate Measurement Input Discount Rate [Member] Convertible Promissory Notes Convertible Promissory Notes [Member] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Assets transfer, Level 1 to 2 Fair Value Assets Level1 To Level2 Transfers Amount Assets transfer, Level 2 to 1 Fair Value Assets Level2 To Level1 Transfers Amount Assets transfer, out of Level 3 Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 Assets transfer, into Level 3 Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 Liabilities transfer, Level 1 to 2 Fair Value Liabilities Level1 To Level2 Transfers Amount Liabilities transfer, Level 2 to 1 Fair Value Liabilities Level2 To Level1 Transfers Amount Liabilities transfer, into of Level 3 Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 Liabilities transfer, out of Level 3 Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 Cash equivalents and short-term investments fair value. Measurement Frequency Fair Value By Measurement Frequency [Axis] Measurement Frequency Fair Value Measurement Frequency [Domain] Fair Value on Recurring Basis Fair Value Measurements Recurring [Member] Asset Class Fair Value By Asset Class [Axis] Asset Class Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain] Money Market Funds Money Market Funds [Member] Commercial Paper Commercial Paper [Member] U.S. Government Securities U S Treasury Securities [Member] U.S. Agency Bonds U S Government Agencies Debt Securities [Member] Corporate Debt Securities Corporate Debt Securities [Member] Fair Value Hierarchy and NAV Fair Value By Fair Value Hierarchy Level [Axis] Fair Value Hierarchy and NAV Fair Value Measurements Fair Value Hierarchy [Domain] Level 1 Fair Value Inputs Level1 [Member] Level 2 Fair Value Inputs Level2 [Member] Level 3 Fair Value Inputs Level3 [Member] Total cash equivalents and short-term investments Cash Equivalents And Short Term Investments Fair Value Cash and cash equivalents (includes cash of $397) Cash And Cash Equivalents Fair Value Disclosure Short-term investments Total cash, cash equivalents and short-term investments Cash Cash Equivalents And Short Term Investments Cash Cash [Member] Cash equivalents fair value disclosure. Cash equivalents Cash Equivalents Fair Value Disclosure Financial liabilities Financial Liabilities Fair Value Disclosure Fair Value, measurement with unobservable inputs reconciliation, issuance of convertible promissory notes. Fair value, measurement with unobservable inputs reconciliation, conversion to convertible preferred stock excluding interest expense. Fair Value, measurement with unobservable inputs reconciliation, changes in fair value of convertible promissory notes. Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table] Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table] Level 3 Significant Unobservable Inputs Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] Fair value as of December 31, 2019 Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value Issuance of convertible promissory notes Fair Value Measurement With Unobservable Inputs Reconciliation Issuance Of Convertible Promissory Notes Conversion to convertible preferred stock (excluding interest expense) Fair Value Measurement With Unobservable Inputs Reconciliation Conversion To Convertible Preferred Stock Excluding Interest Expense Change in fair value of convertible promissory notes (Note 7) Fair Value Measurement With Unobservable Inputs Reconciliation Changes In Fair Value Of Convertible Promissory Notes Fair value as of December 31, 2020 Alternative investment measurement expected term. Alternative investment measurement expected term Alternative Investment Measurement Expected Term Alternative investment, measurement input Alternative Investment Measurement Input Conversion of convertible promissory notes into Series B convertible preferred stock Convertible Preferred Stock Shares Issued Upon Conversion Debt conversion, fair value of debt converted Debt Conversion Original Debt Amount1 Debt conversion, accrued interest of debt converted Debt Conversion Accrued Interest Of Debt Converted Amount Debt conversion, converted instrument, shares Debt Conversion Converted Instrument Shares Issued1 Cash, cash equivalents and investments. Cash, cash equivalents and investments. Cash Cash Equivalents And Investments [Table] Cash Cash Equivalents And Investments [Table] Financial Instrument Financial Instrument [Axis] Financial Instruments Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain] Investment Type Investment Type [Axis] Investments Investment Type Categorization [Member] Cash and Cash Equivalents Cash And Cash Equivalents [Axis] Cash and Cash Equivalents Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member] Cash Cash Equivalents And Investments [Line Items] Cash Cash Equivalents And Investments [Line Items] Cash equivalents, amortized cost Cash Equivalents At Carrying Value Cash equivalents, estimated fair value Cash equivalents and investments amortized cost. Cash equivalents and investments unrealized gain before tax. Cash equivalents and investments unrealized loss before tax. Cash equivalents and investments fair value. Investments, amortized cost Available For Sale Debt Securities Amortized Cost Basis Investments, unrealized gains Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Investments, unrealized losses Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Investments, estimated fair value Available For Sale Securities Debt Securities Cash equivalents and investments, amortized cost Cash Equivalents And Investments Amortized Cost Cash equivalents and investments, unrealized gains Cash Equivalents And Investments Unrealized Gain Before Tax Cash equivalents and investments, unrealized losses Cash Equivalents And Investments Unrealized Loss Before Tax Cash equivalents and investments, estimated fair value Cash Equivalents And Investments Fair Value Due within one year Available For Sale Securities Debt Maturities Within One Year Fair Value Due within one to two years Available For Sale Securities Debt Maturities One To Two Year Fair Value Available-for-Sale Investments Investments Investments, realized gains or losses Debt Securities Available For Sale Realized Gain Loss Marketable securities, gross unrealized loss position Debt Securities Available For Sale Unrealized Loss Position Marketable securities, continuous unrealized loss position, greater than 12 months Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Marketable securities, continuous unrealized loss position, less than 12 months Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Prepaid research current. FICA tax credit receivable current. Prepaid insurance Prepaid Insurance Prepaid research Prepaid Research Current Prepaid other Other Prepaid Expense Current FICA tax credit receivable F I C A Tax Credit Receivable Current Deposits Deposits Assets Current Other current assets Other Assets Current Prepaid and Other Current Assets Schedule Of Property Plant And Equipment [Table] Schedule Of Property Plant And Equipment [Table] Long-Lived Tangible Asset Property Plant And Equipment By Type [Axis] Long-Lived Tangible Asset Property Plant And Equipment Type [Domain] Computer Equipment Computer Equipment [Member] Furniture and Equipment Furniture And Fixtures [Member] Leasehold Improvements Leasehold Improvements [Member] Property Plant And Equipment [Line Items] Property Plant And Equipment [Line Items] Property and equipment, gross Property Plant And Equipment Gross Less: accumulated depreciation and amortization expense Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Property and Equipment, net Depreciation expense Depreciation FICA tax credit receivable non current assets. FICA tax credit receivable F I C A Tax Credit Receivable Non Current Assets Deposits Deposits Assets Noncurrent Other Other Assets Miscellaneous Noncurrent Other non-current assets Debt conversion, accrued interest of debt converted, amount. Changes in fair value of debt instrument. Schedule Of Related Party Transactions By Related Party [Table] Schedule Of Related Party Transactions By Related Party [Table] Related Party Related Party Transactions By Related Party [Axis] Related Party Related Party [Domain] Certain holders of preferred stock investors. Certain Holders of Preferred Stock Investors Certain Holders Of Preferred Stock Investors [Member] 2019 Notes. 2019 Notes Two Thousand And Nineteen Notes [Member] 2020 Notes. 2020 Notes Two Thousand And Twenty Notes [Member] Convertible promissory notes. Related Party Transaction [Line Items] Related Party Transaction [Line Items] Convertible promissory notes aggregate value Debt Instrument Face Amount Changes in fair value of debt instrument Changes In Fair Value Of Debt Instrument Debt conversion, conversion price, percentage. Debt conversion converted instrument twice amount. Debt Instruments [Abstract] Debt Instrument [Table] Debt Instrument [Table] Debt Instrument [Line Items] Debt Instrument [Line Items] Interest rate Debt Instrument Interest Rate Stated Percentage Interest rate terms Debt Instrument Interest Rate Terms Convertible promissory notes, payable description Debt Instrument Maturity Date Description Convertible promissory notes, conversion description Debt Conversion Description Net proceeds from issuance of preferred stock Proceeds From Issuance Of Preferred Stock And Preference Stock Conversion price, percentage Debt Conversion Conversion Price Percentage Conversion of outstanding loan into common stock shares, value Debt Conversion Converted Instrument Amount1 Conversion of outstanding loan into common stock shares, two times value Debt Conversion Converted Instrument Twice Amount Interest expense recognized Interest Expense Debt Fair value of convertible promissory notes Convertible Debt Fair Value Disclosures Accrued interest Interest Payable Current And Noncurrent Equity [Abstract] Schedule Of Stock By Class [Table] Schedule Of Stock By Class [Table] Undesignated preferred stock. Undesignated Preferred Stock Undesignated Preferred Stock [Member] Two Thousand and Eighteen stock issuance plan. 2018 Stock Issuance Plan Two Thousand And Eighteen Stock Issuance Plan [Member] Award Type Award Type [Axis] Award Type Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Common Stock Options Employee Stock Option [Member] Two Thousand Twenty One equity incentive plan. 2021 Equity Incentive Plan Two Thousand Twenty One Equity Incentive Plan [Member] Subsequent Event Type Subsequent Event Type [Axis] Subsequent Event Type Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Restricted stock purchase agreements. Restricted Stock Purchase Agreements Restricted Stock Purchase Agreements [Member] Class Of Stock [Line Items] Class Of Stock [Line Items] Preferred Stock, shares authorized Preferred Stock Shares Authorized Preferred stock, par value Preferred Stock Par Or Stated Value Per Share Number of vote per common stock. Number of vote per common stock Number Of Vote Per Common Stock Common stock, voting rights Common Stock Voting Rights Common stock beneficial ownership limitation percentage. Written notice period to increase common stock beneficial ownership limitation. Common stock, conversion terms Common Stock Conversion Features Common stock, beneficial ownership limitation percentage Common Stock Beneficial Ownership Limitation Percentage Written notice period to increase common stock beneficial ownership limitation Written Notice Period To Increase Common Stock Beneficial Ownership Limitation Convertible preferred stock for aggregate purchase price Dividends, preferred stock Dividends Preferred Stock Potential commitment amount from gross proceeds of underwritten initial public offering. Convertible preferred stock, conversion terms Convertible Preferred Stock Terms Of Conversion Potential commitment amount from gross proceeds of underwritten initial public offering Potential Commitment Amount From Gross Proceeds Of Underwritten Initial Public Offering Convertible preferred stock, voting rights. Number of vote per convertible preferred stock upon conversion into common stock. Convertible preferred stock, voting rights Convertible Preferred Stock Voting Rights Number of vote per convertible preferred stock upon conversion into common stock Number Of Vote Per Convertible Preferred Stock Upon Conversion Into Common Stock Stock options granted Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Common stock, reserved for future issuance Common Stock Capital Shares Reserved For Future Issuance Stock options, grant equity-based awards issued Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Percentage of outstanding number of shares of common stock Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Total Options Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward Total Options Outstanding, Beginning balance Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Total Options, Exercised Total Options Forfeited or cancelled Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Total Options Outstanding, Ending balance Total Options, Vested and expected to vest as of December 31, 2021 Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number Total Options, Vested and exercisable as of December 31, 2021 Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number Weighted-Average Exercise Price Per Share Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward Weighted-Average Exercise Price Per Share Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Weighted-Average Exercise Price Per Share, Granted Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Weighted-Average Exercise Price Per Share, Exercised Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price Weighted-Average Exercise Price Per Share, Forfeited or cancelled Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price Weighted-Average Exercise Price Per Share Weighted-Average Exercise Price Per Share, Vested and expected to vest Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price Weighted-Average Exercise Price Per Share, Vested and exercisable Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price Share based compensation arrangement by share based payment award options weighted average remaining contract term. Weighted-Average Remaining Contract Term Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contract Term [Abstract] Weighted-Average Remaining Contract Term Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Weighted-Average Remaining Contract Term, Vested and expected to vest Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 Weighted-Average Remaining Contract Term, Vested and exercisable Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 Share based compensation arrangement by share based payment award options aggregate intrinsic value. Aggregate Intrinsic Value Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract] Aggregate Intrinsic Value, Outstanding Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Aggregate Intrinsic Value, Exercised Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value Aggregate Intrinsic Value, Vested and expected to vest Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value Aggregate Intrinsic Value, Vested and exercisable Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value Weighted-average grant date fair values of option grants Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value Weighted-average grant date fair values of options forfeited Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value Share based compensation arrangement by share based payment award stock plan offering period. Shares authorized for issuance Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Maximum contribution made by employees compensation Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate Purchase of common stock at discount from market price, offering date Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Offering Date Stock plan offering period Share Based Compensation Arrangement By Share Based Payment Award Stock Plan Offering Period Shares issued in period Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period Shares issued in connection with vesting of restricted stock Shares subject to repurchase Stock Repurchased During Period Shares Share Based Compensation Allocation And Classification In Financial Statements [Abstract] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Income Statement Location Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Research and Development Research And Development Expense [Member] General and Administrative General And Administrative Expense [Member] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Stock-based compensation expense Allocated Share Based Compensation Expense Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract] Risk-free interest rate Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Risk-free interest rate, minimum Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum Risk-free interest rate, maximum Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum Expected volatility Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Expected volatility, minimum Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum Expected volatility, maximum Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum Expected term (in years) Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 Expected dividend yield Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate Unrecognized compensation cost related to outstanding options Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Cost not yet recognized, period for Recognition Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 Reserved for future equity award grants. Reserved for future equity award grants Reserved For Future Equity Award Grants [Member] Reserved for future ESPP issuances. Reserved for future ESPP issuances Reserved For Future E S P P Issuances [Member] Convertible Preferred Stock Convertible Preferred Stock [Member] Stock options Common stock reserved for future issuance License agreements License agreements. License agreements. License Agreements [Table] License Agreements [Table] Collaborative Arrangement and Arrangement Other than Collaborative Type Of Arrangement [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Arrangements And Nonarrangement Transactions [Member] Daiichi Sankyo License Agreement Daiichi Sankyo License Agreement [Member] Counterparty Name Counterparty Name [Axis] Counterparty Name Repurchase Agreement Counterparty Name [Domain] Drexel University Drexel University [Member] Drexel License Agreement Drexel License Agreement [Member] License Agreements [Line Items] License Agreements [Line Items] License agreement, effective date License Agreement Effective Date Upfront payment Upfront Payments Clinical trial payments. Accrued reimbursable clinical trials costs. Sublicensable rights, number of families of patents Sublicensable Rights Number Of Families Of Patents Number of clinical trials Number Of Clinical Trials Clinical trial payments Clinical Trial Payments Accrued reimbursable clinical trials costs Accrued Reimbursable Clinical Trials Costs Maximum future milestone payments Maximum Potential Milestone Payments Milestone payments Milestone Payments Payments for license agreements Payments For License Agreements Accrued milestone payment Accrued Milestone Payment Royalty payments Royalty Expense Royalty obligation termination description Royalty Obligation Termination Description Agreement termination written notice period. Cure period Cure Period Agreement termination written notice period Agreement Termination Written Notice Period Intellectual property license agreement date Intellectual Property License Agreement Date Intellectual property license agreement description Intellectual Property License Agreement Description Intellectual property license agreement period Intellectual Property License Agreement Period One time non refundable initiation fee One Time Non Refundable Initiation Fee Number of equal instalments paid one time non refundable initiation fee Number Of Equal Instalments Paid One Time Non Refundable Initiation Fee One time non-refundable initiation fee paid in each installment One Time Non Refundable Initiation Fee Paid In Each Installment Period of first instalment after effective date Period Of First Installment After Effective Date Period of second instalment after effective date Period Of Second Installment After Effective Date Period of third instalment after effective date Period Of Third Installment After Effective Date Period of fourth instalment after effective date Period Of Fourth Installment After Effective Date Maximum future payments in addition to initiation fee Maximum Future Payments In Addition To Initiation Fee Upper limit of minimum quarterly royalty payments Upper Limit Of Minimum Quarterly Royalty Payments Annual license maintenance fee until first sale of first licensed product. Annual license maintenance fee until first sale of first licensed product Annual License Maintenance Fee Until First Sale Of First Licensed Product Agreement period from first sale of first licensed product Agreement Period From First Sale Of First Licensed Product Lessee operating lease commencement month and year. Lessee operating lease expiration month and year. Increase in annual base rent percentage. Increase in annual base rent month and day of each year. Initial term of operating lease Lessee Operating Lease Term Of Contract Operating lease commencement month and year Lessee Operating Lease Commencement Month And Year Operating lease expiration month and year Lessee Operating Lease Expiration Month And Year Increase in annual base rent percentage Increase In Annual Base Rent Percentage Increase in annual base rent month and day of each year Increase In Annual Base Rent Month And Day Of Each Year Rent relief period. Lessee operating lease extended expiration month and year. Rent relief period Rent Relief Period Operating lease extended expiration month and year Lessee Operating Lease Extended Expiration Month And Year 2022 Lessee Operating Lease Liability Payments Due Next Twelve Months 2023 Lessee Operating Lease Liability Payments Due Year Two 2024 Lessee Operating Lease Liability Payments Due Year Three Total minimum lease payments Lessee Operating Lease Liability Payments Due Less: amount representing interest Lessee Operating Lease Liability Undiscounted Excess Amount Present value of operating lease liabilities Operating Lease Liability Weighted-average remaining lease term (in years) Operating Lease Weighted Average Remaining Lease Term1 Weighted-average incremental borrowing rate Operating Lease Weighted Average Discount Rate Percent Total operating lease expense Operating Lease Cost Operating cash flows used for operating lease Operating Lease Payments Defined contribution plan, employer matching contribution amount. Defined contribution plan, employer matching contribution amount Defined Contribution Plan Employer Matching Contribution Amount Current: Current Income Tax Expense Benefit Continuing Operations [Abstract] State Current State And Local Tax Expense Benefit Provision for income taxes Federal tax benefit at statutory rate Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate State taxes Income Tax Reconciliation State And Local Income Taxes Change in fair value of convertible promissory notes Income Tax Reconciliation Change In Fair Value Of Convertible Promissory Note Non-deductible expenses Income Tax Reconciliation Nondeductible Expense Convertible note interest Income Tax Reconciliation Convertible Notes Interest R&D credits Income Tax Reconciliation Tax Credits Research Change in valuation allowance Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance Other Income Tax Reconciliation Other Adjustments Deferred tax assets accrued expenses and other. Deferred tax assets tax research and development and orphan drug credits. Deferred tax asset lease liability. Deferred tax liabilities right-of-use asset. Components Of Deferred Tax Assets And Liabilities [Abstract] Accrued expenses and other Deferred Tax Assets Accrued Expenses And Other Fixed assets Deferred Tax Assets Property Plant And Equipment Intangibles Deferred Tax Assets Goodwill And Intangible Assets Net operating losses Deferred Tax Assets Operating Loss Carryforwards R&D and Orphan Drug credits Deferred Tax Assets Tax Research And Development And Orphan Drug Credits Stock-based compensation Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost Lease liability Deferred Tax Asset Lease Liability Other Deferred Tax Assets Other Total deferred tax assets Deferred Tax Assets Gross Valuation allowance Deferred Tax Assets Valuation Allowance Total net deferred tax assets Deferred Tax Assets Net Right-of-use asset Deferred Tax Liabilities Right Of Use Asset Total deferred tax liabilities Deferred Tax Liabilities Net deferred tax assets Deferred Tax Assets Liabilities Net Valuation allowance Valuation allowance increase Valuation Allowance Deferred Tax Asset Change In Amount Operating loss carry forward expiration year. Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Income Tax Authority, Name Income Tax Authority Name [Axis] Income Tax Authority, Name Income Tax Authority Name [Domain] Federal Pre Tax Cut And Jobs Act. Federal—Pre TCJA Federal Pre Tax Cut And Jobs Act [Member] Federal Post Tax Cut And Jobs Act. Federal—Post TCJA Federal Post Tax Cut And Jobs Act [Member] State California Franchise Tax Board [Member] R&D and Orphan Drug Credits, Federal. R&D and Orphan Drug Credits, Federal R D And Orphan Drug Credits Federal [Member] R&D Credits, California. R&D Credits, California R D Credits California [Member] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Net operating loss carryforwards, Amount Operating Loss Carryforwards Expiration Years Operating Loss Carry Forward Expiration Year Balance at beginning of year Unrecognized Tax Benefits Additions based on tax positions related to current year Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions Balance at end of year Unrecognized tax benefits Interest or penalties Income Tax Examination Penalties And Interest Expense Weighted average number of share outstanding basic and diluted before adjustment. Numerator: Earnings Per Share Basic And Diluted [Abstract] Denominator: Weighted Average Number Of Shares Outstanding [Abstract] Weighted-average shares of common stock outstanding, basic and diluted Weighted Average Number Of Share Outstanding Basic And Diluted Before Adjustment Less: weighted-average unvested common stock Weighted Average Number Diluted Shares Outstanding Adjustment Weighted-average shares used to compute net loss per share, basic and diluted Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Antidilutive Securities Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis] Antidilutive Securities, Name Antidilutive Securities Name [Domain] ESPP shares Employee Stock [Member] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive securities Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount EX-101.PRE 12 rain-20211231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 13 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Document and Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2021
Feb. 17, 2022
Jun. 30, 2021
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2021    
Document Fiscal Year Focus 2021    
Document Fiscal Period Focus FY    
Entity File Number 001-40356    
Entity Registrant Name Rain Therapeutics Inc.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 82-1130967    
Entity Address, Address Line One 8000 Jarvis Avenue    
Entity Address, Address Line Two Suite 204    
Entity Address, City or Town Newark    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 94560    
City Area Code 510    
Local Phone Number 953-5559    
Title of 12(b) Security Common Stock, par value $0.001 per share    
Trading Symbol RAIN    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Entity Ex Transition Period false    
Entity Shell Company false    
Entity Common Stock, Shares Outstanding   26,510,407  
Entity Public Float     $ 120,166,484
Current Fiscal Year End Date --12-31    
Entity Central Index Key 0001724979    
ICFR Auditor Attestation Flag false    
Auditor Name Ernst & Young LLP    
Auditor Location San Diego, California    
Auditor Firm ID 42    
Documents Incorporated by Reference

Portions of the Registrant’s definitive proxy statement relating to its 2022 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year ended December 31, 2021 are incorporated herein by reference in Part III of this Annual Report on Form 10-K where indicated.

    
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.22.0.1
Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 24,780 $ 58,863
Short-term investments 115,438 0
Prepaid and other current assets 5,928 662
Total current assets 146,146 59,525
Property and equipment, net 165 99
Operating lease right-of-use asset 386 447
Deferred offering costs 0 385
Other assets 443 624
Total assets 147,140 61,080
Current liabilities:    
Accounts payable 6,112 816
Accrued research and development 4,349 1,527
Other accrued liabilities 5,694 935
Operating lease liability, current portion 160 141
Total current liabilities 16,315 3,419
Operating lease liability, net of current portion 252 312
Other long-term liabilities 69 69
Total liabilities 16,636 3,800
Commitments and contingencies
Total convertible preferred stock 0 94,697
Stockholders’ equity (deficit):    
Common Stock, $0.001 par value; 250,000,000 and 24,000,000 shares authorized as of December 31, 2021 and December 31, 2020, respectively; 26,475,812 shares (comprised of 18,748,342 shares of common stock and 7,727,470 shares of non-voting common stock) and 3,530,975 shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively 27 4
Additional paid-in capital 220,530 1,149
Accumulated other comprehensive loss (89) 0
Accumulated deficit (89,964) (38,570)
Total stockholders' equity (deficit) 130,504 (37,417)
Total liabilities, convertible preferred stock, and stockholders’ equity (deficit) 147,140 61,080
Series A Convertible Preferred Stock    
Current liabilities:    
Total convertible preferred stock 0 20,147
Series B Convertible Preferred Stock    
Current liabilities:    
Total convertible preferred stock $ 0 $ 74,550
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.22.0.1
Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2021
Dec. 31, 2020
Convertible preferred stock, Shares outstanding 0  
Common stock, Par value $ 0.001 $ 0.001
Common stock, shares authorized 250,000,000 24,000,000
Common stock, shares issued 26,475,812 3,530,975
Common stock, shares outstanding 26,475,812 3,530,975
Series A Convertible Preferred Stock    
Convertible preferred stock, Par value $ 0.001 $ 0.001
Convertible preferred stock, Shares authorized 0 3,731,208
Convertible preferred stock, Shares issued 0 3,731,208
Convertible preferred stock, Shares outstanding 0 3,731,208
Series B Convertible Preferred Stock    
Convertible preferred stock, Par value $ 0.001 $ 0.001
Convertible preferred stock, Shares authorized 0 12,542,198
Convertible preferred stock, Shares issued 0 12,542,198
Convertible preferred stock, Shares outstanding 0 12,542,198
Common Stock    
Common stock, shares issued 18,748,342  
Common stock, shares outstanding 18,748,342  
Non-voting Common Stock    
Common stock, shares issued 7,727,470  
Common stock, shares outstanding 7,727,470  
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.22.0.1
Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Operating expenses:    
Research and development $ 40,773 $ 15,367
General and administrative 10,739 3,591
Total operating expenses 51,512 18,958
Loss from operations (51,512) (18,958)
Other income (expense):    
Interest income 119 32
Interest expense, related party   (135)
Change in fair value of convertible promissory notes, related party   (2,024)
Other income 1 2
Total other income (expense), net 120 (2,125)
Net loss before income tax expense (51,392) (21,083)
Income tax expense (2)  
Net loss $ (51,394) $ (21,083)
Net loss per share, basic and diluted $ (2.65) $ (6.29)
Weighted-average shares used to compute net loss per share, basic and diluted 19,405,833 3,351,850
Net loss $ (51,394) $ (21,083)
Other comprehensive income:    
Unrealized loss on investments (89)  
Comprehensive loss $ (51,483) $ (21,083)
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.22.0.1
Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)
$ in Thousands
Total
Series A Convertible Preferred Stock
Series B Convertible Preferred Stock
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Accumulated Other Comprehensive Loss
Balance at Dec. 31, 2019 $ (17,248)     $ 3 $ 236 $ (17,487)  
Temporary equity, balance, Shares at Dec. 31, 2019   3,731,208          
Temporary equity, balance at Dec. 31, 2019   $ 20,147          
Balance, Shares at Dec. 31, 2019       2,986,385      
Issuance of Series B convertible preferred stock, net of issuance costs of $320     $ 63,173        
Issuance of Series B convertible preferred stock, net of issuance costs of $320, Shares     10,636,510        
Conversion of convertible promissory notes into Series B convertible preferred stock     $ 11,377        
Conversion of convertible promissory notes into Series B convertible preferred stock, Shares     1,905,688        
Vesting of restricted shares 1     $ 1      
Vesting of restricted shares, Shares       532,455      
Exercise of stock options 48       48    
Exercise of stock options, shares       12,135      
Stock-based compensation expense 865       865    
Net loss (21,083)         (21,083)  
Balance at Dec. 31, 2020 (37,417)     $ 4 1,149 (38,570)  
Temporary equity, balance, Shares at Dec. 31, 2020   3,731,208 12,542,198        
Temporary equity, balance at Dec. 31, 2020 94,697 $ 20,147 $ 74,550        
Balance, Shares at Dec. 31, 2020       3,530,975      
Conversion of convertible preferred stock to common stock 94,697     $ 15 94,682    
Temporary equity conversion of convertible preferred stock to common stock, shares   (3,731,208) (12,542,198)        
Temporary equity conversion of convertible preferred stock to common stock   $ (20,147) $ (74,550)        
Conversion of convertible preferred stock to common stock, shares       15,069,330      
Issuance of common stock upon IPO, net of issuance cost 121,494     $ 8 121,486    
Issuance of common stock upon IPO, net of issuance cost, shares       7,845,011      
Exercise of stock options 121       121    
Exercise of stock options, shares       30,496      
Stock-based compensation expense 3,092       3,092    
Unrealized loss on investments (89)           $ (89)
Net loss (51,394)         (51,394)  
Balance at Dec. 31, 2021 $ 130,504     $ 27 $ 220,530 $ (89,964) $ (89)
Temporary equity, balance, Shares at Dec. 31, 2021 0 0 0        
Temporary equity, balance at Dec. 31, 2021 $ 0 $ 0 $ 0        
Balance, Shares at Dec. 31, 2021       26,475,812      
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.22.0.1
Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
USD ($)
Series B Convertible Preferred Stock  
Stock issuance cost $ 327
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.22.0.1
Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Operating activities    
Net loss $ (51,394) $ (21,083)
Adjustments to reconcile net loss to cash used in operating activities:    
In-process research and development expense 5,500 5,167
Depreciation and amortization expense 71 52
Stock-based compensation expense 3,092 865
Non-cash interest expense, related party   135
Change in fair value of convertible promissory notes, related party   2,024
Amortization of premium and accretion of discounts on short-term investments, net 81  
Fair value loss/(gain) on investments (1)  
Changes in operating assets and liabilities:    
Prepaid and other current assets (5,266) (182)
Operating lease right-of-use asset and liability, net 19 10
Other assets 181 (195)
Accounts payable 5,288 555
Accrued research and development 2,822 1,417
Other accrued liabilities 2,144  
Other long-term liabilities   4
Net cash used in operating activities (37,463) (11,231)
Investing activities    
Purchases of short-term investments (163,557)  
Purchases of property and equipment (128) (24)
Payment of in-process research and development expense (2,500) (5,167)
Maturities of available for sale investments 47,950  
Net cash used in investing activities (118,235) (5,191)
Financing Activities    
Proceeds from initial public offering 133,366  
Proceeds from stock option exercises 121 48
Issuance of common stock for vesting of restricted shares   1
Proceeds from issuance of convertible preferred stock, net of issuance costs   63,173
Proceeds from issuance of convertible promissory notes   6,435
Payments of issuance costs related to the initial public offering (11,872) (166)
Net cash provided by financing activities 121,615 69,491
Net (decrease) increase in cash and cash equivalents (34,083) 53,069
Cash and cash equivalents at beginning of period 58,863 5,794
Cash and cash equivalents at end of period 24,780 58,863
Supplemental schedule of non-cash investing and financing activities:    
Conversion of convertible preferred stock to common stock 94,697  
Non-cash in-process research and development accrual 3,000  
Non-cash additions to property and equipment $ 9  
Conversion of convertible promissory notes and interest into Series B convertible preferred stock   11,377
Accruals for unbilled professional fees related to the IPO   $ 219
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.22.0.1
Organization and Nature of Operations
 12 Months Ended
Dec. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
Organization and Nature of Operations

Note 1 – Organization and Nature of Operations

Description of Business

Rain Therapeutics Inc. (“Rain” or the “Company”) was incorporated in the state of Delaware in April 2017. Rain is a late-stage precision oncology company developing therapies that target oncogenic drivers for which the Company is able to genetically select patients most likely to benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of mouse double minute 2, which may be oncogenic in numerous cancers. In addition to milademetan, the Company is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52. The Company operates in one business segment and its principal operations are in the United States, with its headquarters in Newark, California.

Reverse Stock Split

On April 15, 2021 and April 16, 2021, the Company’s board of directors (the “Board of Directors”) and stockholders, respectively, approved an amended and restated certificate of incorporation of the Company to effect a 1-for-1.0799 reverse stock split of the Company’s common stock. The reverse stock split was effected on April 16, 2021. The Company’s outstanding stock options were also adjusted to reflect the 1-for-1.0799 reverse stock split of the Company’s common stock. Accordingly, all common stock and stock options and related per share amounts in these financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock split. Outstanding stock options were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased. The reverse stock split resulted in an adjustment to the Series A and Series B convertible preferred stock conversion prices to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion.

Initial Public Offering

On April 27, 2021, the Company completed its initial public offering (“IPO”) in which the Company issued and sold 7,352,941 shares of common stock at a public offering price of $17.00 per share. On May 11, 2021, the Company issued an additional 492,070 shares of common stock in connection with the exercise of the underwriters’ option to purchase additional shares at the public offering price. The Company’s net proceeds from the sale of shares in the IPO, including the sale of shares pursuant to the exercise of the underwriters’ option to purchase additional shares, was $121.5 million, net of underwriting discounts and commissions, and other offering fees.

Immediately prior to the closing of the IPO, 8,344,905 shares of the Company’s convertible preferred stock were exchanged for 7,727,470 shares of non-voting common stock. Upon the closing of the IPO, 7,928,501 shares of the Company’s convertible preferred stock were automatically converted into 7,341,860 shares of common stock. Following the IPO, there were no shares of convertible preferred stock outstanding.

Basis of Presentation

The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) promulgated by the Financial Accounting Standards Board (“FASB”).

Liquidity and Capital Resources

The Company has devoted substantially all of its efforts to drug discovery and development, raising capital and building operations. The Company has a limited operating history and has not generated any revenue since its inception, and the sales and income potential of the Company’s business is unproven. The Company has incurred net losses and negative cash flows from operating activities since its inception and expects to continue to incur net losses into the foreseeable future as it continues the development of its product candidates. From

inception through December 31, 2021, the Company has funded its operations through net proceeds from its IPO in April 2021, and the issuance of convertible promissory notes and convertible preferred stock.

The accompanying financial statements have been prepared assuming the Company will continue as a going concern. Management believes that the Company’s current cash, cash equivalents and short-term investments will provide sufficient funds to enable the Company to meet its obligations for at least twelve months from the filing date of this report.
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

Note 2 – Summary of Significant Accounting Policies

Use of Estimates

The preparation of the Company’s financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent liabilities in the Company’s financial statements and accompanying notes. The most significant estimate in the Company’s financial statements relates to the clinical trial expense accruals. Management evaluates its estimates on an ongoing basis. Although these estimates are based on the Company’s historical experience, knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents include commercial paper, readily available money market and checking accounts.

Available-for-Sale Investments

The Company holds investment grade securities consisting of money market funds, commercial paper, corporate debt securities, U.S. government securities and U.S. agency bonds, classified as available-for-sale (“AFS”) securities at the time of purchase, since it is the Company’s intent that these investments be available for current operations. The Company has classified all of its AFS securities as current assets on the balance sheets even though the stated maturity date may be one year or more beyond the current balance sheet date, which reflects management’s intention to use the proceeds from sales of these securities to fund its operations, as necessary.

The Company carries these securities at fair value and reports unrealized gains and losses, if any, as a separate component of accumulated other comprehensive loss. The cost of debt securities is adjusted for amortization of purchase premiums and accretion of discounts to maturity. Such amortization and accretion are included in interest income in the statements of operations and comprehensive loss. Realized gains and losses on sales of securities are determined using the specific identification method and recorded in other income (expense), net in the statement of operations and comprehensive loss.

Investments are considered to be impaired when a decline in fair value is judged to be other-than-temporary. The Company consults with its investment managers and considers available quantitative and qualitative evidence in evaluating potential impairment of its investments on a quarterly basis. If the cost of an individual investment exceeds its fair value, the Company evaluates among other factors, general market conditions, the duration and extent to which the fair value is less than cost, and the Company’s intent and ability to hold the investment. Once an impairment is determined to be other-than-temporary, an impairment charge is recorded and a new cost basis in the investment is established. Declines in the value of AFS securities determined to be other than temporary are included in other income (expense), net.

Fair Value Option

 

As permitted under ASC 825, Financial Instruments (“ASC 825”), the Company has elected the fair value option to account for the convertible promissory notes issued in 2019 (the “2019 Notes”) and 2020 (the “2020 Notes”). In accordance with ASC 825, the Company records these convertible promissory notes at fair value and records changes in fair value as a line item within other income (expense) in the accompanying statements

of operations and comprehensive loss. As a result of applying the fair value option, direct costs and fees related to the 2019 Notes and 2020 Notes were recognized in net loss as incurred and not deferred.

Fair Value of Financial Instruments

 

The carrying amounts of all cash equivalents, prepaid expenses and other assets, accounts payable and accrued and other current liabilities are reasonable estimates of their fair value because of the short-term nature of these items.

Concentration of Credit Risk

 

Financial instruments, which potentially subject the Company to significant concentration of credit risk, consist primarily of cash, cash equivalents and short-term investments. The Company maintains cash and money market deposits in a federally insured major financial institution in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institution in which those deposits are held.

Deferred Offering Costs

The Company capitalized offering costs consisting of all direct and incremental legal, professional, accounting and other third-party fees incurred in connection with the Company’s IPO. Upon the completion of the IPO in April 2021, the total deferred offering costs of $2.5 million were reclassified to additional paid-in capital on the balance sheets.

Research and Development Costs

Research and development costs primarily consist of costs associated with the Company’s research and development activities, including its drug discovery efforts, and the preclinical and clinical development of its product candidates. Research and development costs are expensed as incurred.

Property and Equipment

Property and equipment, net consists of computer equipment, furniture and equipment and leasehold improvements. Leasehold improvements are amortized over the remainder of the lease term. Computer equipment and furniture and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally two to three years). Repairs and maintenance costs are charged to expense as incurred.

Long-Lived Assets

The Company regularly reviews the carrying value and estimated lives of all of its long-lived assets, including property and equipment, to determine whether indicators of impairment may exist which warrant adjustments to carrying values or estimated useful lives. Should an impairment exist, the impairment loss would be measured based on the excess over the carrying amount of the asset’s fair value. The Company has not recognized any impairment losses from inception through December 31, 2021.

Commitments

The Company recognizes a liability with regard to loss contingencies when it believes it is probable that a liability has occurred, and the amount can be reasonably estimated. If some amount within a range of loss appears at the time to be a better estimate than any other amount within the range, the Company accrues that amount. When no amount within the range is a better estimate than any other amount, the Company accrues the minimum amount in the range. The Company has not recorded any such liabilities as of December 31, 2021.

Leases

At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company records the associated lease liability and corresponding right-of-use asset upon commencement of the lease using the implicit rate or a discount rate based on a credit- adjusted secured borrowing rate commensurate

with the term of the lease. The Company additionally evaluates leases at their inception to determine if they are to be accounted for as an operating lease or a finance lease. Operating lease assets represent a right to use an underlying asset for the lease term and operating lease liabilities represent an obligation to make lease payments arising from the lease. Operating lease liabilities with a term greater than one year and their corresponding right-of-use assets are recognized on the balance sheet at the commencement date of the lease based on the present value of lease payments over the expected lease term. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. As the Company’s leases do not typically provide an implicit rate, the Company utilizes the appropriate incremental borrowing rate, determined as the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and in a similar economic environment. Lease cost is recognized on a straight-line basis over the lease term and variable lease payments are recognized as operating expenses in the period in which the obligation for those payments is incurred. Variable lease payments primarily include common area maintenance, utilities, real estate taxes, insurance and other operating costs that are passed on from the lessor in proportion to the space leased by the Company. The Company has elected the practical expedient to not separate lease and non-lease components.

Preclinical Studies and Clinical Trial Accruals

The Company is required to estimate its expenses resulting from its obligations under contracts with vendors, consultants, clinical research organizations and clinical site agreements in connection with conducting preclinical activities and clinical trials. The financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company reflects preclinical study and clinical trial expenses in its financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of the preclinical study or clinical trial as measured by the timing of various aspects of the preclinical study, clinical trial or related activities. The Company determines accrual and prepaid estimates through review of the underlying contracts along with preparation of financial models taking into account correspondence with clinical and other key personnel and third- party service providers as to the progress of preclinical studies, clinical trials or other services being conducted. During the course of a preclinical study or clinical trial, the Company adjusts its expense recognition if actual results differ from its estimates. To date, the Company has not experienced any material differences between accrued costs and actual costs incurred.

In-Process Research and Development

The Company evaluates whether acquired intangible assets are a business under applicable accounting standards. Additionally, the Company evaluates whether the acquired assets have a future alternative use. Intangible assets that do not have future alternative use, such as the license the Company acquired from Daiichi, are considered acquired in-process research and development. When the acquired in-process research and development assets are not part of a business combination, the value of the consideration paid is expensed on the acquisition date. Future costs to develop these assets are recorded to research and development expenses as they are incurred.

Patent Costs

Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.

General and Administrative Expenses

General and administrative expenses consist of salaries, stock-based compensation, facilities and third-party expenses. General and administrative expenses are associated with the activities of the executive, finance, accounting, information technology, legal and human resource functions.

Stock-Based Compensation

Stock-based compensation expense represents the grant date fair value of equity awards recognized over the requisite service period of the awards (generally the vesting period) on a straight-line basis. The Company recognizes forfeitures as they occur. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model. Prior to the IPO, the exercise price for all stock options granted was at the estimated fair value of the underlying common stock as determined on the date of grant by the Company’s Board of Directors.

Income Taxes

The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

The Company recognizes deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.

The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more likely than not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.

Comprehensive Loss

Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company’s comprehensive loss includes unrealized gains / losses from short-term investments.

Net Loss Per Share

Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the sum of the weighted-average number of shares of common stock plus the potential dilutive effects of potential dilutive securities outstanding during the period. Potential dilutive securities are excluded from diluted earnings or loss per share if the effect of such inclusion is antidilutive. The Company’s potentially dilutive securities, which include convertible preferred stock, ESPP shares, and outstanding stock options under the Company’s equity incentive plan, have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For the periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position.

Recent Developments Regarding the COVID-19 Pandemic

Efforts to control the outbreak of COVID-19 have resulted in challenges to businesses and facilities in various industries around the world, including disruptions to the global economy and supply chains. To date, COVID-19 has not had a material impact on the Company’s expenditures.

The Company is unable to predict the ultimate effects of COVID-19 on the U.S. or global economy or its operations. The Company continues to monitor developments affecting its workforce, suppliers, and operations. The extent of the impact of COVID-19 will depend on its duration, actions by government authorities, and impacts on the Company’s customers, employees, or vendors. These developments are continuously evolving, and the Company cannot predict whether COVID-19 will have a material impact on its financial condition, results of operations or cash flows.

Recent Accounting Pronouncements

Financial Instruments. In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The objective of the standard is to provide information about expected credit losses on financial instruments at each reporting date and to change

how other-than temporary impairments on investment securities are recorded. The guidance is effective for the Company beginning on January 1, 2023, with early adoption permitted. The Company does not anticipate that the adoption of ASU 2016-13 will have a significant impact on its financial statements or the related disclosures.

Income Taxes. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which simplifies the accounting for income taxes. ASU 2019-12 is effective for the Company for the fiscal year beginning after December 15, 2021 and early adoption is permitted. The Company does not anticipate that the adoption of ASU 2019-12 will have a significant impact on its financial statements or the related disclosures.

Debt and Equity Instruments. In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40), which addresses the complexity associated with applying generally accepted accounting principles for certain financial instruments with characteristics of liabilities and equity. The guidance is effective for the Company beginning on January 1, 2024, with early adoption permitted. The Company elected to adopt this standard on January 1, 2020 under the modified retrospective transition method with no material impact on its financial statements or the related disclosures.

There were no other significant updates to the recently issued accounting standards other than as disclosed herein for the year ended December 31, 2021. Although there are several other new accounting pronouncements issued or proposed by the FASB, based on the Company’s preliminary assessment, the Company does not believe any of those accounting pronouncements have had or will have a material impact on its financial position or operating results.
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value Measurements
 12 Months Ended
Dec. 31, 2021
Fair Value Disclosures [Abstract]  
Fair Value Measurements

Note 3 – Fair Value Measurements

The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

The carrying amounts of cash, prepaid expenses and other current assets, deferred offering costs, other assets, accounts payable, accrued research and development, other current liabilities and other long-term liabilities are reasonable estimates of their fair value due to the short-term nature of these accounts.

The Company’s money market funds under cash and cash equivalents are classified using Level 1 inputs within the fair value hierarchy because they are valued using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. There were no transfers between levels of the fair value hierarchy during the years ended December 31, 2021 and 2020, respectively.

The following table summarizes financial assets that the Company measured at fair value on a recurring basis, classified in accordance with the fair value hierarchy (in thousands):

 

 

 

Fair Value Measurements at Reporting Date Using:

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

As of December 31, 2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

10,585

 

 

$

—

 

 

$

—

 

 

$

10,585

 

Commercial paper

 

 

—

 

 

 

84,616

 

 

 

—

 

 

 

84,616

 

U.S. government securities

 

 

27,824

 

 

 

 

 

 

 

—

 

 

 

27,824

 

U.S. agency bonds

 

 

—

 

 

 

8,531

 

 

 

—

 

 

 

8,531

 

Corporate debt securities

 

 

—

 

 

 

8,265

 

 

 

—

 

 

 

8,265

 

Total cash equivalents and short-term investments

 

$

38,409

 

 

$

101,412

 

 

$

—

 

 

$

139,821

 

Reported as:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents (includes cash of $397)

 

 

 

 

 

 

 

 

 

 

 

 

 

$

24,780

 

Short-term investments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

115,438

 

Total cash, cash equivalents and short-term investments

 

 

 

 

 

 

 

 

 

 

 

 

 

$

140,218

 

 

 

 

Fair Value Measurements at Reporting Date Using:

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

As of December 31, 2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents

 

$

19,257

 

 

$

—

 

 

$

—

 

 

$

19,257

 

 

There were no liabilities measured at fair value on a recurring basis as of December 31, 2021 and 2020.

The following table provides a reconciliation of all liabilities measured at fair value using Level 3 significant unobservable inputs (in thousands) during the year ended December 31, 2020.

 

 

 

Convertible

Promissory

Notes

 

Fair value as of December 31, 2019

 

$

2,751

 

Issuance of convertible promissory notes

 

 

6,435

 

Conversion to convertible preferred stock (excluding interest expense)

 

 

(11,210

)

Change in fair value of convertible promissory notes (Note 7)

 

 

2,024

 

Fair value as of December 31, 2020

 

$

—

 

 

Convertible Promissory Notes

As further described in Note 7, the Company issued convertible promissory notes in October 2019 (the “2019 Notes”) and in June 2020 (the “2020 Notes”) to investors. The Company elected the ASC 825, Financial Instruments, fair value option for the convertible promissory notes. The fair value of the convertible promissory notes was determined using a scenario-based analysis that estimated the fair value of the convertible promissory notes based on the probability-weighted present value of expected future investment returns, considering possible outcomes available to the noteholders, including conversions in subsequent equity financings. The 2019 Notes and 2020 Notes were valued upon issuance, remeasured to fair value each reporting period and remeasured immediately prior to conversion into Series B convertible preferred stock based on changes in the expected time to closing ranging from 0 to 0.67 years and the relevant discount rate of 25% during the period. In September 2020, the 2019 Notes and 2020 Notes were converted to 1,905,688 shares of Series B convertible preferred stock.

In September 2020, all outstanding convertible promissory notes with a total fair value of $11.2 million and accrued interest of $167,000 were converted to 1,905,688 shares of Series B convertible preferred stock. Upon conversion, the Company no longer is required to adjust the carrying value of the convertible promissory notes at each reporting date.
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.22.0.1
Investments
 12 Months Ended
Dec. 31, 2021
Investments Debt And Equity Securities [Abstract]  
Investments

Note 4 – Investments

Financial assets measured at fair value on a recurring basis consist of the Company’s cash equivalents and AFS securities. The Company obtains pricing information from its investment manager and generally determines the fair value of investment securities using standard observable inputs, including reported trades, broker/dealer quotes, and bids and/or offers.

Investments are classified as Level 1 within the fair value hierarchy if their quoted prices are available in active markets for identical securities. Investments in money market funds and U.S. government securities were classified as Level 1 instruments.

Investments in commercial paper, corporate debt securities and U.S. agency bonds are valued using Level 2 inputs. The Company classifies investments within Level 2 if the investments are valued using model driven valuations using observable inputs such as quoted market prices, benchmark yields, reported trades, broker/dealer quotes or alternative pricing sources with reasonable levels of price transparency. Investments are held by custodians who obtain investment prices from a third-party pricing provider that incorporates standard inputs in various asset price models.

The following table summarizes, by major types of cash equivalents, and investments that are measured at fair value on a recurring basis (in thousands):

 

 

 

December 31, 2021

 

 

 

Amortized

Cost

 

 

Unrealized

Gains

 

 

Unrealized

Losses

 

 

Estimated

Fair Value

 

Money market funds

 

$

10,585

 

 

 

—

 

 

 

—

 

 

$

10,585

 

Commercial paper

 

 

84,642

 

 

 

2

 

 

 

(28

)

 

 

84,616

 

U.S. government securities

 

 

27,870

 

 

 

—

 

 

 

(46

)

 

 

27,824

 

U.S. agency bonds

 

 

8,546

 

 

 

—

 

 

 

(15

)

 

 

8,531

 

Corporate debt securities

 

 

8,267

 

 

 

—

 

 

 

(2

)

 

 

8,265

 

Cash equivalents and investments

 

$

139,910

 

 

$

2

 

 

$

(91

)

 

$

139,821

 

 

The contractual maturities of the Company’s AFS securities were as follows (in thousands):

 

 

 

December 31,

2021

 

Due within one year

 

$

105,173

 

Due within one to two years

 

 

10,265

 

Available-for-Sale Investments

 

$

115,438

 

 

The available-for-sale investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date, which reflects management’s intention to use the proceeds from sales of these securities to fund the Company’s operations, as necessary. As of December 31, 2020, the Company did not own any investments. There were no realized gains or losses due to investment sales for the year ended December 31, 2021. As of December 31, 2021, $129.2 million of the Company’s marketable securities were in gross unrealized loss positions, of which none had been in such position for greater than 12 months and $23.8 million will mature within three months of December 31, 2021.

At each reporting date, the Company performs an evaluation of its marketable securities to determine if any unrealized losses are other-than-temporary. Factors considered in determining whether a loss is other-than-temporary include (i) the financial strength of the issuing institution, (ii) the length of time and extent for which fair value has been less than the cost basis and (iii) the Company’s intent and ability to hold its investments in unrealized loss positions until their amortized cost basis has been recovered. Based on the Company’s evaluation, it determined that its unrealized losses were not other-than-temporary at December 31, 2021. The Company does not intend to sell the investments before maturity and it is unlikely that the Company will be required to sell the investments before recovery of their amortized cost bases.
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.22.0.1
Balance Sheet Details
 12 Months Ended
Dec. 31, 2021
Balance Sheet Related Disclosures [Abstract]  
Balance Sheet Details

 

 

Note 5 - Balance Sheet Details

Prepaid and Other Current Assets

Prepaid and other current assets consist of the following (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Prepaid insurance

 

$

827

 

 

$

—

 

Prepaid research

 

 

4,329

 

 

 

371

 

Prepaid other

 

 

96

 

 

 

159

 

FICA tax credit receivable

 

 

452

 

 

 

110

 

Deposits

 

 

19

 

 

 

22

 

Other current assets

 

 

205

 

 

 

—

 

Prepaid and Other Current Assets

 

$

5,928

 

 

$

662

 

 

Property and equipment, net, consist of the following (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Computer equipment

 

$

50

 

 

$

45

 

Furniture and equipment

 

 

204

 

 

 

72

 

Leasehold improvements

 

 

67

 

 

 

67

 

 

 

$

321

 

 

$

184

 

Less: accumulated depreciation and amortization expense

 

$

(156

)

 

 

(85

)

Property and Equipment, net

 

$

165

 

 

$

99

 

Depreciation expense for years ended December 31, 2021 and 2020 were $0.1 million, respectively.

Other Non-Current Assets

Other non-current assets consist of the following (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

FICA tax credit receivable

 

$

298

 

 

$

549

 

Deposits

 

 

75

 

 

 

75

 

Other

 

 

70

 

 

 

—

 

Other non-current assets

 

$

443

 

 

$

624

 
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.22.0.1
Related Party Transactions
 12 Months Ended
Dec. 31, 2021
Related Party Transactions [Abstract]  
Related Party Transactions

Note 6 – Related Party Transactions

As further described in Note 7, the Company issued the 2019 Notes in October 2019 to certain holders of convertible preferred stock, for an aggregate purchase price of $2.5 million and the 2020 Notes in June 2020 to certain holders of convertible preferred stock, for an aggregate purchase price of $6.4 million. In September 2020, all outstanding convertible promissory notes with a total fair value of $11.2 million and accrued interest of $167,000 were converted to 1,905,688 shares of Series B convertible preferred stock. The change in fair value of the convertible promissory notes for the year ended December 31, 2020 was $2.0 million.
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.22.0.1
Convertible Promissory Notes
 12 Months Ended
Dec. 31, 2021
Debt Disclosure [Abstract]  
Convertible Promissory Notes

Note 7 – Convertible Promissory Notes

In October 2019, the Company entered into a convertible note purchase agreement with certain holders of preferred stock and issued the 2019 Notes for an aggregate purchase price of $2.5 million. The 2019 Notes bore an interest rate of the lesser of (a) 5% per annum and (b) the maximum rate permissible by law. The 2019 Notes were due and payable on demand from the holders on or after 18 months after the date of issuance (“2019 Notes Maturity Date”), unless repaid in full or automatically converted per the Automatic Conversion feature. Under the Automatic Conversion feature, the 2019 Notes were to automatically convert to convertible preferred stock, upon the closing of the Company’s next issuance of preferred stock for capital-raising purposes resulting in net proceeds to the Company of at least $10.0 million (excluding any amounts received in connection with the conversion of the 2019 Notes) (“Future Qualifying Financing”). The 2019 Notes would convert into that whole number of shares of the securities equal to the number obtained by dividing the principal plus accrued interest of the 2019 Notes by 80% of the price per share paid by cash investors in the Future Qualifying Financing. The convertible notes included other optional redemption features as follows (i) optionally converted upon a non-qualified equity financing with a conversion price of 80% of the price paid per share in such financing, (ii) any time after the 2019 Notes Maturity Date, demand immediate repayment of an amount equal to the then-outstanding loan balance, or convert the outstanding loan balance into shares of common stock of the Company in an amount equal to the ratio of the then-outstanding loan balance over the ratio of $38.4 million divided by the number of shares of capital stock of the Company outstanding, (iii) automatically upon the occurrence of change in control or an IPO with a conversion of the loan balance into shares of common stock in an amount equal to the ratio of the then-outstanding loan balance over the ratio of $76.8 million divided by the fully diluted capitalization prior to the change in control or IPO, or demand immediate repayment of two times the outstanding loan balance, and (iv) upon certain events of default, immediately due and payable in full.

In June 2020, the Company entered into a convertible note purchase agreement with certain holders of preferred stock and issued the 2020 Notes for an aggregate purchase price of $6.4 million. The 2020 Notes bore an interest rate of the lesser of (a) 5% per annum and (b) the maximum rate permissible by law. The 2020 Notes were due and payable on demand from the holders on or after 18 months after the date of issuance (“2020 Notes Maturity Date”), unless repaid in full or automatically converted per the Automatic Conversion feature. Under the Automatic Conversion feature, the 2020 Notes were to automatically convert to convertible preferred stock, upon the closing of the Company’s next issuance of preferred stock for capital-raising purposes resulting in net proceeds to the Company of at least $10.0 million (excluding any amounts received in connection with the conversion of the 2020 Notes) (“Qualifying Financing”). The 2020 Notes would convert into that whole number of shares of the securities equal to the number obtained by dividing the principal plus accrued interest of the 2020 Notes by 80% of the price per share paid by cash investors in the Qualifying Financing. The convertible notes included other optional redemption features as follows (i) optionally converted upon a non-qualified equity financing with a conversion price of 80% of the price paid per share in such financing, (ii) any time after the 2020 Notes Maturity Date, demand immediate repayment of an amount equal to the then-outstanding loan balance, or convert the outstanding loan balance into shares of common stock of the Company in an amount equal to the ratio of the then-outstanding loan balance over the ratio of $38.4 million divided by the number of shares of capital stock of the Company outstanding, (iii) automatically upon the occurrence of change in control or an IPO with a conversion of the loan balance into shares of common stock in an amount equal to the ratio of the then-outstanding loan balance over the ratio of $76.8 million divided by the fully diluted capitalization prior to the change in control or IPO, or demand immediate repayment of two times the outstanding loan balance, (iv) automatically upon the consummation of a transaction in which the Company merges with a public company and (v) upon certain events of default, immediately due and payable in full.

For the year ended December 31, 2020, the Company recognized interest expense of $135,000 in connection with the 2019 Notes and 2020 Notes. In September 2020, all outstanding convertible promissory notes with a total fair value of $11.2 million and accrued interest of $167,000 were converted to 1,905,688 shares of Series B convertible preferred stock.

 
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.22.0.1
Convertible Preferred Stock and Stockholders' Equity (Deficit)
 12 Months Ended
Dec. 31, 2021
Stockholders Equity Note [Abstract]  
Convertible Preferred Stock and Stockholders' Equity (Deficit)

Note 8 – Convertible Preferred Stock and Stockholders’ Equity (Deficit)

In 2020, the Company amended its Certificate of Incorporation to authorize the issuance of 24,000,000 shares of common stock, par value $0.001 per share, and 16,273,406 shares of preferred stock, par value $0.001 per share, of which 3,731,208 shares were designated Series A convertible preferred stock and 12,542,198 shares were designated Series B convertible preferred stock.

In connection with the reverse stock split on April 16, 2021, the Company filed a certificate of amendment to its certificate of incorporation, which authorized 260,000,000 shares of capital stock, consisting of 250,000,000 shares of common stock, par value $0.001 per share, and 10,000,000 shares of undesignated preferred stock, par value $0.001 per share that may be issued from time to time by the Company’s Board of Directors in one or more series. Of the 250,000,000 shares of common stock, 200,000,000 shares were designated as “Common Stock” and 50,000,000 shares were designated as “Non-Voting Common Stock”.

Rights, preferences, powers, privileges and restrictions, qualifications and limitations for holders of the Company’s Common Stock and Non-Voting Common Stock are:

 

a)

Voting Common Stock Voting Rights. Each holder of Voting Common Stock, as such, shall be entitled to one vote for each share of Voting Common Stock held of record by such holder on all matters on which stockholders generally are entitled to vote; provided, however, that, except as otherwise required by law, holders of Voting Common Stock, as such, shall not be entitled to vote on any amendment to the Certificate of Incorporation, including any certificate of designations relating to any series of Preferred Stock (each hereinafter referred to as a “Preferred Stock Designation”), that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together with the holders of one or more other such series, to vote thereon pursuant to the Certificate of Incorporation (including any Preferred Stock Designation).

 

b)

Non-Voting Common Stock Voting Rights. Non-Voting Common Stock (i) shall be non-voting except as may be required by law and (ii) shall not entitle the holder thereof to vote on the election of directors at any time.

 

c)

Non-Voting Common Stock Conversion. Each holder of shares of Non-Voting Common Stock shall have the right to convert each share of Non-Voting Common Stock held by such holder into one share (subject to appropriate adjustment in the event of any stock dividend, stock split, reverse stock split, combination or other similar recapitalization with respect to the Voting Common Stock) of Voting Common Stock at such holder’s election by providing written notice to the Corporation; provided, however, that such shares of Non-Voting Common Stock may only be converted into shares of Voting Common Stock during such time or times as immediately prior to or as a result of such conversion would not result in the holder(s) thereof beneficially owning (for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended and the rules and regulations promulgated thereunder (collectively, the “Exchange Act”)), when aggregated with affiliates with whom such holder is required to aggregate beneficial ownership for purposes of Section 13(d) of the Exchange Act, in excess of the Beneficial Ownership Limitation. The “Beneficial Ownership Limitation” means initially 9.99% of the Voting Common Stock. Any holder of Non-Voting Common Stock may increase the Beneficial Ownership Limitation with respect to such holder, not to exceed 19.99% of the Voting Common Stock, upon 61 days’ prior written notice to the Corporation and may decrease the Beneficial Ownership Limitation at any time upon providing written notice of such election to the Corporation; provided, however, that no holder may make such an election to change the percentage with respect to such holder unless all holders managed by the same investment advisor as such electing holder make the same election. Before any holder of Non-Voting Common Stock shall be entitled to convert any shares of Non-Voting Common Stock into shares of Voting Common Stock, such holder shall (A) surrender the certificate or certificates therefor (if any), duly endorsed, at the principal corporate office of the Corporation or of any transfer agent for the Non-Voting Common Stock, and (B) provide written notice to the Corporation, during regular business hours at its principal corporate office, of such conversion election (in form satisfactory to the Corporation) and shall state therein the name or names (i) in which the certificate or certificates representing the shares of Voting Common Stock into which the shares of Non-Voting Common Stock are so converted are to be issued (if such shares of Voting Common Stock are certificated) or (ii) in which such shares of Voting Common Stock are to be registered in book-entry form (if such shares of Voting Common Stock are uncertificated). If the shares of Voting Common Stock into which the shares of Non-Voting Common Stock are to be converted are to be issued in a name or names other than the name of the holder of the shares of Non-Voting Common Stock being converted, such notice shall be accompanied by a written instrument or instruments of transfer, in form satisfactory to the Corporation, duly executed by the holder. The Corporation shall, as soon as practicable thereafter, issue and deliver at such office to such holder, or to the nominee or nominees of such holder, a certificate or certificates representing the number of shares of Voting Common Stock to which such holder shall be entitled upon such

 

conversion (if such shares of Voting Common Stock are certificated) or shall register such shares of Voting Common Stock in book-entry form (if such shares of Voting Common Stock are uncertificated). Such conversion shall be deemed to be effective immediately prior to the close of business on the date of such surrender of the shares of Non-Voting Common Stock to be converted following or contemporaneously with the provision of written notice of such conversion election as required by this section, the shares of Voting Common Stock issuable upon such conversion shall be deemed to be outstanding as of such time, and the person or persons entitled to receive the shares of Voting Common Stock issuable upon such conversion shall be deemed to be the record holder or holders of such shares of Voting Common Stock as of such time. Notwithstanding anything herein to the contrary, shares of Non-Voting Common Stock represented by a lost, stolen or destroyed stock certificate may be converted if the holder thereof notifies the Corporation or its transfer agent that such certificate has been lost, stolen or destroyed and makes an affidavit of that fact acceptable to the Corporation and executes an agreement acceptable to the Corporation to indemnify the Corporation from any loss incurred by it in connection with such certificate. The effectiveness of any conversion of any shares of Non-Voting Common Stock into shares of Voting Common Stock is subject to the expiration or early termination of any applicable premerger notification and waiting period requirements of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules and regulations promulgated thereunder.

 

d)

Dividends. Subject to the rights of the holders of any outstanding series of Preferred Stock, the holders of shares of Common Stock shall be entitled to receive any dividends to the extent permitted by law when, as and if declared by the board of directors of the Corporation (the “Board”).

 

e)

Liquidation. Upon the dissolution, liquidation or winding up of the Corporation, subject to the rights of the holders of any outstanding series of Preferred Stock, the holders of shares of Common Stock shall be entitled to receive the assets of the Corporation available for distribution to its stockholders ratably in proportion to the number of shares held by them. The Non-Voting Common Stock shall rank on parity with the Voting Common Stock as to distributions of assets upon dissolution, liquidation or winding up of the Corporation, whether voluntary or involuntary.

Convertible Preferred Stock

Series A Convertible Preferred Stock. In April 2018, the Company entered into a Series A convertible preferred stock purchase agreement, pursuant to which the Company issued 2,098,269 shares of Series A convertible preferred stock for an aggregate purchase price of $11.0 million, net of issuance costs. In December 2018, the Company issued an additional 1,390,788 shares of Series A convertible preferred stock for an aggregate purchase price of $7.3 million, net of issuance costs.

Series B Convertible Preferred Stock. In September 2020, the Company entered into a Series B convertible preferred stock purchase agreement, pursuant to which the Company issued 10,636,510 shares of Series B convertible preferred stock for an aggregate purchase price of $63.2 million, net of issuance costs.

Rights, preferences, powers, privileges and restrictions, qualifications and limitations for holders of the Company’s Series A convertible preferred stock and Series B convertible preferred stock are:

 

•

Dividends: Each holder of the Company’s Series A and Series B convertible preferred stock is entitled to receive non-cumulative dividends, when and if declared by the Company’s Board of Directors. No dividends have been declared to date.

 

•

Liquidation Preferences: In the event of any liquidation, dissolution or winding up of the Company, the holders of the Series A and Series B convertible preferred stock shall be entitled to receive, prior and in preference to any distribution of any of the assets of the Company to the holders of common stock, an amount per share equal to the original issue price plus declared but unpaid dividends.

 

•

Conversion: Each share of Series A and Series B convertible preferred stock is convertible at the option of the holder, at any time, into the number of shares of common stock determined by dividing the applicable purchase price by the applicable conversion price at the time of conversion. Each share of Series A and Series B convertible preferred stock will be automatically converted into common stock immediately upon (i) the closing of a firm commitment underwritten IPO resulting in at least $50.0 million of gross proceeds to the Company or (ii) the receipt by the Company of a written request for automatic conversion from the holders of a majority of the outstanding shares of Series A and Series B convertible preferred stock.

 

•

Voting: The holders of the Series A and Series B convertible preferred stock are entitled to one vote for each share of common stock into which such shares of Series A and Series B convertible preferred stock could then be converted; and with respect to such vote, such holders shall have full voting rights and powers equal to the voting rights and powers of the holders of the common stock.

 

•

Redemption: The Series A and Series B convertible preferred stock are not explicitly redeemable at the option of the holder at a specified date in the future or at the option of the Company.

Prior to the IPO, the Company’s Series A and Series B convertible preferred stock were classified as temporary equity on the accompanying balance sheet instead of in stockholders’ equity (deficit) as events triggering redemption that were not solely within the Company’s control because the preferred stockholders had the ability to effect a liquidation event. The Company determined not to adjust the carrying values of the Series A and Series B convertible preferred stock to the liquidation preferences of such shares because of the uncertainty of whether or when such liquidation events would occur.

On April 27, 2021, immediately prior to the closing of the IPO, 8,344,905 shares of the Company’s convertible preferred stock were exchanged for 7,727,470 shares of Non-Voting common stock and 7,928,501 shares of the Company’s convertible preferred stock converted into 7,341,860 shares of common stock. There were no outstanding shares of the Company’s convertible preferred stock as of December 31, 2021.

Equity Incentive Plan

In August 2020, the Company’s Board of Directors amended the Amended and Restated 2018 Stock Option—Stock Issuance Plan (the “2018 Plan”) to increase the maximum number of shares of common stock that may be issued over the term of the plan. The 2018 Plan provides for the grant of stock options, non-statutory stock options, incentive stock options and stock issuances to employees, nonemployees and consultants of the Company.

In April 2021, the Company’s 2021 Equity Incentive Plan (the “2021 Plan”) was approved by the Company’s Board of Directors and became effective on April 15, 2021. Upon the effectiveness of the 2021 Plan, no further grants may be made under the Company’s 2018 Plan.

The 2021 Plan allows the Company to grant equity-based awards to its officers, employees, directors and other key persons (including consultants). The Company initially reserved up to 3,246,120 shares of common stock for issuance under the 2021 Plan, plus (i) 1,722 shares that remained available for the issuance of awards under the 2018 Plan at the time the 2021 Plan became effective, and (ii) any shares subject to outstanding options or other share awards that were granted under the 2018 Plan that terminate or expire prior to exercise or settlement; are forfeited because of the failure to vest; or are reacquired or withheld (or not issued) to satisfy a tax withholding obligation or the purchase or exercise price. The 2021 Plan provides that the number of shares reserved and available for issuance under the plan will automatically increase each January 1, beginning on January 1, 2022 and each January 1 thereafter through January 31, 2032, by 4.0% of the outstanding number of shares of common stock on the immediately preceding December 31, or such lesser number of shares as determined by the Company’s Board of Directors.

A summary of the Company’s stock option activities during the year ended December 31, 2021 are as follows (in thousands, except share and per share amounts and years):

 

 

 

Total

Options

 

 

Weighted-

Average

Exercise

Price Per

Share

 

 

Weighted-

Average

Remaining

Contract

Term

 

 

Aggregate

Intrinsic

Value

 

Outstanding as of December 31, 2020

 

 

882,942

 

 

$

3.72

 

 

 

9.0

 

 

$

1,263

 

Granted

 

 

932,296

 

 

$

12.80

 

 

 

 

 

 

 

 

 

Exercised

 

 

(30,496

)

 

$

3.96

 

 

 

 

 

 

$

171

 

Forfeited or cancelled

 

 

(50,046

)

 

$

7.00

 

 

 

 

 

 

 

 

 

Outstanding as of December 31, 2021

 

 

1,734,696

 

 

$

8.50

 

 

 

8.8

 

 

$

7,594

 

Vested and expected to vest as of December 31, 2021

 

 

1,734,696

 

 

$

8.50

 

 

 

8.8

 

 

$

7,594

 

Vested and exercisable as of December 31, 2021

 

 

621,869

 

 

$

4.15

 

 

 

8.2

 

 

$

5,429

 

 

 

The weighted-average grant date fair values of option grants during the years ended December 31, 2021 and 2020 were $12.14 and $2.74 per share, respectively. The weighted-average grant date fair values of options forfeited during the years ended December 31, 2021 and 2020 were $6.08 and $2.82 per share, respectively.

Employee Stock Purchase Plan

The 2021 Employee Share Purchase Plan (the “ESPP”) was approved by the Board of Directors and became effective on April 15, 2021. The ESPP initially reserved and authorized the issuance of up to 259,689 shares of common stock to participating employees. Under the ESPP, eligible employees can contribute up to 15% of their eligible compensation, as defined in the ESPP, towards the purchase of the Company’s common stock at a price of 85% of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the last trading day of the offering period. The ESPP provides for twenty-four-month offering periods with four six-month purchase periods in each offering period. The ESPP provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2022 and each January 1 thereafter through January 31, 2032, by 1.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year. As of December 31, 2021, no shares had been issued under the ESPP, and 259,689 shares authorized under the ESPP were available for issuance. In January 2022, the Company issued 26,804 shares under the ESPP.

Liability for Restricted Stock

In 2017, the Company entered into restricted stock purchase agreements with various employees for 3,518,842 shares of common stock, which are subject to time-based vesting. The Company had the option to repurchase any unvested shares at the original purchase price upon any voluntary or involuntary separation of an employee from the Company. The shares purchased pursuant to the restricted stock purchase agreements were not deemed, for accounting purposes, to be outstanding until those shares vest. The cash received in exchange for unvested shares of the restricted stock granted were recorded as a liability on the accompanying balance sheet and were transferred into common stock and additional paid-in capital as the restricted stock vested.

The Company issued 532,455 shares in 2020 in connection with the vesting of the restricted stock. As of December 31, 2020, no shares remained subject to repurchase by the Company.

Stock-Based Compensation Expense

The Company recognized stock-based compensation expense as follows (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Research and development

 

$

2,486

 

 

$

581

 

General and administrative

 

 

606

 

 

 

284

 

Stock-based compensation expense

 

$

3,092

 

 

$

865

 

 

The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the stock option grants were as follows:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Risk-free interest rate

 

0.8% - 1.3%

 

 

0.2% - 0.9%

 

Expected volatility

 

113.2% - 118.7%

 

 

96.9% - 116.2%

 

Expected term (in years)

 

5.0 – 6.1

 

 

1.5 – 6.1

 

Expected dividend yield

 

0%

 

 

0%

 

 

As of December 31, 2021, the unrecognized compensation cost related to outstanding options was $9.8 million and is expected to be recognized as expense over approximately 3.1 years.

The weighted average assumptions used in Black-Scholes option pricing model to estimate the fair value of purchase rights granted under the ESPP were as follows:

 

 

 

Year Ended December 31,

 

 

 

2021

 

Risk-free interest rate

 

0.1%

 

Expected volatility

 

127.8%

 

Expected term (in years)

 

1.4

 

Expected dividend yield

 

0%

 

 

As of December 31, 2021, there was $0.5 million of unrecognized compensation cost related to the ESPP and is expected to be recognized over approximately 1.5 years.

The determination of the fair value of share-based payment awards utilizing the Black-Scholes option-pricing model is affected by the Company’s stock price and the following assumptions:

Risk-free interest rate. The risk-free interest rate assumption is based on the U.S. Treasury instruments, the terms of which were consistent with the expected term of the Company’s stock-based awards.

Expected volatility. Due to the Company’s limited operating history and lack of company-specific historical or implied volatility, the expected volatility assumption was determined by examining the historical volatilities of a group of industry peers whose share prices are publicly available.

Expected term. The expected term represents the weighted-average period the stock-based awards are expected to be outstanding. The Company uses the simplified method for estimating the expected term. The simplified method calculates the expected term as the average of the time-to-vesting and the contractual life of the stock-based awards.

Expected dividend yield. The expected dividend assumption is based on the Company’s history and expectation of dividend payouts. The Company has not paid and does not intend to pay dividends.

Forfeitures. The Company reduces stock-based compensation expense for actual forfeitures during the period.

Common Stock Reserved for Future Issuance

Common stock reserved for future issuance consist of the following:

 

 

 

As of December 31,

 

 

 

2021

 

 

2020

 

Stock options

 

 

1,734,696

 

 

 

882,942

 

Reserved for future equity award grants

 

 

2,933,930

 

 

 

582,203

 

Reserved for future ESPP issuances

 

 

259,689

 

 

 

—

 

Convertible preferred stock

 

 

—

 

 

 

15,069,330

 

Common stock reserved for future issuance

 

 

4,928,315

 

 

 

16,534,475

 

 
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.22.0.1
License and Clinical Supply Agreements
 12 Months Ended
Dec. 31, 2021
License Agreements [Abstract]  
License and Clinical Supply Agreements

Note 9 – License and Clinical Supply Agreements

The Company has entered into license agreements, accounted for as asset acquisitions, under which the Company is required to use commercially reasonable efforts to meet certain specified development and regulatory milestones related to the licensed technologies within specified time periods. In consideration of the rights granted to the Company under the agreements, the Company is required to make cash milestone payments to the licensors upon the completion of certain development, regulatory and commercial milestones. For the arrangements that the Company accounted for as asset acquisitions, contingent consideration liabilities are recorded as an additional cost of the acquired assets when the contingency is resolved, and the consideration is paid or becomes payable. Additionally, the Company has agreed to pay royalties on net sales of products applicable to the license agreements. The Company may terminate the agreements upon written notice to the licensors.

Daiichi Sankyo License Agreement

On September 2, 2020, the Company licensed the rights to milademetan (DS-3032b) for all human prophylactic or therapeutic uses in all countries and territories of the world from Daiichi Sankyo Company, Limited, (“Daiichi Sankyo”), a Japanese corporation (the “Daiichi Sankyo License Agreement”). Daiichi Sankyo conducted clinical studies of milademetan prior to the Company’s licensing the rights to this product. The Company refers to this product candidate as milademetan.

In accordance with the terms of the Daiichi Sankyo License Agreement, the Company paid Daiichi Sankyo an initial upfront payment of $5.0 million during the year ended December 31, 2020.

Under the Daiichi Sankyo License Agreement, the Company obtained worldwide, sublicensable exclusive rights to seven families of patents with respect to milademetan. The Company is solely responsible under the Daiichi Sankyo License Agreement for the research, development and registration of milademetan. Pursuant to the Daiichi Sankyo License Agreement, Daiichi Sankyo had the right to continue to conduct three clinical trials and prepare final reports with respect to these clinical trials, and such right expires upon all subjects completing the study treatment. The Company has agreed to reimburse Daiichi Sankyo certain third-party expenses incurred while conducting such trials. The Company made clinical trials payments of $0.2 million under the Daiichi Sankyo License Agreement for the year ended December 31, 2021. The Company made no clinical trials payments to Daiichi Sankyo for the year ended December 31, 2020. As of December 31, 2021, the accrued Daiichi Sankyo reimbursable clinical trials costs were $2.0 million, which was recorded in accrued research and development in the balance sheet.

The Company is required to make aggregate future milestone payments of up to $222.5 million, contingent on the attainment of certain development, regulatory and sales milestones. On July 20, 2021, the Company announced that the first patient has been randomized in the multicenter, open-label, Phase 3 registrational trial (MANTRA) evaluating milademetan for the treatment of de-differentiated liposarcoma. Accordingly, pursuant to the Daiichi Sankyo License Agreement, the Company recorded $5.5 million in milestone fees as research and development expense in the statement of operations. Of the $5.5 million milestone fees, $2.5 million was paid in the third quarter of 2021 and $3.0 million was accrued as part of accrued research and development in the balance sheet as of December 31, 2021.

Additionally, the Company is required to pay Daiichi Sankyo a high single digit royalty based on the annual net sales of the Products, subject to reduction at an agreed rate upon the expiration of the licensed patent in the particular country where the Products are sold. To date, no royalty payments have been made to Daiichi Sankyo under the Daiichi Sankyo License Agreement. The royalty obligation terminates on a country-by-country and Product-by-Product basis on the later of: (i) loss of all market exclusivity for such Product in such country, (ii) the last-to-expire patent that covers the Licensed Compound or the Product in such country and (iii) twelve years from launch of the first Product sold by the Company in such country.

Unless sooner terminated or extended, the Daiichi Sankyo License Agreement will remain in full force and effect until the Company, its affiliates and its sublicensees cease all development and commercial activity related to milademetan. Either party may terminate the Daiichi Sankyo License Agreement for cause in the event of an uncured material breach (subject to a 90-day cure period). However, the Company may only terminate the Daiichi Sankyo License Agreement with respect to the countries affected by such uncured material breach. Daiichi Sankyo may also terminate the Daiichi Sankyo License Agreement in the event of Rain’s bankruptcy or insolvency. Additionally, Daiichi Sankyo may terminate the Daiichi Sankyo License Agreement immediately upon written notice if the Company, its affiliates or its sublicensors initiate or join any challenge to the validity or enforceability of a licensed patent, subject to certain exclusions. Furthermore, the Company may terminate the Daiichi Sankyo License Agreement in its entirety or on a country-by-country basis for bona fide material concerns regarding the (i) lack of safety for human use arising from toxicity of the Licensed Compound or Product(s), (ii) lack of efficacy of the Licensed Compound or Product(s) or (iii) adverse economic impact to the Company in connection with its continued development of the Products, in each case, upon six months’ prior written notice to Daiichi Sankyo. In addition, if the Company is acquired by a third party that is developing and commercializing a competing compound and the acquiring party decides not to discontinue the development or commercialization of such competing compound, such third party must terminate the Daiichi Sankyo License Agreement within 30 days of such acquisition if it does not discontinue such development or commercialization. Upon termination of the Daiichi Sankyo License Agreement by Daiichi Sankyo for the Company’s uncured material breach or by the Company for its bona fide material concerns regarding the safety, efficacy or adverse economic impacts relating to the Licensed Compound or Products, or its development thereof, the Company is required to, among other actions, if requested by Daiichi Sankyo (i) transfer to Daiichi Sankyo ongoing clinical trials, data, reports, records

and materials, (ii) grant to Daiichi Sankyo an exclusive, irrevocable, sublicensable, fully paid-up license under any patents and know-how that are controlled and actually used by the Company at the time of termination in connection with the Products to allow Daiichi Sankyo exploit the Licensed Compound or Products in countries that are affected by the termination, (iii) grant to Daiichi Sankyo an exclusive, irrevocable, sublicensable, fully paid up license to use trademarks that are specific to the Products and (iv) assign any applicable sublicenses.

Drexel License Agreement and Sponsored Research Agreement

On July 30, 2020 (the “Effective Date”), the Company entered into an intellectual property license agreement (the “Drexel License Agreement”) with Drexel University (“Drexel”). Pursuant to the Drexel License Agreement, Drexel granted to the Company (i) a worldwide, exclusive license to make and commercialize products under a single issued patent and two patent applications related to RAD52 inhibitors for the treatment of cancer (the “Patent Rights”) and (ii) a worldwide, nonexclusive license to make, use and commercialize certain technical information and know-how related to the Patent Rights. The license grant includes the right to sublicense after the first anniversary of the Effective Date, subject to express conditions set forth in the Drexel License Agreement.

The Company is obligated to use commercially reasonable efforts to (i) develop, commercialize, market and sell licensed products in a manner consistent with a development plan and (ii) achieve certain milestone events, including, among other things, receiving investigational new drug application (“IND”) approval for a licensed product by the fourth anniversary of the Effective Date. Under the Drexel License Agreement, for a period of five years from the Effective Date, the Company is granted a first option to license Drexel’s rights in certain improvements, developments or inventions developed by Drexel (or jointly by the parties) during the five-year period that are directly related to the licensed products or to RAD52 or compounds that have been generated to specifically target RAD52.

In addition to a one-time, non-refundable initiation fee of $20,000 paid in four equal installments of $5,000 each within ten days after the Effective Date and six, twelve and eighteen months after the Effective Date, the Drexel License Agreement requires the Company to make further payments to Drexel of up to an aggregate of $6.25 million, for the achievement of specified development milestones for certain licensed products. The Company is also required to reimburse Drexel (i) after the filing of the first IND for the first licensed product, for all costs related to the filing, prosecution and maintenance of the Patent Rights accumulated prior to the Effective Date, and (ii) for all reasonable costs related to the filing, prosecution and maintenance of the Patent Rights after the Effective Date. In addition, the Company is also required to pay Drexel, on a quarterly basis, a low single digit royalty on net sales by the Company, its affiliates and sublicensees of certain licensed products, subject to specified reductions and a minimum quarterly royalty payment of up to $6,250.

Lastly, the Company is also obligated to pay Drexel (i) an annual license maintenance fee of $15,000 commencing upon filing of the first IND for a licensed product until the first sale of the first licensed product, (ii) a sublicense fee of low double digits percentage on all consideration received by the Company from its sublicensees, subject to certain reductions and (iii) a one-time transaction fee equal to the actual amount of Drexel’s licensing and legal expenses in connection with the Drexel License Agreement and the Sponsored Research Agreement the parties simultaneously entered into with the Drexel License Agreement (the Sponsored Research Agreement).

The Company made payments of $34,387 and $11,720 under the Drexel License Agreement for the years ended December 31, 2021 and 2020, respectively.

Unless sooner terminated or extended, the term of the Drexel License Agreement with respect to any licensed product and country continues until the later of (i) the expiration or abandonment of the last-to-expire valid claim of the Patent Rights that covers the sale of such licensed product in such country, (ii) the expiration of any granted statutory period of marketing and/or data exclusivity for such licensed product that confers upon the Company exclusive commercialization, (iii) the month of the first sale of a generic equivalent of such licensed product in such country and (iv) ten years after the first sale of the first licensed product.

The Company may terminate the Drexel License Agreement at any time by providing 60 days’ prior written notice to Drexel, in which case the Company will be required to cease exploitation of all licensed products, terminate all permitted sublicenses and pay all amounts owed to Drexel under the Drexel License Agreement and the Sponsored Research Agreement through the effective date of termination. Drexel may terminate the Drexel License Agreement for the Company’s uncured material breach (with 30-135 day cure periods), for the

Company’s bankruptcy or insolvency, for the Company’s uncured material default under the Sponsored Research Agreement, or if the Company challenges the validity or enforceability of the licensed patent rights.

Roche Clinical Supply Agreement

In December 2021, the Company entered into a clinical supply agreement with Roche for the supply of the anti-Programmed Death Ligand-1 (PD-L1) monoclonal antibody, atezolizumab. Clinical trials are planned to evaluate milademetan, in combination with atezolizumab for the treatment of patients in genetically selected populations. Under this agreement, Rain is the sponsor of the anticipated clinical trials, and Roche will supply atezolizumab. The Company does not have any financial commitments to Roche under this agreement.
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitments and Contingencies
 12 Months Ended
Dec. 31, 2021
Commitments And Contingencies Disclosure [Abstract]  
Commitments and Contingencies

Note 10 – Commitments and Contingencies

Leases

In September 2018, the Company entered into a noncancelable operating lease agreement for office space for its corporate headquarters in Newark, California with an initial term of 5.25 years. The lease commenced in January 2019 and ends March 2024. Under the terms of the lease, the Company pays annual base rent, subject to an annual fixed percentage increase of 3% on March 1st of each year. The Company is obligated to pay for its share of direct expenses including operating expense and taxes, which are considered variable lease costs and are expensed as incurred.

In March 2020, Governor Newsom issued State of California Executive Order No. N-33-20 instructing all individuals in California to stay at home due to the COVID-19 pandemic. In connection with such order, the Company entered into an amendment to the noncancelable operating lease agreement in June 2020. The amendment provided the Company rent relief for three months in 2020. In consideration of the rent relief, the Company agreed to adjust the base rent annual fixed percentage increase of 3% on February 1st of each year and extend the lease until September 2024. The amendment was determined to be a lease modification that qualified as a change of accounting on the existing lease and not a separate contract. Remeasurement of the right-of-use asset and operating lease liabilities at the date of modification did not result in a material increase of the right-of-use asset and operating lease liabilities.

The future minimum lease payments required under the operating lease are summarized as follows (in thousands):

 

 

 

As of December 31,

 

 

 

2021

 

2022

 

 

167

 

2023

 

 

171

 

2024

 

 

129

 

Total minimum lease payments

 

$

467

 

Less: amount representing interest

 

 

(55

)

Present value of operating lease liabilities

 

$

412

 

Operating lease liabilities, current

 

 

160

 

Operating lease liabilities, non-current

 

 

252

 

Total operating lease liabilities

 

$

412

 

 

 

 

 

 

Weighted-average remaining lease term (in years)

 

 

2.7

 

Weighted-average incremental borrowing rate

 

 

10.0

%

 

The table below summarizes the Company’s lease costs and cash payments in connection with operating lease obligations (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Total operating lease expense

 

$

160

 

 

$

130

 

Operating cash flows used for operating lease

 

$

162

 

 

$

130

 

 

 

Contingencies

In the event the Company becomes subject to claims or suits arising in the ordinary course of business, the Company would accrue a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated.
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.22.0.1
Employee Benefits
 12 Months Ended
Dec. 31, 2021
Compensation And Retirement Disclosure [Abstract]  
Employee Benefits

Note 11 – Employee Benefits

The Company has a defined contribution 401(k) plan available to eligible employees. Under the terms of the plan, employees may make voluntary contributions as a percent of compensation, limited to the maximum amount allowable under federal tax regulations. The Company, at its discretion, may make certain contributions to the 401(k) plan. The Company made matching contributions of $233,831 and $79,000 for the years ended December 31, 2021 and 2020, respectively.

XML 31 R19.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes
 12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Income Taxes

Note 12 – Income Taxes

The Company recorded de minimis state income tax expense for the years ended December 31, 2021 and 2020 primarily as a result of the Company maintaining a full valuation allowance against its loss from operations for tax purposes. The net losses for the years ended December 31, 2021 and 2020 were generated solely in the United States.

The provision for income taxes is comprised of the following (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Current:

 

 

 

 

 

 

 

 

State

 

$

2

 

 

$

—

 

Provision for income taxes

 

$

2

 

 

$

—

 

 

The provision for income taxes differs from the amount computed by applying the federal statutory income tax rate to income before taxes as follows (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Federal tax benefit at statutory rate

 

$

(10,792

)

 

$

(4,426

)

State taxes

 

 

604

 

 

 

(1,640

)

Change in fair value of convertible promissory notes

 

 

—

 

 

 

425

 

Non-deductible expenses

 

 

490

 

 

 

(11

)

Convertible note interest

 

 

—

 

 

 

28

 

R&D credits

 

 

(2,177

)

 

 

(187

)

Change in valuation allowance

 

 

11,870

 

 

 

5,797

 

Other

 

 

7

 

 

 

14

 

Provision for income taxes

 

$

2

 

 

$

—

 

 

 

Deferred income taxes reflect the tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The components of deferred income tax assets and liabilities are as follows (in thousands):

 

 

 

As of December 31,

 

 

 

2021

 

 

2020

 

Deferred tax assets:

 

 

 

 

 

 

 

 

Accrued expenses and other

 

$

407

 

 

$

188

 

Fixed assets

 

 

10

 

 

 

11

 

Intangibles

 

 

2,378

 

 

 

1,698

 

Net operating losses

 

 

16,993

 

 

 

8,254

 

R&D and Orphan Drug credits

 

 

2,615

 

 

 

438

 

Stock-based compensation

 

 

287

 

 

 

236

 

Lease liability

 

 

87

 

 

 

135

 

Other

 

 

2

 

 

 

—

 

Total deferred tax assets

 

$

22,779

 

 

$

10,960

 

Valuation allowance

 

 

(22,698

)

 

 

(10,827

)

Total net deferred tax assets

 

$

81

 

 

$

133

 

Deferred tax liabilities:

 

 

 

 

 

 

 

 

Right-of-use asset

 

$

(81

)

 

 

(133

)

Total deferred tax liabilities

 

$

(81

)

 

$

(133

)

Net deferred tax assets

 

$

—

 

 

$

—

 

 

Realization of deferred tax assets is dependent upon the Company’s ability to generate sufficient taxable income within the carryforward period. In assessing the realizability of some portion or all of the deferred tax assets, the Company evaluated both positive and negative evidence to determine if some or all of its deferred tax assets should be recognized. Based on the available objective evidence, the Company has concluded it is not more likely than not that its deferred tax assets will be realized.

Therefore, a valuation allowance in the amount of $22.7 million has been recorded for 2021 against the Company’s deferred tax assets.

The net valuation allowance increased by $11.9 million and $5.8 million during the years ended December 31, 2021 and 2020, respectively.

The following table sets forth the Company’s federal and state net operating loss carryforwards as of December 31, 2021 (in thousands):

 

 

 

Amount

 

 

Expiration Years

Net operating losses, Federal—pre TCJA

 

$

159

 

 

2037

Net operating losses, Federal—post TCJA

 

$

69,085

 

 

N/A

Net operating losses, state

 

$

27,801

 

 

2031-2041

R&D and Orphan Drug credits, Federal

 

$

3,110

 

 

2039-2041

R&D credits, California

 

$

948

 

 

N/A

 

Utilization of the Company’s net operating loss and R&D credits may be subject to substantial limitations due to the ownership changes limitations provided by the Internal Revenue Code and similar state provisions. Such annual limitations could result in the expiration of the net operating loss before their utilization. Sections 382 and 383 of the Internal Revenue Code (“IRC Sections 382 and 383”) impose limitations on a corporation’s ability to utilize its net operating losses and credit carryforwards if it experiences an “ownership change” as defined by IRC Sections 382 and 383. The Company has performed an analysis under Section 382 of the Internal Revenue Code which subjects the amount of pre-change net operating losses and certain other tax attributes that can be utilized to an annual limitation. Based on the analysis, ownership changes have occurred in 2018 and 2021.

The Company is required to recognize in the financial statements the impact of a tax position, if that position is more likely than not of being sustained on audit, based on the technical merits of the position.

The following table reflects changes in the gross unrecognized tax benefits (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Balance at beginning of year

 

$

402

 

 

$

215

 

Additions based on tax positions related to

   current year

 

 

1,040

 

 

 

187

 

Balance at end of year

 

$

1,442

 

 

$

402

 

 

The Company recognizes interest and penalties as a component of income tax expense. There were no interest or penalties recognized in the statements of operations and comprehensive loss. The total unrecognized tax benefits of $1.4 million and $0.4 million were recorded as of December 31, 2021 and 2020, respectively, which, if recognized currently, should not impact the effective tax rate due to the Company maintaining a full valuation allowance. The Company expects the unrecognized tax benefits will not change significantly within the next 12 months.

The Company is subject to examination by the United States federal and state tax authorities for the tax years 2017 and later.

 
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.22.0.1
Net Loss Per Share
 12 Months Ended
Dec. 31, 2021
Earnings Per Share [Abstract]  
Net Loss Per Share

Note 13 – Net Loss Per Share

The following tables summarize the computation of the basic and diluted net loss per share (in thousands, except share and per share data):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Numerator:

 

 

 

 

 

 

 

 

Net loss

 

$

(51,394

)

 

$

(21,083

)

Denominator:

 

 

 

 

 

 

 

 

Weighted-average shares of common stock outstanding, basic and

   diluted

 

 

19,405,833

 

 

 

3,519,728

 

Less: weighted-average unvested common stock

 

 

—

 

 

 

(167,878

)

Weighted-average shares used to compute net loss per share, basic and

   diluted

 

 

19,405,833

 

 

 

3,351,850

 

Net loss per share, basic and diluted

 

$

(2.65

)

 

$

(6.29

)

 

The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their inclusion would be anti-dilutive:

 

 

 

As of December 31,

 

 

 

2021

 

 

2020

 

Stock options

 

 

1,734,696

 

 

 

882,942

 

Series A convertible preferred stock

 

 

—

 

 

 

3,731,208

 

Series B convertible preferred stock

 

 

—

 

 

 

12,542,198

 

ESPP shares

 

 

85,031

 

 

 

—

 

Total

 

 

1,819,727

 

 

 

17,156,348

 

 
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Use of Estimates

Use of Estimates

The preparation of the Company’s financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent liabilities in the Company’s financial statements and accompanying notes. The most significant estimate in the Company’s financial statements relates to the clinical trial expense accruals. Management evaluates its estimates on an ongoing basis. Although these estimates are based on the Company’s historical experience, knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.
Cash and Cash Equivalents

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents include commercial paper, readily available money market and checking accounts.
Available-for-Sale Investments

Available-for-Sale Investments

The Company holds investment grade securities consisting of money market funds, commercial paper, corporate debt securities, U.S. government securities and U.S. agency bonds, classified as available-for-sale (“AFS”) securities at the time of purchase, since it is the Company’s intent that these investments be available for current operations. The Company has classified all of its AFS securities as current assets on the balance sheets even though the stated maturity date may be one year or more beyond the current balance sheet date, which reflects management’s intention to use the proceeds from sales of these securities to fund its operations, as necessary.

The Company carries these securities at fair value and reports unrealized gains and losses, if any, as a separate component of accumulated other comprehensive loss. The cost of debt securities is adjusted for amortization of purchase premiums and accretion of discounts to maturity. Such amortization and accretion are included in interest income in the statements of operations and comprehensive loss. Realized gains and losses on sales of securities are determined using the specific identification method and recorded in other income (expense), net in the statement of operations and comprehensive loss.

Investments are considered to be impaired when a decline in fair value is judged to be other-than-temporary. The Company consults with its investment managers and considers available quantitative and qualitative evidence in evaluating potential impairment of its investments on a quarterly basis. If the cost of an individual investment exceeds its fair value, the Company evaluates among other factors, general market conditions, the duration and extent to which the fair value is less than cost, and the Company’s intent and ability to hold the investment. Once an impairment is determined to be other-than-temporary, an impairment charge is recorded and a new cost basis in the investment is established. Declines in the value of AFS securities determined to be other than temporary are included in other income (expense), net.
Fair Value Option

Fair Value Option

 

As permitted under ASC 825, Financial Instruments (“ASC 825”), the Company has elected the fair value option to account for the convertible promissory notes issued in 2019 (the “2019 Notes”) and 2020 (the “2020 Notes”). In accordance with ASC 825, the Company records these convertible promissory notes at fair value and records changes in fair value as a line item within other income (expense) in the accompanying statements

of operations and comprehensive loss. As a result of applying the fair value option, direct costs and fees related to the 2019 Notes and 2020 Notes were recognized in net loss as incurred and not deferred.
Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

The carrying amounts of all cash equivalents, prepaid expenses and other assets, accounts payable and accrued and other current liabilities are reasonable estimates of their fair value because of the short-term nature of these items.
Concentration of Credit Risk

Concentration of Credit Risk

 

Financial instruments, which potentially subject the Company to significant concentration of credit risk, consist primarily of cash, cash equivalents and short-term investments. The Company maintains cash and money market deposits in a federally insured major financial institution in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institution in which those deposits are held.
Deferred Offering Costs

Deferred Offering Costs

The Company capitalized offering costs consisting of all direct and incremental legal, professional, accounting and other third-party fees incurred in connection with the Company’s IPO. Upon the completion of the IPO in April 2021, the total deferred offering costs of $2.5 million were reclassified to additional paid-in capital on the balance sheets.
Research and Development Costs

Research and Development Costs

Research and development costs primarily consist of costs associated with the Company’s research and development activities, including its drug discovery efforts, and the preclinical and clinical development of its product candidates. Research and development costs are expensed as incurred.
Property and Equipment

Property and Equipment

Property and equipment, net consists of computer equipment, furniture and equipment and leasehold improvements. Leasehold improvements are amortized over the remainder of the lease term. Computer equipment and furniture and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally two to three years). Repairs and maintenance costs are charged to expense as incurred.
Long-Lived Assets

Long-Lived Assets

The Company regularly reviews the carrying value and estimated lives of all of its long-lived assets, including property and equipment, to determine whether indicators of impairment may exist which warrant adjustments to carrying values or estimated useful lives. Should an impairment exist, the impairment loss would be measured based on the excess over the carrying amount of the asset’s fair value. The Company has not recognized any impairment losses from inception through December 31, 2021.
Commitments

Commitments

The Company recognizes a liability with regard to loss contingencies when it believes it is probable that a liability has occurred, and the amount can be reasonably estimated. If some amount within a range of loss appears at the time to be a better estimate than any other amount within the range, the Company accrues that amount. When no amount within the range is a better estimate than any other amount, the Company accrues the minimum amount in the range. The Company has not recorded any such liabilities as of December 31, 2021.
Leases

Leases

At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company records the associated lease liability and corresponding right-of-use asset upon commencement of the lease using the implicit rate or a discount rate based on a credit- adjusted secured borrowing rate commensurate

with the term of the lease. The Company additionally evaluates leases at their inception to determine if they are to be accounted for as an operating lease or a finance lease. Operating lease assets represent a right to use an underlying asset for the lease term and operating lease liabilities represent an obligation to make lease payments arising from the lease. Operating lease liabilities with a term greater than one year and their corresponding right-of-use assets are recognized on the balance sheet at the commencement date of the lease based on the present value of lease payments over the expected lease term. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. As the Company’s leases do not typically provide an implicit rate, the Company utilizes the appropriate incremental borrowing rate, determined as the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and in a similar economic environment. Lease cost is recognized on a straight-line basis over the lease term and variable lease payments are recognized as operating expenses in the period in which the obligation for those payments is incurred. Variable lease payments primarily include common area maintenance, utilities, real estate taxes, insurance and other operating costs that are passed on from the lessor in proportion to the space leased by the Company. The Company has elected the practical expedient to not separate lease and non-lease components.

Preclinical Studies and Clinical Trial Accruals

Preclinical Studies and Clinical Trial Accruals

The Company is required to estimate its expenses resulting from its obligations under contracts with vendors, consultants, clinical research organizations and clinical site agreements in connection with conducting preclinical activities and clinical trials. The financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company reflects preclinical study and clinical trial expenses in its financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of the preclinical study or clinical trial as measured by the timing of various aspects of the preclinical study, clinical trial or related activities. The Company determines accrual and prepaid estimates through review of the underlying contracts along with preparation of financial models taking into account correspondence with clinical and other key personnel and third- party service providers as to the progress of preclinical studies, clinical trials or other services being conducted. During the course of a preclinical study or clinical trial, the Company adjusts its expense recognition if actual results differ from its estimates. To date, the Company has not experienced any material differences between accrued costs and actual costs incurred.
In-Process Research and Development

In-Process Research and Development

The Company evaluates whether acquired intangible assets are a business under applicable accounting standards. Additionally, the Company evaluates whether the acquired assets have a future alternative use. Intangible assets that do not have future alternative use, such as the license the Company acquired from Daiichi, are considered acquired in-process research and development. When the acquired in-process research and development assets are not part of a business combination, the value of the consideration paid is expensed on the acquisition date. Future costs to develop these assets are recorded to research and development expenses as they are incurred.
Patent Costs

Patent Costs

Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.
General and Administrative Expenses

General and Administrative Expenses

General and administrative expenses consist of salaries, stock-based compensation, facilities and third-party expenses. General and administrative expenses are associated with the activities of the executive, finance, accounting, information technology, legal and human resource functions.
Stock-Based Compensation

Stock-Based Compensation

Stock-based compensation expense represents the grant date fair value of equity awards recognized over the requisite service period of the awards (generally the vesting period) on a straight-line basis. The Company recognizes forfeitures as they occur. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model. Prior to the IPO, the exercise price for all stock options granted was at the estimated fair value of the underlying common stock as determined on the date of grant by the Company’s Board of Directors.
Income Taxes

Income Taxes

The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

The Company recognizes deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.

The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more likely than not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.
Comprehensive Loss

Comprehensive Loss

Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company’s comprehensive loss includes unrealized gains / losses from short-term investments.
Net Loss Per Share

Net Loss Per Share

Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the sum of the weighted-average number of shares of common stock plus the potential dilutive effects of potential dilutive securities outstanding during the period. Potential dilutive securities are excluded from diluted earnings or loss per share if the effect of such inclusion is antidilutive. The Company’s potentially dilutive securities, which include convertible preferred stock, ESPP shares, and outstanding stock options under the Company’s equity incentive plan, have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For the periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position.
Recent Developments Regarding the COVID-19 Pandemic

Recent Developments Regarding the COVID-19 Pandemic

Efforts to control the outbreak of COVID-19 have resulted in challenges to businesses and facilities in various industries around the world, including disruptions to the global economy and supply chains. To date, COVID-19 has not had a material impact on the Company’s expenditures.

The Company is unable to predict the ultimate effects of COVID-19 on the U.S. or global economy or its operations. The Company continues to monitor developments affecting its workforce, suppliers, and operations. The extent of the impact of COVID-19 will depend on its duration, actions by government authorities, and impacts on the Company’s customers, employees, or vendors. These developments are continuously evolving, and the Company cannot predict whether COVID-19 will have a material impact on its financial condition, results of operations or cash flows.
Recent Accounting Pronouncements

Recent Accounting Pronouncements

Financial Instruments. In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The objective of the standard is to provide information about expected credit losses on financial instruments at each reporting date and to change

how other-than temporary impairments on investment securities are recorded. The guidance is effective for the Company beginning on January 1, 2023, with early adoption permitted. The Company does not anticipate that the adoption of ASU 2016-13 will have a significant impact on its financial statements or the related disclosures.

Income Taxes. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which simplifies the accounting for income taxes. ASU 2019-12 is effective for the Company for the fiscal year beginning after December 15, 2021 and early adoption is permitted. The Company does not anticipate that the adoption of ASU 2019-12 will have a significant impact on its financial statements or the related disclosures.

Debt and Equity Instruments. In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40), which addresses the complexity associated with applying generally accepted accounting principles for certain financial instruments with characteristics of liabilities and equity. The guidance is effective for the Company beginning on January 1, 2024, with early adoption permitted. The Company elected to adopt this standard on January 1, 2020 under the modified retrospective transition method with no material impact on its financial statements or the related disclosures.

There were no other significant updates to the recently issued accounting standards other than as disclosed herein for the year ended December 31, 2021. Although there are several other new accounting pronouncements issued or proposed by the FASB, based on the Company’s preliminary assessment, the Company does not believe any of those accounting pronouncements have had or will have a material impact on its financial position or operating results.
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value Measurements (Tables)
 12 Months Ended
Dec. 31, 2021
Fair Value Disclosures [Abstract]  
Summary of Financial Assets Measured at Fair Value on Recurring Basis

The following table summarizes financial assets that the Company measured at fair value on a recurring basis, classified in accordance with the fair value hierarchy (in thousands):

 

 

 

Fair Value Measurements at Reporting Date Using:

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

As of December 31, 2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

10,585

 

 

$

—

 

 

$

—

 

 

$

10,585

 

Commercial paper

 

 

—

 

 

 

84,616

 

 

 

—

 

 

 

84,616

 

U.S. government securities

 

 

27,824

 

 

 

 

 

 

 

—

 

 

 

27,824

 

U.S. agency bonds

 

 

—

 

 

 

8,531

 

 

 

—

 

 

 

8,531

 

Corporate debt securities

 

 

—

 

 

 

8,265

 

 

 

—

 

 

 

8,265

 

Total cash equivalents and short-term investments

 

$

38,409

 

 

$

101,412

 

 

$

—

 

 

$

139,821

 

Reported as:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents (includes cash of $397)

 

 

 

 

 

 

 

 

 

 

 

 

 

$

24,780

 

Short-term investments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

115,438

 

Total cash, cash equivalents and short-term investments

 

 

 

 

 

 

 

 

 

 

 

 

 

$

140,218

 

 

 

 

Fair Value Measurements at Reporting Date Using:

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

As of December 31, 2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents

 

$

19,257

 

 

$

—

 

 

$

—

 

 

$

19,257

 
Reconciliation of Liabilities Measured at Fair Value Using Level 3 Significant Unobservable Inputs

The following table provides a reconciliation of all liabilities measured at fair value using Level 3 significant unobservable inputs (in thousands) during the year ended December 31, 2020.

 

 

 

Convertible

Promissory

Notes

 

Fair value as of December 31, 2019

 

$

2,751

 

Issuance of convertible promissory notes

 

 

6,435

 

Conversion to convertible preferred stock (excluding interest expense)

 

 

(11,210

)

Change in fair value of convertible promissory notes (Note 7)

 

 

2,024

 

Fair value as of December 31, 2020

 

$

—

 
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.22.0.1
Investments (Tables)
 12 Months Ended
Dec. 31, 2021
Investments Debt And Equity Securities [Abstract]  
Summary of Cash Equivalents and Investments Measured at Fair Value on Recurring Basis

The following table summarizes, by major types of cash equivalents, and investments that are measured at fair value on a recurring basis (in thousands):

 

 

 

December 31, 2021

 

 

 

Amortized

Cost

 

 

Unrealized

Gains

 

 

Unrealized

Losses

 

 

Estimated

Fair Value

 

Money market funds

 

$

10,585

 

 

 

—

 

 

 

—

 

 

$

10,585

 

Commercial paper

 

 

84,642

 

 

 

2

 

 

 

(28

)

 

 

84,616

 

U.S. government securities

 

 

27,870

 

 

 

—

 

 

 

(46

)

 

 

27,824

 

U.S. agency bonds

 

 

8,546

 

 

 

—

 

 

 

(15

)

 

 

8,531

 

Corporate debt securities

 

 

8,267

 

 

 

—

 

 

 

(2

)

 

 

8,265

 

Cash equivalents and investments

 

$

139,910

 

 

$

2

 

 

$

(91

)

 

$

139,821

 
Schedule of Contractual Maturities of AFS Securities

The contractual maturities of the Company’s AFS securities were as follows (in thousands):

 

 

 

December 31,

2021

 

Due within one year

 

$

105,173

 

Due within one to two years

 

 

10,265

 

Available-for-Sale Investments

 

$

115,438

 
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.22.0.1
Balance Sheet Details (Tables)
 12 Months Ended
Dec. 31, 2021
Balance Sheet Related Disclosures [Abstract]  
Schedule of Prepaid and Other Current Assets

Prepaid and other current assets consist of the following (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Prepaid insurance

 

$

827

 

 

$

—

 

Prepaid research

 

 

4,329

 

 

 

371

 

Prepaid other

 

 

96

 

 

 

159

 

FICA tax credit receivable

 

 

452

 

 

 

110

 

Deposits

 

 

19

 

 

 

22

 

Other current assets

 

 

205

 

 

 

—

 

Prepaid and Other Current Assets

 

$

5,928

 

 

$

662

 
Schedule of Property and Equipment, Net

Property and equipment, net, consist of the following (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Computer equipment

 

$

50

 

 

$

45

 

Furniture and equipment

 

 

204

 

 

 

72

 

Leasehold improvements

 

 

67

 

 

 

67

 

 

 

$

321

 

 

$

184

 

Less: accumulated depreciation and amortization expense

 

$

(156

)

 

 

(85

)

Property and Equipment, net

 

$

165

 

 

$

99

 
Schedule of Other Non-Current Assets

Other non-current assets consist of the following (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

FICA tax credit receivable

 

$

298

 

 

$

549

 

Deposits

 

 

75

 

 

 

75

 

Other

 

 

70

 

 

 

—

 

Other non-current assets

 

$

443

 

 

$

624

 
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.22.0.1
Convertible Preferred Stock and Stockholders' Equity (Deficit) (Tables)
 12 Months Ended
Dec. 31, 2021
Summary of Stock Option Activities

A summary of the Company’s stock option activities during the year ended December 31, 2021 are as follows (in thousands, except share and per share amounts and years):

 

 

 

Total

Options

 

 

Weighted-

Average

Exercise

Price Per

Share

 

 

Weighted-

Average

Remaining

Contract

Term

 

 

Aggregate

Intrinsic

Value

 

Outstanding as of December 31, 2020

 

 

882,942

 

 

$

3.72

 

 

 

9.0

 

 

$

1,263

 

Granted

 

 

932,296

 

 

$

12.80

 

 

 

 

 

 

 

 

 

Exercised

 

 

(30,496

)

 

$

3.96

 

 

 

 

 

 

$

171

 

Forfeited or cancelled

 

 

(50,046

)

 

$

7.00

 

 

 

 

 

 

 

 

 

Outstanding as of December 31, 2021

 

 

1,734,696

 

 

$

8.50

 

 

 

8.8

 

 

$

7,594

 

Vested and expected to vest as of December 31, 2021

 

 

1,734,696

 

 

$

8.50

 

 

 

8.8

 

 

$

7,594

 

Vested and exercisable as of December 31, 2021

 

 

621,869

 

 

$

4.15

 

 

 

8.2

 

 

$

5,429

 

 

 
Summary of Stock-Based Compensation Expense Recognized

The Company recognized stock-based compensation expense as follows (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Research and development

 

$

2,486

 

 

$

581

 

General and administrative

 

 

606

 

 

 

284

 

Stock-based compensation expense

 

$

3,092

 

 

$

865

 

 
Weighted-Average Assumptions Used in Black-Scholes Option Pricing Model to Determine Fair Value of Stock Option Grants

The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the stock option grants were as follows:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Risk-free interest rate

 

0.8% - 1.3%

 

 

0.2% - 0.9%

 

Expected volatility

 

113.2% - 118.7%

 

 

96.9% - 116.2%

 

Expected term (in years)

 

5.0 – 6.1

 

 

1.5 – 6.1

 

Expected dividend yield

 

0%

 

 

0%

 

 
Schedule of Common Stock Reserved for Future Issuance

Common stock reserved for future issuance consist of the following:

 

 

 

As of December 31,

 

 

 

2021

 

 

2020

 

Stock options

 

 

1,734,696

 

 

 

882,942

 

Reserved for future equity award grants

 

 

2,933,930

 

 

 

582,203

 

Reserved for future ESPP issuances

 

 

259,689

 

 

 

—

 

Convertible preferred stock

 

 

—

 

 

 

15,069,330

 

Common stock reserved for future issuance

 

 

4,928,315

 

 

 

16,534,475

 

 
2021 Employee Share Purchase Plan  
Weighted-Average Assumptions Used in Black-Scholes Option Pricing Model to Determine Fair Value of Stock Option Grants

The weighted average assumptions used in Black-Scholes option pricing model to estimate the fair value of purchase rights granted under the ESPP were as follows:

 

 

 

Year Ended December 31,

 

 

 

2021

 

Risk-free interest rate

 

0.1%

 

Expected volatility

 

127.8%

 

Expected term (in years)

 

1.4

 

Expected dividend yield

 

0%

 

 
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitments and Contingencies (Tables)
 12 Months Ended
Dec. 31, 2021
Commitments And Contingencies Disclosure [Abstract]  
Schedule of Future Minimum Lease Payments Required under Operating Lease

The future minimum lease payments required under the operating lease are summarized as follows (in thousands):

 

 

 

As of December 31,

 

 

 

2021

 

2022

 

 

167

 

2023

 

 

171

 

2024

 

 

129

 

Total minimum lease payments

 

$

467

 

Less: amount representing interest

 

 

(55

)

Present value of operating lease liabilities

 

$

412

 

Operating lease liabilities, current

 

 

160

 

Operating lease liabilities, non-current

 

 

252

 

Total operating lease liabilities

 

$

412

 

 

 

 

 

 

Weighted-average remaining lease term (in years)

 

 

2.7

 

Weighted-average incremental borrowing rate

 

 

10.0

%
Summary of Lease Costs and Cash Payments

The table below summarizes the Company’s lease costs and cash payments in connection with operating lease obligations (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Total operating lease expense

 

$

160

 

 

$

130

 

Operating cash flows used for operating lease

 

$

162

 

 

$

130

 
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Components of Provision for Income Taxes

The provision for income taxes is comprised of the following (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Current:

 

 

 

 

 

 

 

 

State

 

$

2

 

 

$

—

 

Provision for income taxes

 

$

2

 

 

$

—

 
Computation of Provision for Income Taxes by Applying Federal Statutory Income Tax Rate to Income Before Taxes

The provision for income taxes differs from the amount computed by applying the federal statutory income tax rate to income before taxes as follows (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Federal tax benefit at statutory rate

 

$

(10,792

)

 

$

(4,426

)

State taxes

 

 

604

 

 

 

(1,640

)

Change in fair value of convertible promissory notes

 

 

—

 

 

 

425

 

Non-deductible expenses

 

 

490

 

 

 

(11

)

Convertible note interest

 

 

—

 

 

 

28

 

R&D credits

 

 

(2,177

)

 

 

(187

)

Change in valuation allowance

 

 

11,870

 

 

 

5,797

 

Other

 

 

7

 

 

 

14

 

Provision for income taxes

 

$

2

 

 

$

—

 
Components of Deferred Income Tax Assets and Liabilities The components of deferred income tax assets and liabilities are as follows (in thousands):

 

 

 

As of December 31,

 

 

 

2021

 

 

2020

 

Deferred tax assets:

 

 

 

 

 

 

 

 

Accrued expenses and other

 

$

407

 

 

$

188

 

Fixed assets

 

 

10

 

 

 

11

 

Intangibles

 

 

2,378

 

 

 

1,698

 

Net operating losses

 

 

16,993

 

 

 

8,254

 

R&D and Orphan Drug credits

 

 

2,615

 

 

 

438

 

Stock-based compensation

 

 

287

 

 

 

236

 

Lease liability

 

 

87

 

 

 

135

 

Other

 

 

2

 

 

 

—

 

Total deferred tax assets

 

$

22,779

 

 

$

10,960

 

Valuation allowance

 

 

(22,698

)

 

 

(10,827

)

Total net deferred tax assets

 

$

81

 

 

$

133

 

Deferred tax liabilities:

 

 

 

 

 

 

 

 

Right-of-use asset

 

$

(81

)

 

 

(133

)

Total deferred tax liabilities

 

$

(81

)

 

$

(133

)

Net deferred tax assets

 

$

—

 

 

$

—

 

 
Schedule of Federal and State Net Operating Loss Carryforwards

The following table sets forth the Company’s federal and state net operating loss carryforwards as of December 31, 2021 (in thousands):

 

 

 

Amount

 

 

Expiration Years

Net operating losses, Federal—pre TCJA

 

$

159

 

 

2037

Net operating losses, Federal—post TCJA

 

$

69,085

 

 

N/A

Net operating losses, state

 

$

27,801

 

 

2031-2041

R&D and Orphan Drug credits, Federal

 

$

3,110

 

 

2039-2041

R&D credits, California

 

$

948

 

 

N/A
Changes in Gross Unrecognized Tax Benefits

The following table reflects changes in the gross unrecognized tax benefits (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Balance at beginning of year

 

$

402

 

 

$

215

 

Additions based on tax positions related to

   current year

 

 

1,040

 

 

 

187

 

Balance at end of year

 

$

1,442

 

 

$

402

 
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.22.0.1
Net Loss Per Share (Tables)
 12 Months Ended
Dec. 31, 2021
Earnings Per Share [Abstract]  
Schedule of Computation of Basic and Diluted Net Loss per Share

The following tables summarize the computation of the basic and diluted net loss per share (in thousands, except share and per share data):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Numerator:

 

 

 

 

 

 

 

 

Net loss

 

$

(51,394

)

 

$

(21,083

)

Denominator:

 

 

 

 

 

 

 

 

Weighted-average shares of common stock outstanding, basic and

   diluted

 

 

19,405,833

 

 

 

3,519,728

 

Less: weighted-average unvested common stock

 

 

—

 

 

 

(167,878

)

Weighted-average shares used to compute net loss per share, basic and

   diluted

 

 

19,405,833

 

 

 

3,351,850

 

Net loss per share, basic and diluted

 

$

(2.65

)

 

$

(6.29

)

 
Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share

The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their inclusion would be anti-dilutive:

 

 

 

As of December 31,

 

 

 

2021

 

 

2020

 

Stock options

 

 

1,734,696

 

 

 

882,942

 

Series A convertible preferred stock

 

 

—

 

 

 

3,731,208

 

Series B convertible preferred stock

 

 

—

 

 

 

12,542,198

 

ESPP shares

 

 

85,031

 

 

 

—

 

Total

 

 

1,819,727

 

 

 

17,156,348

 

 
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.22.0.1
Organization and Nature of Operations - Additional Information (Details)
$ / shares in Units, $ in Millions
 12 Months Ended
May 11, 2021
shares
Apr. 27, 2021
$ / shares
shares
Apr. 16, 2021
Dec. 31, 2021
USD ($)
Segment
shares
Organization And Nature Of Operations [Line Items]        
Entity incorporation date       Apr. 30, 2017
Number of operating segments | Segment       1
Convertible preferred stock, Shares outstanding   0   0
Common Stock        
Organization And Nature Of Operations [Line Items]        
Conversion of convertible preferred stock   8,344,905    
Conversion of convertible preferred stock to common stock, shares   7,341,860    
Non-voting Common Stock        
Organization And Nature Of Operations [Line Items]        
Conversion of convertible preferred stock   7,928,501    
Conversion of convertible preferred stock to common stock, shares   7,727,470    
IPO and Over Allotment Option        
Organization And Nature Of Operations [Line Items]        
Proceeds from issuance of common stock | $       $ 121.5
Common Stock        
Organization And Nature Of Operations [Line Items]        
Reverse stock split description       On April 15, 2021 and April 16, 2021, the Company’s board of directors (the “Board of Directors”) and stockholders, respectively, approved an amended and restated certificate of incorporation of the Company to effect a 1-for-1.0799 reverse stock split of the Company’s common stock. The reverse stock split was effected on April 16, 2021. The Company’s outstanding stock options were also adjusted to reflect the 1-for-1.0799 reverse stock split of the Company’s common stock.
Reverse stock split conversion ratio     0.9260  
Number of shares issued and sold       7,845,011
Conversion of convertible preferred stock to common stock, shares       15,069,330
Common Stock | IPO        
Organization And Nature Of Operations [Line Items]        
Number of shares issued and sold   7,352,941    
Public offering price per share | $ / shares   $ 17.00    
Common Stock | Underwriters Option        
Organization And Nature Of Operations [Line Items]        
Number of shares issued and sold 492,070      
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)
 12 Months Ended 56 Months Ended
Dec. 31, 2021
Dec. 31, 2021
Apr. 30, 2021
Summary Of Significant Accounting Policies [Line Items]      
Impairment losses on long-lived assets   $ 0  
ASU 2020 - 06      
Summary Of Significant Accounting Policies [Line Items]      
Change in accounting principle, accounting standards update, early adopted true true  
Change in accounting principle, accounting standards update, adoption date Jan. 01, 2020 Jan. 01, 2020  
Change in accounting principle, accounting standards update, immaterial effect true true  
Minimum      
Summary Of Significant Accounting Policies [Line Items]      
Estimated useful lives of assets 2 years    
Maximum      
Summary Of Significant Accounting Policies [Line Items]      
Estimated useful lives of assets 3 years    
IPO      
Summary Of Significant Accounting Policies [Line Items]      
Deferred offering costs     $ 2,500,000
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value Measurements - Additional Information (Details)
 1 Months Ended 12 Months Ended
Sep. 30, 2020
USD ($)
shares
Dec. 31, 2021
USD ($)
shares
Dec. 31, 2020
USD ($)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]      
Assets transfer, Level 1 to 2   $ 0  
Assets transfer, Level 2 to 1   0  
Assets transfer, out of Level 3   0  
Assets transfer, into Level 3   0  
Liabilities transfer, Level 1 to 2   0  
Liabilities transfer, Level 2 to 1   0  
Liabilities transfer, into of Level 3   0  
Liabilities transfer, out of Level 3   0  
Financial liabilities   $ 0 $ 0
Series B Convertible Preferred Stock      
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]      
Debt conversion, converted instrument, shares | shares 1,905,688 1,905,688  
Measurement Input, Discount Rate      
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]      
Alternative investment, measurement input   25  
Minimum | Measurement Input, Expected Term      
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]      
Alternative investment measurement expected term   0 days  
Maximum | Measurement Input, Expected Term      
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]      
Alternative investment measurement expected term   8 months 1 day  
2019 and 2020 Notes      
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]      
Conversion of convertible promissory notes into Series B convertible preferred stock | shares 1,905,688    
Convertible Promissory Notes      
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]      
Debt conversion, fair value of debt converted $ 11,200,000    
Debt conversion, accrued interest of debt converted $ 167,000    
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Short-term investments $ 115,438 $ 0
Fair Value on Recurring Basis    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total cash equivalents and short-term investments 139,821  
Cash and cash equivalents (includes cash of $397) 24,780  
Short-term investments 115,438  
Total cash, cash equivalents and short-term investments 140,218  
Cash equivalents   19,257
Fair Value on Recurring Basis | Level 1    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total cash equivalents and short-term investments 38,409  
Cash equivalents   $ 19,257
Fair Value on Recurring Basis | Level 2    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total cash equivalents and short-term investments 101,412  
Fair Value on Recurring Basis | Money Market Funds    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total cash equivalents and short-term investments 10,585  
Fair Value on Recurring Basis | Money Market Funds | Level 1    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total cash equivalents and short-term investments 10,585  
Fair Value on Recurring Basis | Commercial Paper    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total cash equivalents and short-term investments 84,616  
Fair Value on Recurring Basis | Commercial Paper | Level 2    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total cash equivalents and short-term investments 84,616  
Fair Value on Recurring Basis | U.S. Government Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total cash equivalents and short-term investments 27,824  
Fair Value on Recurring Basis | U.S. Government Securities | Level 1    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total cash equivalents and short-term investments 27,824  
Fair Value on Recurring Basis | U.S. Agency Bonds    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total cash equivalents and short-term investments 8,531  
Fair Value on Recurring Basis | U.S. Agency Bonds | Level 2    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total cash equivalents and short-term investments 8,531  
Fair Value on Recurring Basis | Corporate Debt Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total cash equivalents and short-term investments 8,265  
Fair Value on Recurring Basis | Corporate Debt Securities | Level 2    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total cash equivalents and short-term investments $ 8,265  
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Parenthetical) (Details) - Fair Value on Recurring Basis
$ in Thousands
Dec. 31, 2021
USD ($)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]  
Cash and cash equivalents (includes cash of $397) $ 24,780
Cash  
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]  
Cash and cash equivalents (includes cash of $397) $ 397
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value Using Level 3 Significant Unobservable Inputs (Details) - Level 3 Significant Unobservable Inputs
$ in Thousands
 12 Months Ended
Dec. 31, 2020
USD ($)
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]  
Fair value as of December 31, 2019 $ 2,751
Issuance of convertible promissory notes 6,435
Conversion to convertible preferred stock (excluding interest expense) (11,210)
Change in fair value of convertible promissory notes (Note 7) $ 2,024
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.22.0.1
Investments - Summary of Cash Equivalents and Investments Measured at Fair Value on Recurring Basis (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Cash Cash Equivalents And Investments [Line Items]    
Investments, estimated fair value $ 115,438,000 $ 0
Fair Value on Recurring Basis    
Cash Cash Equivalents And Investments [Line Items]    
Cash equivalents, estimated fair value   $ 19,257,000
Cash equivalents and investments, amortized cost 139,910,000  
Cash equivalents and investments, unrealized gains 2,000  
Cash equivalents and investments, unrealized losses (91,000)  
Cash equivalents and investments, estimated fair value 139,821,000  
Fair Value on Recurring Basis | Money Market Funds    
Cash Cash Equivalents And Investments [Line Items]    
Cash equivalents, amortized cost 10,585,000  
Cash equivalents, estimated fair value 10,585,000  
Fair Value on Recurring Basis | Commercial Paper    
Cash Cash Equivalents And Investments [Line Items]    
Investments, amortized cost 84,642,000  
Investments, unrealized gains 2,000  
Investments, unrealized losses (28,000)  
Investments, estimated fair value 84,616,000  
Fair Value on Recurring Basis | U.S. Government Securities    
Cash Cash Equivalents And Investments [Line Items]    
Investments, amortized cost 27,870,000  
Investments, unrealized losses (46,000)  
Investments, estimated fair value 27,824,000  
Fair Value on Recurring Basis | U.S. Agency Bonds    
Cash Cash Equivalents And Investments [Line Items]    
Investments, amortized cost 8,546,000  
Investments, unrealized losses (15,000)  
Investments, estimated fair value 8,531,000  
Fair Value on Recurring Basis | Corporate Debt Securities    
Cash Cash Equivalents And Investments [Line Items]    
Investments, amortized cost 8,267,000  
Investments, unrealized losses (2,000)  
Investments, estimated fair value $ 8,265,000  
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.22.0.1
Investments - Schedule of Contractual Maturities of AFS Securities (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Investments Debt And Equity Securities [Abstract]    
Due within one year $ 105,173,000  
Due within one to two years 10,265,000  
Available-for-Sale Investments $ 115,438,000 $ 0
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.22.0.1
Investments - Additional Information (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Investments Debt And Equity Securities [Abstract]    
Investments $ 115,438,000 $ 0
Investments, realized gains or losses 0  
Marketable securities, gross unrealized loss position 129,200,000  
Marketable securities, continuous unrealized loss position, greater than 12 months 0  
Marketable securities, continuous unrealized loss position, less than 12 months $ 23,800,000  
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.22.0.1
Balance Sheet Details - Schedule of Prepaid and Other Current Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Balance Sheet Related Disclosures [Abstract]    
Prepaid insurance $ 827  
Prepaid research 4,329 $ 371
Prepaid other 96 159
FICA tax credit receivable 452 110
Deposits 19 22
Other current assets 205  
Prepaid and Other Current Assets $ 5,928 $ 662
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.22.0.1
Balance Sheet Details - Schedule of Property and Equipment, Net (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Property Plant And Equipment [Line Items]    
Property and equipment, gross $ 321 $ 184
Less: accumulated depreciation and amortization expense (156) (85)
Property and Equipment, net 165 99
Computer Equipment    
Property Plant And Equipment [Line Items]    
Property and equipment, gross 50 45
Furniture and Equipment    
Property Plant And Equipment [Line Items]    
Property and equipment, gross 204 72
Leasehold Improvements    
Property Plant And Equipment [Line Items]    
Property and equipment, gross $ 67 $ 67
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.22.0.1
Balance Sheet Details - Additional Information (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Balance Sheet Related Disclosures [Abstract]    
Depreciation expense $ 0.1 $ 0.1
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.22.0.1
Balance Sheet Details - Schedule of Other Non-Current Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Balance Sheet Related Disclosures [Abstract]    
FICA tax credit receivable $ 298 $ 549
Deposits 75 75
Other 70  
Other non-current assets $ 443 $ 624
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.22.0.1
Related Party Transactions - Additional Information (Details) - USD ($)
 1 Months Ended 12 Months Ended
Sep. 30, 2020
Dec. 31, 2021
Jun. 30, 2020
Oct. 31, 2019
2019 Notes        
Related Party Transaction [Line Items]        
Convertible promissory notes aggregate value       $ 2,500,000
2020 Notes        
Related Party Transaction [Line Items]        
Convertible promissory notes aggregate value     $ 6,400,000  
Convertible Promissory Notes        
Related Party Transaction [Line Items]        
Debt conversion, fair value of debt converted $ 11,200,000      
Debt conversion, accrued interest of debt converted $ 167,000      
Changes in fair value of debt instrument   $ 2,000,000.0    
Certain Holders of Preferred Stock Investors | 2019 Notes        
Related Party Transaction [Line Items]        
Convertible promissory notes aggregate value       $ 2,500,000
Certain Holders of Preferred Stock Investors | 2020 Notes        
Related Party Transaction [Line Items]        
Convertible promissory notes aggregate value     $ 6,400,000  
Series B Convertible Preferred Stock        
Related Party Transaction [Line Items]        
Debt conversion, converted instrument, shares 1,905,688 1,905,688    
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.22.0.1
Convertible Promissory Notes - Additional Information (Detail) - USD ($)
 1 Months Ended 12 Months Ended
Jun. 30, 2020
Sep. 30, 2020
Oct. 31, 2019
Dec. 31, 2021
Dec. 31, 2020
Debt Instrument [Line Items]          
Interest expense recognized         $ 135,000
Fair value of convertible promissory notes       $ 11,200,000  
Accrued interest       $ 167,000  
Series B Convertible Preferred Stock          
Debt Instrument [Line Items]          
Debt conversion, converted instrument, shares   1,905,688   1,905,688  
2019 Notes          
Debt Instrument [Line Items]          
Convertible promissory notes aggregate value     $ 2,500,000    
Interest rate     5.00%    
Interest rate terms       The 2019 Notes bore an interest rate of the lesser of (a) 5% per annum and (b) the maximum rate permissible by law.  
Convertible promissory notes, payable description       The 2019 Notes were due and payable on demand from the holders on or after 18 months after the date of issuance (“2019 Notes Maturity Date”), unless repaid in full or automatically converted per the Automatic Conversion feature.  
Convertible promissory notes, conversion description       Under the Automatic Conversion feature, the 2019 Notes were to automatically convert to convertible preferred stock, upon the closing of the Company’s next issuance of preferred stock for capital-raising purposes resulting in net proceeds to the Company of at least $10.0 million (excluding any amounts received in connection with the conversion of the 2019 Notes) (“Future Qualifying Financing”).  
Conversion price, percentage     80.00%    
2019 Notes | Minimum          
Debt Instrument [Line Items]          
Net proceeds from issuance of preferred stock     $ 10,000,000.0    
2019 Notes | Common Stock          
Debt Instrument [Line Items]          
Conversion of outstanding loan into common stock shares, value     38,400,000    
Conversion of outstanding loan into common stock shares, two times value     $ 76,800,000    
2020 Notes          
Debt Instrument [Line Items]          
Convertible promissory notes aggregate value $ 6,400,000        
Interest rate 5.00%        
Interest rate terms       The 2020 Notes bore an interest rate of the lesser of (a) 5% per annum and (b) the maximum rate permissible by law.  
Convertible promissory notes, payable description       The 2020 Notes were due and payable on demand from the holders on or after 18 months after the date of issuance (“2020 Notes Maturity Date”), unless repaid in full or automatically converted per the Automatic Conversion feature.  
Convertible promissory notes, conversion description       Under the Automatic Conversion feature, the 2020 Notes were to automatically convert to convertible preferred stock, upon the closing of the Company’s next issuance of preferred stock for capital-raising purposes resulting in net proceeds to the Company of at least $10.0 million (excluding any amounts received in connection with the conversion of the 2020 Notes) (“Qualifying Financing”).  
Conversion price, percentage 80.00%        
2020 Notes | Minimum          
Debt Instrument [Line Items]          
Net proceeds from issuance of preferred stock $ 10,000,000.0        
2020 Notes | Common Stock          
Debt Instrument [Line Items]          
Conversion of outstanding loan into common stock shares, value 38,400,000        
Conversion of outstanding loan into common stock shares, two times value $ 76,800,000        
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.22.0.1
Convertible Preferred Stock and Stockholders' Equity (Deficit) - Additional Information (Details)
 1 Months Ended 12 Months Ended 16 Months Ended 45 Months Ended
Apr. 27, 2021
shares
Apr. 15, 2021
shares
Jan. 31, 2022
shares
Sep. 30, 2020
USD ($)
shares
Dec. 31, 2018
USD ($)
shares
Apr. 30, 2018
USD ($)
shares
Dec. 31, 2021
USD ($)
Vote
$ / shares
shares
Dec. 31, 2020
USD ($)
$ / shares
shares
Dec. 31, 2021
USD ($)
$ / shares
shares
Dec. 31, 2021
USD ($)
$ / shares
shares
Apr. 16, 2021
$ / shares
shares
Dec. 31, 2019
shares
Dec. 31, 2017
shares
Class Of Stock [Line Items]                          
Common stock, shares authorized             250,000,000 24,000,000 250,000,000 250,000,000 250,000,000    
Common stock, Par value | $ / shares             $ 0.001 $ 0.001 $ 0.001 $ 0.001 $ 0.001    
Preferred Stock, shares authorized               16,273,406          
Preferred stock, par value | $ / shares               $ 0.001          
Number of vote per common stock | Vote             1            
Common stock, voting rights             Each holder of Voting Common Stock, as such, shall be entitled to one vote for each share of Voting Common Stock held            
Convertible preferred stock for aggregate purchase price | $               $ 63,173,000          
Convertible preferred stock, conversion terms             Each share of Series A and Series B convertible preferred stock will be automatically converted into common stock immediately upon (i) the closing of a firm commitment underwritten IPO resulting in at least $50.0 million of gross proceeds to the Company or (ii) the receipt by the Company of a written request for automatic conversion from the holders of a majority of the outstanding shares of Series A and Series B convertible preferred stock.            
Potential commitment amount from gross proceeds of underwritten initial public offering | $             $ 50,000,000.0   $ 50,000,000.0 $ 50,000,000.0      
Convertible preferred stock, voting rights             The holders of the Series A and Series B convertible preferred stock are entitled to one vote for each share of common stock into which such shares of Series A and Series B convertible preferred stock could then be converted; and with respect to such vote, such holders shall have full voting rights and powers equal to the voting rights and powers of the holders of the common stock.            
Convertible preferred stock, Shares outstanding 0           0   0 0      
Common stock, reserved for future issuance             4,928,315 16,534,475 4,928,315 4,928,315      
Weighted-average grant date fair values of option grants | $ / shares             $ 12.14 $ 2.74          
Weighted-average grant date fair values of options forfeited | $ / shares             $ 6.08 $ 2.82          
Unrecognized compensation cost related to outstanding options | $             $ 9,800,000   $ 9,800,000 $ 9,800,000      
Cost not yet recognized, period for Recognition             3 years 1 month 6 days            
Common Stock Options                          
Class Of Stock [Line Items]                          
Common stock, reserved for future issuance             1,734,696 882,942 1,734,696 1,734,696      
2018 Stock Issuance Plan                          
Class Of Stock [Line Items]                          
Stock options granted   0                      
2018 Stock Issuance Plan | Common Stock Options                          
Class Of Stock [Line Items]                          
Stock options, grant equity-based awards issued             1,722   1,722 1,722      
2021 Equity Incentive Plan                          
Class Of Stock [Line Items]                          
Stock options granted             932,296            
Percentage of outstanding number of shares of common stock   4.00%                      
2021 Employee Share Purchase Plan                          
Class Of Stock [Line Items]                          
Stock options, grant equity-based awards issued             259,689   259,689 259,689      
Percentage of outstanding number of shares of common stock   1.00%                      
Maximum contribution made by employees compensation   15.00%                      
Purchase of common stock at discount from market price, offering date   85.00%                      
Stock plan offering period   24 months                      
Shares issued in period             0            
Unrecognized compensation cost related to outstanding options | $             $ 500,000   $ 500,000 $ 500,000      
Cost not yet recognized, period for Recognition             1 year 6 months            
2021 Employee Share Purchase Plan | Subsequent Event                          
Class Of Stock [Line Items]                          
Shares issued in period     26,804                    
Restricted Stock Purchase Agreements                          
Class Of Stock [Line Items]                          
Shares authorized for issuance                         3,518,842
Shares issued in connection with vesting of restricted stock             532,455            
Shares subject to repurchase             0            
Maximum | 2021 Equity Incentive Plan | Common Stock Options                          
Class Of Stock [Line Items]                          
Common stock, reserved for future issuance   3,246,120                      
Maximum | 2021 Employee Share Purchase Plan                          
Class Of Stock [Line Items]                          
Shares authorized for issuance   259,689                      
IPO                          
Class Of Stock [Line Items]                          
Common stock, shares authorized                     260,000,000    
Series A Convertible Preferred Stock                          
Class Of Stock [Line Items]                          
Convertible preferred stock, Shares authorized             0 3,731,208 0 0      
Convertible preferred stock, Shares issued         1,390,788 2,098,269 0 3,731,208 0 0      
Convertible preferred stock for aggregate purchase price | $         $ 7,300,000 $ 11,000,000.0              
Dividends, preferred stock | $                   $ 0      
Number of vote per convertible preferred stock upon conversion into common stock | Vote             1            
Conversion of convertible preferred stock             3,731,208            
Convertible preferred stock, Shares outstanding             0 3,731,208 0 0   3,731,208  
Series B Convertible Preferred Stock                          
Class Of Stock [Line Items]                          
Convertible preferred stock, Shares authorized             0 12,542,198 0 0      
Convertible preferred stock, Shares issued       10,636,510     0 12,542,198 0 0      
Convertible preferred stock for aggregate purchase price | $       $ 63,200,000                  
Dividends, preferred stock | $                 $ 0        
Number of vote per convertible preferred stock upon conversion into common stock | Vote             1            
Conversion of convertible preferred stock             12,542,198            
Convertible preferred stock, Shares outstanding             0 12,542,198 0 0      
Undesignated Preferred Stock                          
Class Of Stock [Line Items]                          
Preferred Stock, shares authorized                     10,000,000    
Preferred stock, par value | $ / shares                     $ 0.001    
Common Stock                          
Class Of Stock [Line Items]                          
Common stock, shares authorized                     200,000,000    
Conversion of convertible preferred stock 8,344,905                        
Conversion of convertible preferred stock to common stock, shares 7,341,860                        
Non-voting Common Stock                          
Class Of Stock [Line Items]                          
Common stock, shares authorized                     50,000,000    
Common stock, conversion terms             Each holder of shares of Non-Voting Common Stock shall have the right to convert each share of Non-Voting Common Stock held by such holder into one share (subject to appropriate adjustment in the event of any stock dividend, stock split, reverse stock split, combination or other similar recapitalization with respect to the Voting Common Stock) of Voting Common Stock at such holder’s election by providing written notice to the Corporation            
Common stock, beneficial ownership limitation percentage             9.99%            
Written notice period to increase common stock beneficial ownership limitation             61 days            
Conversion of convertible preferred stock 7,928,501                        
Conversion of convertible preferred stock to common stock, shares 7,727,470                        
Non-voting Common Stock | Maximum                          
Class Of Stock [Line Items]                          
Common stock, beneficial ownership limitation percentage             19.99%            
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.22.0.1
Convertible Preferred Stock and Stockholders' Equity (Deficit) - Summary of Stock Option Activities (Details) - 2021 Equity Incentive Plan - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Total Options    
Total Options Outstanding, Beginning balance 882,942  
Stock options granted 932,296  
Total Options, Exercised (30,496)  
Total Options Forfeited or cancelled (50,046)  
Total Options Outstanding, Ending balance 1,734,696 882,942
Total Options, Vested and expected to vest as of December 31, 2021 1,734,696  
Total Options, Vested and exercisable as of December 31, 2021 621,869  
Weighted-Average Exercise Price Per Share    
Weighted-Average Exercise Price Per Share $ 3.72  
Weighted-Average Exercise Price Per Share, Granted 12.80  
Weighted-Average Exercise Price Per Share, Exercised 3.96  
Weighted-Average Exercise Price Per Share, Forfeited or cancelled 7.00  
Weighted-Average Exercise Price Per Share 8.50 $ 3.72
Weighted-Average Exercise Price Per Share, Vested and expected to vest 8.50  
Weighted-Average Exercise Price Per Share, Vested and exercisable $ 4.15  
Weighted-Average Remaining Contract Term    
Weighted-Average Remaining Contract Term 8 years 9 months 18 days 9 years
Weighted-Average Remaining Contract Term, Vested and expected to vest 8 years 9 months 18 days  
Weighted-Average Remaining Contract Term, Vested and exercisable 8 years 2 months 12 days  
Aggregate Intrinsic Value    
Aggregate Intrinsic Value, Outstanding $ 7,594 $ 1,263
Aggregate Intrinsic Value, Exercised 171  
Aggregate Intrinsic Value, Vested and expected to vest 7,594  
Aggregate Intrinsic Value, Vested and exercisable $ 5,429  
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.22.0.1
Convertible Preferred Stock and Stockholders' Equity (Deficit) - Summary of Stock-Based Compensation Expense Recognized (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]    
Stock-based compensation expense $ 3,092 $ 865
Research and Development    
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]    
Stock-based compensation expense 2,486 581
General and Administrative    
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]    
Stock-based compensation expense $ 606 $ 284
XML 59 R47.htm IDEA: XBRL DOCUMENT v3.22.0.1
Convertible Preferred Stock and Stockholders' Equity (Deficit) - Weighted-Average Assumptions Used in Black-Scholes Option Pricing Model to Determine Fair Value of Stock Option Grants (Details)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Risk-free interest rate, minimum 0.80% 0.20%
Risk-free interest rate, maximum 1.30% 0.90%
Expected volatility, minimum 113.20% 96.90%
Expected volatility, maximum 118.70% 116.20%
Expected dividend yield 0.00% 0.00%
2021 Employee Share Purchase Plan    
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Risk-free interest rate 0.10%  
Expected volatility 127.80%  
Expected term (in years) 1 year 4 months 24 days  
Expected dividend yield 0.00%  
Minimum    
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Expected term (in years) 5 years 1 year 6 months
Maximum    
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Expected term (in years) 6 years 1 month 6 days 6 years 1 month 6 days
XML 60 R48.htm IDEA: XBRL DOCUMENT v3.22.0.1
Convertible Preferred Stock and Stockholders' Equity (Deficit) - Schedule of Common Stock Reserved for Future Issuance (Details) - shares
Dec. 31, 2021
Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Common stock reserved for future issuance 4,928,315 16,534,475
Stock options    
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Common stock reserved for future issuance 1,734,696 882,942
Reserved for future equity award grants    
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Common stock reserved for future issuance 2,933,930 582,203
Reserved for future ESPP issuances    
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Common stock reserved for future issuance 259,689 0
Convertible Preferred Stock    
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Common stock reserved for future issuance 0 15,069,330
XML 61 R49.htm IDEA: XBRL DOCUMENT v3.22.0.1
License and Clinical Supply Agreements - Additional Information (Details)
 3 Months Ended 12 Months Ended
Sep. 30, 2021
USD ($)
Dec. 31, 2021
USD ($)
FamiliesofPatent
Trial
Installment
Dec. 31, 2020
USD ($)
Daiichi Sankyo License Agreement      
License Agreements [Line Items]      
License agreement, effective date   Sep. 02, 2020  
Upfront payment     $ 5,000,000.0
Sublicensable rights, number of families of patents | FamiliesofPatent   7  
Number of clinical trials | Trial   3  
Clinical trial payments   $ 200,000 0
Accrued reimbursable clinical trials costs   2,000,000.0  
Maximum future milestone payments   222,500,000  
Milestone payments   5,500,000  
Payments for license agreements $ 2,500,000    
Accrued milestone payment   3,000,000.0  
Royalty payments   $ 0  
Royalty obligation termination description   The royalty obligation terminates on a country-by-country and Product-by-Product basis on the later of: (i) loss of all market exclusivity for such Product in such country, (ii) the last-to-expire patent that covers the Licensed Compound or the Product in such country and (iii) twelve years from launch of the first Product sold by the Company in such country.  
Cure period   90 days  
Agreement termination written notice period   6 months  
Drexel License Agreement | Drexel University      
License Agreements [Line Items]      
Payments for license agreements   $ 34,387 $ 11,720
Agreement termination written notice period   60 days  
Intellectual property license agreement date   Jul. 30, 2020  
Intellectual property license agreement description   Pursuant to the Drexel License Agreement, Drexel granted to the Company (i) a worldwide, exclusive license to make and commercialize products under a single issued patent and two patent applications related to RAD52 inhibitors for the treatment of cancer (the “Patent Rights”) and (ii) a worldwide, nonexclusive license to make, use and commercialize certain technical information and know-how related to the Patent Rights. The license grant includes the right to sublicense after the first anniversary of the Effective Date, subject to express conditions set forth in the Drexel License Agreement.  
Intellectual property license agreement period   5 years  
One time non refundable initiation fee   $ 20,000  
Number of equal instalments paid one time non refundable initiation fee | Installment   4  
One time non-refundable initiation fee paid in each installment   $ 5,000  
Period of first instalment after effective date   10 days  
Period of second instalment after effective date   6 months  
Period of third instalment after effective date   12 months  
Period of fourth instalment after effective date   18 months  
Maximum future payments in addition to initiation fee   $ 6,250,000  
Upper limit of minimum quarterly royalty payments   6,250  
Annual license maintenance fee until first sale of first licensed product   $ 15,000  
Agreement period from first sale of first licensed product   10 years  
Drexel License Agreement | Drexel University | Minimum      
License Agreements [Line Items]      
Cure period   30 days  
Drexel License Agreement | Drexel University | Maximum      
License Agreements [Line Items]      
Cure period   135 days  
XML 62 R50.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitments and Contingencies - Additional Information (Details)
 1 Months Ended
Jun. 30, 2020
Sep. 30, 2018
Commitments And Contingencies Disclosure [Abstract]    
Initial term of operating lease   5 years 3 months
Operating lease commencement month and year   2019-01
Operating lease expiration month and year   2024-03
Increase in annual base rent percentage   3.00%
Increase in annual base rent month and day of each year --02-01 --03-01
Rent relief period 3 months  
Operating lease extended expiration month and year 2024-09  
XML 63 R51.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitments and Contingencies - Schedule of Future Minimum Lease Payments Required under Operating Lease (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Commitments And Contingencies Disclosure [Abstract]    
2022 $ 167  
2023 171  
2024 129  
Total minimum lease payments 467  
Less: amount representing interest (55)  
Present value of operating lease liabilities 412  
Operating lease liability, current portion 160 $ 141
Operating lease liability, net of current portion $ 252 $ 312
Weighted-average remaining lease term (in years) 2 years 8 months 12 days  
Weighted-average incremental borrowing rate 10.00%  
XML 64 R52.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitments and Contingencies - Summary of Lease Costs and Cash Payments (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Commitments And Contingencies Disclosure [Abstract]    
Total operating lease expense $ 160 $ 130
Operating cash flows used for operating lease $ 162 $ 130
XML 65 R53.htm IDEA: XBRL DOCUMENT v3.22.0.1
Employee Benefits - Additional Information (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Compensation And Retirement Disclosure [Abstract]    
Defined contribution plan, employer matching contribution amount $ 233,831 $ 79,000
XML 66 R54.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Components of Provision for Income Taxes (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
USD ($)
Current:  
State $ 2
Provision for income taxes $ 2
XML 67 R55.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Computation of Provision for Income Taxes by Applying Federal Statutory Income Tax Rate to Income Before Taxes (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Income Tax Disclosure [Abstract]    
Federal tax benefit at statutory rate $ (10,792) $ (4,426)
State taxes 604 (1,640)
Change in fair value of convertible promissory notes   425
Non-deductible expenses 490 (11)
Convertible note interest   28
R&D credits (2,177) (187)
Change in valuation allowance 11,870 5,797
Other 7 $ 14
Provision for income taxes $ 2  
XML 68 R56.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Components of Deferred Income Tax Assets and Liabilities (Detail) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Components Of Deferred Tax Assets And Liabilities [Abstract]    
Accrued expenses and other $ 407 $ 188
Fixed assets 10 11
Intangibles 2,378 1,698
Net operating losses 16,993 8,254
R&D and Orphan Drug credits 2,615 438
Stock-based compensation 287 236
Lease liability 87 135
Other 2  
Total deferred tax assets 22,779 10,960
Valuation allowance (22,698) (10,827)
Total net deferred tax assets 81 133
Right-of-use asset (81) (133)
Total deferred tax liabilities $ (81) $ (133)
XML 69 R57.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Additional Information (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Income Tax Disclosure [Abstract]      
Valuation allowance $ 22,698,000 $ 10,827,000  
Valuation allowance increase 11,900,000 5,800,000  
Unrecognized tax benefits 1,442,000 402,000 $ 215,000
Interest or penalties $ 0 $ 0  
XML 70 R58.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Schedule of Federal and State Net Operating Loss Carryforwards (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
USD ($)
Federal—Pre TCJA  
Operating Loss Carryforwards [Line Items]  
Net operating loss carryforwards, Amount $ 159
Federal—Pre TCJA | Minimum  
Operating Loss Carryforwards [Line Items]  
Expiration Years 2037
Federal—Post TCJA  
Operating Loss Carryforwards [Line Items]  
Net operating loss carryforwards, Amount $ 69,085
State  
Operating Loss Carryforwards [Line Items]  
Net operating loss carryforwards, Amount $ 27,801
State | Minimum  
Operating Loss Carryforwards [Line Items]  
Expiration Years 2031
State | Maximum  
Operating Loss Carryforwards [Line Items]  
Expiration Years 2041
R&D and Orphan Drug Credits, Federal  
Operating Loss Carryforwards [Line Items]  
Net operating loss carryforwards, Amount $ 3,110
R&D and Orphan Drug Credits, Federal | Minimum  
Operating Loss Carryforwards [Line Items]  
Expiration Years 2039
R&D and Orphan Drug Credits, Federal | Maximum  
Operating Loss Carryforwards [Line Items]  
Expiration Years 2041
R&D Credits, California  
Operating Loss Carryforwards [Line Items]  
Net operating loss carryforwards, Amount $ 948
XML 71 R59.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Changes in Gross Unrecognized Tax Benefits (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Income Tax Disclosure [Abstract]    
Balance at beginning of year $ 402 $ 215
Additions based on tax positions related to current year 1,040 187
Balance at end of year $ 1,442 $ 402
XML 72 R60.htm IDEA: XBRL DOCUMENT v3.22.0.1
Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Numerator:    
Net loss $ (51,394) $ (21,083)
Denominator:    
Weighted-average shares of common stock outstanding, basic and diluted 19,405,833 3,519,728
Less: weighted-average unvested common stock   (167,878)
Weighted-average shares used to compute net loss per share, basic and diluted 19,405,833 3,351,850
Net loss per share, basic and diluted $ (2.65) $ (6.29)
XML 73 R61.htm IDEA: XBRL DOCUMENT v3.22.0.1
Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details) - shares
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Antidilutive securities 1,819,727 17,156,348
Stock options    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Antidilutive securities 1,734,696 882,942
Series A Convertible Preferred Stock    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Antidilutive securities   3,731,208
Series B Convertible Preferred Stock    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Antidilutive securities   12,542,198
ESPP shares    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Antidilutive securities 85,031  
XML 74 rain-10k_20211231_htm.xml IDEA: XBRL DOCUMENT 0001724979 2021-01-01 2021-12-31 0001724979 2022-02-17 0001724979 2021-06-30 0001724979 2021-12-31 0001724979 2020-12-31 0001724979 rain:SeriesAConvertiblePreferredStockMember 2021-12-31 0001724979 rain:SeriesAConvertiblePreferredStockMember 2020-12-31 0001724979 rain:SeriesBConvertiblePreferredStockMember 2021-12-31 0001724979 rain:SeriesBConvertiblePreferredStockMember 2020-12-31 0001724979 rain:UndesignatedCommonStockMember 2021-12-31 0001724979 us-gaap:NonvotingCommonStockMember 2021-12-31 0001724979 2020-01-01 2020-12-31 0001724979 rain:SeriesAConvertiblePreferredStockMember 2019-12-31 0001724979 us-gaap:CommonStockMember 2019-12-31 0001724979 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001724979 us-gaap:RetainedEarningsMember 2019-12-31 0001724979 2019-12-31 0001724979 rain:SeriesBConvertiblePreferredStockMember 2020-01-01 2020-12-31 0001724979 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001724979 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001724979 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001724979 us-gaap:CommonStockMember 2020-12-31 0001724979 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001724979 us-gaap:RetainedEarningsMember 2020-12-31 0001724979 rain:SeriesAConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001724979 rain:SeriesBConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001724979 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001724979 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001724979 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001724979 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001724979 us-gaap:CommonStockMember 2021-12-31 0001724979 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001724979 us-gaap:RetainedEarningsMember 2021-12-31 0001724979 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001724979 rain:TwoThousandAndTwentyOneEmployeeSharePurchasePlanMember 2021-01-01 2021-12-31 0001724979 us-gaap:CommonStockMember 2021-04-16 2021-04-16 0001724979 us-gaap:CommonStockMember us-gaap:IPOMember 2021-04-27 2021-04-27 0001724979 us-gaap:CommonStockMember us-gaap:IPOMember 2021-04-27 0001724979 us-gaap:CommonStockMember us-gaap:OverAllotmentOptionMember 2021-05-11 2021-05-11 0001724979 rain:IPOAndOverAllotmentOptionMember 2021-01-01 2021-12-31 0001724979 rain:UndesignatedCommonStockMember 2021-04-27 2021-04-27 0001724979 us-gaap:NonvotingCommonStockMember 2021-04-27 2021-04-27 0001724979 2021-04-27 0001724979 us-gaap:IPOMember 2021-04-30 0001724979 srt:MinimumMember 2021-01-01 2021-12-31 0001724979 srt:MaximumMember 2021-01-01 2021-12-31 0001724979 2017-04-30 2021-12-31 0001724979 us-gaap:AccountingStandardsUpdate202006Member 2021-12-31 0001724979 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001724979 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001724979 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001724979 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001724979 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001724979 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001724979 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001724979 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001724979 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001724979 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001724979 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001724979 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001724979 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001724979 us-gaap:CashMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001724979 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001724979 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001724979 us-gaap:FairValueInputsLevel3Member 2019-12-31 0001724979 us-gaap:FairValueInputsLevel3Member 2020-01-01 2020-12-31 0001724979 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember 2021-01-01 2021-12-31 0001724979 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember 2021-01-01 2021-12-31 0001724979 us-gaap:MeasurementInputDiscountRateMember 2021-12-31 0001724979 rain:TwoThousandNineteenAndTwentyConvertiblePromissoryNotesMember 2020-09-30 0001724979 rain:ConvertiblePromissoryNotesMember 2020-09-01 2020-09-30 0001724979 rain:SeriesBConvertiblePreferredStockMember 2020-09-01 2020-09-30 0001724979 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001724979 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0001724979 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0001724979 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001724979 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001724979 us-gaap:ComputerEquipmentMember 2021-12-31 0001724979 us-gaap:ComputerEquipmentMember 2020-12-31 0001724979 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001724979 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001724979 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001724979 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001724979 rain:TwoThousandAndNineteenNotesMember rain:CertainHoldersOfPreferredStockInvestorsMember 2019-10-31 0001724979 rain:TwoThousandAndTwentyNotesMember rain:CertainHoldersOfPreferredStockInvestorsMember 2020-06-30 0001724979 rain:ConvertiblePromissoryNotesMember 2021-01-01 2021-12-31 0001724979 rain:TwoThousandAndNineteenNotesMember 2019-10-31 0001724979 rain:TwoThousandAndNineteenNotesMember 2021-01-01 2021-12-31 0001724979 srt:MinimumMember rain:TwoThousandAndNineteenNotesMember 2019-10-01 2019-10-31 0001724979 rain:TwoThousandAndNineteenNotesMember 2019-10-01 2019-10-31 0001724979 rain:TwoThousandAndNineteenNotesMember us-gaap:CommonStockMember 2019-10-01 2019-10-31 0001724979 rain:TwoThousandAndTwentyNotesMember 2020-06-30 0001724979 rain:TwoThousandAndTwentyNotesMember 2021-01-01 2021-12-31 0001724979 srt:MinimumMember rain:TwoThousandAndTwentyNotesMember 2020-06-30 2020-06-30 0001724979 rain:TwoThousandAndTwentyNotesMember 2020-06-30 2020-06-30 0001724979 rain:TwoThousandAndTwentyNotesMember us-gaap:CommonStockMember 2020-06-30 2020-06-30 0001724979 us-gaap:IPOMember 2021-04-16 0001724979 2021-04-16 0001724979 rain:UndesignatedPreferredStockMember 2021-04-16 0001724979 rain:UndesignatedCommonStockMember 2021-04-16 0001724979 us-gaap:NonvotingCommonStockMember 2021-04-16 0001724979 us-gaap:NonvotingCommonStockMember 2021-01-01 2021-12-31 0001724979 srt:MaximumMember us-gaap:NonvotingCommonStockMember 2021-01-01 2021-12-31 0001724979 rain:SeriesAConvertiblePreferredStockMember 2018-04-30 0001724979 rain:SeriesAConvertiblePreferredStockMember 2018-12-31 0001724979 rain:SeriesAConvertiblePreferredStockMember 2018-04-01 2018-04-30 0001724979 rain:SeriesAConvertiblePreferredStockMember 2018-12-01 2018-12-31 0001724979 rain:SeriesBConvertiblePreferredStockMember 2020-09-30 0001724979 rain:SeriesAConvertiblePreferredStockMember 2018-04-01 2021-12-31 0001724979 rain:SeriesBConvertiblePreferredStockMember 2020-09-01 2021-12-31 0001724979 rain:TwoThousandAndEighteenStockIssuancePlanMember 2021-04-15 2021-04-15 0001724979 srt:MaximumMember us-gaap:EmployeeStockOptionMember rain:TwoThousandTwentyOneEquityIncentivePlanMember 2021-04-15 0001724979 us-gaap:EmployeeStockOptionMember rain:TwoThousandAndEighteenStockIssuancePlanMember 2021-12-31 0001724979 rain:TwoThousandTwentyOneEquityIncentivePlanMember 2021-04-15 2021-04-15 0001724979 rain:TwoThousandTwentyOneEquityIncentivePlanMember 2020-12-31 0001724979 rain:TwoThousandTwentyOneEquityIncentivePlanMember 2021-01-01 2021-12-31 0001724979 rain:TwoThousandTwentyOneEquityIncentivePlanMember 2021-12-31 0001724979 rain:TwoThousandTwentyOneEquityIncentivePlanMember 2020-01-01 2020-12-31 0001724979 srt:MaximumMember rain:TwoThousandAndTwentyOneEmployeeSharePurchasePlanMember 2021-04-15 0001724979 rain:TwoThousandAndTwentyOneEmployeeSharePurchasePlanMember 2021-04-15 0001724979 rain:TwoThousandAndTwentyOneEmployeeSharePurchasePlanMember 2021-04-15 2021-04-15 0001724979 rain:TwoThousandAndTwentyOneEmployeeSharePurchasePlanMember 2021-12-31 0001724979 rain:TwoThousandAndTwentyOneEmployeeSharePurchasePlanMember us-gaap:SubsequentEventMember 2022-01-01 2022-01-31 0001724979 rain:RestrictedStockPurchaseAgreementsMember 2017-12-31 0001724979 rain:RestrictedStockPurchaseAgreementsMember 2021-01-01 2021-12-31 0001724979 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001724979 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001724979 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0001724979 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-12-31 0001724979 srt:MinimumMember 2020-01-01 2020-12-31 0001724979 srt:MaximumMember 2020-01-01 2020-12-31 0001724979 us-gaap:EmployeeStockOptionMember 2021-12-31 0001724979 us-gaap:EmployeeStockOptionMember 2020-12-31 0001724979 rain:ReservedForFutureEquityAwardGrantsMember 2021-12-31 0001724979 rain:ReservedForFutureEquityAwardGrantsMember 2020-12-31 0001724979 rain:ReservedForFutureESPPIssuancesMember 2021-12-31 0001724979 rain:ReservedForFutureESPPIssuancesMember 2020-12-31 0001724979 us-gaap:ConvertiblePreferredStockMember 2021-12-31 0001724979 us-gaap:ConvertiblePreferredStockMember 2020-12-31 0001724979 rain:DaiichiSankyoLicenseAgreementMember 2021-01-01 2021-12-31 0001724979 rain:DaiichiSankyoLicenseAgreementMember 2020-01-01 2020-12-31 0001724979 rain:DaiichiSankyoLicenseAgreementMember 2021-12-31 0001724979 rain:DaiichiSankyoLicenseAgreementMember 2021-07-01 2021-09-30 0001724979 rain:DrexelUniversityMember rain:DrexelLicenseAgreementMember 2021-01-01 2021-12-31 0001724979 rain:DrexelUniversityMember rain:DrexelLicenseAgreementMember 2021-12-31 0001724979 rain:DrexelUniversityMember rain:DrexelLicenseAgreementMember 2020-01-01 2020-12-31 0001724979 rain:DrexelUniversityMember srt:MinimumMember rain:DrexelLicenseAgreementMember 2021-01-01 2021-12-31 0001724979 rain:DrexelUniversityMember srt:MaximumMember rain:DrexelLicenseAgreementMember 2021-01-01 2021-12-31 0001724979 2018-09-30 0001724979 2018-09-01 2018-09-30 0001724979 2020-06-01 2020-06-30 0001724979 rain:FederalPreTaxCutAndJobsActMember 2021-12-31 0001724979 rain:FederalPostTaxCutAndJobsActMember 2021-12-31 0001724979 us-gaap:CaliforniaFranchiseTaxBoardMember 2021-12-31 0001724979 rain:RDAndOrphanDrugCreditsFederalMember 2021-12-31 0001724979 rain:RDCreditsCaliforniaMember 2021-12-31 0001724979 srt:MinimumMember rain:FederalPreTaxCutAndJobsActMember 2021-01-01 2021-12-31 0001724979 srt:MinimumMember us-gaap:CaliforniaFranchiseTaxBoardMember 2021-01-01 2021-12-31 0001724979 srt:MinimumMember rain:RDAndOrphanDrugCreditsFederalMember 2021-01-01 2021-12-31 0001724979 srt:MaximumMember us-gaap:CaliforniaFranchiseTaxBoardMember 2021-01-01 2021-12-31 0001724979 srt:MaximumMember rain:RDAndOrphanDrugCreditsFederalMember 2021-01-01 2021-12-31 0001724979 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001724979 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001724979 rain:SeriesAConvertiblePreferredStockMember 2020-01-01 2020-12-31 0001724979 rain:SeriesBConvertiblePreferredStockMember 2020-01-01 2020-12-31 0001724979 us-gaap:EmployeeStockMember 2021-01-01 2021-12-31 shares iso4217:USD iso4217:USD shares rain:Segment pure rain:Vote rain:FamiliesofPatent rain:Trial rain:Installment false 2021 FY --12-31 0001724979 0.9260 true true P6M P12M P30D 2021 2017-04-30 P8M1D P0D P24M P5Y P9Y P8Y9M18D P8Y9M18D P8Y2M12D 0.008 0.002 0.013 0.009 1.132 0.969 1.187 1.162 P5Y P1Y6M P6Y1M6D P6Y1M6D P1Y4M24D P2Y8M12D 2031 2039 2041 2041 10-K true 2021-12-31 false 001-40356 Rain Therapeutics Inc. DE 82-1130967 8000 Jarvis Avenue Suite 204 Newark CA 94560 510 953-5559 Common Stock, par value $0.001 per share RAIN NASDAQ No No Yes Yes Non-accelerated Filer true true false false false 120166484 26510407 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portions of the Registrant’s definitive proxy statement relating to its 2022 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year ended December 31, 2021 are incorporated herein by reference in Part III of this Annual Report on Form 10-K where indicated.</p> Ernst & Young LLP San Diego, California 42 24780000 58863000 115438000 0 5928000 662000 146146000 59525000 165000 99000 386000 447000 0 385000 443000 624000 147140000 61080000 6112000 816000 4349000 1527000 5694000 935000 160000 141000 16315000 3419000 252000 312000 69000 69000 16636000 3800000 0.001 0.001 0 0 0 3731208 3731208 3731208 0 20147000 0.001 0.001 0 0 0 12542198 12542198 12542198 0 74550000 0 94697000 0.001 0.001 250000000 24000000 26475812 26475812 18748342 18748342 7727470 7727470 3530975 3530975 27000 4000 220530000 1149000 -89000 0 -89964000 -38570000 130504000 -37417000 147140000 61080000 40773000 15367000 10739000 3591000 51512000 18958000 -51512000 -18958000 119000 32000 135000 2024000 1000 2000 120000 -2125000 -51392000 -21083000 2000 -51394000 -21083000 -2.65 -6.29 19405833 3351850 -51394000 -21083000 -89000 -51483000 -21083000 3731208 20147000 2986385 3000 236000 -17487000 -17248000 327000 10636510 63173000 1905688 11377000 532455 1000 1000 12135 48000 48000 865000 865000 -21083000 -21083000 3731208 20147000 12542198 74550000 3530975 4000 1149000 -38570000 -37417000 3731208 20147000 12542198 74550000 15069330 15000 94682000 94697000 7845011 8000 121486000 121494000 30496 121000 121000 3092000 3092000 -89000 -89000 -51394000 -51394000 26475812 27000 220530000 -89964000 -89000 130504000 -51394000 -21083000 5500000 5167000 71000 52000 3092000 865000 135000 2024000 -81000 1000 5266000 182000 19000 10000 -181000 195000 5288000 555000 2822000 1417000 2144000 4000 -37463000 -11231000 163557000 128000 24000 2500000 5167000 47950000 -118235000 -5191000 133366000 121000 48000 1000 63173000 6435000 11872000 166000 121615000 69491000 -34083000 53069000 58863000 5794000 24780000 58863000 94697000 3000000 9000 11377000 219000 <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 1 – Organization and Nature of Operations</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Description of Business</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;color:#231F20;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rain<span style="letter-spacing:-0.05pt;"> </span>Therapeutics<span style="letter-spacing:-0.05pt;"> </span>Inc.<span style="letter-spacing:0.05pt;"> </span>(“Rain” or<span style="letter-spacing:0.05pt;"> </span>the “Company”)<span style="letter-spacing:0.05pt;"> </span>was incorporated in the state<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>Delaware<span style="letter-spacing:-0.05pt;"> </span>in <span style="-sec-ix-hidden:F_000320">April<span style="letter-spacing:-0.05pt;"> </span>2017</span>. Rain<span style="letter-spacing:-0.05pt;"> </span>is a late-stage<span style="letter-spacing:-0.05pt;"> </span>precision<span style="letter-spacing:-0.05pt;"> </span>oncology<span style="letter-spacing:-0.05pt;"> </span>company developing<span style="letter-spacing:-0.1pt;"> </span>therapies that<span style="letter-spacing:0.05pt;"> </span>target oncogenic<span style="letter-spacing:-0.05pt;"> </span>drivers for<span style="letter-spacing:0.05pt;"> </span>which<span style="letter-spacing:-0.05pt;"> </span>the Company is able<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>genetically<span style="letter-spacing:-0.05pt;"> </span>select patients most likely to<span style="letter-spacing:-0.05pt;"> </span>benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s<span style="letter-spacing:-0.05pt;"> </span>lead<span style="letter-spacing:-0.05pt;"> </span>product candidate, <span style="color:#000000;">milademetan</span>, is a small molecule, oral inhibitor<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>mouse double minute 2,<span style="letter-spacing:0.05pt;"> </span>which<span style="letter-spacing:-0.05pt;"> </span>may be oncogenic<span style="letter-spacing:-0.05pt;"> </span>in numerous cancers.<span style="letter-spacing:0.05pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>addition<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span><span style="color:#000000;">milademetan</span>, the Company is also developing<span style="letter-spacing:-0.1pt;"> </span>a preclinical<span style="letter-spacing:-0.1pt;"> </span>program<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>is focused on inducing<span style="letter-spacing:-0.05pt;"> </span>synthetic lethality<span style="letter-spacing:-0.05pt;"> </span>in cancer cells<span style="letter-spacing:-0.05pt;"> </span>by inhibiting<span style="letter-spacing:-0.1pt;"> </span>RAD52.<span style="letter-spacing:-0.05pt;"> </span>The Company operates in one business<span style="letter-spacing:-0.05pt;"> </span>segment and its principal<span style="letter-spacing:-0.05pt;"> </span>operations are in the United<span style="letter-spacing:-0.05pt;"> </span>States,<span style="letter-spacing:0.05pt;"> </span>with its headquarters in Newark, California.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;margin-left:5.26%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Reverse Stock Split</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 15, 2021 and April 16, 2021, the Company’s board of directors (the “Board of Directors”) and stockholders, respectively, approved an amended and restated certificate of incorporation of the Company to effect a 1-for-1.0799 reverse stock split of the Company’s common stock. The reverse stock split was effected on April 16, 2021. The Company’s outstanding stock options were also adjusted to reflect the 1-for-1.0799 reverse stock split of the Company’s common stock. Accordingly, all common stock and stock options and related per share amounts in these financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock split. Outstanding stock options were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased. The reverse stock split resulted in an adjustment to the Series A and Series B convertible preferred stock conversion prices to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;margin-left:5.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Initial Public Offering</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 27, 2021, the Company completed its initial public offering (“IPO”) in which the Company issued and sold 7,352,941 shares of common stock at a public offering price of $17.00 per share. On May 11, 2021, the Company issued an additional 492,070 shares of common stock in connection with the exercise of the underwriters’ option to purchase additional shares at the public offering price. The Company’s net proceeds from the sale of shares in the IPO, including the sale of shares pursuant to the exercise of the underwriters’ option to purchase additional shares, was $121.5 million, <span style="color:#231F20;">net of </span><span style="color:#000000;">underwriting discounts and commissions, and other offering fees</span>.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Immediately prior to the closing of the IPO, 8,344,905 shares of the Company’s convertible preferred stock were exchanged for 7,727,470 shares of non-voting common stock. Upon the closing of the IPO, 7,928,501 shares of the Company’s convertible preferred stock were automatically converted into 7,341,860 shares of common stock. Following the IPO, there were no shares of convertible preferred stock outstanding. </p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) promulgated by the Financial Accounting Standards Board (“FASB”).<span style="font-weight:bold;font-style:italic;"> </span></p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Liquidity and Capital Resources</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has devoted substantially all of its efforts to drug discovery and development, raising capital and building operations. The Company has a limited operating history and has not generated any revenue since its inception, and the sales and income potential of the Company’s business is unproven. The Company has incurred net losses and negative cash flows from operating activities since its inception and expects to continue to incur net losses into the foreseeable future as it continues the development of its product candidates. From </p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">inception through </span><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</span><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Company has funded its operations through net proceeds from its IPO in April 2021, and the issuance of convertible promissory notes and convertible preferred stock.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying financial statements have been prepared assuming the Company will continue as a going concern. Management believes that the Company’s current cash, cash equivalents and short-term investments<span style="font-family:Times New Roman;"> </span>will provide sufficient funds to enable the Company to meet its obligations for at least twelve months from the filing date of this report.</p> 1 On April 15, 2021 and April 16, 2021, the Company’s board of directors (the “Board of Directors”) and stockholders, respectively, approved an amended and restated certificate of incorporation of the Company to effect a 1-for-1.0799 reverse stock split of the Company’s common stock. The reverse stock split was effected on April 16, 2021. The Company’s outstanding stock options were also adjusted to reflect the 1-for-1.0799 reverse stock split of the Company’s common stock. 7352941 17.00 492070 121500000 8344905 7727470 7928501 7341860 0 <p style="margin-top:18pt;margin-bottom:0pt;margin-right:10.23%;text-indent:0%;font-weight:bold;color:#231F20;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 2 – Summary of Significant Accounting Policies</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:5.26%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company’s financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent liabilities in the Company’s financial statements and accompanying notes. The most significant estimate in the Company’s financial statements relates to the clinical trial expense accruals. Management evaluates its estimates on an ongoing basis. Although these estimates are based on the Company’s historical experience, knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:5.26%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents include commercial paper, readily available money market and checking accounts.</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.26%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Available-for-Sale Investments</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company holds investment grade securities consisting of money market funds, commercial paper, corporate debt securities, U.S. government securities and U.S. agency bonds, classified as available-for-sale (“AFS”) securities at the time of purchase, since it is the Company’s intent that these investments be available for current operations. The Company has classified all of its AFS securities as current assets on the balance sheets even though the stated maturity date may be one year or more beyond the current balance sheet date, which reflects management’s intention to use the proceeds from sales of these securities to fund its operations, as necessary.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company carries these securities at fair value and reports unrealized gains and losses, if any, as a separate component of accumulated other comprehensive loss. The cost of debt securities is adjusted for amortization of purchase premiums and accretion of discounts to maturity. Such amortization and accretion are included in interest income in the statements of operations and comprehensive loss. Realized gains and losses on sales of securities are determined using the specific identification method and recorded in other income (expense), net in the statement of operations and comprehensive loss.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments are considered to be impaired when a decline in fair value is judged to be other-than-temporary. The Company consults with its investment managers and considers available quantitative and qualitative evidence in evaluating potential impairment of its investments on a quarterly basis. If the cost of an individual investment exceeds its fair value, the Company evaluates among other factors, general market conditions, the duration and extent to which the fair value is less than cost, and the Company’s intent and ability to hold the investment. Once an impairment is determined to be other-than-temporary, an impairment charge is recorded and a new cost basis in the investment is established. <span style="color:#000000;">Declines in the value of AFS securities determined to be other than temporary are included in other income (expense), net.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.84%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value Option</p> <p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.88%;margin-right:0.88%;text-indent:4.03%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As permitted under ASC 825, Financial Instruments (“ASC 825”), the Company has elected the fair value option to account for the convertible promissory notes issued in 2019 (the “2019 Notes”) and 2020 (the “2020 Notes”). In accordance with ASC 825, the Company records these convertible promissory notes at fair value and records changes in fair value as a line item within other income (expense) in the accompanying statements </p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.88%;margin-right:0.88%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of operations and comprehensive loss. As a result of applying the fair value option, direct costs and fees related to the 2019 Notes and 2020 Notes were recognized in net loss as incurred and not deferred.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments</p> <p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.88%;margin-right:0.15%;text-indent:4.03%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of all cash equivalents, prepaid expenses and other assets, accounts payable and accrued and other current liabilities are reasonable estimates of their fair value because of the short-term nature of these items.</p> <p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to significant concentration of credit risk, consist primarily of cash, cash equivalents and short-term investments. The Company maintains cash and money market deposits in a federally insured major financial institution in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institution in which those deposits are held.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.26%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Deferred Offering Costs</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company capitalized offering costs consisting of all direct and incremental legal, professional, accounting and other third-party fees incurred in connection with the Company’s IPO. Upon the completion of the IPO in April 2021, the total deferred offering costs of $2.5 million were reclassified to additional paid-in capital on the balance sheets.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.26%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Research and Development Costs</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs primarily consist of costs associated with the Company’s research and development activities, including its drug discovery efforts, and the preclinical and clinical development of its product candidates. Research and development costs are expensed as incurred.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.26%;font-weight:bold;color:#auto;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Property and Equipment</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consists of computer equipment, furniture and equipment and leasehold improvements. Leasehold improvements are amortized over the remainder of the lease term. Computer equipment and furniture and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally two to three years). Repairs and maintenance costs are charged to expense as incurred.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.26%;font-weight:bold;color:#auto;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Long-Lived Assets</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company regularly reviews the carrying value and estimated lives of all of its long-lived assets, including property and equipment, to determine whether indicators of impairment may exist which warrant adjustments to carrying values or estimated useful lives. Should an impairment exist, the impairment loss would be measured based on the excess over the carrying amount of the asset’s fair value. The Company has not recognized any impairment losses from inception through <span style="color:#000000;">December 31, 2021</span>.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.26%;font-weight:bold;color:#auto;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Commitments</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes a liability with regard to loss contingencies when it believes it is probable that a liability has occurred, and the amount can be reasonably estimated. If some amount within a range of loss appears at the time to be a better estimate than any other amount within the range, the Company accrues that amount. When no amount within the range is a better estimate than any other amount, the Company accrues the minimum amount in the range. The Company has not recorded any such liabilities as of <span style="color:#000000;">December 31, 2021</span>.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.26%;font-weight:bold;color:#auto;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Leases</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company records the associated lease liability and corresponding right-of-use asset upon commencement of the lease using the implicit rate or a discount rate based on a credit- adjusted secured borrowing rate commensurate </p> <p style="margin-top:6pt;margin-bottom:0pt;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with the term of the lease. The Company additionally evaluates leases at their inception to determine if they are to be accounted for as an operating lease or a finance lease. Operating lease assets represent a right to use an underlying asset for the lease term and operating lease liabilities represent an obligation to make lease payments arising from the lease. Operating lease liabilities with a term greater than one year and their corresponding right-of-use assets are recognized on the balance sheet at the commencement date of the lease based on the present value of lease payments over the expected lease term. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. As the Company’s</span><span style="color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> leases do not typically provide an implicit rate, the Company utilizes the appropriate incremental borrowing rate, determined as the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and in a similar economic environment. Lease cost is recognized on a straight-line basis over the lease term and variable lease payments are recognized as operating expenses in the period in which the obligation for those payments is incurred. Variable lease payments primarily include common area maintenance, utilities, real estate taxes, insurance and other operating costs that are passed on from the lessor in proportion to the space leased by the Company. The Company has elected the practical expedient to not separate lease and non-lease components. </span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.26%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Preclinical Studies and Clinical Trial Accruals</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is required to estimate its expenses resulting from its obligations under contracts with vendors, consultants, clinical research organizations and clinical site agreements in connection with conducting preclinical activities and clinical trials. The financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company reflects preclinical study and clinical trial expenses in its financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of the preclinical study or clinical trial as measured by the timing of various aspects of the preclinical study, clinical trial or related activities. The Company determines accrual and prepaid estimates through review of the underlying contracts along with preparation of financial models taking into account correspondence with clinical and other key personnel and third- party service providers as to the progress of preclinical studies, clinical trials or other services being conducted. During the course of a preclinical study or clinical trial, the Company adjusts its expense recognition if actual results differ from its estimates. To date, the Company has not experienced any material differences between accrued costs and actual costs incurred.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.26%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">In-Process Research and Development</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluates whether acquired intangible assets are a business under applicable accounting standards. Additionally, the Company evaluates whether the acquired assets have a future alternative use. Intangible assets that do not have future alternative use, such as the license the Company acquired from Daiichi, are considered acquired in-process research and development. When the acquired in-process research and development assets are not part of a business combination, the value of the consideration paid is expensed on the acquisition date. Future costs to develop these assets are recorded to research and development expenses as they are incurred.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.26%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Patent Costs</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.26%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">General and Administrative Expenses</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses consist of salaries, stock-based compensation, facilities and third-party expenses. General and administrative expenses are associated with the activities of the executive, finance, accounting, information technology, legal and human resource functions.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.26%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Stock-Based Compensation</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense represents the grant date fair value of equity awards recognized over the requisite service period of the awards (generally the vesting period) on a straight-line basis. The Company recognizes forfeitures as they occur. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model. Prior to the IPO, the exercise price for all stock options granted was at the estimated fair value of the underlying common stock as determined on the date of grant by the Company’s Board of Directors.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.26%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Income Taxes</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more likely than not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.26%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Comprehensive Loss</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company’s comprehensive loss includes unrealized gains / losses from short-term investments.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.26%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Net Loss Per Share</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the sum of the weighted-average number of shares of common stock plus the potential dilutive effects of potential dilutive securities outstanding during the period. Potential dilutive securities are excluded from diluted earnings or loss per share if the effect of such inclusion is antidilutive. The Company’s potentially dilutive securities, which include convertible preferred stock, ESPP shares, and outstanding stock options under the Company’s equity incentive plan, have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For the periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.26%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Recent Developments Regarding the COVID-19 Pandemic</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Efforts to control the outbreak of COVID-19 have resulted in challenges to businesses and facilities in various industries around the world, including disruptions to the global economy and supply chains. To date, COVID-19 has not had a material impact on the Company’s expenditures.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is unable to predict the ultimate effects of COVID-19 on the U.S. or global economy or its operations. The Company continues to monitor developments affecting its workforce, suppliers, and operations. The extent of the impact of COVID-19 will depend on its duration, actions by government authorities, and impacts on the Company’s customers, employees, or vendors. These developments are continuously evolving, and the Company cannot predict whether COVID-19 will have a material impact on its financial condition, results of operations or cash flows.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:5.26%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;font-style:italic;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Financial Instruments.<span style="font-style:normal;"> In June 2016, the FASB issued ASU 2016-13, </span>Financial Instruments—Credit Losses (Topic 326)<span style="font-style:normal;">: Measurement of Credit Losses on Financial Instruments. The objective of the standard is to provide information about expected credit losses on financial instruments at each reporting date and to change </span></p> <p style="margin-top:6pt;margin-bottom:0pt;font-style:italic;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:normal;">how other-than temporary impairments on investment securities are recorded. The guidance is effective for the </span><span style="font-style:normal;">Company </span><span style="font-style:normal;">beginning on January 1, 2023, with early adoption permitted. The Company does not anticipate that the adoption of ASU 2016-13 will have a significant impact on its</span><span style="font-style:normal;"> </span><span style="font-style:normal;">financial statements or the related disclosures.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;font-style:italic;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Income Taxes.<span style="font-style:normal;"> In December 2019, the FASB issued ASU 2019-12, </span>Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes <span style="font-style:normal;">(“ASU 2019-12”), which simplifies the accounting for income taxes. ASU 2019-12 is effective for the Company for the fiscal year beginning after December 15, 2021 and early adoption is permitted. The Company does not anticipate that the adoption of ASU 2019-12 will have a significant impact on its financial statements or the related disclosures.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Debt and Equity Instruments. <span style="color:#auto;font-style:normal;">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#auto;">Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)</span><span style="color:#auto;font-style:normal;">, which addresses the complexity associated with applying generally accepted accounting principles for certain financial instruments with characteristics of liabilities and equity. The guidance is effective for the Company beginning on January 1, 2024, with early adoption permitted. The Company elected to adopt this standard on January 1, 2020 under the modified retrospective transition method with no material impact on its financial statements or the related disclosures</span>.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no other significant updates to the recently issued accounting standards other than as disclosed herein for the year ended December 31, 2021. Although there are several other new accounting pronouncements issued or proposed by the FASB, based on the Company’s preliminary assessment, the Company does not believe any of those accounting pronouncements have had or will have a material impact on its financial position or operating results.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:5.26%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company’s financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent liabilities in the Company’s financial statements and accompanying notes. The most significant estimate in the Company’s financial statements relates to the clinical trial expense accruals. Management evaluates its estimates on an ongoing basis. Although these estimates are based on the Company’s historical experience, knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:5.26%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents include commercial paper, readily available money market and checking accounts.</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.26%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Available-for-Sale Investments</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company holds investment grade securities consisting of money market funds, commercial paper, corporate debt securities, U.S. government securities and U.S. agency bonds, classified as available-for-sale (“AFS”) securities at the time of purchase, since it is the Company’s intent that these investments be available for current operations. The Company has classified all of its AFS securities as current assets on the balance sheets even though the stated maturity date may be one year or more beyond the current balance sheet date, which reflects management’s intention to use the proceeds from sales of these securities to fund its operations, as necessary.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company carries these securities at fair value and reports unrealized gains and losses, if any, as a separate component of accumulated other comprehensive loss. The cost of debt securities is adjusted for amortization of purchase premiums and accretion of discounts to maturity. Such amortization and accretion are included in interest income in the statements of operations and comprehensive loss. Realized gains and losses on sales of securities are determined using the specific identification method and recorded in other income (expense), net in the statement of operations and comprehensive loss.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments are considered to be impaired when a decline in fair value is judged to be other-than-temporary. The Company consults with its investment managers and considers available quantitative and qualitative evidence in evaluating potential impairment of its investments on a quarterly basis. If the cost of an individual investment exceeds its fair value, the Company evaluates among other factors, general market conditions, the duration and extent to which the fair value is less than cost, and the Company’s intent and ability to hold the investment. Once an impairment is determined to be other-than-temporary, an impairment charge is recorded and a new cost basis in the investment is established. <span style="color:#000000;">Declines in the value of AFS securities determined to be other than temporary are included in other income (expense), net.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.84%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value Option</p> <p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.88%;margin-right:0.88%;text-indent:4.03%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As permitted under ASC 825, Financial Instruments (“ASC 825”), the Company has elected the fair value option to account for the convertible promissory notes issued in 2019 (the “2019 Notes”) and 2020 (the “2020 Notes”). In accordance with ASC 825, the Company records these convertible promissory notes at fair value and records changes in fair value as a line item within other income (expense) in the accompanying statements </p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.88%;margin-right:0.88%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of operations and comprehensive loss. As a result of applying the fair value option, direct costs and fees related to the 2019 Notes and 2020 Notes were recognized in net loss as incurred and not deferred.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments</p> <p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.88%;margin-right:0.15%;text-indent:4.03%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of all cash equivalents, prepaid expenses and other assets, accounts payable and accrued and other current liabilities are reasonable estimates of their fair value because of the short-term nature of these items.</p> <p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to significant concentration of credit risk, consist primarily of cash, cash equivalents and short-term investments. The Company maintains cash and money market deposits in a federally insured major financial institution in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institution in which those deposits are held.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.26%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Deferred Offering Costs</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company capitalized offering costs consisting of all direct and incremental legal, professional, accounting and other third-party fees incurred in connection with the Company’s IPO. Upon the completion of the IPO in April 2021, the total deferred offering costs of $2.5 million were reclassified to additional paid-in capital on the balance sheets.</p> 2500000 <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.26%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Research and Development Costs</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs primarily consist of costs associated with the Company’s research and development activities, including its drug discovery efforts, and the preclinical and clinical development of its product candidates. Research and development costs are expensed as incurred.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.26%;font-weight:bold;color:#auto;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Property and Equipment</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consists of computer equipment, furniture and equipment and leasehold improvements. Leasehold improvements are amortized over the remainder of the lease term. Computer equipment and furniture and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally two to three years). Repairs and maintenance costs are charged to expense as incurred.</p> P2Y P3Y <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.26%;font-weight:bold;color:#auto;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Long-Lived Assets</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company regularly reviews the carrying value and estimated lives of all of its long-lived assets, including property and equipment, to determine whether indicators of impairment may exist which warrant adjustments to carrying values or estimated useful lives. Should an impairment exist, the impairment loss would be measured based on the excess over the carrying amount of the asset’s fair value. The Company has not recognized any impairment losses from inception through <span style="color:#000000;">December 31, 2021</span>.</p> 0 <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.26%;font-weight:bold;color:#auto;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Commitments</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes a liability with regard to loss contingencies when it believes it is probable that a liability has occurred, and the amount can be reasonably estimated. If some amount within a range of loss appears at the time to be a better estimate than any other amount within the range, the Company accrues that amount. When no amount within the range is a better estimate than any other amount, the Company accrues the minimum amount in the range. The Company has not recorded any such liabilities as of <span style="color:#000000;">December 31, 2021</span>.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.26%;font-weight:bold;color:#auto;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Leases</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company records the associated lease liability and corresponding right-of-use asset upon commencement of the lease using the implicit rate or a discount rate based on a credit- adjusted secured borrowing rate commensurate </p> <p style="margin-top:6pt;margin-bottom:0pt;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with the term of the lease. The Company additionally evaluates leases at their inception to determine if they are to be accounted for as an operating lease or a finance lease. Operating lease assets represent a right to use an underlying asset for the lease term and operating lease liabilities represent an obligation to make lease payments arising from the lease. Operating lease liabilities with a term greater than one year and their corresponding right-of-use assets are recognized on the balance sheet at the commencement date of the lease based on the present value of lease payments over the expected lease term. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. As the Company’s</span><span style="color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> leases do not typically provide an implicit rate, the Company utilizes the appropriate incremental borrowing rate, determined as the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and in a similar economic environment. Lease cost is recognized on a straight-line basis over the lease term and variable lease payments are recognized as operating expenses in the period in which the obligation for those payments is incurred. Variable lease payments primarily include common area maintenance, utilities, real estate taxes, insurance and other operating costs that are passed on from the lessor in proportion to the space leased by the Company. The Company has elected the practical expedient to not separate lease and non-lease components. </span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.26%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Preclinical Studies and Clinical Trial Accruals</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is required to estimate its expenses resulting from its obligations under contracts with vendors, consultants, clinical research organizations and clinical site agreements in connection with conducting preclinical activities and clinical trials. The financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company reflects preclinical study and clinical trial expenses in its financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of the preclinical study or clinical trial as measured by the timing of various aspects of the preclinical study, clinical trial or related activities. The Company determines accrual and prepaid estimates through review of the underlying contracts along with preparation of financial models taking into account correspondence with clinical and other key personnel and third- party service providers as to the progress of preclinical studies, clinical trials or other services being conducted. During the course of a preclinical study or clinical trial, the Company adjusts its expense recognition if actual results differ from its estimates. To date, the Company has not experienced any material differences between accrued costs and actual costs incurred.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.26%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">In-Process Research and Development</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluates whether acquired intangible assets are a business under applicable accounting standards. Additionally, the Company evaluates whether the acquired assets have a future alternative use. Intangible assets that do not have future alternative use, such as the license the Company acquired from Daiichi, are considered acquired in-process research and development. When the acquired in-process research and development assets are not part of a business combination, the value of the consideration paid is expensed on the acquisition date. Future costs to develop these assets are recorded to research and development expenses as they are incurred.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.26%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Patent Costs</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.26%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">General and Administrative Expenses</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses consist of salaries, stock-based compensation, facilities and third-party expenses. General and administrative expenses are associated with the activities of the executive, finance, accounting, information technology, legal and human resource functions.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.26%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Stock-Based Compensation</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense represents the grant date fair value of equity awards recognized over the requisite service period of the awards (generally the vesting period) on a straight-line basis. The Company recognizes forfeitures as they occur. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model. Prior to the IPO, the exercise price for all stock options granted was at the estimated fair value of the underlying common stock as determined on the date of grant by the Company’s Board of Directors.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.26%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Income Taxes</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more likely than not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.26%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Comprehensive Loss</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company’s comprehensive loss includes unrealized gains / losses from short-term investments.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.26%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Net Loss Per Share</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the sum of the weighted-average number of shares of common stock plus the potential dilutive effects of potential dilutive securities outstanding during the period. Potential dilutive securities are excluded from diluted earnings or loss per share if the effect of such inclusion is antidilutive. The Company’s potentially dilutive securities, which include convertible preferred stock, ESPP shares, and outstanding stock options under the Company’s equity incentive plan, have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For the periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.26%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Recent Developments Regarding the COVID-19 Pandemic</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Efforts to control the outbreak of COVID-19 have resulted in challenges to businesses and facilities in various industries around the world, including disruptions to the global economy and supply chains. To date, COVID-19 has not had a material impact on the Company’s expenditures.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is unable to predict the ultimate effects of COVID-19 on the U.S. or global economy or its operations. The Company continues to monitor developments affecting its workforce, suppliers, and operations. The extent of the impact of COVID-19 will depend on its duration, actions by government authorities, and impacts on the Company’s customers, employees, or vendors. These developments are continuously evolving, and the Company cannot predict whether COVID-19 will have a material impact on its financial condition, results of operations or cash flows.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:5.26%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;font-style:italic;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Financial Instruments.<span style="font-style:normal;"> In June 2016, the FASB issued ASU 2016-13, </span>Financial Instruments—Credit Losses (Topic 326)<span style="font-style:normal;">: Measurement of Credit Losses on Financial Instruments. The objective of the standard is to provide information about expected credit losses on financial instruments at each reporting date and to change </span></p> <p style="margin-top:6pt;margin-bottom:0pt;font-style:italic;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:normal;">how other-than temporary impairments on investment securities are recorded. The guidance is effective for the </span><span style="font-style:normal;">Company </span><span style="font-style:normal;">beginning on January 1, 2023, with early adoption permitted. The Company does not anticipate that the adoption of ASU 2016-13 will have a significant impact on its</span><span style="font-style:normal;"> </span><span style="font-style:normal;">financial statements or the related disclosures.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;font-style:italic;color:#auto;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Income Taxes.<span style="font-style:normal;"> In December 2019, the FASB issued ASU 2019-12, </span>Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes <span style="font-style:normal;">(“ASU 2019-12”), which simplifies the accounting for income taxes. ASU 2019-12 is effective for the Company for the fiscal year beginning after December 15, 2021 and early adoption is permitted. The Company does not anticipate that the adoption of ASU 2019-12 will have a significant impact on its financial statements or the related disclosures.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Debt and Equity Instruments. <span style="color:#auto;font-style:normal;">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#auto;">Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)</span><span style="color:#auto;font-style:normal;">, which addresses the complexity associated with applying generally accepted accounting principles for certain financial instruments with characteristics of liabilities and equity. The guidance is effective for the Company beginning on January 1, 2024, with early adoption permitted. The Company elected to adopt this standard on January 1, 2020 under the modified retrospective transition method with no material impact on its financial statements or the related disclosures</span>.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no other significant updates to the recently issued accounting standards other than as disclosed herein for the year ended December 31, 2021. Although there are several other new accounting pronouncements issued or proposed by the FASB, based on the Company’s preliminary assessment, the Company does not believe any of those accounting pronouncements have had or will have a material impact on its financial position or operating results.</p> 2020-01-01 <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 3 – Fair Value Measurements</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:10.53%;text-indent:-5.26%;font-style:italic;font-family:Arial;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level 1<span style="font-style:normal;">: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:10.53%;text-indent:-5.26%;font-style:italic;font-family:Arial;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level 2<span style="font-style:normal;">: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span></p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:10.53%;text-indent:-5.26%;font-style:italic;font-family:Arial;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level 3<span style="font-style:normal;">: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of cash, prepaid expenses and other current assets, deferred offering costs, other assets, accounts payable, accrued research and development, other current liabilities and other long-term liabilities are reasonable estimates of their fair value due to the short-term nature of these accounts.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s money market funds under cash and cash equivalents are classified using Level 1 inputs within the fair value hierarchy because they are valued using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. There were no transfers between levels of the fair value hierarchy during the years ended December 31, 2021 and 2020, respectively.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes financial assets that the Company measured at fair value on a recurring basis, classified in accordance with the fair value hierarchy (in thousands):</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.48%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at Reporting Date Using:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.86%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.86%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,585</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,585</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.86%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84,616</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84,616</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.86%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,824</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,824</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.86%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. agency bonds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,531</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,531</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.86%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,265</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,265</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.86%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents and short-term investments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,409</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101,412</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139,821</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.86%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reported as:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.86%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents (includes cash of $397)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,780</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.86%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115,438</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.86%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents and short-term investments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140,218</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.48%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at Reporting Date Using:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.86%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.86%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,257</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,257</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.26%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no liabilities measured at fair value on a recurring basis as of December 31, 2021 and 2020.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a reconciliation of all liabilities measured at fair value using Level 3 significant unobservable inputs (in thousands) during the year ended December 31, 2020.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:75.88%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Convertible</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Promissory</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Notes</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.88%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value as of December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,751</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.88%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of convertible promissory notes</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,435</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.88%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion to convertible preferred stock (excluding interest expense)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,210</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:75.88%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of convertible promissory notes (Note 7)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,024</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:75.88%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value as of December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.56%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <p style="margin-top:8pt;margin-bottom:0pt;text-indent:5.26%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Convertible Promissory Notes</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As further described in Note 7, the Company issued convertible promissory notes in October 2019 (the “2019 Notes”) and in June 2020 (the “2020 Notes”) to investors. The Company elected the ASC 825, Financial Instruments, fair value option for the convertible promissory notes. The fair value of the convertible promissory notes was determined using a scenario-based analysis that estimated the fair value of the convertible promissory notes based on the probability-weighted present value of expected future investment returns, considering possible outcomes available to the noteholders, including conversions in subsequent equity financings. The 2019 Notes and 2020 Notes were valued upon issuance, remeasured to fair value each reporting period and remeasured immediately prior to conversion into Series B convertible preferred stock based on changes in the expected time to closing ranging from <span style="-sec-ix-hidden:F_000373">0 to 0.67 years</span> and the relevant discount rate of 25% during the period. In September 2020, the 2019 Notes and 2020 Notes were converted to 1,905,688 shares of Series B convertible preferred stock.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.26%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2020, all outstanding convertible promissory notes with a total fair value of $11.2 million and accrued interest of $167,000 were converted to 1,905,688 shares of Series B convertible preferred stock. Upon conversion, the Company no longer is required to adjust the carrying value of the convertible promissory notes at each reporting date.</p> 0 0 0 0 0 0 0 0 <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes financial assets that the Company measured at fair value on a recurring basis, classified in accordance with the fair value hierarchy (in thousands):</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.48%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at Reporting Date Using:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.86%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.86%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,585</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,585</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.86%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84,616</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84,616</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.86%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,824</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,824</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.86%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. agency bonds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,531</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,531</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.86%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,265</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,265</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.86%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents and short-term investments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,409</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101,412</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139,821</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.86%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reported as:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.86%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents (includes cash of $397)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,780</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.86%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115,438</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.86%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents and short-term investments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140,218</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.48%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at Reporting Date Using:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.86%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.86%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,257</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,257</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 10585000 10585000 84616000 84616000 27824000 27824000 8531000 8531000 8265000 8265000 38409000 101412000 139821000 397000 24780000 115438000 140218000 19257000 19257000 0 0 <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a reconciliation of all liabilities measured at fair value using Level 3 significant unobservable inputs (in thousands) during the year ended December 31, 2020.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:75.88%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Convertible</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Promissory</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Notes</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.88%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value as of December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,751</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.88%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of convertible promissory notes</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,435</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.88%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion to convertible preferred stock (excluding interest expense)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,210</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:75.88%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of convertible promissory notes (Note 7)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,024</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:75.88%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value as of December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.56%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 2751000 6435000 -11210000 2024000 25 1905688 11200000 167000 1905688 <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 4 – Investments</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets measured at fair value on a recurring basis consist of the Company’s cash equivalents and AFS securities. The Company obtains pricing information from its investment manager and generally determines the fair value of investment securities using standard observable inputs, including reported trades, broker/dealer quotes, and bids and/or offers.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments are classified as Level 1 within the fair value hierarchy if their quoted prices are available in active markets for identical securities. Investments in money market funds and U.S. government securities were classified as Level 1 instruments.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments in commercial paper, corporate debt securities and U.S. agency bonds are valued using Level 2 inputs. The Company classifies investments within Level 2 if the investments are valued using model driven valuations using observable inputs such as quoted market prices, benchmark yields, reported trades, broker/dealer quotes or alternative pricing sources with reasonable levels of price transparency. Investments are held by custodians who obtain investment prices from a third-party pricing provider that incorporates standard inputs in various asset price models.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes, by major types of cash equivalents, and investments that are measured at fair value on a recurring basis (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.26%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.74%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,585</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.86%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,585</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84,642</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.86%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84,616</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,870</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.86%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,824</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. agency bonds</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,546</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.86%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,531</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.5%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,267</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,265</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.5%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents and investments</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139,910</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.86%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(91</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139,821</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.26%;font-family:Times New Roman;"> </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The contractual maturities of the Company’s AFS securities were as follows (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.22%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due within one year</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105,173</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.22%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due within one to two years</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,265</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.22%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-Sale Investments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115,438</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The available-for-sale investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date, which reflects management’s intention to use the proceeds from sales of these securities to fund the Company’s operations, as necessary. As of December 31, 2020, the Company did not own any investments. There were no realized gains or losses due to investment sales for the year ended December 31, 2021. As of December 31, 2021, $129.2 million of the Company’s marketable securities were in gross unrealized loss positions, of which none had been in such position for greater than 12 months and $23.8 million will mature within three months of December 31, 2021. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At each reporting date, the Company performs an evaluation of its marketable securities to determine if any unrealized losses are other-than-temporary. Factors considered in determining whether a loss is other-than-temporary include (i) the financial strength of the issuing institution, (ii) the length of time and extent for which fair value has been less than the cost basis and (iii) the Company’s intent and ability to hold its investments in unrealized loss positions until their amortized cost basis has been recovered. Based on the Company’s evaluation, it determined that its unrealized losses were not other-than-temporary at December 31, 2021. The Company does not intend to sell the investments before maturity and it is unlikely that the Company will be required to sell the investments before recovery of their amortized cost bases.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes, by major types of cash equivalents, and investments that are measured at fair value on a recurring basis (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.26%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.74%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,585</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.86%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,585</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84,642</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.86%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84,616</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,870</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.86%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,824</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. agency bonds</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,546</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.86%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,531</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.5%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,267</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,265</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.5%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents and investments</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139,910</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.86%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(91</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139,821</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 10585000 10585000 84642000 2000 28000 84616000 27870000 46000 27824000 8546000 15000 8531000 8267000 2000 8265000 139910000 2000 91000 139821000 <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The contractual maturities of the Company’s AFS securities were as follows (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.22%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due within one year</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105,173</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.22%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due within one to two years</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,265</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.22%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-Sale Investments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115,438</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 105173000 10265000 115438000 0 0 129200000 0 23800000 <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Note 5 - Balance Sheet Details</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Prepaid and Other Current Assets</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid and other current assets consist of the following (in thousands):</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.2%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.02%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.74%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.2%; border-bottom:solid 0.75pt #CCEEFF;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.02%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.2%; border-top:solid 0.75pt #CCEEFF;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid insurance</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">827</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.2%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid research</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.94%;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,329</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.48%;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">371</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.2%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid other</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.94%;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.48%;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.2%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FICA tax credit receivable</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.94%;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">452</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.48%;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.2%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deposits</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.94%;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.48%;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.2%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.02%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">205</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.2%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid and Other Current Assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.02%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,928</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">662</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net, consist of the following (in thousands):</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.28%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.12%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.28%; border-bottom:solid 0.75pt #CCEEFF;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.12%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.28%; border-top:solid 0.75pt #CCEEFF;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.06%;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.28%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and equipment</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">204</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.06%;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.28%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.06%;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.28%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">321</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.06%;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">184</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.28%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation and amortization expense</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.12%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(156</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.06%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(85</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.28%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and Equipment, net</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.12%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">165</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.06%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense for years ended <span style="color:#000000;">December 31, 2021</span> and <span style="color:#000000;">2020</span> were $0.1 million, respectively.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.26%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Other Non-Current Assets</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other non-current assets consist of the following (in thousands):</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.28%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.12%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.28%; border-bottom:solid 0.75pt #CCEEFF;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-bottom:solid 0.75pt #CCEEFF;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.28%; border-top:solid 0.75pt #CCEEFF;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FICA tax credit receivable</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-top:solid 0.75pt #CCEEFF;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">298</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.06%;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">549</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.28%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deposits</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.06%;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.28%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.12%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.28%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other non-current assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.12%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">443</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.06%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">624</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid and other current assets consist of the following (in thousands):</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.2%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.02%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.74%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.2%; border-bottom:solid 0.75pt #CCEEFF;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.02%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.2%; border-top:solid 0.75pt #CCEEFF;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid insurance</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">827</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.2%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid research</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.94%;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,329</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.48%;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">371</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.2%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid other</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.94%;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.48%;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.2%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FICA tax credit receivable</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.94%;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">452</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.48%;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.2%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deposits</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.94%;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.48%;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.2%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.02%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">205</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.2%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid and Other Current Assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.02%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,928</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">662</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 827000 4329000 371000 96000 159000 452000 110000 19000 22000 205000 5928000 662000 <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net, consist of the following (in thousands):</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.28%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.12%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.28%; border-bottom:solid 0.75pt #CCEEFF;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.12%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.28%; border-top:solid 0.75pt #CCEEFF;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.06%;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.28%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and equipment</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">204</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.06%;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.28%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.06%;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.28%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">321</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.06%;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">184</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.28%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation and amortization expense</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.12%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(156</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.06%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(85</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.28%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and Equipment, net</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.12%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">165</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.06%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 50000 45000 204000 72000 67000 67000 321000 184000 156000 85000 165000 99000 100000 100000 <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other non-current assets consist of the following (in thousands):</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.28%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.12%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.28%; border-bottom:solid 0.75pt #CCEEFF;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-bottom:solid 0.75pt #CCEEFF;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.28%; border-top:solid 0.75pt #CCEEFF;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FICA tax credit receivable</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-top:solid 0.75pt #CCEEFF;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">298</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.06%;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">549</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.28%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deposits</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.06%;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.28%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.12%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.28%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other non-current assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.12%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">443</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.06%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">624</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 298000 549000 75000 75000 70000 443000 624000 <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Note 6 – Related Party Transactions</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As further described in Note 7, the Company issued the 2019 Notes in October 2019 to certain holders of convertible preferred stock, for an aggregate purchase price of $2.5 million and the 2020 Notes in June 2020 to certain holders of convertible preferred stock, for an aggregate purchase price of $6.4 million. In September 2020, all outstanding convertible promissory notes with a total fair value of $11.2 million and accrued interest of $167,000 were converted to 1,905,688 shares of Series B convertible preferred stock. The change in fair value of the convertible promissory notes for the year ended December 31, 2020 was $2.0<span style="color:#0000FF;"> </span>million.</p> 2500000 6400000 11200000 167000 1905688 2000000.0 <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Note 7 – Convertible Promissory Notes</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2019, the Company entered into a convertible note purchase agreement with certain holders of preferred stock and issued the 2019 Notes for an aggregate purchase price of $2.5 million. The 2019 Notes bore an interest rate of the lesser of (a) 5% per annum and (b) the maximum rate permissible by law. The 2019 Notes were due and payable on demand from the holders on or after 18 months after the date of issuance (“2019 Notes Maturity Date”), unless repaid in full or automatically converted per the Automatic Conversion feature. Under the Automatic Conversion feature, the 2019 Notes were to automatically convert to convertible preferred stock, upon the closing of the Company’s next issuance of preferred stock for capital-raising purposes resulting in net proceeds to the Company of at least $10.0 million (excluding any amounts received in connection with the conversion of the 2019 Notes) (“Future Qualifying Financing”). The 2019 Notes would convert into that whole number of shares of the securities equal to the number obtained by dividing the principal plus accrued interest of the 2019 Notes by 80% of the price per share paid by cash investors in the Future Qualifying Financing. The convertible notes included other optional redemption features as follows (i) optionally converted upon a non-qualified equity financing with a conversion price of 80% of the price paid per share in such financing, (ii) any time after the 2019 Notes Maturity Date, demand immediate repayment of an amount equal to the then-outstanding loan balance, or convert the outstanding loan balance into shares of common stock of the Company in an amount equal to the ratio of the then-outstanding loan balance over the ratio of $38.4 million divided by the number of shares of capital stock of the Company outstanding, (iii) automatically upon the occurrence of change in control or an IPO with a conversion of the loan balance into shares of common stock in an amount equal to the ratio of the then-outstanding loan balance over the ratio of $76.8 million divided by the fully diluted capitalization prior to the change in control or IPO, or demand immediate repayment of two times the outstanding loan balance, and (iv) upon certain events of default, immediately due and payable in full.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2020, the Company entered into a convertible note purchase agreement with certain holders of preferred stock and issued the 2020 Notes for an aggregate purchase price of $6.4 million. The 2020 Notes bore an interest rate of the lesser of (a) 5% per annum and (b) the maximum rate permissible by law. The 2020 Notes were due and payable on demand from the holders on or after 18 months after the date of issuance (“2020 Notes Maturity Date”), unless repaid in full or automatically converted per the Automatic Conversion feature. Under the Automatic Conversion feature, the 2020 Notes were to automatically convert to convertible preferred stock, upon the closing of the Company’s next issuance of preferred stock for capital-raising purposes resulting in net proceeds to the Company of at least $10.0 million (excluding any amounts received in connection with the conversion of the 2020 Notes) (“Qualifying Financing”). The 2020 Notes would convert into that whole number of shares of the securities equal to the number obtained by dividing the principal plus accrued interest of the 2020 Notes by 80% of the price per share paid by cash investors in the Qualifying Financing. The convertible notes included other optional redemption features as follows (i) optionally converted upon a non-qualified equity financing with a conversion price of 80% of the price paid per share in such financing, (ii) any time after the 2020 Notes Maturity Date, demand immediate repayment of an amount equal to the then-outstanding loan balance, or convert the outstanding loan balance into shares of common stock of the Company in an amount equal to the ratio of the then-outstanding loan balance over the ratio of $38.4 million divided by the number of shares of capital stock of the Company outstanding, (iii) automatically upon the occurrence of change in control or an IPO with a conversion of the loan balance into shares of common stock in an amount equal to the ratio of the then-outstanding loan balance over the ratio of $76.8 million divided by the fully diluted capitalization prior to the change in control or IPO, or demand immediate repayment of two times the outstanding loan balance, (iv) automatically upon the consummation of a transaction in which the Company merges with a public company and (v) upon certain events of default, immediately due and payable in full.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2020, the Company recognized interest expense of<span style="color:#000000;"> $135,000</span> in connection with the 2019 Notes and 2020 Notes. In September 2020, all outstanding convertible promissory notes with a total fair value of $11.2 million and accrued interest of $167,000 were converted to 1,905,688 shares of Series B convertible preferred stock.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;font-family:Times New Roman;font-size:10pt;"> </p> 2500000 The 2019 Notes bore an interest rate of the lesser of (a) 5% per annum and (b) the maximum rate permissible by law. 0.05 The 2019 Notes were due and payable on demand from the holders on or after 18 months after the date of issuance (“2019 Notes Maturity Date”), unless repaid in full or automatically converted per the Automatic Conversion feature. Under the Automatic Conversion feature, the 2019 Notes were to automatically convert to convertible preferred stock, upon the closing of the Company’s next issuance of preferred stock for capital-raising purposes resulting in net proceeds to the Company of at least $10.0 million (excluding any amounts received in connection with the conversion of the 2019 Notes) (“Future Qualifying Financing”). 10000000.0 0.80 38400000 76800000 6400000 The 2020 Notes bore an interest rate of the lesser of (a) 5% per annum and (b) the maximum rate permissible by law. 0.05 The 2020 Notes were due and payable on demand from the holders on or after 18 months after the date of issuance (“2020 Notes Maturity Date”), unless repaid in full or automatically converted per the Automatic Conversion feature. Under the Automatic Conversion feature, the 2020 Notes were to automatically convert to convertible preferred stock, upon the closing of the Company’s next issuance of preferred stock for capital-raising purposes resulting in net proceeds to the Company of at least $10.0 million (excluding any amounts received in connection with the conversion of the 2020 Notes) (“Qualifying Financing”). 10000000.0 0.80 38400000 76800000 135000 11200000 167000 1905688 <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Note 8 – Convertible Preferred Stock and Stockholders’ Equity (Deficit)</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2020, the Company amended its Certificate of Incorporation to authorize the issuance of 24,000,000 shares of common stock, par value $0.001 per share, and 16,273,406 shares of preferred stock, par value $0.001 per share, of which 3,731,208 shares were designated Series A convertible preferred stock and 12,542,198 shares were designated Series B convertible preferred stock.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the reverse stock split on April 16, 2021, the Company filed a certificate of amendment to its certificate of incorporation, which authorized 260,000,000 shares of capital stock, consisting of 250,000,000 shares of common stock, par value $0.001 per share,<span style="Background-color:#FFFFFF;"> and 10,000,000 shares of undesignated preferred stock, </span>par value $0.001 per share <span style="Background-color:#FFFFFF;">that may be issued from time to time by the Company’s Board of Directors in one or more series</span>. Of the 250,000,000 shares of common stock, <span style="Background-color:#FFFFFF;">200,000,000</span> shares were designated as “Common Stock” and 50,000,000 shares were designated as “Non-Voting Common Stock”.<span style="Background-color:#FFFFFF;"> </span></p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Rights, preferences, powers, privileges and restrictions, qualifications and limitations for holders of the Company’s Common Stock and Non-Voting Common Stock are:</span></p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.26%;white-space:nowrap" valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"> </p></td> <td style="width:2.63%;white-space:nowrap" valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#FFFFFF;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">a)</span></p></td> <td valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#FFFFFF;text-decoration:none;"/><span style="color:#000000;"/><span style="text-decoration:underline;font-size:10pt;font-family:Arial;">Voting Common Stock Voting Rights</span><span style="font-size:10pt;font-family:Arial;">. Each holder of Voting Common Stock, as such, shall be entitled to one vote for each share of Voting Common Stock held of record by such holder on all matters on which stockholders generally are entitled to vote; provided, however, that, except as otherwise required by law, holders of Voting Common Stock, as such, shall not be entitled to vote on any amendment to the Certificate of Incorporation, including any certificate of designations relating to any series of Preferred Stock (each hereinafter referred to as a “Preferred Stock Designation”), that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together with the holders of one or more other such series, to vote thereon pursuant to the Certificate of Incorporation (including any Preferred Stock Designation).</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.26%;white-space:nowrap" valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"> </p></td> <td style="width:2.63%;white-space:nowrap" valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#FFFFFF;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">b)</span></p></td> <td valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#FFFFFF;text-decoration:none;"/><span style="color:#000000;"/><span style="text-decoration:underline;font-size:10pt;font-family:Arial;">Non-Voting Common Stock Voting Rights</span><span style="font-size:10pt;font-family:Arial;">. Non-Voting Common Stock (i) shall be non-voting except as may be required by law and (ii) shall not entitle the holder thereof to vote on the election of directors at any time.</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.26%;white-space:nowrap" valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"> </p></td> <td style="width:2.63%;white-space:nowrap" valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#FFFFFF;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">c)</span></p></td> <td valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#FFFFFF;text-decoration:none;"/><span style="color:#000000;"/><span style="text-decoration:underline;font-size:10pt;font-family:Arial;">Non-Voting Common Stock Conversion</span><span style="font-size:10pt;font-family:Arial;">. Each holder of shares of Non-Voting Common Stock shall have the right to convert each share of Non-Voting Common Stock held by such holder into one share (subject to appropriate adjustment in the event of any stock dividend, stock split, reverse stock split, combination or other similar recapitalization with respect to the Voting Common Stock) of Voting Common Stock at such holder’s election by providing written notice to the Corporation; provided, however, that such shares of Non-Voting Common Stock may only be converted into shares of Voting Common Stock during such time or times as immediately prior to or as a result of such conversion would not result in the holder(s) thereof beneficially owning (for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended and the rules and regulations promulgated thereunder (collectively, the “Exchange Act”)), when aggregated with affiliates with whom such holder is required to aggregate beneficial ownership for purposes of Section 13(d) of the Exchange Act, in excess of the Beneficial Ownership Limitation. The “Beneficial Ownership Limitation” means initially 9.99% of the Voting Common Stock. Any holder of Non-Voting Common Stock may increase</span><span style="Background-color:#FFFFFF;font-size:10pt;font-family:Arial;"> </span><span style="font-size:10pt;font-family:Arial;">the Beneficial Ownership Limitation with respect to such holder, not to exceed 19.99% of the Voting Common Stock, upon 61 days’ prior written notice to the Corporation and may decrease the Beneficial Ownership Limitation at any time upon providing written notice of such election to the Corporation; provided, however, that no holder may make such an election to change the percentage with respect to such holder unless all holders managed by the same investment advisor as such electing holder make the same election. Before any holder of Non-Voting Common Stock shall be entitled to convert any shares of Non-Voting Common Stock into shares of Voting Common Stock, such holder shall (A) surrender the certificate or certificates therefor (if any), duly endorsed, at the principal corporate office of the Corporation or of any transfer agent for the Non-Voting Common Stock, and (B) provide written notice to the Corporation, during regular business hours at its principal corporate office, of such conversion election (in form satisfactory to the Corporation) and shall state therein the name or names (i) in which the certificate or certificates representing the shares of Voting Common Stock into which the shares of Non-Voting Common Stock are so converted are to be issued (if such shares of Voting Common Stock are certificated) or (ii) in which such shares of Voting Common Stock are to be registered in book-entry form (if such shares of Voting Common Stock are uncertificated). If the shares of Voting Common Stock into which the shares of Non-Voting Common Stock are to be converted are to be issued in a name or names other than the name of the holder of the shares of Non-Voting Common Stock being converted, such notice shall be accompanied by a written instrument or instruments of transfer, in form satisfactory to the Corporation, duly executed by the holder. The Corporation shall, as soon as practicable thereafter, issue and deliver at such office to such holder, or to the nominee or nominees of such holder, a certificate or certificates representing the number of shares of Voting Common Stock to which such holder shall be entitled upon such </span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.26%;white-space:nowrap" valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"> </p></td> <td style="width:2.63%;white-space:nowrap" valign="top"/> <td valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="font-size:10pt;font-family:Arial;">conversion (if such shares of Voting Common Stock are certificated) or shall register such shares of Voting Common Stock in book-entry form (if such shares of Voting Common Stock are uncertificated). Such conversion shall be deemed to be effective immediately prior to the close of business on the date of such surrender of the shares of Non-Voting Common Stock to be converted following or contemporaneously with the provision of written notice of such conversion election as required by this section, the shares of Voting Common Stock issuable upon such conversion shall be deemed to be outstanding as of such time, and the person or persons entitled to receive the shares of Voting Common Stock issuable upon such conversion shall be deemed to be the record holder or holders of such shares of Voting Common Stock as of such time. Notwithstanding anything herein to the contrary, shares of Non-Voting Common Stock represented by a lost, stolen or destroyed stock certificate may be converted if the holder thereof notifies the Corporation or its transfer agent that such certificate has been lost, stolen or destroyed and makes an affidavit of that fact acceptable to the Corporation and executes an agreement acceptable to the Corporation to indemnify the Corporation from any loss incurred by it in connection with such certificate. The effectiveness of any conversion of any shares of Non-Voting Common Stock into shares of Voting Common Stock is subject to the expiration or early termination of any applicable premerger notification and waiting period requirements of the Hart-Scott-</span><span style="font-size:10pt;font-family:Arial;">Rodino</span><span style="font-size:10pt;font-family:Arial;"> Antitrust Improvements Act of 1976, as amended, and the rules and regulations promulgated thereunder</span><span style="font-size:10pt;font-family:Arial;">.</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.26%;white-space:nowrap" valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"> </p></td> <td style="width:2.63%;white-space:nowrap" valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#FFFFFF;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">d)</span></p></td> <td valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#FFFFFF;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;font-family:Arial;">Dividends. Subject to the rights of the holders of any outstanding series of Preferred Stock, the holders of shares of Common Stock shall be entitled to receive any dividends to the extent permitted by law when, as and if declared by the board of directors of the Corporation (the “Board”).</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.26%;white-space:nowrap" valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"> </p></td> <td style="width:2.63%;white-space:nowrap" valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#FFFFFF;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">e)</span></p></td> <td valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#FFFFFF;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;font-family:Arial;">Liquidation. Upon the dissolution, liquidation or winding up of the Corporation, subject to the rights of the holders of any outstanding series of Preferred Stock, the holders of shares of Common Stock shall be entitled to receive the assets of the Corporation available for distribution to its stockholders ratably in proportion to the number of shares held by them. The Non-Voting Common Stock shall rank on parity with the Voting Common Stock as to distributions of assets upon dissolution, liquidation or winding up of the Corporation, whether voluntary or involuntary.</span></p></td></tr></table></div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:5.26%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Convertible Preferred Stock</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Series A Convertible Preferred Stock.<span style="font-style:normal;"> In April 2018, the Company entered into a Series A convertible preferred stock purchase agreement, pursuant to which the Company issued 2,098,269 shares of Series A convertible preferred stock for an aggregate purchase price of $11.0 million, net of issuance costs. In December 2018, the Company issued an additional 1,390,788 shares of Series A convertible preferred stock for an aggregate purchase price of $7.3 million, net of issuance costs.</span></p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Series B Convertible Preferred Stock.<span style="font-style:normal;"> In September 2020, the Company entered into a Series B convertible preferred stock purchase agreement, pursuant to which the Company issued 10,636,510 shares of Series B convertible preferred stock for an aggregate purchase price of $63.2 million, net of issuance costs.</span></p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rights, preferences, powers, privileges and restrictions, qualifications and limitations for holders of the Company’s Series A convertible preferred stock and Series B convertible preferred stock are:</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.26%;white-space:nowrap" valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"> </p></td> <td style="width:2.63%;white-space:nowrap" valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;font-family:Arial;">Dividends: Each holder of the Company’s Series A and Series B convertible preferred stock is entitled to receive non-cumulative dividends, when and if declared by the Company’s Board of Directors. No dividends have been declared to date.</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.26%;white-space:nowrap" valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"> </p></td> <td style="width:2.63%;white-space:nowrap" valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;font-family:Arial;">Liquidation Preferences: In the event of any liquidation, dissolution or winding up of the Company, the holders of the Series A and Series B convertible preferred stock shall be entitled to receive, prior and in preference to any distribution of any of the assets of the Company to the holders of common stock, an amount per share equal to the original issue price plus declared but unpaid dividends.</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.26%;white-space:nowrap" valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"> </p></td> <td style="width:2.63%;white-space:nowrap" valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;font-family:Arial;">Conversion: Each share of Series A and Series B convertible preferred stock is convertible at the option of the holder, at any time, into the number of shares of common stock determined by dividing the applicable purchase price by the applicable conversion price at the time of conversion. Each share of Series A and Series B convertible preferred stock will be automatically converted into common stock immediately upon (i) the closing of a firm commitment underwritten IPO resulting in at least $50.0 million of gross proceeds to the Company or (ii) the receipt by the Company of a written request for automatic conversion from the holders of a majority of the outstanding shares of Series A and Series B convertible preferred stock.</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.26%;white-space:nowrap" valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"> </p></td> <td style="width:2.63%;white-space:nowrap" valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;font-family:Arial;">Voting: The holders of the Series A and Series B convertible preferred stock are entitled to one vote for each share of common stock into which such shares of Series A and Series B convertible preferred stock could then be converted; and with respect to such vote, such holders shall have full voting rights and powers equal to the voting rights and powers of the holders of the common stock.</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.26%;white-space:nowrap" valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"> </p></td> <td style="width:2.63%;white-space:nowrap" valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;font-family:Arial;">Redemption: The Series A and Series B convertible preferred stock are not explicitly redeemable at the option of the holder at a specified date in the future or at the option of the Company.</span></p></td></tr></table></div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the IPO, the Company’s Series A and Series B convertible preferred stock were classified as temporary equity on the accompanying balance sheet instead of in stockholders’ equity (deficit) as events triggering redemption that were not solely within the Company’s control because the preferred stockholders had the ability to effect a liquidation event. The Company determined not to adjust the carrying values of the Series A and Series B convertible preferred stock to the liquidation preferences of such shares because of the uncertainty of whether or when such liquidation events would occur.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 27, 2021, immediately prior to the closing of the IPO, 8,344,905 shares of the Company’s convertible preferred stock were exchanged for 7,727,470 shares of Non-Voting common stock and 7,928,501 shares of the Company’s convertible preferred stock converted into 7,341,860 shares of common stock. There were no outstanding shares of the Company’s convertible preferred stock as of December 31, 2021.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:5.26%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Equity Incentive Plan</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the Company’s Board of Directors amended the Amended and Restated 2018 Stock Option—Stock Issuance Plan (the “2018 Plan”) to increase the maximum number of shares of common stock that may be issued over the term of the plan. The 2018 Plan provides for the grant of stock options, non-statutory stock options, incentive stock options and stock issuances to employees, nonemployees and consultants of the Company.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2021, the Company’s 2021 Equity Incentive Plan (the “2021 Plan”) was approved by the Company’s Board of Directors and became effective on April 15, 2021. Upon the effectiveness of the 2021 Plan, no further grants may be made under the Company’s 2018 Plan.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2021 Plan allows the Company to grant equity-based awards to its officers, employees, directors and other key persons (including consultants). The Company initially reserved up to 3,246,120 shares of common stock for issuance under the 2021 Plan, plus (i) 1,722 shares that remained available for the issuance of awards under the 2018 Plan at the time the 2021 Plan became effective, and (ii) any shares subject to outstanding options or other share awards that were granted under the 2018 Plan that terminate or expire prior to exercise or settlement; are forfeited because of the failure to vest; or are reacquired or withheld (or not issued) to satisfy a tax withholding obligation or the purchase or exercise price. The 2021 Plan provides that the number of shares reserved and available for issuance under the plan will automatically increase each January 1, beginning on January 1, 2022 and each January 1 thereafter through January 31, 2032, by 4.0% of the outstanding number of shares of common stock on the immediately preceding December 31, or such lesser number of shares as determined by the Company’s Board of Directors.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the Company’s stock option activities during the year ended December 31, 2021<span style="color:#000000;"> </span>are as follows (in thousands, except share and per share amounts and years):</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.26%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Price Per</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Share</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contract</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Term</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.66%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">882,942</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.72</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000524">9.0</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,263</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.66%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">932,296</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.80</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.66%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(30,496</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.96</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.66%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited or cancelled</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(50,046</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.3%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.00</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.84%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.66%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,734,696</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.9%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.3%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.50</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.84%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000525">8.8</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,594</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.66%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest as of December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,734,696</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.3%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.50</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.84%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000526">8.8</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,594</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.66%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and exercisable as of December 31, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">621,869</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.9%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.3%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.15</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.84%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000527">8.2</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,429</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average grant date fair values of option grants during the years ended December 31, 2021 <span style="color:#000000;">and 2020</span> were $12.14 and $2.74 per share, respectively.<span style="font-size:12pt;font-family:Times New Roman;color:#000000;"> </span>The weighted-average grant date fair values of options forfeited during the years ended December 31, 2021<span style="color:#000000;"> and 2020</span> were $6.08 and $2.82 per share, respectively. </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:5.26%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Employee Stock Purchase Plan</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2021 Employee Share Purchase Plan (the “ESPP”) was approved by the Board of Directors and became effective on April 15, 2021. The ESPP initially reserved and authorized the issuance of up to 259,689 shares of common stock to participating employees. Under the <span style="Background-color:#FFFFFF;">ESPP, </span>eligible<span style="Background-color:#FFFFFF;"> employees can contribute up to 15% of their eligible compensation, as defined in the ESPP, towards the purchase of the Company’s common stock at a price of 85% of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the last trading day of the offering period. The ESPP provides for <span style="-sec-ix-hidden:F_000540">twenty-four-month</span> offering periods with four six-month purchase periods in each offering period. </span>The ESPP provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2022 and each January 1 thereafter through January 31, 2032, by 1.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year. As of December 31, 2021, no shares had been issued under the ESPP, and 259,689 shares authorized under the ESPP were available for issuance. In January 2022, the Company issued 26,804 shares under the ESPP.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:5.26%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Liability for Restricted Stock</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2017, the Company entered into restricted stock purchase agreements with various employees for 3,518,842 shares of common stock, which are subject to time-based vesting. The Company had the option to repurchase any unvested shares at the original purchase price upon any voluntary or involuntary separation of an employee from the Company. The shares purchased pursuant to the restricted stock purchase agreements were not deemed, for accounting purposes, to be outstanding until those shares vest. The cash received in exchange for unvested shares of the restricted stock granted were recorded as a liability on the accompanying balance sheet and were transferred into common stock and additional paid-in capital as the restricted stock vested.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company issued 532,455 shares in 2020 in connection with the vesting of the restricted stock. As of <span style="color:#000000;">December 31, 2020</span>, no shares remained subject to repurchase by the Company.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:5.26%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Stock-Based Compensation Expense</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized stock-based compensation expense as follows (in thousands):</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.26%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,486</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">581</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.3%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">606</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">284</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.3%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,092</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">865</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the stock option grants were as follows:</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.26%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="4" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.14%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.8% - 1.3%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.14%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.2% - 0.9%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.14%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113.2% - 118.7%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.14%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96.9% - 116.2%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.14%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.0 – 6.1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.14%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.5 – 6.1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.14%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.14%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.26%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, the unrecognized compensation cost related to outstanding options was $9.8 million and is expected to be recognized as expense over approximately 3.1 years.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted average assumptions used in Black-Scholes option pricing model to estimate the fair value of purchase rights granted under the ESPP were as follows:</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.26%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.64%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.64%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.48%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.48%; border-top:solid 0.75pt #000000;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.1%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.48%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127.8%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.48%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000572">1.4</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.48%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, there was $0.5 million of unrecognized compensation cost related to the ESPP and is expected to be recognized over approximately 1.5 years.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The determination of the fair value of share-based payment awards utilizing the Black-Scholes option-pricing model is affected by the Company’s stock price and the following assumptions:</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Risk-free interest rate.<span style="font-style:normal;"> The risk-free interest rate assumption is based on the U.S. Treasury instruments, the terms of which were consistent with the expected term of the Company’s stock-based awards.</span></p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Expected volatility. <span style="font-style:normal;">Due to the Company’s limited operating history and lack of company-specific historical or implied volatility, the expected volatility assumption was determined by examining the historical volatilities of a group of industry peers whose share prices are publicly available.</span></p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Expected term.<span style="font-style:normal;"> The expected term represents the weighted-average period the stock-based awards are expected to be outstanding. The Company uses the simplified method for estimating the expected term. The simplified method calculates the expected term as the average of the time-to-vesting and the contractual life of the stock-based awards.</span></p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Expected dividend yield.<span style="font-style:normal;"> The expected dividend assumption is based on the Company’s history and expectation of dividend payouts. The Company has not paid and does not intend to pay dividends.</span></p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Forfeitures<span style="font-style:normal;">. The Company reduces stock-based compensation expense for actual forfeitures during the period.</span></p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:8pt;text-indent:5.26%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Common Stock Reserved for Future Issuance</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock reserved for future issuance consist of the following:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.48%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,734,696</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">882,942</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reserved for future equity award grants</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.02%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,933,930</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.44%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">582,203</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reserved for future ESPP issuances</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.02%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">259,689</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.44%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.44%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,069,330</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.44%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock reserved for future issuance</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.04%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,928,315</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,534,475</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.26%;font-family:Times New Roman;font-size:10pt;"> </p> 24000000 0.001 16273406 0.001 3731208 12542198 260000000 250000000 0.001 10000000 0.001 250000000 200000000 50000000 Each holder of Voting Common Stock, as such, shall be entitled to one vote for each share of Voting Common Stock held 1 Each holder of shares of Non-Voting Common Stock shall have the right to convert each share of Non-Voting Common Stock held by such holder into one share (subject to appropriate adjustment in the event of any stock dividend, stock split, reverse stock split, combination or other similar recapitalization with respect to the Voting Common Stock) of Voting Common Stock at such holder’s election by providing written notice to the Corporation 0.0999 0.1999 P61D 2098269 11000000.0 1390788 7300000 10636510 63200000 0 0 Each share of Series A and Series B convertible preferred stock will be automatically converted into common stock immediately upon (i) the closing of a firm commitment underwritten IPO resulting in at least $50.0 million of gross proceeds to the Company or (ii) the receipt by the Company of a written request for automatic conversion from the holders of a majority of the outstanding shares of Series A and Series B convertible preferred stock. 50000000.0 The holders of the Series A and Series B convertible preferred stock are entitled to one vote for each share of common stock into which such shares of Series A and Series B convertible preferred stock could then be converted; and with respect to such vote, such holders shall have full voting rights and powers equal to the voting rights and powers of the holders of the common stock. 1 1 8344905 7727470 7928501 7341860 0 0 3246120 1722 0.040 <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the Company’s stock option activities during the year ended December 31, 2021<span style="color:#000000;"> </span>are as follows (in thousands, except share and per share amounts and years):</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.26%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Price Per</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Share</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contract</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Term</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.66%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">882,942</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.72</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000524">9.0</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,263</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.66%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">932,296</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.80</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.66%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(30,496</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.96</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.66%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited or cancelled</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(50,046</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.3%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.00</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.84%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.66%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,734,696</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.9%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.3%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.50</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.84%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000525">8.8</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,594</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.66%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest as of December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,734,696</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.3%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.50</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.84%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000526">8.8</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,594</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.66%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and exercisable as of December 31, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">621,869</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.9%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.3%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.15</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.84%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000527">8.2</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,429</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> 882942 3.72 1263000 932296 12.80 30496 3.96 171000 50046 7.00 1734696 8.50 7594000 1734696 8.50 7594000 621869 4.15 5429000 12.14 2.74 6.08 2.82 259689 0.15 0.85 0.010 0 259689 26804 3518842 532455 0 <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized stock-based compensation expense as follows (in thousands):</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.26%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,486</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">581</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.3%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">606</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">284</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.3%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,092</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">865</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> 2486000 581000 606000 284000 3092000 865000 <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the stock option grants were as follows:</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.26%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="4" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.14%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.8% - 1.3%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.14%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.2% - 0.9%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.14%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113.2% - 118.7%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.14%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96.9% - 116.2%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.14%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.0 – 6.1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.14%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.5 – 6.1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.14%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.14%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.26%;font-family:Times New Roman;font-size:10pt;"> </p> 0 0 9800000 P3Y1M6D <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted average assumptions used in Black-Scholes option pricing model to estimate the fair value of purchase rights granted under the ESPP were as follows:</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.26%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.64%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.48%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.64%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.48%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.48%; border-top:solid 0.75pt #000000;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.1%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.48%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127.8%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.48%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000572">1.4</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.48%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> 0.001 1.278 0 500000 P1Y6M <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock reserved for future issuance consist of the following:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.48%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,734,696</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">882,942</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reserved for future equity award grants</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.02%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,933,930</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.44%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">582,203</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reserved for future ESPP issuances</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.02%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">259,689</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.44%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.44%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,069,330</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.44%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock reserved for future issuance</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.04%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,928,315</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,534,475</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.26%;font-family:Times New Roman;font-size:10pt;"> </p> 1734696 882942 2933930 582203 259689 0 0 15069330 4928315 16534475 <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Note 9 – License and Clinical Supply Agreements</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into license agreements, accounted for as asset acquisitions, under which the Company is required to use commercially reasonable efforts to meet certain specified development and regulatory milestones related to the licensed technologies within specified time periods. In consideration of the rights granted to the Company under the agreements, the Company is required to make cash milestone payments to the licensors upon the completion of certain development, regulatory and commercial milestones. For the arrangements that the Company accounted for as asset acquisitions, contingent consideration liabilities are recorded as an additional cost of the acquired assets when the contingency is resolved, and the consideration is paid or becomes payable. Additionally, the Company has agreed to pay royalties on net sales of products applicable to the license agreements. The Company may terminate the agreements upon written notice to the licensors.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Daiichi Sankyo License Agreement</span></p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 2, 2020, the Company licensed the rights to milademetan (DS-3032b) for all human prophylactic or therapeutic uses in all countries and territories of the world from Daiichi Sankyo Company, Limited, (“Daiichi Sankyo”), a Japanese corporation (the “Daiichi Sankyo License Agreement”). Daiichi Sankyo conducted clinical studies of milademetan prior to the Company’s licensing the rights to this product. The Company refers to this product candidate as milademetan.<span style="font-size:12pt;font-family:Times New Roman;color:#000000;"> </span></p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with the terms of the Daiichi Sankyo License Agreement, the Company paid Daiichi Sankyo an initial upfront payment of $5.0 million during the year ended <span style="color:#000000;">December 31, 2020</span>.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Daiichi Sankyo License Agreement, the Company obtained worldwide, sublicensable exclusive rights to seven families of patents with respect to milademetan. The Company is solely responsible under the Daiichi Sankyo License Agreement for the research, development and registration of milademetan. Pursuant to the Daiichi Sankyo License Agreement, Daiichi Sankyo had the right to continue to conduct three clinical trials and prepare final reports with respect to these clinical trials, and such right expires upon all subjects completing the study treatment. The Company has agreed to reimburse Daiichi Sankyo certain third-party expenses incurred while conducting such trials. The Company made clinical trials payments of $0.2 million under the Daiichi Sankyo License Agreement for the year ended December 31, 2021.<span style="color:#000000;"> The Company made no clinical trials payments to </span>Daiichi Sankyo for the year ended <span style="color:#000000;">December 31, 2020</span>. As of December 31, 2021<span style="color:#000000;">, the accrued Daiichi Sankyo reimbursable clinical trials costs were $2.0 million, which was recorded in accrued research and development in the balance sheet.</span></p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is required to make aggregate future milestone payments of up to $222.5 million, contingent on the attainment of certain development, regulatory and sales milestones. <span style="color:#000000;">On July 20, 2021, the Company announced that the first patient has been randomized in the multicenter, open-label, Phase 3 registrational trial (MANTRA) evaluating milademetan for the treatment of de-differentiated liposarcoma. Accordingly, </span><span style="Background-color:#FFFFFF;color:#000000;">pursuant to the Daiichi Sankyo License Agreement, </span><span style="color:#000000;">the Company recorded $5.5 million in milestone fees as research and development expense in the statement of operations. Of the $5.5 million milestone fees, $2.5 million was paid in the third quarter of 2021 and $3.0 million was accrued as part of accrued research and development in the balance sheet as of December 31, 2021</span>.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the Company is required to pay Daiichi Sankyo a high single digit royalty based on the annual net sales of the Products, subject to reduction at an agreed rate upon the expiration of the licensed patent in the particular country where the Products are sold. To date, no royalty payments have been made to Daiichi Sankyo under the Daiichi Sankyo License Agreement. The royalty obligation terminates on a country-by-country and Product-by-Product basis on the later of: (i) loss of all market exclusivity for such Product in such country, (ii) the last-to-expire patent that covers the Licensed Compound or the Product in such country and (iii) twelve years from launch of the first Product sold by the Company in such country.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless sooner terminated or extended, the Daiichi Sankyo License Agreement will remain in full force and effect until the Company, its affiliates and its sublicensees cease all development and commercial activity related to milademetan. Either party may terminate the Daiichi Sankyo License Agreement for cause in the event of an uncured material breach (subject to a 90-day cure period). <span style="color:#000000;">However, the Company may only terminate the Daiichi Sankyo License Agreement with respect to the countries affected by such uncured material breach. Daiichi Sankyo may also terminate the Daiichi Sankyo License Agreement in the event of Rain’s bankruptcy or insolvency. Additionally, Daiichi Sankyo may terminate the Daiichi Sankyo License Agreement immediately upon written notice if the Company, its affiliates or its sublicensors initiate or join any challenge to the validity or enforceability of a licensed patent, subject to certain exclusions. Furthermore, the Company may terminate the Daiichi Sankyo License Agreement in its entirety or on a country-by-country basis for bona fide material concerns regarding the (i) lack of safety for human use arising from toxicity of the Licensed Compound or Product(s), (ii) lack of efficacy of the Licensed Compound or Product(s) or (iii) adverse economic impact to the Company in connection with its continued development of the Products, in each case, upon six months’ prior written notice to Daiichi Sankyo. In addition, if the Company is acquired by a third party that is developing and commercializing a competing compound and the acquiring party decides not to discontinue the development or commercialization of such competing compound, such third party must terminate the Daiichi Sankyo License Agreement within 30 days of such acquisition if it does not discontinue such development or commercialization. Upon termination of the Daiichi Sankyo License Agreement by Daiichi Sankyo for the Company’s uncured material breach or by the Company for its bona fide material concerns regarding the safety, efficacy or adverse economic impacts relating to the Licensed Compound or Products, or its development thereof, the Company is required to, among other actions, if requested by Daiichi Sankyo (i) transfer to Daiichi Sankyo ongoing clinical trials, data, reports, records </span></p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;">and materials, (ii) grant to Daiichi Sankyo an exclusive, irrevocable, sublicensable, fully paid-up license under any patents and know-how that are controlled and actually used by </span><span style="color:#000000;">the Company</span><span style="color:#000000;"> at the time of termination in connection with the Products to allow Daiichi Sankyo exploit the Licensed Compound or Products in countries that are affected by the termination, (iii) grant to Daiichi Sankyo an exclusive, irrevocable, sublicensable, fully paid up license to use trademarks that are specific to the Products and (iv) assign any applicable sublicenses.</span></p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:5.26%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Drexel License Agreement and Sponsored Research Agreement</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 30, 2020 (the “Effective Date”), the Company entered into an intellectual property license agreement (the “Drexel License Agreement”) with Drexel University (“Drexel”). Pursuant to the Drexel License Agreement, Drexel granted to the Company (i) a worldwide, exclusive license to make and commercialize products under a single issued patent and two patent applications related to RAD52 inhibitors for the treatment of cancer (the “Patent Rights”) and (ii) a worldwide, nonexclusive license to make, use and commercialize certain technical information and know-how related to the Patent Rights. The license grant includes the right to sublicense after the first anniversary of the Effective Date, subject to express conditions set forth in the Drexel License Agreement.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is obligated to use commercially reasonable efforts to (i) develop, commercialize, market and sell licensed products in a manner consistent with a development plan and (ii) achieve certain milestone events, including, among other things, receiving investigational new drug application (“IND”) approval for a licensed product by the fourth anniversary of the Effective Date. Under the Drexel License Agreement, for a period of five years from the Effective Date, the Company is granted a first option to license Drexel’s rights in certain improvements, developments or inventions developed by Drexel (or jointly by the parties) during the <span style="-sec-ix-hidden:F_000605">five-year</span> period that are directly related to the licensed products or to RAD52 or compounds that have been generated to specifically target RAD52.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to a one-time, non-refundable initiation fee of $20,000 paid in four equal installments of $5,000 each within ten days after the Effective Date and six, twelve and eighteen months after the Effective Date, the Drexel License Agreement requires the Company to make further payments to Drexel of up to an aggregate of $6.25 million, for the achievement of specified development milestones for certain licensed products. The Company is also required to reimburse Drexel (i) after the filing of the first IND for the first licensed product, for all costs related to the filing, prosecution and maintenance of the Patent Rights accumulated prior to the Effective Date, and (ii) for all reasonable costs related to the filing, prosecution and maintenance of the Patent Rights after the Effective Date. In addition, the Company is also required to pay Drexel, on a quarterly basis, a low single digit royalty on net sales by the Company, its affiliates and sublicensees of certain licensed products, subject to specified reductions and a minimum quarterly royalty payment of up to $6,250.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lastly, the Company is also obligated to pay Drexel (i) an annual license maintenance fee of $15,000 commencing upon filing of the first IND for a licensed product until the first sale of the first licensed product, (ii) a sublicense fee of low double digits percentage on all consideration received by the Company from its sublicensees, subject to certain reductions and (iii) a one-time transaction fee equal to the actual amount of Drexel’s licensing and legal expenses in connection with the Drexel License Agreement and the Sponsored Research Agreement the parties simultaneously entered into with the Drexel License Agreement (the Sponsored Research Agreement).</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company made payments of $34,387 and $11,720 under the Drexel License Agreement for the years ended December 31, 2021 <span style="color:#000000;">and 2020</span>, respectively.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless sooner terminated or extended, the term of the Drexel License Agreement with respect to any licensed product and country continues until the later of (i) the expiration or abandonment of the last-to-expire valid claim of the Patent Rights that covers the sale of such licensed product in such country, (ii) the expiration of any granted statutory period of marketing and/or data exclusivity for such licensed product that confers upon the Company exclusive commercialization, (iii) the month of the first sale of a generic equivalent of such licensed product in such country and (iv) ten years after the first sale of the first licensed product.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may terminate the Drexel License Agreement at any time by providing 60 days’ prior written notice to Drexel, in which case the Company will be required to cease exploitation of all licensed products, terminate all permitted sublicenses and pay all amounts owed to Drexel under the Drexel License Agreement and the Sponsored Research Agreement through the effective date of termination. Drexel may terminate the Drexel License Agreement for the Company’s uncured material breach (with 30-135 day cure periods), for the </p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company’s</span><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> bankruptcy or insolvency, for </span><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Company’s</span><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> uncured material default under the Sponsored Research Agreement, or if </span><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Company</span><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> challenge</span><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the validity or enforceability of the licensed patent rights.</span></p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:5.26%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Roche Clinical Supply Agreement</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2021, the Company entered into a clinical supply agreement with Roche for the supply of the anti-Programmed Death Ligand-1 (PD-L1) monoclonal antibody, atezolizumab. Clinical trials are planned to evaluate milademetan, in combination with atezolizumab for the treatment of patients in genetically selected populations. Under this agreement, Rain is the sponsor of the anticipated clinical trials, and Roche will supply atezolizumab. The Company does not have any financial commitments to Roche under this agreement.</p> 2020-09-02 5000000.0 7 3 200000 0 2000000.0 222500000 5500000 5500000 2500000 3000000.0 0 The royalty obligation terminates on a country-by-country and Product-by-Product basis on the later of: (i) loss of all market exclusivity for such Product in such country, (ii) the last-to-expire patent that covers the Licensed Compound or the Product in such country and (iii) twelve years from launch of the first Product sold by the Company in such country. P90D P6M 2020-07-30 Pursuant to the Drexel License Agreement, Drexel granted to the Company (i) a worldwide, exclusive license to make and commercialize products under a single issued patent and two patent applications related to RAD52 inhibitors for the treatment of cancer (the “Patent Rights”) and (ii) a worldwide, nonexclusive license to make, use and commercialize certain technical information and know-how related to the Patent Rights. The license grant includes the right to sublicense after the first anniversary of the Effective Date, subject to express conditions set forth in the Drexel License Agreement. P5Y 20000 4 5000 P10D P18M 6250000 6250 15000 34387 11720 P10Y P60D P135D <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Note 10 – Commitments and Contingencies</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Leases</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2018, the Company entered into a noncancelable operating lease agreement for office space for its corporate headquarters in Newark, California with an initial term of 5.25 years. The lease commenced in January 2019 and ends March 2024. Under the terms of the lease, the Company pays annual base rent, subject to an annual fixed percentage increase of 3% on March 1st of each year. The Company is obligated to pay for its share of direct expenses including operating expense and taxes, which are considered variable lease costs and are expensed as incurred.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, Governor Newsom issued State of California Executive Order No. N-33-20 instructing all individuals in California to stay at home due to the COVID-19 pandemic. In connection with such order, the Company entered into an amendment to the noncancelable operating lease agreement in June 2020. The amendment provided the Company rent relief for three months in 2020. In consideration of the rent relief, the Company agreed to adjust the base rent annual fixed percentage increase of 3% on February 1st of each year and extend the lease until September 2024. The amendment was determined to be a lease modification that qualified as a change of accounting on the existing lease and not a separate contract. Remeasurement of the right-of-use asset and operating lease liabilities at the date of modification did not result in a material increase of the right-of-use asset and operating lease liabilities.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The future minimum lease payments required under the operating lease are summarized as follows (in thousands):</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.38%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">167</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.38%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.64%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum lease payments</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">467</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.64%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: amount representing interest</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(55</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.64%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of operating lease liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.94%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">412</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, current</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.38%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.64%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, non-current</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">252</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.64%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.94%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">412</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.38%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term (in years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.38%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000639">2.7</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average incremental borrowing rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.38%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below summarizes the Company’s lease costs and cash payments in connection with operating lease obligations (in thousands):</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease expense</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows used for operating lease</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">162</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.26%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Contingencies</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event the Company becomes subject to claims or suits arising in the ordinary course of business, the Company would accrue a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated.</p> P5Y3M 2019-01 2024-03 0.03 --03-01 P3M --02-01 2024-09 <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The future minimum lease payments required under the operating lease are summarized as follows (in thousands):</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.38%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">167</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.38%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.64%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum lease payments</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">467</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.64%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: amount representing interest</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(55</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.64%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of operating lease liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.94%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">412</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, current</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.38%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.64%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, non-current</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">252</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.64%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.94%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">412</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.38%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term (in years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.38%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000639">2.7</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average incremental borrowing rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.38%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> </table></div> 167000 171000 129000 467000 55000 412000 160000 252000 412000 0.100 <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below summarizes the Company’s lease costs and cash payments in connection with operating lease obligations (in thousands):</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease expense</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows used for operating lease</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">162</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 160000 130000 162000 130000 <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Note 11 – Employee Benefits</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has a defined contribution 401(k) plan available to eligible employees. Under the terms of the plan, employees may make voluntary contributions as a percent of compensation, limited to the maximum amount allowable under federal tax regulations. The Company, at its discretion, may make certain contributions to the 401(k) plan. The Company made matching contributions of $233,831 and $79,000 for the years ended <span style="color:#000000;">December 31, 2021</span> and 2020, respectively. </p> 233831 79000 <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <span style="font-weight:bold;color:#000000;">Note 12 – Income Taxes</span></p> <p style="margin-top:6pt;margin-bottom:0pt;margin-right:0.44%;text-indent:5.26%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded de minimis state income tax expense for the years ended December 31, 2021 and 2020 primarily as a result of the Company maintaining a full valuation allowance against its loss from operations for tax purposes. The net losses for the years ended December 31, 2021 and 2020 were generated solely in the United States.</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-right:0.15%;text-indent:5.26%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The provision for income taxes is comprised of the following (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.26%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for income taxes</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:6pt;margin-bottom:0pt;margin-right:0.15%;text-indent:5.26%;font-family:Times New Roman;"> </p> <p style="margin-top:6pt;margin-bottom:0pt;margin-right:0.15%;text-indent:5.26%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The provision for income taxes differs from the amount computed by applying the federal statutory income tax rate to income before taxes as follows (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-right:0.15%;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal tax benefit at statutory rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,792</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,426</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State taxes</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">604</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,640</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of convertible promissory notes</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">425</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-deductible expenses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">490</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible note interest</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R&amp;D credits</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,177</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(187</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,870</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,797</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for income taxes</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;margin-right:0.58%;text-indent:5.26%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred income taxes reflect the tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The components of deferred income tax assets and liabilities are as follows (in thousands):</p> <p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;text-indent:5.26%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">407</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">188</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangibles</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,378</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,698</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating losses</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,993</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,254</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R&amp;D and Orphan Drug credits</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,615</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">438</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">287</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">236</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liability</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,779</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,960</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,698</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,827</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total net deferred tax assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use asset</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(81</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(133</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(81</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(133</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;text-indent:5.26%;font-family:Times New Roman;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;margin-right:1.9%;text-indent:5.26%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Realization of deferred tax assets is dependent upon the Company’s ability to generate sufficient taxable income within the carryforward period. In assessing the realizability of some portion or all of the deferred tax assets, the Company evaluated both positive and negative evidence to determine if some or all of its deferred tax assets should be recognized. Based on the available objective evidence, the Company has concluded it is not more likely than not that its deferred tax assets will be realized.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Therefore, a valuation allowance in the amount of $22.7 million has been recorded for 2021 against the Company’s deferred tax assets.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The net valuation allowance increased by $11.9 million and $5.8 million during the years ended December 31, 2021 and 2020, respectively.</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-right:4.53%;text-indent:5.26%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the Company’s federal and state net operating loss carryforwards as of December 31, 2021 (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Expiration Years</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.42%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating losses, Federal—pre TCJA</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2037</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.42%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating losses, Federal—post TCJA</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,085</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.42%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating losses, state</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,801</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000698">2031-2041</span></p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.42%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R&amp;D and Orphan Drug credits, Federal</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,110</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000699">2039-2041</span></p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.42%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R&amp;D credits, California</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">948</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;margin-right:0.58%;text-indent:5.26%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Utilization of the Company’s net operating loss and R&amp;D credits may be subject to substantial limitations due to the ownership changes limitations provided by the Internal Revenue Code and similar state provisions. Such annual limitations could result in the expiration of the net operating loss before their utilization. Sections 382 and 383 of the Internal Revenue Code (“IRC Sections 382 and 383”) impose limitations on a corporation’s ability to utilize its net operating losses and credit carryforwards if it experiences an “ownership change” as defined by IRC Sections 382 and 383. The Company has performed an analysis under Section 382 of the Internal Revenue Code which subjects the amount of pre-change net operating losses and certain other tax attributes that can be utilized to an annual limitation. Based on the analysis, ownership changes have occurred in 2018 and 2021.</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-right:0.73%;text-indent:5.26%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is required to recognize in the financial statements the impact of a tax position, if that position is more likely than not of being sustained on audit, based on the technical merits of the position.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table reflects changes in the gross unrecognized tax benefits (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at beginning of year</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">402</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">215</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions based on tax positions related to</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   current year</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,040</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">187</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at end of year</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,442</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">402</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;margin-right:1.17%;text-indent:5.26%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes interest and penalties as a component of income tax expense. There were no interest or penalties recognized in the statements of operations and comprehensive loss. The total unrecognized tax benefits of $1.4 million and $0.4 million were recorded as of December 31, 2021 and 2020, respectively, which, if recognized currently, should not impact the effective tax rate due to the Company maintaining a full valuation allowance. The Company expects the unrecognized tax benefits will not change significantly within the next 12 months.</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-right:0.29%;text-indent:5.26%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to examination by the United States federal and state tax authorities for the tax years 2017 and later.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:6pt;margin-bottom:0pt;margin-right:0.15%;text-indent:5.26%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The provision for income taxes is comprised of the following (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.26%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for income taxes</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 2000 2000 <p style="margin-top:6pt;margin-bottom:0pt;margin-right:0.15%;text-indent:5.26%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The provision for income taxes differs from the amount computed by applying the federal statutory income tax rate to income before taxes as follows (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-right:0.15%;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal tax benefit at statutory rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,792</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,426</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State taxes</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">604</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,640</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of convertible promissory notes</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">425</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-deductible expenses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">490</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible note interest</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R&amp;D credits</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,177</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(187</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,870</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,797</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for income taxes</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> -10792000 -4426000 604000 -1640000 425000 490000 -11000 28000 2177000 187000 11870000 5797000 7000 14000 2000 The components of deferred income tax assets and liabilities are as follows (in thousands): <p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;text-indent:5.26%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">407</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">188</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangibles</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,378</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,698</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating losses</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,993</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,254</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R&amp;D and Orphan Drug credits</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,615</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">438</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">287</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">236</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liability</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,779</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,960</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,698</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,827</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total net deferred tax assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use asset</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(81</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(133</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(81</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(133</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;text-indent:5.26%;font-family:Times New Roman;"> </p> 407000 188000 10000 11000 2378000 1698000 16993000 8254000 2615000 438000 287000 236000 87000 135000 2000 22779000 10960000 22698000 10827000 81000 133000 81000 133000 81000 133000 22700000 11900000 5800000 <p style="margin-top:6pt;margin-bottom:0pt;margin-right:4.53%;text-indent:5.26%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the Company’s federal and state net operating loss carryforwards as of December 31, 2021 (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Expiration Years</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.42%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating losses, Federal—pre TCJA</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2037</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.42%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating losses, Federal—post TCJA</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,085</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.42%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating losses, state</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,801</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000698">2031-2041</span></p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.42%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R&amp;D and Orphan Drug credits, Federal</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,110</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000699">2039-2041</span></p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.42%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R&amp;D credits, California</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">948</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.3%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</p></td> </tr> </table></div> 159000 2037 69085000 27801000 3110000 948000 <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.26%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table reflects changes in the gross unrecognized tax benefits (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at beginning of year</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">402</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">215</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions based on tax positions related to</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   current year</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,040</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">187</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at end of year</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,442</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">402</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 402000 215000 1040000 187000 1442000 402000 0 0 1400000 400000 <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Note 13 – Net Loss Per Share</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables summarize the computation of the basic and diluted net loss per share (in thousands, except share and per share data):</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51,394</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,083</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares of common stock outstanding, basic and</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   diluted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,405,833</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,519,728</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: weighted-average unvested common stock</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(167,878</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares used to compute net loss per share, basic and</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   diluted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,405,833</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,351,850</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, basic and diluted</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.65</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6.29</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their inclusion would be anti-dilutive:</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,734,696</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">882,942</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A convertible preferred stock</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,731,208</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series B convertible preferred stock</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,542,198</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ESPP shares</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,031</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,819,727</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,156,348</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables summarize the computation of the basic and diluted net loss per share (in thousands, except share and per share data):</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51,394</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,083</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares of common stock outstanding, basic and</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   diluted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,405,833</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,519,728</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: weighted-average unvested common stock</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(167,878</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares used to compute net loss per share, basic and</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   diluted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,405,833</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,351,850</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, basic and diluted</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.65</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6.29</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> -51394000 -21083000 19405833 3519728 167878 19405833 3351850 -2.65 -6.29 <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.26%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their inclusion would be anti-dilutive:</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,734,696</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">882,942</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A convertible preferred stock</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,731,208</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series B convertible preferred stock</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,542,198</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ESPP shares</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,031</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,819,727</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,156,348</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> 1734696 882942 3731208 12542198 85031 1819727 17156348 EXCEL 75 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 76 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 77 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 78 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 166 479 1 false 63 0 false 9 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://rainthera.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Balance Sheets Sheet http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets Balance Sheets Statements 2 false false R3.htm 100020 - Statement - Balance Sheets (Parenthetical) Sheet http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Statements of Operations and Comprehensive Loss Sheet http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 100040 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) Sheet http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) Statements 5 false false R6.htm 100050 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) Sheet http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) Statements 6 false false R7.htm 100060 - Statement - Statements of Cash Flows Sheet http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows Statements of Cash Flows Statements 7 false false R8.htm 100070 - Disclosure - Organization and Nature of Operations Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfOperations Organization and Nature of Operations Notes 8 false false R9.htm 100080 - Disclosure - Summary of Significant Accounting Policies Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 100090 - Disclosure - Fair Value Measurements Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 10 false false R11.htm 100100 - Disclosure - Investments Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureInvestments Investments Notes 11 false false R12.htm 100110 - Disclosure - Balance Sheet Details Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetails Balance Sheet Details Notes 12 false false R13.htm 100120 - Disclosure - Related Party Transactions Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactions Related Party Transactions Notes 13 false false R14.htm 100130 - Disclosure - Convertible Promissory Notes Notes http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePromissoryNotes Convertible Promissory Notes Notes 14 false false R15.htm 100140 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficit Convertible Preferred Stock and Stockholders' Equity (Deficit) Notes 15 false false R16.htm 100150 - Disclosure - License and Clinical Supply Agreements Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreements License and Clinical Supply Agreements Notes 16 false false R17.htm 100160 - Disclosure - Commitments and Contingencies Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 17 false false R18.htm 100170 - Disclosure - Employee Benefits Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureEmployeeBenefits Employee Benefits Notes 18 false false R19.htm 100180 - Disclosure - Income Taxes Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxes Income Taxes Notes 19 false false R20.htm 100190 - Disclosure - Net Loss Per Share Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureNetLossPerShare Net Loss Per Share Notes 20 false false R21.htm 100200 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies 21 false false R22.htm 100210 - Disclosure - Fair Value Measurements (Tables) Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurements 22 false false R23.htm 100220 - Disclosure - Investments (Tables) Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsTables Investments (Tables) Tables http://rainthera.com/20211231/taxonomy/role/DisclosureInvestments 23 false false R24.htm 100230 - Disclosure - Balance Sheet Details (Tables) Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsTables Balance Sheet Details (Tables) Tables http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetails 24 false false R25.htm 100240 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) (Tables) Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitTables Convertible Preferred Stock and Stockholders' Equity (Deficit) (Tables) Tables http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficit 25 false false R26.htm 100250 - Disclosure - Commitments and Contingencies (Tables) Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://rainthera.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies 26 false false R27.htm 100260 - Disclosure - Income Taxes (Tables) Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables Income Taxes (Tables) Tables http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxes 27 false false R28.htm 100270 - Disclosure - Net Loss Per Share (Tables) Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureNetLossPerShareTables Net Loss Per Share (Tables) Tables http://rainthera.com/20211231/taxonomy/role/DisclosureNetLossPerShare 28 false false R29.htm 100280 - Disclosure - Organization and Nature of Operations - Additional Information (Details) Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails Organization and Nature of Operations - Additional Information (Details) Details 29 false false R30.htm 100290 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails Summary of Significant Accounting Policies - Additional Information (Details) Details 30 false false R31.htm 100300 - Disclosure - Fair Value Measurements - Additional Information (Details) Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails Fair Value Measurements - Additional Information (Details) Details 31 false false R32.htm 100310 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Details) Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Details) Details 32 false false R33.htm 100320 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Parenthetical) (Details) Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisParentheticalDetails Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Parenthetical) (Details) Details 33 false false R34.htm 100330 - Disclosure - Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value Using Level 3 Significant Unobservable Inputs (Details) Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueUsingLevel3SignificantUnobservableInputsDetails Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value Using Level 3 Significant Unobservable Inputs (Details) Details 34 false false R35.htm 100340 - Disclosure - Investments - Summary of Cash Equivalents and Investments Measured at Fair Value on Recurring Basis (Details) Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsSummaryOfCashEquivalentsAndInvestmentsMeasuredAtFairValueOnRecurringBasisDetails Investments - Summary of Cash Equivalents and Investments Measured at Fair Value on Recurring Basis (Details) Details 35 false false R36.htm 100350 - Disclosure - Investments - Schedule of Contractual Maturities of AFS Securities (Details) Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsScheduleOfContractualMaturitiesOfAFSSecuritiesDetails Investments - Schedule of Contractual Maturities of AFS Securities (Details) Details 36 false false R37.htm 100360 - Disclosure - Investments - Additional Information (Details) Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails Investments - Additional Information (Details) Details 37 false false R38.htm 100370 - Disclosure - Balance Sheet Details - Schedule of Prepaid and Other Current Assets (Details) Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidAndOtherCurrentAssetsDetails Balance Sheet Details - Schedule of Prepaid and Other Current Assets (Details) Details 38 false false R39.htm 100380 - Disclosure - Balance Sheet Details - Schedule of Property and Equipment, Net (Details) Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails Balance Sheet Details - Schedule of Property and Equipment, Net (Details) Details 39 false false R40.htm 100390 - Disclosure - Balance Sheet Details - Additional Information (Details) Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetails Balance Sheet Details - Additional Information (Details) Details 40 false false R41.htm 100400 - Disclosure - Balance Sheet Details - Schedule of Other Non-Current Assets (Details) Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfOtherNonCurrentAssetsDetails Balance Sheet Details - Schedule of Other Non-Current Assets (Details) Details 41 false false R42.htm 100410 - Disclosure - Related Party Transactions - Additional Information (Details) Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails Related Party Transactions - Additional Information (Details) Details 42 false false R43.htm 100420 - Disclosure - Convertible Promissory Notes - Additional Information (Detail) Notes http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePromissoryNotesAdditionalInformationDetail Convertible Promissory Notes - Additional Information (Detail) Details 43 false false R44.htm 100430 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) - Additional Information (Details) Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails Convertible Preferred Stock and Stockholders' Equity (Deficit) - Additional Information (Details) Details http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitTables 44 false false R45.htm 100440 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) - Summary of Stock Option Activities (Details) Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitSummaryOfStockOptionActivitiesDetails Convertible Preferred Stock and Stockholders' Equity (Deficit) - Summary of Stock Option Activities (Details) Details http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitTables 45 false false R46.htm 100450 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) - Summary of Stock-Based Compensation Expense Recognized (Details) Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitSummaryOfStockBasedCompensationExpenseRecognizedDetails Convertible Preferred Stock and Stockholders' Equity (Deficit) - Summary of Stock-Based Compensation Expense Recognized (Details) Details http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitTables 46 false false R47.htm 100460 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) - Weighted-Average Assumptions Used in Black-Scholes Option Pricing Model to Determine Fair Value of Stock Option Grants (Details) Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionGrantsDetails Convertible Preferred Stock and Stockholders' Equity (Deficit) - Weighted-Average Assumptions Used in Black-Scholes Option Pricing Model to Determine Fair Value of Stock Option Grants (Details) Details http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitTables 47 false false R48.htm 100470 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) - Schedule of Common Stock Reserved for Future Issuance (Details) Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureIssuanceDetails Convertible Preferred Stock and Stockholders' Equity (Deficit) - Schedule of Common Stock Reserved for Future Issuance (Details) Details http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitTables 48 false false R49.htm 100480 - Disclosure - License and Clinical Supply Agreements - Additional Information (Details) Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreementsAdditionalInformationDetails License and Clinical Supply Agreements - Additional Information (Details) Details 49 false false R50.htm 100490 - Disclosure - Commitments and Contingencies - Additional Information (Details) Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) Details 50 false false R51.htm 100500 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments Required under Operating Lease (Details) Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsRequiredUnderOperatingLeaseDetails Commitments and Contingencies - Schedule of Future Minimum Lease Payments Required under Operating Lease (Details) Details 51 false false R52.htm 100520 - Disclosure - Commitments and Contingencies - Summary of Lease Costs and Cash Payments (Details) Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndCashPaymentsDetails Commitments and Contingencies - Summary of Lease Costs and Cash Payments (Details) Details 52 false false R53.htm 100530 - Disclosure - Employee Benefits - Additional Information (Details) Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetails Employee Benefits - Additional Information (Details) Details 53 false false R54.htm 100540 - Disclosure - Income Taxes - Components of Provision for Income Taxes (Details) Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails Income Taxes - Components of Provision for Income Taxes (Details) Details 54 false false R55.htm 100550 - Disclosure - Income Taxes - Computation of Provision for Income Taxes by Applying Federal Statutory Income Tax Rate to Income Before Taxes (Detail) Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComputationOfProvisionForIncomeTaxesByApplyingFederalStatutoryIncomeTaxRateToIncomeBeforeTaxesDetail Income Taxes - Computation of Provision for Income Taxes by Applying Federal Statutory Income Tax Rate to Income Before Taxes (Detail) Details 55 false false R56.htm 100560 - Disclosure - Income Taxes - Components of Deferred Income Tax Assets and Liabilities (Detail) Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail Income Taxes - Components of Deferred Income Tax Assets and Liabilities (Detail) Details 56 false false R57.htm 100570 - Disclosure - Income Taxes - Additional Information (Details) Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails Income Taxes - Additional Information (Details) Details 57 false false R58.htm 100580 - Disclosure - Income Taxes - Schedule of Federal and State Net Operating Loss Carryforwards (Details) Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfFederalAndStateNetOperatingLossCarryforwardsDetails Income Taxes - Schedule of Federal and State Net Operating Loss Carryforwards (Details) Details 58 false false R59.htm 100590 - Disclosure - Income Taxes - Changes in Gross Unrecognized Tax Benefits (Detail) Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesChangesInGrossUnrecognizedTaxBenefitsDetail Income Taxes - Changes in Gross Unrecognized Tax Benefits (Detail) Details 59 false false R60.htm 100600 - Disclosure - Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss per Share (Details) Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss per Share (Details) Details 60 false false R61.htm 100610 - Disclosure - Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details) Sheet http://rainthera.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details) Details 61 false false All Reports Book All Reports rain-10k_20211231.htm rain-20211231.xsd rain-20211231_cal.xml rain-20211231_def.xml rain-20211231_lab.xml rain-20211231_pre.xml rain-ex231_75.htm rain-ex311_76.htm rain-ex312_77.htm rain-ex321_73.htm rain-ex43_74.htm gxcvxnmtxzcp000001.jpg http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 81 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "rain-10k_20211231.htm": { "axisCustom": 0, "axisStandard": 23, "contextCount": 166, "dts": { "calculationLink": { "local": [ "rain-20211231_cal.xml" ] }, "definitionLink": { "local": [ "rain-20211231_def.xml" ] }, "inline": { "local": [ "rain-10k_20211231.htm" ] }, "labelLink": { "local": [ "rain-20211231_lab.xml" ] }, "presentationLink": { "local": [ "rain-20211231_pre.xml" ] }, "schema": { "local": [ "rain-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 573, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 23, "http://rainthera.com/20211231": 11, "http://xbrl.sec.gov/dei/2021q4": 7, "total": 41 }, "keyCustom": 90, "keyStandard": 389, "memberCustom": 23, "memberStandard": 32, "nsprefix": "rain", "nsuri": "http://rainthera.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://rainthera.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Fair Value Measurements", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Investments", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestments", "shortName": "Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Balance Sheet Details", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetails", "shortName": "Balance Sheet Details", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Related Party Transactions", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "rain:ConvertibleDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Convertible Promissory Notes", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePromissoryNotes", "shortName": "Convertible Promissory Notes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "rain:ConvertibleDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit)", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficit", "shortName": "Convertible Preferred Stock and Stockholders' Equity (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "rain:LicenseAgreementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - License and Clinical Supply Agreements", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreements", "shortName": "License and Clinical Supply Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "rain:LicenseAgreementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Commitments and Contingencies", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Employee Benefits", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureEmployeeBenefits", "shortName": "Employee Benefits", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Income Taxes", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Balance Sheets", "role": "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets", "shortName": "Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Net Loss Per Share", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureNetLossPerShare", "shortName": "Net Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Fair Value Measurements (Tables)", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "rain:ScheduleOfCashCashEquivalentsAndInvestmentsReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Investments (Tables)", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsTables", "shortName": "Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "rain:ScheduleOfCashCashEquivalentsAndInvestmentsReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Balance Sheet Details (Tables)", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsTables", "shortName": "Balance Sheet Details (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) (Tables)", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitTables", "shortName": "Convertible Preferred Stock and Stockholders' Equity (Deficit) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Income Taxes (Tables)", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Net Loss Per Share (Tables)", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureNetLossPerShareTables", "shortName": "Net Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "us-gaap:NatureOfOperations", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "U_rainSegment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Organization and Nature of Operations - Additional Information (Details)", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails", "shortName": "Organization and Nature of Operations - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:NatureOfOperations", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "U_rainSegment", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:TemporaryEquitySharesOutstanding", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100020 - Statement - Balance Sheets (Parenthetical)", "role": "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical", "shortName": "Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20211231", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "p", "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20170430_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:TangibleAssetImpairmentCharges", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20170430_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:TangibleAssetImpairmentCharges", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Fair Value Measurements - Additional Information (Details)", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "shortName": "Fair Value Measurements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShortTermInvestments", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Details)", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails", "shortName": "Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231", "decimals": "-3", "lang": null, "name": "rain:CashEquivalentsAndShortTermInvestmentsFairValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Parenthetical) (Details)", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisParentheticalDetails", "shortName": "Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Parenthetical) (Details)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_us-gaapFairValueByAssetClassAxis_us-gaapCashMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231", "decimals": "-3", "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value Using Level 3 Significant Unobservable Inputs (Details)", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueUsingLevel3SignificantUnobservableInputsDetails", "shortName": "Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value Using Level 3 Significant Unobservable Inputs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Investments - Summary of Cash Equivalents and Investments Measured at Fair Value on Recurring Basis (Details)", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsSummaryOfCashEquivalentsAndInvestmentsMeasuredAtFairValueOnRecurringBasisDetails", "shortName": "Investments - Summary of Cash Equivalents and Investments Measured at Fair Value on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "rain:ScheduleOfCashCashEquivalentsAndInvestmentsReconciliationTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231", "decimals": "-3", "lang": null, "name": "rain:CashEquivalentsAndInvestmentsAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Investments - Schedule of Contractual Maturities of AFS Securities (Details)", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsScheduleOfContractualMaturitiesOfAFSSecuritiesDetails", "shortName": "Investments - Schedule of Contractual Maturities of AFS Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Investments - Additional Information (Details)", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails", "shortName": "Investments - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": "INF", "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PrepaidInsurance", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Balance Sheet Details - Schedule of Prepaid and Other Current Assets (Details)", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidAndOtherCurrentAssetsDetails", "shortName": "Balance Sheet Details - Schedule of Prepaid and Other Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PrepaidInsurance", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Balance Sheet Details - Schedule of Property and Equipment, Net (Details)", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails", "shortName": "Balance Sheet Details - Schedule of Property and Equipment, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - Statements of Operations and Comprehensive Loss", "role": "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss", "shortName": "Statements of Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Balance Sheet Details - Additional Information (Details)", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetails", "shortName": "Balance Sheet Details - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20211231", "decimals": "-3", "first": true, "lang": null, "name": "rain:FICATaxCreditReceivableNonCurrentAssets", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Balance Sheet Details - Schedule of Other Non-Current Assets (Details)", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfOtherNonCurrentAssetsDetails", "shortName": "Balance Sheet Details - Schedule of Other Non-Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20211231", "decimals": "-3", "first": true, "lang": null, "name": "rain:FICATaxCreditReceivableNonCurrentAssets", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "rain:ConvertibleDebtTextBlock", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_us-gaapDebtInstrumentAxis_rainTwoThousandAndNineteenNotesMember_20191031", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Related Party Transactions - Additional Information (Details)", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "shortName": "Related Party Transactions - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_us-gaapDebtInstrumentAxis_rainConvertiblePromissoryNotesMember_20210101_20211231", "decimals": "-5", "lang": null, "name": "rain:ChangesInFairValueOfDebtInstrument", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "p", "rain:ConvertibleDebtTextBlock", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20200101_20201231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InterestExpenseDebt", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Convertible Promissory Notes - Additional Information (Detail)", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePromissoryNotesAdditionalInformationDetail", "shortName": "Convertible Promissory Notes - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "rain:ConvertibleDebtTextBlock", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20200101_20201231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InterestExpenseDebt", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) - Additional Information (Details)", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "shortName": "Convertible Preferred Stock and Stockholders' Equity (Deficit) - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210416", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_us-gaapPlanNameAxis_rainTwoThousandTwentyOneEquityIncentivePlanMember_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) - Summary of Stock Option Activities (Details)", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitSummaryOfStockOptionActivitiesDetails", "shortName": "Convertible Preferred Stock and Stockholders' Equity (Deficit) - Summary of Stock Option Activities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_us-gaapPlanNameAxis_rainTwoThousandTwentyOneEquityIncentivePlanMember_20210101_20211231", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) - Summary of Stock-Based Compensation Expense Recognized (Details)", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitSummaryOfStockBasedCompensationExpenseRecognizedDetails", "shortName": "Convertible Preferred Stock and Stockholders' Equity (Deficit) - Summary of Stock-Based Compensation Expense Recognized (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) - Weighted-Average Assumptions Used in Black-Scholes Option Pricing Model to Determine Fair Value of Stock Option Grants (Details)", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionGrantsDetails", "shortName": "Convertible Preferred Stock and Stockholders' Equity (Deficit) - Weighted-Average Assumptions Used in Black-Scholes Option Pricing Model to Determine Fair Value of Stock Option Grants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "rain:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) - Schedule of Common Stock Reserved for Future Issuance (Details)", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureIssuanceDetails", "shortName": "Convertible Preferred Stock and Stockholders' Equity (Deficit) - Schedule of Common Stock Reserved for Future Issuance (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "rain:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_us-gaapStatementClassOfStockAxis_rainReservedForFutureEquityAwardGrantsMember_20211231", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_us-gaapTypeOfArrangementAxis_rainDaiichiSankyoLicenseAgreementMember_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "rain:LicenseAgreementEffectiveDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - License and Clinical Supply Agreements - Additional Information (Details)", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreementsAdditionalInformationDetails", "shortName": "License and Clinical Supply Agreements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_us-gaapTypeOfArrangementAxis_rainDaiichiSankyoLicenseAgreementMember_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "rain:LicenseAgreementEffectiveDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)", "role": "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "shortName": "Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100490 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "shortName": "Commitments and Contingencies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100500 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments Required under Operating Lease (Details)", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsRequiredUnderOperatingLeaseDetails", "shortName": "Commitments and Contingencies - Schedule of Future Minimum Lease Payments Required under Operating Lease (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100520 - Disclosure - Commitments and Contingencies - Summary of Lease Costs and Cash Payments (Details)", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndCashPaymentsDetails", "shortName": "Commitments and Contingencies - Summary of Lease Costs and Cash Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DefinedContributionPlanTextBlock", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": "0", "first": true, "lang": null, "name": "rain:DefinedContributionPlanEmployerMatchingContributionAmount", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100530 - Disclosure - Employee Benefits - Additional Information (Details)", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetails", "shortName": "Employee Benefits - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DefinedContributionPlanTextBlock", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": "0", "first": true, "lang": null, "name": "rain:DefinedContributionPlanEmployerMatchingContributionAmount", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100540 - Disclosure - Income Taxes - Components of Provision for Income Taxes (Details)", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails", "shortName": "Income Taxes - Components of Provision for Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100550 - Disclosure - Income Taxes - Computation of Provision for Income Taxes by Applying Federal Statutory Income Tax Rate to Income Before Taxes (Detail)", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComputationOfProvisionForIncomeTaxesByApplyingFederalStatutoryIncomeTaxRateToIncomeBeforeTaxesDetail", "shortName": "Income Taxes - Computation of Provision for Income Taxes by Applying Federal Statutory Income Tax Rate to Income Before Taxes (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20211231", "decimals": "-3", "first": true, "lang": null, "name": "rain:DeferredTaxAssetsAccruedExpensesAndOther", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100560 - Disclosure - Income Taxes - Components of Deferred Income Tax Assets and Liabilities (Detail)", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail", "shortName": "Income Taxes - Components of Deferred Income Tax Assets and Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20211231", "decimals": "-3", "first": true, "lang": null, "name": "rain:DeferredTaxAssetsAccruedExpensesAndOther", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100570 - Disclosure - Income Taxes - Additional Information (Details)", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "shortName": "Income Taxes - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": "-5", "lang": null, "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "rain:ScheduleOfFederalAndStateNetOperatingLossCarryforwardsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_us-gaapIncomeTaxAuthorityNameAxis_rainFederalPreTaxCutAndJobsActMember_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100580 - Disclosure - Income Taxes - Schedule of Federal and State Net Operating Loss Carryforwards (Details)", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfFederalAndStateNetOperatingLossCarryforwardsDetails", "shortName": "Income Taxes - Schedule of Federal and State Net Operating Loss Carryforwards (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "rain:ScheduleOfFederalAndStateNetOperatingLossCarryforwardsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_us-gaapIncomeTaxAuthorityNameAxis_rainFederalPreTaxCutAndJobsActMember_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100590 - Disclosure - Income Taxes - Changes in Gross Unrecognized Tax Benefits (Detail)", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesChangesInGrossUnrecognizedTaxBenefitsDetail", "shortName": "Income Taxes - Changes in Gross Unrecognized Tax Benefits (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": "-3", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_us-gaapStatementClassOfStockAxis_rainSeriesBConvertiblePreferredStockMember_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "rain:TemporaryEquityIssuanceCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)", "role": "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical", "shortName": "Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_us-gaapStatementClassOfStockAxis_rainSeriesBConvertiblePreferredStockMember_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "rain:TemporaryEquityIssuanceCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100600 - Disclosure - Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss per Share (Details)", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails", "shortName": "Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": "0", "lang": null, "name": "rain:WeightedAverageNumberOfShareOutstandingBasicAndDilutedBeforeAdjustment", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100610 - Disclosure - Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details)", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails", "shortName": "Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100060 - Statement - Statements of Cash Flows", "role": "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows", "shortName": "Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": "-3", "lang": null, "name": "us-gaap:ResearchAndDevelopmentInProcess", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100070 - Disclosure - Organization and Nature of Operations", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfOperations", "shortName": "Organization and Nature of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100080 - Disclosure - Summary of Significant Accounting Policies", "role": "http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rain-10k_20211231.htm", "contextRef": "C_0001724979_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 63, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r613", "r614", "r615" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm Id", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r613", "r614", "r615" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r613", "r614", "r615" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r613", "r614", "r615" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r616" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "verboseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r611" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated By Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r610" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r610" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r627" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r610" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationDateOfIncorporation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date when an entity was incorporated", "label": "Entity Incorporation Date Of Incorporation", "terseLabel": "Entity incorporation date" } } }, "localname": "EntityIncorporationDateOfIncorporation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r625" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r610" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r610" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r610" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r610" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r626" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well Known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r613", "r614", "r615" ], "lang": { "en-us": { "role": { "label": "Icfr Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r609" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r612" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "rain_AccrualsForUnbilledProfessionalFeesRelatedToIPO": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accruals for unbilled professional fees related to IPO.", "label": "Accruals For Unbilled Professional Fees Related To I P O", "terseLabel": "Accruals for unbilled professional fees related to the IPO" } } }, "localname": "AccrualsForUnbilledProfessionalFeesRelatedToIPO", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rain_AccruedMilestonePayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accrued Milestone Payment", "terseLabel": "Accrued milestone payment" } } }, "localname": "AccruedMilestonePayment", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rain_AccruedReimbursableClinicalTrialsCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued reimbursable clinical trials costs.", "label": "Accrued Reimbursable Clinical Trials Costs", "terseLabel": "Accrued reimbursable clinical trials costs" } } }, "localname": "AccruedReimbursableClinicalTrialsCosts", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rain_AccruedResearchAndDevelopmentCurrent": { "auth_ref": [], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10130.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued research and development current.", "label": "Accrued Research And Development Current", "terseLabel": "Accrued research and development" } } }, "localname": "AccruedResearchAndDevelopmentCurrent", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "rain_AgreementPeriodFromFirstSaleOfFirstLicensedProduct": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Agreement Period From First Sale Of First Licensed Product", "terseLabel": "Agreement period from first sale of first licensed product" } } }, "localname": "AgreementPeriodFromFirstSaleOfFirstLicensedProduct", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "rain_AgreementTerminationWrittenNoticePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement termination written notice period.", "label": "Agreement Termination Written Notice Period", "terseLabel": "Agreement termination written notice period" } } }, "localname": "AgreementTerminationWrittenNoticePeriod", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "rain_AlternativeInvestmentMeasurementExpectedTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Alternative investment measurement expected term.", "label": "Alternative Investment Measurement Expected Term", "terseLabel": "Alternative investment measurement expected term" } } }, "localname": "AlternativeInvestmentMeasurementExpectedTerm", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "rain_AnnualLicenseMaintenanceFeeUntilFirstSaleOfFirstLicensedProduct": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Annual license maintenance fee until first sale of first licensed product.", "label": "Annual License Maintenance Fee Until First Sale Of First Licensed Product", "terseLabel": "Annual license maintenance fee until first sale of first licensed product" } } }, "localname": "AnnualLicenseMaintenanceFeeUntilFirstSaleOfFirstLicensedProduct", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rain_AvailableForSaleSecuritiesDebtMaturitiesOneToTwoYearFairValue": { "auth_ref": [], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsScheduleOfContractualMaturitiesOfAFSSecuritiesDetails": { "order": 10020.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Available For Sale Securities Debt Maturities One To Two Year Fair Value", "terseLabel": "Due within one to two years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesOneToTwoYearFairValue", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsScheduleOfContractualMaturitiesOfAFSSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "rain_CashCashEquivalentsAndInvestmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash, cash equivalents and investments.", "label": "Cash Cash Equivalents And Investments [Line Items]", "terseLabel": "Cash Cash Equivalents And Investments [Line Items]" } } }, "localname": "CashCashEquivalentsAndInvestmentsLineItems", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsSummaryOfCashEquivalentsAndInvestmentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "rain_CashCashEquivalentsAndInvestmentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash, cash equivalents and investments.", "label": "Cash Cash Equivalents And Investments [Table]", "terseLabel": "Cash Cash Equivalents And Investments [Table]" } } }, "localname": "CashCashEquivalentsAndInvestmentsTable", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsSummaryOfCashEquivalentsAndInvestmentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "rain_CashEquivalentsAndInvestmentsAmortizedCost": { "auth_ref": [], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsSummaryOfCashEquivalentsAndInvestmentsMeasuredAtFairValueOnRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash equivalents and investments amortized cost.", "label": "Cash Equivalents And Investments Amortized Cost", "totalLabel": "Cash equivalents and investments, amortized cost" } } }, "localname": "CashEquivalentsAndInvestmentsAmortizedCost", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsSummaryOfCashEquivalentsAndInvestmentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "rain_CashEquivalentsAndInvestmentsFairValue": { "auth_ref": [], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsSummaryOfCashEquivalentsAndInvestmentsMeasuredAtFairValueOnRecurringBasisDetails": { "order": 10950.0, "parentTag": "rain_CashEquivalentsAndInvestmentsAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash equivalents and investments fair value.", "label": "Cash Equivalents And Investments Fair Value", "terseLabel": "Cash equivalents and investments, estimated fair value" } } }, "localname": "CashEquivalentsAndInvestmentsFairValue", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsSummaryOfCashEquivalentsAndInvestmentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "rain_CashEquivalentsAndInvestmentsUnrealizedGainBeforeTax": { "auth_ref": [], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsSummaryOfCashEquivalentsAndInvestmentsMeasuredAtFairValueOnRecurringBasisDetails": { "order": 10930.0, "parentTag": "rain_CashEquivalentsAndInvestmentsAmortizedCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash equivalents and investments unrealized gain before tax.", "label": "Cash Equivalents And Investments Unrealized Gain Before Tax", "terseLabel": "Cash equivalents and investments, unrealized gains" } } }, "localname": "CashEquivalentsAndInvestmentsUnrealizedGainBeforeTax", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsSummaryOfCashEquivalentsAndInvestmentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "rain_CashEquivalentsAndInvestmentsUnrealizedLossBeforeTax": { "auth_ref": [], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsSummaryOfCashEquivalentsAndInvestmentsMeasuredAtFairValueOnRecurringBasisDetails": { "order": 10940.0, "parentTag": "rain_CashEquivalentsAndInvestmentsAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash equivalents and investments unrealized loss before tax.", "label": "Cash Equivalents And Investments Unrealized Loss Before Tax", "negatedLabel": "Cash equivalents and investments, unrealized losses" } } }, "localname": "CashEquivalentsAndInvestmentsUnrealizedLossBeforeTax", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsSummaryOfCashEquivalentsAndInvestmentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "rain_CashEquivalentsAndShortTermInvestmentsFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash equivalents and short-term investments fair value.", "label": "Cash Equivalents And Short Term Investments Fair Value", "terseLabel": "Total cash equivalents and short-term investments" } } }, "localname": "CashEquivalentsAndShortTermInvestmentsFairValue", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "rain_CashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash equivalents fair value disclosure.", "label": "Cash Equivalents Fair Value Disclosure", "positiveTerseLabel": "Cash equivalents, estimated fair value", "terseLabel": "Cash equivalents" } } }, "localname": "CashEquivalentsFairValueDisclosure", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsSummaryOfCashEquivalentsAndInvestmentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "rain_CertainHoldersOfPreferredStockInvestorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Certain holders of preferred stock investors.", "label": "Certain Holders Of Preferred Stock Investors [Member]", "terseLabel": "Certain Holders of Preferred Stock Investors" } } }, "localname": "CertainHoldersOfPreferredStockInvestorsMember", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rain_ChangeInFairValueOfConvertiblePromissoryNotesRelatedParty": { "auth_ref": [], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10190.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 10090.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in fair value of convertible promissory notes, related party", "label": "Change In Fair Value Of Convertible Promissory Notes Related Party", "negatedLabel": "Change in fair value of convertible promissory notes, related party", "terseLabel": "Change in fair value of convertible promissory notes, related party" } } }, "localname": "ChangeInFairValueOfConvertiblePromissoryNotesRelatedParty", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows", "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "rain_ChangesInFairValueOfDebtInstrument": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Changes in fair value of debt instrument.", "label": "Changes In Fair Value Of Debt Instrument", "terseLabel": "Changes in fair value of debt instrument" } } }, "localname": "ChangesInFairValueOfDebtInstrument", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rain_ClinicalTrialPayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Clinical trial payments.", "label": "Clinical Trial Payments", "terseLabel": "Clinical trial payments" } } }, "localname": "ClinicalTrialPayments", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rain_CommonStockBeneficialOwnershipLimitationPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock beneficial ownership limitation percentage.", "label": "Common Stock Beneficial Ownership Limitation Percentage", "terseLabel": "Common stock, beneficial ownership limitation percentage" } } }, "localname": "CommonStockBeneficialOwnershipLimitationPercentage", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "rain_ConversionOfConvertiblePromissoryNotesAndInterestIntoSeriesBConvertiblePreferredStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Conversion of convertible promissory notes and interest into series b convertible preferred stock.", "label": "Conversion Of Convertible Promissory Notes And Interest Into Series B Convertible Preferred Stock", "terseLabel": "Conversion of convertible promissory notes and interest into Series B convertible preferred stock" } } }, "localname": "ConversionOfConvertiblePromissoryNotesAndInterestIntoSeriesBConvertiblePreferredStock", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rain_ConvertibleDebtTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible debt.", "label": "Convertible Debt [Text Block]", "terseLabel": "Convertible Promissory Notes" } } }, "localname": "ConvertibleDebtTextBlock", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePromissoryNotes" ], "xbrltype": "textBlockItemType" }, "rain_ConvertiblePreferredStockVotingRights": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible preferred stock, voting rights.", "label": "Convertible Preferred Stock Voting Rights", "terseLabel": "Convertible preferred stock, voting rights" } } }, "localname": "ConvertiblePreferredStockVotingRights", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "rain_ConvertiblePromissoryNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible promissory notes.", "label": "Convertible Promissory Notes [Member]", "terseLabel": "Convertible Promissory Notes" } } }, "localname": "ConvertiblePromissoryNotesMember", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rain_CurePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cure Period", "terseLabel": "Cure period" } } }, "localname": "CurePeriod", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "rain_DaiichiSankyoLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Daiichi Sankyo License Agreement [Member]", "terseLabel": "Daiichi Sankyo License Agreement" } } }, "localname": "DaiichiSankyoLicenseAgreementMember", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rain_DebtConversionAccruedInterestOfDebtConvertedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt conversion, accrued interest of debt converted, amount.", "label": "Debt Conversion Accrued Interest Of Debt Converted Amount", "terseLabel": "Debt conversion, accrued interest of debt converted" } } }, "localname": "DebtConversionAccruedInterestOfDebtConvertedAmount", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rain_DebtConversionConversionPricePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt conversion, conversion price, percentage.", "label": "Debt Conversion Conversion Price Percentage", "terseLabel": "Conversion price, percentage" } } }, "localname": "DebtConversionConversionPricePercentage", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePromissoryNotesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "rain_DebtConversionConvertedInstrumentTwiceAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt conversion converted instrument twice amount.", "label": "Debt Conversion Converted Instrument Twice Amount", "terseLabel": "Conversion of outstanding loan into common stock shares, two times value" } } }, "localname": "DebtConversionConvertedInstrumentTwiceAmount", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePromissoryNotesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "rain_DeferredOfferingCostNoncurrent": { "auth_ref": [], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10190.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred offering cost noncurrent.", "label": "Deferred Offering Cost Noncurrent", "terseLabel": "Deferred offering costs" } } }, "localname": "DeferredOfferingCostNoncurrent", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "rain_DeferredOfferingCostsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred offering costs.", "label": "Deferred Offering Costs Policy [Text Block]", "terseLabel": "Deferred Offering Costs" } } }, "localname": "DeferredOfferingCostsPolicyTextBlock", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "rain_DeferredTaxAssetLeaseLiability": { "auth_ref": [], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail": { "order": 10120.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax asset lease liability.", "label": "Deferred Tax Asset Lease Liability", "terseLabel": "Lease liability" } } }, "localname": "DeferredTaxAssetLeaseLiability", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "rain_DeferredTaxAssetsAccruedExpensesAndOther": { "auth_ref": [], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail": { "order": 10060.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets accrued expenses and other.", "label": "Deferred Tax Assets Accrued Expenses And Other", "terseLabel": "Accrued expenses and other" } } }, "localname": "DeferredTaxAssetsAccruedExpensesAndOther", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "rain_DeferredTaxAssetsTaxResearchAndDevelopmentAndOrphanDrugCredits": { "auth_ref": [], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail": { "order": 10100.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets tax research and development and orphan drug credits.", "label": "Deferred Tax Assets Tax Research And Development And Orphan Drug Credits", "terseLabel": "R&D and Orphan Drug credits" } } }, "localname": "DeferredTaxAssetsTaxResearchAndDevelopmentAndOrphanDrugCredits", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "rain_DeferredTaxLiabilitiesRightOfUseAsset": { "auth_ref": [], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail": { "order": 10030.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred tax liabilities right-of-use asset.", "label": "Deferred Tax Liabilities Right Of Use Asset", "negatedLabel": "Right-of-use asset" } } }, "localname": "DeferredTaxLiabilitiesRightOfUseAsset", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "rain_DefinedContributionPlanEmployerMatchingContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Defined contribution plan, employer matching contribution amount.", "label": "Defined Contribution Plan Employer Matching Contribution Amount", "terseLabel": "Defined contribution plan, employer matching contribution amount" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionAmount", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rain_DrexelLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Drexel License Agreement [Member]", "terseLabel": "Drexel License Agreement" } } }, "localname": "DrexelLicenseAgreementMember", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rain_DrexelUniversityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Drexel University [Member]", "terseLabel": "Drexel University" } } }, "localname": "DrexelUniversityMember", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rain_FICATaxCreditReceivableCurrent": { "auth_ref": [], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidAndOtherCurrentAssetsDetails": { "order": 10040.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "FICA tax credit receivable current.", "label": "F I C A Tax Credit Receivable Current", "terseLabel": "FICA tax credit receivable" } } }, "localname": "FICATaxCreditReceivableCurrent", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "rain_FICATaxCreditReceivableNonCurrentAssets": { "auth_ref": [], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfOtherNonCurrentAssetsDetails": { "order": 10010.0, "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "FICA tax credit receivable non current assets.", "label": "F I C A Tax Credit Receivable Non Current Assets", "terseLabel": "FICA tax credit receivable" } } }, "localname": "FICATaxCreditReceivableNonCurrentAssets", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfOtherNonCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "rain_FairValueMeasurementWithUnobservableInputsReconciliationChangesInFairValueOfConvertiblePromissoryNotes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair Value, measurement with unobservable inputs reconciliation, changes in fair value of convertible promissory notes.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Changes In Fair Value Of Convertible Promissory Notes", "terseLabel": "Change in fair value of convertible promissory notes (Note 7)" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationChangesInFairValueOfConvertiblePromissoryNotes", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueUsingLevel3SignificantUnobservableInputsDetails" ], "xbrltype": "monetaryItemType" }, "rain_FairValueMeasurementWithUnobservableInputsReconciliationConversionToConvertiblePreferredStockExcludingInterestExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, measurement with unobservable inputs reconciliation, conversion to convertible preferred stock excluding interest expense.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Conversion To Convertible Preferred Stock Excluding Interest Expense", "terseLabel": "Conversion to convertible preferred stock (excluding interest expense)" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationConversionToConvertiblePreferredStockExcludingInterestExpense", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueUsingLevel3SignificantUnobservableInputsDetails" ], "xbrltype": "monetaryItemType" }, "rain_FairValueMeasurementWithUnobservableInputsReconciliationIssuanceOfConvertiblePromissoryNotes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair Value, measurement with unobservable inputs reconciliation, issuance of convertible promissory notes.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Issuance Of Convertible Promissory Notes", "terseLabel": "Issuance of convertible promissory notes" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationIssuanceOfConvertiblePromissoryNotes", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueUsingLevel3SignificantUnobservableInputsDetails" ], "xbrltype": "monetaryItemType" }, "rain_FederalPostTaxCutAndJobsActMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Federal Post Tax Cut And Jobs Act.", "label": "Federal Post Tax Cut And Jobs Act [Member]", "terseLabel": "Federal\u2014Post TCJA" } } }, "localname": "FederalPostTaxCutAndJobsActMember", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfFederalAndStateNetOperatingLossCarryforwardsDetails" ], "xbrltype": "domainItemType" }, "rain_FederalPreTaxCutAndJobsActMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Federal Pre Tax Cut And Jobs Act.", "label": "Federal Pre Tax Cut And Jobs Act [Member]", "terseLabel": "Federal\u2014Pre TCJA" } } }, "localname": "FederalPreTaxCutAndJobsActMember", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfFederalAndStateNetOperatingLossCarryforwardsDetails" ], "xbrltype": "domainItemType" }, "rain_IPOAndOverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "IPO and over allotment option.", "label": "I P O And Over Allotment Option [Member]", "terseLabel": "IPO and Over Allotment Option" } } }, "localname": "IPOAndOverAllotmentOptionMember", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rain_IncomeTaxReconciliationChangeInFairValueOfConvertiblePromissoryNote": { "auth_ref": [], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComputationOfProvisionForIncomeTaxesByApplyingFederalStatutoryIncomeTaxRateToIncomeBeforeTaxesDetail": { "order": 10030.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income tax reconciliation change in fair value of convertible promissory note.", "label": "Income Tax Reconciliation Change In Fair Value Of Convertible Promissory Note", "terseLabel": "Change in fair value of convertible promissory notes" } } }, "localname": "IncomeTaxReconciliationChangeInFairValueOfConvertiblePromissoryNote", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComputationOfProvisionForIncomeTaxesByApplyingFederalStatutoryIncomeTaxRateToIncomeBeforeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "rain_IncomeTaxReconciliationConvertibleNotesInterest": { "auth_ref": [], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComputationOfProvisionForIncomeTaxesByApplyingFederalStatutoryIncomeTaxRateToIncomeBeforeTaxesDetail": { "order": 10050.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income tax reconciliation convertible notes interest.", "label": "Income Tax Reconciliation Convertible Notes Interest", "terseLabel": "Convertible note interest" } } }, "localname": "IncomeTaxReconciliationConvertibleNotesInterest", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComputationOfProvisionForIncomeTaxesByApplyingFederalStatutoryIncomeTaxRateToIncomeBeforeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "rain_IncreaseDecreaseInAccruedResearchAndDevelopment": { "auth_ref": [], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10260.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in accrued research and development.", "label": "Increase Decrease In Accrued Research And Development", "terseLabel": "Accrued research and development" } } }, "localname": "IncreaseDecreaseInAccruedResearchAndDevelopment", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rain_IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet": { "auth_ref": [], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10230.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in operating lease right-of-use asset and liability net.", "label": "Increase Decrease In Operating Lease Right Of Use Asset And Liability Net", "terseLabel": "Operating lease right-of-use asset and liability, net" } } }, "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rain_IncreaseInAnnualBaseRentMonthAndDayOfEachYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Increase in annual base rent month and day of each year.", "label": "Increase In Annual Base Rent Month And Day Of Each Year", "terseLabel": "Increase in annual base rent month and day of each year" } } }, "localname": "IncreaseInAnnualBaseRentMonthAndDayOfEachYear", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "gMonthDayItemType" }, "rain_IncreaseInAnnualBaseRentPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Increase in annual base rent percentage.", "label": "Increase In Annual Base Rent Percentage", "terseLabel": "Increase in annual base rent percentage" } } }, "localname": "IncreaseInAnnualBaseRentPercentage", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "rain_IntellectualPropertyLicenseAgreementDate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intellectual Property License Agreement Date", "terseLabel": "Intellectual property license agreement date" } } }, "localname": "IntellectualPropertyLicenseAgreementDate", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreementsAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "rain_IntellectualPropertyLicenseAgreementDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intellectual Property License Agreement Description", "terseLabel": "Intellectual property license agreement description" } } }, "localname": "IntellectualPropertyLicenseAgreementDescription", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "rain_IntellectualPropertyLicenseAgreementPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intellectual Property License Agreement Period", "terseLabel": "Intellectual property license agreement period" } } }, "localname": "IntellectualPropertyLicenseAgreementPeriod", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "rain_LesseeOperatingLeaseCommencementMonthAndYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee operating lease commencement month and year.", "label": "Lessee Operating Lease Commencement Month And Year", "terseLabel": "Operating lease commencement month and year" } } }, "localname": "LesseeOperatingLeaseCommencementMonthAndYear", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "gYearMonthItemType" }, "rain_LesseeOperatingLeaseExpirationMonthAndYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee operating lease expiration month and year.", "label": "Lessee Operating Lease Expiration Month And Year", "terseLabel": "Operating lease expiration month and year" } } }, "localname": "LesseeOperatingLeaseExpirationMonthAndYear", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "gYearMonthItemType" }, "rain_LesseeOperatingLeaseExtendedExpirationMonthAndYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee operating lease extended expiration month and year.", "label": "Lessee Operating Lease Extended Expiration Month And Year", "terseLabel": "Operating lease extended expiration month and year" } } }, "localname": "LesseeOperatingLeaseExtendedExpirationMonthAndYear", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "gYearMonthItemType" }, "rain_LicenseAgreementEffectiveDate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "License Agreement Effective Date", "terseLabel": "License agreement, effective date" } } }, "localname": "LicenseAgreementEffectiveDate", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreementsAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "rain_LicenseAgreementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License agreements", "label": "License Agreements [Abstract]" } } }, "localname": "LicenseAgreementsAbstract", "nsuri": "http://rainthera.com/20211231", "xbrltype": "stringItemType" }, "rain_LicenseAgreementsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License agreements.", "label": "License Agreements [Line Items]", "terseLabel": "License Agreements [Line Items]" } } }, "localname": "LicenseAgreementsLineItems", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "rain_LicenseAgreementsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License agreements.", "label": "License Agreements [Table]", "terseLabel": "License Agreements [Table]" } } }, "localname": "LicenseAgreementsTable", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "rain_LicenseAgreementsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "License Agreements [Text Block]", "terseLabel": "License and Clinical Supply Agreements" } } }, "localname": "LicenseAgreementsTextBlock", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreements" ], "xbrltype": "textBlockItemType" }, "rain_MaximumFuturePaymentsInAdditionToInitiationFee": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Maximum Future Payments In Addition To Initiation Fee", "terseLabel": "Maximum future payments in addition to initiation fee" } } }, "localname": "MaximumFuturePaymentsInAdditionToInitiationFee", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rain_MaximumPotentialMilestonePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Maximum Potential Milestone Payments", "terseLabel": "Maximum future milestone payments" } } }, "localname": "MaximumPotentialMilestonePayments", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rain_MilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Milestone Payments", "terseLabel": "Milestone payments" } } }, "localname": "MilestonePayments", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rain_NonCashAdditionsToPropertyAndEquipment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non cash additions to property and equipment.", "label": "Non Cash Additions To Property And Equipment", "terseLabel": "Non-cash additions to property and equipment" } } }, "localname": "NonCashAdditionsToPropertyAndEquipment", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rain_NonCashInProcessResearchAndDevelopmentAccrual": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non cash in process research and development accrual.", "label": "Non Cash In Process Research And Development Accrual", "terseLabel": "Non-cash in-process research and development accrual" } } }, "localname": "NonCashInProcessResearchAndDevelopmentAccrual", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rain_NumberOfClinicalTrials": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number Of Clinical Trials", "terseLabel": "Number of clinical trials" } } }, "localname": "NumberOfClinicalTrials", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreementsAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "rain_NumberOfEqualInstalmentsPaidOneTimeNonRefundableInitiationFee": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number Of Equal Instalments Paid One Time Non Refundable Initiation Fee", "terseLabel": "Number of equal instalments paid one time non refundable initiation fee" } } }, "localname": "NumberOfEqualInstalmentsPaidOneTimeNonRefundableInitiationFee", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreementsAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "rain_NumberOfVotePerCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of vote per common stock.", "label": "Number Of Vote Per Common Stock", "terseLabel": "Number of vote per common stock" } } }, "localname": "NumberOfVotePerCommonStock", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "rain_NumberOfVotePerConvertiblePreferredStockUponConversionIntoCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of vote per convertible preferred stock upon conversion into common stock.", "label": "Number Of Vote Per Convertible Preferred Stock Upon Conversion Into Common Stock", "terseLabel": "Number of vote per convertible preferred stock upon conversion into common stock" } } }, "localname": "NumberOfVotePerConvertiblePreferredStockUponConversionIntoCommonStock", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "rain_OneTimeNonRefundableInitiationFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "One Time Non Refundable Initiation Fee", "terseLabel": "One time non refundable initiation fee" } } }, "localname": "OneTimeNonRefundableInitiationFee", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rain_OneTimeNonRefundableInitiationFeePaidInEachInstallment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "One Time Non Refundable Initiation Fee Paid In Each Installment", "terseLabel": "One time non-refundable initiation fee paid in each installment" } } }, "localname": "OneTimeNonRefundableInitiationFeePaidInEachInstallment", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rain_OperatingLossCarryForwardExpirationYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating loss carry forward expiration year.", "label": "Operating Loss Carry Forward Expiration Year", "terseLabel": "Expiration Years" } } }, "localname": "OperatingLossCarryForwardExpirationYear", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfFederalAndStateNetOperatingLossCarryforwardsDetails" ], "xbrltype": "gYearItemType" }, "rain_OrganizationAndNatureOfOperationsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization and nature of operations.", "label": "Organization And Nature Of Operations [Line Items]", "terseLabel": "Organization And Nature Of Operations [Line Items]" } } }, "localname": "OrganizationAndNatureOfOperationsLineItems", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "rain_OrganizationAndNatureOfOperationsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization and nature of operations.", "label": "Organization And Nature Of Operations [Table]", "terseLabel": "Organization And Nature Of Operations [Table]" } } }, "localname": "OrganizationAndNatureOfOperationsTable", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "rain_PaymentsForLicenseAgreements": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Payments For License Agreements", "terseLabel": "Payments for license agreements" } } }, "localname": "PaymentsForLicenseAgreements", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rain_PeriodOfFirstInstallmentAfterEffectiveDate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Period Of First Installment After Effective Date", "terseLabel": "Period of first instalment after effective date" } } }, "localname": "PeriodOfFirstInstallmentAfterEffectiveDate", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "rain_PeriodOfFourthInstallmentAfterEffectiveDate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Period Of Fourth Installment After Effective Date", "terseLabel": "Period of fourth instalment after effective date" } } }, "localname": "PeriodOfFourthInstallmentAfterEffectiveDate", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "rain_PeriodOfSecondInstallmentAfterEffectiveDate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Period Of Second Installment After Effective Date", "terseLabel": "Period of second instalment after effective date" } } }, "localname": "PeriodOfSecondInstallmentAfterEffectiveDate", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "rain_PeriodOfThirdInstallmentAfterEffectiveDate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Period Of Third Installment After Effective Date", "terseLabel": "Period of third instalment after effective date" } } }, "localname": "PeriodOfThirdInstallmentAfterEffectiveDate", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "rain_PotentialCommitmentAmountFromGrossProceedsOfUnderwrittenInitialPublicOffering": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Potential commitment amount from gross proceeds of underwritten initial public offering.", "label": "Potential Commitment Amount From Gross Proceeds Of Underwritten Initial Public Offering", "terseLabel": "Potential commitment amount from gross proceeds of underwritten initial public offering" } } }, "localname": "PotentialCommitmentAmountFromGrossProceedsOfUnderwrittenInitialPublicOffering", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rain_PreclinicalStudiesAndClinicalTrialAccrualsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preclinical studies and clinical trial accruals.", "label": "Preclinical Studies And Clinical Trial Accruals Policy [Text Block]", "terseLabel": "Preclinical Studies and Clinical Trial Accruals" } } }, "localname": "PreclinicalStudiesAndClinicalTrialAccrualsPolicyTextBlock", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "rain_PrepaidResearchCurrent": { "auth_ref": [], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidAndOtherCurrentAssetsDetails": { "order": 10020.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid research current.", "label": "Prepaid Research Current", "terseLabel": "Prepaid research" } } }, "localname": "PrepaidResearchCurrent", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "rain_RDAndOrphanDrugCreditsFederalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "R&D and Orphan Drug Credits, Federal.", "label": "R D And Orphan Drug Credits Federal [Member]", "terseLabel": "R&D and Orphan Drug Credits, Federal" } } }, "localname": "RDAndOrphanDrugCreditsFederalMember", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfFederalAndStateNetOperatingLossCarryforwardsDetails" ], "xbrltype": "domainItemType" }, "rain_RDCreditsCaliforniaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "R&D Credits, California.", "label": "R D Credits California [Member]", "terseLabel": "R&D Credits, California" } } }, "localname": "RDCreditsCaliforniaMember", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfFederalAndStateNetOperatingLossCarryforwardsDetails" ], "xbrltype": "domainItemType" }, "rain_RecentDevelopmentsRegardingTheCOVID19Pandemic": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Recent developments regarding the COVID-19 pandemic.", "label": "Recent Developments Regarding The C O V I D19 Pandemic", "terseLabel": "Recent Developments Regarding the COVID-19 Pandemic" } } }, "localname": "RecentDevelopmentsRegardingTheCOVID19Pandemic", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "rain_RentReliefPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rent relief period.", "label": "Rent Relief Period", "terseLabel": "Rent relief period" } } }, "localname": "RentReliefPeriod", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "rain_ReservedForFutureESPPIssuancesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reserved for future ESPP issuances.", "label": "Reserved For Future E S P P Issuances [Member]", "terseLabel": "Reserved for future ESPP issuances" } } }, "localname": "ReservedForFutureESPPIssuancesMember", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "rain_ReservedForFutureEquityAwardGrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reserved for future equity award grants.", "label": "Reserved For Future Equity Award Grants [Member]", "terseLabel": "Reserved for future equity award grants" } } }, "localname": "ReservedForFutureEquityAwardGrantsMember", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "rain_RestrictedStockPurchaseAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted stock purchase agreements.", "label": "Restricted Stock Purchase Agreements [Member]", "terseLabel": "Restricted Stock Purchase Agreements" } } }, "localname": "RestrictedStockPurchaseAgreementsMember", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rain_RoyaltyObligationTerminationDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Royalty Obligation Termination Description", "terseLabel": "Royalty obligation termination description" } } }, "localname": "RoyaltyObligationTerminationDescription", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "rain_ScheduleOfCashCashEquivalentsAndInvestmentsReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of cash, cash equivalents and investments reconciliation.", "label": "Schedule Of Cash Cash Equivalents And Investments Reconciliation Table [Text Block]", "terseLabel": "Summary of Cash Equivalents and Investments Measured at Fair Value on Recurring Basis" } } }, "localname": "ScheduleOfCashCashEquivalentsAndInvestmentsReconciliationTableTextBlock", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "rain_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of common stock reserved for future issuance.", "label": "Schedule Of Common Stock Reserved For Future Issuance Table [Text Block]", "terseLabel": "Schedule of Common Stock Reserved for Future Issuance" } } }, "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitTables" ], "xbrltype": "textBlockItemType" }, "rain_ScheduleOfFederalAndStateNetOperatingLossCarryforwardsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Federal and State net operating loss carryforwards.", "label": "Schedule Of Federal And State Net Operating Loss Carryforwards Table [Text Block]", "terseLabel": "Schedule of Federal and State Net Operating Loss Carryforwards" } } }, "localname": "ScheduleOfFederalAndStateNetOperatingLossCarryforwardsTableTextBlock", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "rain_SeriesAConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A convertible preferred stock.", "label": "Series A Convertible Preferred Stock [Member]", "terseLabel": "Series A Convertible Preferred Stock" } } }, "localname": "SeriesAConvertiblePreferredStockMember", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails", "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets", "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical", "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "rain_SeriesBConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series B convertible preferred stock.", "label": "Series B Convertible Preferred Stock [Member]", "terseLabel": "Series B Convertible Preferred Stock" } } }, "localname": "SeriesBConvertiblePreferredStockMember", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePromissoryNotesAdditionalInformationDetail", "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets", "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical", "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "rain_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options aggregate intrinsic value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]", "terseLabel": "Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitSummaryOfStockOptionActivitiesDetails" ], "xbrltype": "stringItemType" }, "rain_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractTermAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options weighted average remaining contract term.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contract Term [Abstract]", "terseLabel": "Weighted-Average Remaining Contract Term" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractTermAbstract", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitSummaryOfStockOptionActivitiesDetails" ], "xbrltype": "stringItemType" }, "rain_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award stock plan offering period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Stock Plan Offering Period", "terseLabel": "Stock plan offering period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "rain_SublicensableRightsNumberOfFamiliesOfPatents": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Sublicensable Rights Number Of Families Of Patents", "terseLabel": "Sublicensable rights, number of families of patents" } } }, "localname": "SublicensableRightsNumberOfFamiliesOfPatents", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreementsAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "rain_SummaryOfSignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policies.", "label": "Summary Of Significant Accounting Policies [Line Items]", "terseLabel": "Summary Of Significant Accounting Policies [Line Items]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "rain_SummaryOfSignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policies.", "label": "Summary Of Significant Accounting Policies [Table]", "terseLabel": "Summary Of Significant Accounting Policies [Table]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesTable", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "rain_TemporaryEquityIssuanceCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Temporary equity issuance cost.", "label": "Temporary Equity Issuance Cost", "terseLabel": "Stock issuance cost" } } }, "localname": "TemporaryEquityIssuanceCost", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "monetaryItemType" }, "rain_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary equity stock issued during period shares conversion of share.", "label": "Temporary Equity Stock Issued During Period Shares Conversion Of Share", "negatedLabel": "Temporary equity conversion of convertible preferred stock to common stock, shares", "terseLabel": "Conversion of convertible preferred stock" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodSharesConversionOfShare", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "rain_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary equity stock issued during period shares new issues.", "label": "Temporary Equity Stock Issued During Period Shares New Issues", "terseLabel": "Issuance of Series B convertible preferred stock, net of issuance costs of $320, Shares" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "rain_TemporaryEquityStockIssuedDuringPeriodValueConversionOfShare": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Temporary equity stock issued during period value conversion of share.", "label": "Temporary Equity Stock Issued During Period Value Conversion Of Share", "negatedLabel": "Temporary equity conversion of convertible preferred stock to common stock" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodValueConversionOfShare", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "rain_TemporaryEquityStockSharesConversionOfConvertiblePromissoryNotesIntoConvertiblePreferredStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary equity stock shares conversion of convertible promissory notes into convertible preferred stock.", "label": "Temporary Equity Stock Shares Conversion Of Convertible Promissory Notes Into Convertible Preferred Stock", "terseLabel": "Conversion of convertible promissory notes into Series B convertible preferred stock, Shares" } } }, "localname": "TemporaryEquityStockSharesConversionOfConvertiblePromissoryNotesIntoConvertiblePreferredStock", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "rain_TemporaryEquityStockValueConversionOfConvertiblePromissoryNotesIntoConvertiblePreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Temporary Equity Stock Value Conversion of Convertible Promissory Notes into Convertible Preferred Stock.", "label": "Temporary Equity Stock Value Conversion Of Convertible Promissory Notes Into Convertible Preferred Stock", "terseLabel": "Conversion of convertible promissory notes into Series B convertible preferred stock" } } }, "localname": "TemporaryEquityStockValueConversionOfConvertiblePromissoryNotesIntoConvertiblePreferredStock", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "rain_TwoThousandAndEighteenStockIssuancePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand and Eighteen stock issuance plan.", "label": "Two Thousand And Eighteen Stock Issuance Plan [Member]", "terseLabel": "2018 Stock Issuance Plan" } } }, "localname": "TwoThousandAndEighteenStockIssuancePlanMember", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rain_TwoThousandAndNineteenNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2019 Notes.", "label": "Two Thousand And Nineteen Notes [Member]", "terseLabel": "2019 Notes" } } }, "localname": "TwoThousandAndNineteenNotesMember", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePromissoryNotesAdditionalInformationDetail", "http://rainthera.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rain_TwoThousandAndTwentyNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 Notes.", "label": "Two Thousand And Twenty Notes [Member]", "terseLabel": "2020 Notes" } } }, "localname": "TwoThousandAndTwentyNotesMember", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePromissoryNotesAdditionalInformationDetail", "http://rainthera.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rain_TwoThousandAndTwentyOneEmployeeSharePurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Two Thousand And Twenty One Employee Share Purchase Plan [Member]", "terseLabel": "2021 Employee Share Purchase Plan" } } }, "localname": "TwoThousandAndTwentyOneEmployeeSharePurchasePlanMember", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitTables", "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionGrantsDetails" ], "xbrltype": "domainItemType" }, "rain_TwoThousandNineteenAndTwentyConvertiblePromissoryNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand nineteen and twenty convertible promissory notes.", "label": "Two Thousand Nineteen And Twenty Convertible Promissory Notes [Member]", "terseLabel": "2019 and 2020 Notes" } } }, "localname": "TwoThousandNineteenAndTwentyConvertiblePromissoryNotesMember", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rain_TwoThousandTwentyOneEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand Twenty One equity incentive plan.", "label": "Two Thousand Twenty One Equity Incentive Plan [Member]", "terseLabel": "2021 Equity Incentive Plan" } } }, "localname": "TwoThousandTwentyOneEquityIncentivePlanMember", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitSummaryOfStockOptionActivitiesDetails" ], "xbrltype": "domainItemType" }, "rain_UndesignatedCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Undesignated Common Stock.", "label": "Undesignated Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "UndesignatedCommonStockMember", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "rain_UndesignatedPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Undesignated preferred stock.", "label": "Undesignated Preferred Stock [Member]", "terseLabel": "Undesignated Preferred Stock" } } }, "localname": "UndesignatedPreferredStockMember", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rain_UpfrontPayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Upfront Payments", "terseLabel": "Upfront payment" } } }, "localname": "UpfrontPayments", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rain_UpperLimitOfMinimumQuarterlyRoyaltyPayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Upper Limit Of Minimum Quarterly Royalty Payments", "terseLabel": "Upper limit of minimum quarterly royalty payments" } } }, "localname": "UpperLimitOfMinimumQuarterlyRoyaltyPayments", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rain_WeightedAverageNumberOfShareOutstandingBasicAndDilutedBeforeAdjustment": { "auth_ref": [], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails": { "order": 10010.0, "parentTag": "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Weighted average number of share outstanding basic and diluted before adjustment.", "label": "Weighted Average Number Of Share Outstanding Basic And Diluted Before Adjustment", "terseLabel": "Weighted-average shares of common stock outstanding, basic and diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDilutedBeforeAdjustment", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "rain_WrittenNoticePeriodToIncreaseCommonStockBeneficialOwnershipLimitation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Written notice period to increase common stock beneficial ownership limitation.", "label": "Written Notice Period To Increase Common Stock Beneficial Ownership Limitation", "terseLabel": "Written notice period to increase common stock beneficial ownership limitation" } } }, "localname": "WrittenNoticePeriodToIncreaseCommonStockBeneficialOwnershipLimitation", "nsuri": "http://rainthera.com/20211231", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r57", "r59", "r114", "r115", "r254", "r280" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r253", "r279", "r321", "r322", "r492", "r493", "r494", "r495", "r496", "r497", "r516", "r570", "r571", "r606", "r607" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionGrantsDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePromissoryNotesAdditionalInformationDetail", "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfFederalAndStateNetOperatingLossCarryforwardsDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreementsAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r253", "r279", "r321", "r322", "r492", "r493", "r494", "r495", "r496", "r497", "r516", "r570", "r571", "r606", "r607" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionGrantsDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePromissoryNotesAdditionalInformationDetail", "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfFederalAndStateNetOperatingLossCarryforwardsDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreementsAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r253", "r279", "r309", "r321", "r322", "r492", "r493", "r494", "r495", "r496", "r497", "r516", "r570", "r571", "r606", "r607" ], "lang": { "en-us": { "role": { "label": "Range [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionGrantsDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePromissoryNotesAdditionalInformationDetail", "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfFederalAndStateNetOperatingLossCarryforwardsDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreementsAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r253", "r279", "r309", "r321", "r322", "r492", "r493", "r494", "r495", "r496", "r497", "r516", "r570", "r571", "r606", "r607" ], "lang": { "en-us": { "role": { "label": "Range [Member]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionGrantsDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePromissoryNotesAdditionalInformationDetail", "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfFederalAndStateNetOperatingLossCarryforwardsDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreementsAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r58", "r59", "r114", "r115", "r254", "r280" ], "lang": { "en-us": { "role": { "label": "Repurchase Agreement Counterparty Name [Domain]", "terseLabel": "Counterparty Name" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate202006Member": { "auth_ref": [ "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity.", "label": "Accounting Standards Update202006 [Member]", "terseLabel": "ASU 2020 - 06" } } }, "localname": "AccountingStandardsUpdate202006Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r42", "r484" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10120.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r98" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10200.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion Amortization Of Discounts And Premiums Investments", "negatedLabel": "Amortization of premium and accretion of discounts on short-term investments, net" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r39", "r225" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails": { "order": 10020.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment", "negatedLabel": "Less: accumulated depreciation and amortization expense" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r30", "r63", "r64", "r65", "r559", "r579", "r583" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10070.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income Loss Net Of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r62", "r65", "r72", "r73", "r74", "r118", "r119", "r120", "r409", "r574", "r575", "r632" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Income [Member]", "terseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r28" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10060.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid In Capital Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r118", "r119", "r120", "r356", "r357", "r358", "r422" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid In Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r122", "r123", "r124", "r125", "r134", "r172", "r173", "r199", "r200", "r201", "r202", "r204", "r205", "r238", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r393", "r394", "r395", "r396", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r439", "r440", "r442", "r443", "r444", "r445", "r446", "r447", "r473", "r519", "r520", "r521", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r628", "r629", "r630", "r631", "r632" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Adjustments For New Accounting Pronouncements [Axis]", "terseLabel": "Accounting Standards Update" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r323", "r325", "r362", "r363" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r325", "r348", "r361" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share Based Compensation Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitSummaryOfStockBasedCompensationExpenseRecognizedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AlternativeInvestmentMeasurementInput": { "auth_ref": [ "r430" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure alternative investment.", "label": "Alternative Investment Measurement Input", "terseLabel": "Alternative investment, measurement input" } } }, "localname": "AlternativeInvestmentMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r142" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount", "terseLabel": "Antidilutive securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r142" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r142" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Arrangements And Nonarrangement Transactions [Member]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r109", "r163", "r165", "r169", "r194", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r407", "r410", "r438", "r482", "r484", "r536", "r558" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r10", "r12", "r56", "r109", "r194", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r407", "r410", "r438", "r482", "r484" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10160.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r180" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsSummaryOfCashEquivalentsAndInvestmentsMeasuredAtFairValueOnRecurringBasisDetails": { "order": 10960.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax", "terseLabel": "Investments, unrealized gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsSummaryOfCashEquivalentsAndInvestmentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r181" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsSummaryOfCashEquivalentsAndInvestmentsMeasuredAtFairValueOnRecurringBasisDetails": { "order": 10970.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax", "negatedLabel": "Investments, unrealized losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsSummaryOfCashEquivalentsAndInvestmentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r178", "r211" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsSummaryOfCashEquivalentsAndInvestmentsMeasuredAtFairValueOnRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Debt Securities Amortized Cost Basis", "totalLabel": "Investments, amortized cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsSummaryOfCashEquivalentsAndInvestmentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r182", "r183", "r550" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsScheduleOfContractualMaturitiesOfAFSSecuritiesDetails": { "order": 10010.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Available For Sale Securities Debt Maturities Within One Year Fair Value", "terseLabel": "Due within one year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsScheduleOfContractualMaturitiesOfAFSSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r175", "r179", "r211", "r542" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsScheduleOfContractualMaturitiesOfAFSSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsSummaryOfCashEquivalentsAndInvestmentsMeasuredAtFairValueOnRecurringBasisDetails": { "order": 10980.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Securities Debt Securities", "terseLabel": "Investments, estimated fair value", "totalLabel": "Available-for-Sale Investments", "verboseLabel": "Investments" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsScheduleOfContractualMaturitiesOfAFSSecuritiesDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsSummaryOfCashEquivalentsAndInvestmentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r326", "r350" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Balance Sheet Related Disclosures [Abstract]" } } }, "localname": "BalanceSheetRelatedDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CaliforniaFranchiseTaxBoardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government of the state of California.", "label": "California Franchise Tax Board [Member]", "terseLabel": "State" } } }, "localname": "CaliforniaFranchiseTaxBoardMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfFederalAndStateNetOperatingLossCarryforwardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r7", "r36", "r99" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10210.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash And Cash Equivalents At Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash And Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsSummaryOfCashEquivalentsAndInvestmentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails": { "order": 10010.0, "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash And Cash Equivalents Fair Value Disclosure", "terseLabel": "Cash and cash equivalents (includes cash of $397)" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisParentheticalDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r17", "r100" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash And Cash Equivalents Policy [Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "auth_ref": [ "r36" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.", "label": "Cash Cash Equivalents And Short Term Investments", "totalLabel": "Total cash, cash equivalents and short-term investments" } } }, "localname": "CashCashEquivalentsAndShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r94", "r99", "r104" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r94", "r448" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect", "totalLabel": "Net (decrease) increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r36" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents At Carrying Value", "positiveLabel": "Cash equivalents, amortized cost" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsSummaryOfCashEquivalentsAndInvestmentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental schedule of non-cash investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CashMember": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.", "label": "Cash [Member]", "terseLabel": "Cash" } } }, "localname": "CashMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisParentheticalDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": { "auth_ref": [ "r0", "r1", "r118", "r119", "r128", "r172", "r173", "r195", "r196", "r197", "r199", "r200", "r238", "r352", "r353", "r354", "r393", "r412", "r414", "r415", "r416", "r419", "r439", "r441", "r442", "r443", "r446", "r447", "r460", "r473", "r519", "r520", "r572", "r573", "r628" ], "lang": { "en-us": { "role": { "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.", "label": "Change In Accounting Principle Accounting Standards Update Adoption Date", "terseLabel": "Change in accounting principle, accounting standards update, adoption date" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption": { "auth_ref": [ "r4", "r121", "r173", "r195", "r198", "r201", "r238", "r355", "r394", "r412", "r416", "r419", "r440", "r441", "r444", "r445", "r447", "r460", "r521", "r572", "r573", "r603" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether accounting standards update was early adopted.", "label": "Change In Accounting Principle Accounting Standards Update Early Adoption", "terseLabel": "Change in accounting principle, accounting standards update, early adopted" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": { "auth_ref": [ "r122", "r133", "r174", "r203", "r359", "r397" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.", "label": "Change In Accounting Principle Accounting Standards Update Immaterial Effect", "terseLabel": "Change in accounting principle, accounting standards update, immaterial effect" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r106", "r109", "r135", "r136", "r137", "r139", "r141", "r147", "r148", "r149", "r194", "r239", "r243", "r244", "r245", "r248", "r249", "r277", "r278", "r282", "r286", "r438", "r617" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class Of Stock [Domain]", "terseLabel": "Class of Stock" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureIssuanceDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePromissoryNotesAdditionalInformationDetail", "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets", "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical", "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class Of Stock [Line Items]", "terseLabel": "Class Of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsSummaryOfCashEquivalentsAndInvestmentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r50", "r234", "r544", "r563" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10020.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments And Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments And Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r231", "r232", "r233", "r235", "r601" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments And Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "auth_ref": [ "r236", "r602" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.", "label": "Commitments And Contingencies Policy [Text Block]", "terseLabel": "Commitments" } } }, "localname": "CommitmentsAndContingenciesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock Capital Shares Reserved For Future Issuance", "terseLabel": "Common stock, reserved for future issuance", "verboseLabel": "Common stock reserved for future issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockConversionFeatures": { "auth_ref": [ "r295", "r298", "r300", "r301" ], "lang": { "en-us": { "role": { "documentation": "Description of common stock conversion feature. Includes, but is not limited to, conversion price; conversion right; timing of right; terms, event or change in circumstance causing contingency to be met or adjustment to conversion price or number of shares; manner of settlement upon conversion; and method of settlement.", "label": "Common Stock Conversion Features", "terseLabel": "Common stock, conversion terms" } } }, "localname": "CommonStockConversionFeatures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r118", "r119", "r422" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePromissoryNotesAdditionalInformationDetail", "http://rainthera.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock Par Or Stated Value Per Share", "terseLabel": "Common stock, Par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock Shares Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r27", "r294" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock Shares Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r27", "r484" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10050.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock Value", "terseLabel": "Common Stock, $0.001 par value; 250,000,000 and 24,000,000 shares authorized as of December 31, 2021 and December 31, 2020, respectively; 26,475,812 shares (comprised of 18,748,342 shares of common stock and 7,727,470 shares of non-voting common stock) and 3,530,975 shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockVotingRights": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Common Stock Voting Rights", "terseLabel": "Common stock, voting rights" } } }, "localname": "CommonStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Compensation And Retirement Disclosure [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components Of Deferred Tax Assets And Liabilities [Abstract]" } } }, "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r67", "r69", "r70", "r77", "r547", "r566" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income Net Of Tax", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income Policy Policy [Text Block]", "terseLabel": "Comprehensive Loss" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer Equipment" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r153", "r555" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk Credit Risk", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConversionOfStockAmountConverted1": { "auth_ref": [ "r101", "r102", "r103" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion Of Stock Amount Converted1", "terseLabel": "Conversion of convertible preferred stock to common stock" } } }, "localname": "ConversionOfStockAmountConverted1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtFairValueDisclosures": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt Fair Value Disclosures", "terseLabel": "Fair value of convertible promissory notes" } } }, "localname": "ConvertibleDebtFairValueDisclosures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePromissoryNotesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertiblePreferredStockMember": { "auth_ref": [ "r277", "r278", "r282" ], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Preferred Stock [Member]", "terseLabel": "Convertible Preferred Stock" } } }, "localname": "ConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "auth_ref": [ "r25", "r26", "r289", "r295", "r299" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.", "label": "Convertible Preferred Stock Shares Issued Upon Conversion", "terseLabel": "Conversion of convertible promissory notes into Series B convertible preferred stock" } } }, "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertiblePreferredStockTermsOfConversion": { "auth_ref": [ "r25", "r26", "r295", "r302", "r303", "r304" ], "lang": { "en-us": { "role": { "documentation": "Description of conversion terms for preferred stock.", "label": "Convertible Preferred Stock Terms Of Conversion", "terseLabel": "Convertible preferred stock, conversion terms" } } }, "localname": "ConvertiblePreferredStockTermsOfConversion", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r310", "r318", "r584" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate Debt Securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsSummaryOfCashEquivalentsAndInvestmentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Income Tax Expense Benefit Continuing Operations [Abstract]", "terseLabel": "Current:" } } }, "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r110", "r391", "r400" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails": { "order": 10010.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State And Local Tax Expense Benefit", "terseLabel": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r101", "r103" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion Converted Instrument Amount1", "terseLabel": "Conversion of outstanding loan into common stock shares, value" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePromissoryNotesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r101", "r103" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt Conversion Converted Instrument Shares Issued1", "terseLabel": "Debt conversion, converted instrument, shares" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePromissoryNotesAdditionalInformationDetail", "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtConversionDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion Description", "terseLabel": "Convertible promissory notes, conversion description" } } }, "localname": "DebtConversionDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePromissoryNotesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtConversionOriginalDebtAmount1": { "auth_ref": [ "r101", "r103" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion Original Debt Amount1", "terseLabel": "Debt conversion, fair value of debt converted" } } }, "localname": "DebtConversionOriginalDebtAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r20", "r22", "r23", "r108", "r116", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r269", "r270", "r271", "r272", "r458", "r537", "r538", "r556" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePromissoryNotesAdditionalInformationDetail", "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r250", "r269", "r270", "r457", "r458", "r459" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument Face Amount", "terseLabel": "Convertible promissory notes aggregate value" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePromissoryNotesAdditionalInformationDetail", "http://rainthera.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r46", "r251" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument Interest Rate Stated Percentage", "terseLabel": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePromissoryNotesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateTerms": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.", "label": "Debt Instrument Interest Rate Terms", "terseLabel": "Interest rate terms" } } }, "localname": "DebtInstrumentInterestRateTerms", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePromissoryNotesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePromissoryNotesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDateDescription": { "auth_ref": [ "r47" ], "lang": { "en-us": { "role": { "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.", "label": "Debt Instrument Maturity Date Description", "terseLabel": "Convertible promissory notes, payable description" } } }, "localname": "DebtInstrumentMaturityDateDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePromissoryNotesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r48", "r108", "r116", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r269", "r270", "r271", "r272", "r458" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument Name [Domain]", "terseLabel": "Debt Instrument, Name" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePromissoryNotesAdditionalInformationDetail", "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r48", "r108", "r116", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r269", "r270", "r271", "r272", "r295", "r302", "r303", "r304", "r456", "r457", "r458", "r459", "r554" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Debt Instrument [Table]", "terseLabel": "Debt Instrument [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePromissoryNotesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Instruments [Abstract]" } } }, "localname": "DebtInstrumentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "auth_ref": [ "r187", "r214", "r217" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer", "terseLabel": "Marketable securities, continuous unrealized loss position, greater than 12 months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "auth_ref": [ "r187", "r214", "r217" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months", "terseLabel": "Marketable securities, continuous unrealized loss position, less than 12 months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": { "auth_ref": [ "r188" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities Available For Sale Realized Gain Loss", "terseLabel": "Investments, realized gains or losses" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r189" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities Available For Sale Table [Text Block]", "terseLabel": "Schedule of Contractual Maturities of AFS Securities" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "auth_ref": [ "r186", "r212", "r217" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.", "label": "Debt Securities Available For Sale Unrealized Loss Position", "terseLabel": "Marketable securities, gross unrealized loss position" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.", "label": "Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Text Block]", "terseLabel": "Schedule of Prepaid and Other Current Assets" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredOfferingCosts": { "auth_ref": [ "r55", "r220" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.", "label": "Deferred Offering Costs", "terseLabel": "Deferred offering costs" } } }, "localname": "DeferredOfferingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "auth_ref": [], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail": { "order": 10080.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.", "label": "Deferred Tax Assets Goodwill And Intangible Assets", "terseLabel": "Intangibles" } } }, "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r382" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail": { "order": 10040.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets Gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r384" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets Liabilities Net", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r384" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail": { "order": 10010.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets Net", "totalLabel": "Total net deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r389", "r390" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail": { "order": 10090.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets Operating Loss Carryforwards", "terseLabel": "Net operating losses" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r389", "r390" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail": { "order": 10130.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": { "auth_ref": [], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail": { "order": 10070.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.", "label": "Deferred Tax Assets Property Plant And Equipment", "terseLabel": "Fixed assets" } } }, "localname": "DeferredTaxAssetsPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r389", "r390" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail": { "order": 10110.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost", "terseLabel": "Stock-based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r383" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail": { "order": 10050.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets Valuation Allowance", "negatedLabel": "Valuation allowance", "terseLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r370", "r384" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail": { "order": 10020.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities", "negatedTotalLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredIncomeTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanTextBlock": { "auth_ref": [ "r319", "r320" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for defined contribution plan.", "label": "Defined Contribution Plan [Text Block]", "terseLabel": "Employee Benefits" } } }, "localname": "DefinedContributionPlanTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureEmployeeBenefits" ], "xbrltype": "textBlockItemType" }, "us-gaap_DepositsAssetsCurrent": { "auth_ref": [ "r41" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidAndOtherCurrentAssetsDetails": { "order": 10050.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.", "label": "Deposits Assets Current", "terseLabel": "Deposits" } } }, "localname": "DepositsAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositsAssetsNoncurrent": { "auth_ref": [ "r41" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfOtherNonCurrentAssetsDetails": { "order": 10020.0, "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.", "label": "Deposits Assets Noncurrent", "terseLabel": "Deposits" } } }, "localname": "DepositsAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfOtherNonCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r97", "r223" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r97", "r223" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10160.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation And Amortization", "terseLabel": "Depreciation and amortization expense" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DividendsPreferredStock": { "auth_ref": [ "r305", "r553" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).", "label": "Dividends Preferred Stock", "terseLabel": "Dividends, preferred stock" } } }, "localname": "DividendsPreferredStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share Basic And Diluted", "terseLabel": "Net loss per share, basic and diluted" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails", "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share Basic And Diluted [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r142", "r143" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share Policy [Text Block]", "terseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r142", "r143", "r144", "r145" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureNetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]", "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitSummaryOfStockBasedCompensationExpenseRecognizedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r349" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized", "terseLabel": "Unrecognized compensation cost related to outstanding options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1", "terseLabel": "Cost not yet recognized, period for Recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "ESPP shares" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Common Stock Options", "verboseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureIssuanceDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r72", "r73", "r74", "r118", "r119", "r120", "r123", "r130", "r132", "r146", "r202", "r294", "r305", "r356", "r357", "r358", "r395", "r396", "r422", "r449", "r450", "r451", "r452", "r453", "r454", "r574", "r575", "r576", "r632" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePromissoryNotesAdditionalInformationDetail", "http://rainthera.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisParentheticalDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r425", "r426", "r427", "r434" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisParentheticalDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount": { "auth_ref": [ "r427" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.", "label": "Fair Value Assets Level1 To Level2 Transfers Amount", "terseLabel": "Assets transfer, Level 1 to 2" } } }, "localname": "FairValueAssetsLevel1ToLevel2TransfersAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount": { "auth_ref": [ "r427" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.", "label": "Fair Value Assets Level2 To Level1 Transfers Amount", "terseLabel": "Assets transfer, Level 2 to 1" } } }, "localname": "FairValueAssetsLevel2ToLevel1TransfersAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r425", "r426" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value Assets Measured On Recurring Basis [Text Block]", "terseLabel": "Summary of Financial Assets Measured at Fair Value on Recurring Basis" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r431" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]", "terseLabel": "Asset Class" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisParentheticalDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r425", "r434" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Fair Value By Asset Class [Axis]", "terseLabel": "Asset Class" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisParentheticalDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r259", "r269", "r270", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r318", "r426", "r489", "r490", "r491" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value By Fair Value Hierarchy Level [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueUsingLevel3SignificantUnobservableInputsDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r425", "r426", "r429", "r430", "r435" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Fair Value By Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisParentheticalDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsSummaryOfCashEquivalentsAndInvestmentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r259", "r310", "r311", "r316", "r318", "r426", "r489" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value Inputs Level1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r259", "r269", "r270", "r310", "r311", "r316", "r318", "r426", "r490" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value Inputs Level2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r259", "r269", "r270", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r318", "r426", "r491" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Inputs Level3 [Member]", "terseLabel": "Level 3", "verboseLabel": "Level 3 Significant Unobservable Inputs" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueUsingLevel3SignificantUnobservableInputsDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount": { "auth_ref": [ "r427" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.", "label": "Fair Value Liabilities Level1 To Level2 Transfers Amount", "terseLabel": "Liabilities transfer, Level 1 to 2" } } }, "localname": "FairValueLiabilitiesLevel1ToLevel2TransfersAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount": { "auth_ref": [ "r427" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.", "label": "Fair Value Liabilities Level2 To Level1 Transfers Amount", "terseLabel": "Liabilities transfer, Level 2 to 1" } } }, "localname": "FairValueLiabilitiesLevel2ToLevel1TransfersAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueUsingLevel3SignificantUnobservableInputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r431", "r434" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueUsingLevel3SignificantUnobservableInputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r431", "r434" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]", "terseLabel": "Reconciliation of Liabilities Measured at Fair Value Using Level 3 Significant Unobservable Inputs" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Fair Value Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisParentheticalDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsSummaryOfCashEquivalentsAndInvestmentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement Policy Policy [Text Block]", "terseLabel": "Fair Value Option" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3": { "auth_ref": [ "r432" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3", "terseLabel": "Liabilities transfer, into of Level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3": { "auth_ref": [ "r432" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3", "terseLabel": "Liabilities transfer, out of Level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": { "auth_ref": [ "r432" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3", "terseLabel": "Assets transfer, into Level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": { "auth_ref": [ "r432" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3", "terseLabel": "Assets transfer, out of Level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r431" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value", "periodEndLabel": "Fair value as of December 31, 2020", "periodStartLabel": "Fair value as of December 31, 2019" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueUsingLevel3SignificantUnobservableInputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r259", "r269", "r270", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r318", "r489", "r490", "r491" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Measurements Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueUsingLevel3SignificantUnobservableInputsDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r433", "r435" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value Measurements Recurring [Member]", "terseLabel": "Fair Value on Recurring Basis" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisParentheticalDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsSummaryOfCashEquivalentsAndInvestmentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r436", "r437" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value Of Financial Instruments Policy", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r184", "r185", "r190", "r191", "r192", "r206", "r207", "r208", "r209", "r210", "r213", "r215", "r216", "r217", "r267", "r292", "r413", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r617", "r618", "r619", "r620", "r621", "r622", "r623" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsSummaryOfCashEquivalentsAndInvestmentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.", "label": "Financial Liabilities Fair Value Disclosure", "terseLabel": "Financial liabilities" } } }, "localname": "FinancialLiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture And Fixtures [Member]", "terseLabel": "Furniture and Equipment" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnInvestments": { "auth_ref": [ "r83", "r97", "r177" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10210.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized and unrealized gain (loss) on investment.", "label": "Gain Loss On Investments", "negatedLabel": "Fair value loss/(gain) on investments" } } }, "localname": "GainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r81" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 10130.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General And Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r78" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General And Administrative Expense [Member]", "terseLabel": "General and Administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitSummaryOfStockBasedCompensationExpenseRecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "I P O [Member]", "terseLabel": "IPO" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r222", "r229" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment Or Disposal Of Long Lived Assets Policy [Text Block]", "terseLabel": "Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InProcessResearchAndDevelopmentPolicy": { "auth_ref": [ "r40", "r366" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.", "label": "In Process Research And Development Policy", "terseLabel": "In-Process Research and Development" } } }, "localname": "InProcessResearchAndDevelopmentPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r75", "r163", "r164", "r167", "r168", "r170", "r534", "r545", "r548", "r568" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 10030.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest", "totalLabel": "Net loss before income tax expense" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r228", "r230" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitSummaryOfStockBasedCompensationExpenseRecognizedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitSummaryOfStockBasedCompensationExpenseRecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityNameAxis": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Information by name of taxing authority.", "label": "Income Tax Authority Name [Axis]", "terseLabel": "Income Tax Authority, Name" } } }, "localname": "IncomeTaxAuthorityNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfFederalAndStateNetOperatingLossCarryforwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority Name [Domain]", "terseLabel": "Income Tax Authority, Name" } } }, "localname": "IncomeTaxAuthorityNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfFederalAndStateNetOperatingLossCarryforwardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r111", "r373", "r380", "r386", "r398", "r401", "r403", "r404", "r405" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": { "auth_ref": [ "r374" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.", "label": "Income Tax Examination Penalties And Interest Expense", "terseLabel": "Interest or penalties" } } }, "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r112", "r131", "r132", "r162", "r371", "r399", "r402", "r569" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComputationOfProvisionForIncomeTaxesByApplyingFederalStatutoryIncomeTaxRateToIncomeBeforeTaxesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 10040.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense Benefit", "negatedLabel": "Income tax expense", "totalLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComputationOfProvisionForIncomeTaxesByApplyingFederalStatutoryIncomeTaxRateToIncomeBeforeTaxesDetail", "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r71", "r368", "r369", "r380", "r381", "r385", "r392" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax Policy [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r372" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComputationOfProvisionForIncomeTaxesByApplyingFederalStatutoryIncomeTaxRateToIncomeBeforeTaxesDetail": { "order": 10070.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance", "terseLabel": "Change in valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComputationOfProvisionForIncomeTaxesByApplyingFederalStatutoryIncomeTaxRateToIncomeBeforeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r372" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComputationOfProvisionForIncomeTaxesByApplyingFederalStatutoryIncomeTaxRateToIncomeBeforeTaxesDetail": { "order": 10010.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate", "terseLabel": "Federal tax benefit at statutory rate" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComputationOfProvisionForIncomeTaxesByApplyingFederalStatutoryIncomeTaxRateToIncomeBeforeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpense": { "auth_ref": [ "r372" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComputationOfProvisionForIncomeTaxesByApplyingFederalStatutoryIncomeTaxRateToIncomeBeforeTaxesDetail": { "order": 10040.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.", "label": "Income Tax Reconciliation Nondeductible Expense", "terseLabel": "Non-deductible expenses" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComputationOfProvisionForIncomeTaxesByApplyingFederalStatutoryIncomeTaxRateToIncomeBeforeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "auth_ref": [ "r372" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComputationOfProvisionForIncomeTaxesByApplyingFederalStatutoryIncomeTaxRateToIncomeBeforeTaxesDetail": { "order": 10080.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Income Tax Reconciliation Other Adjustments", "terseLabel": "Other" } } }, "localname": "IncomeTaxReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComputationOfProvisionForIncomeTaxesByApplyingFederalStatutoryIncomeTaxRateToIncomeBeforeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r372" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComputationOfProvisionForIncomeTaxesByApplyingFederalStatutoryIncomeTaxRateToIncomeBeforeTaxesDetail": { "order": 10020.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).", "label": "Income Tax Reconciliation State And Local Income Taxes", "terseLabel": "State taxes" } } }, "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComputationOfProvisionForIncomeTaxesByApplyingFederalStatutoryIncomeTaxRateToIncomeBeforeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": { "auth_ref": [ "r372" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComputationOfProvisionForIncomeTaxesByApplyingFederalStatutoryIncomeTaxRateToIncomeBeforeTaxesDetail": { "order": 10060.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Income Tax Reconciliation Tax Credits Research", "negatedLabel": "R&D credits" } } }, "localname": "IncomeTaxReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesComputationOfProvisionForIncomeTaxesByApplyingFederalStatutoryIncomeTaxRateToIncomeBeforeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r96" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10250.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase Decrease In Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase Decrease In Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": { "auth_ref": [ "r96" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10270.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.", "label": "Increase Decrease In Other Accrued Liabilities", "terseLabel": "Other accrued liabilities" } } }, "localname": "IncreaseDecreaseInOtherAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r96" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10240.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase Decrease In Other Noncurrent Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "auth_ref": [], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10280.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.", "label": "Increase Decrease In Other Noncurrent Liabilities", "terseLabel": "Other long-term liabilities" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r96" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10220.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets", "negatedLabel": "Prepaid and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend": { "auth_ref": [ "r221" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the treatment of costs incurred to renew or extend the term of a recognized intangible asset.", "label": "Intangible Assets Finite Lived Policy Costs Incurred To Renew Or Extend", "terseLabel": "Patent Costs" } } }, "localname": "IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r85", "r264", "r268", "r271", "r272" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense Debt", "terseLabel": "Interest expense recognized" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePromissoryNotesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseRelatedParty": { "auth_ref": [], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10180.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 10080.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense incurred on a debt or other obligation to related party.", "label": "Interest Expense Related Party", "negatedLabel": "Interest expense, related party", "terseLabel": "Non-cash interest expense, related party" } } }, "localname": "InterestExpenseRelatedParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows", "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "auth_ref": [ "r543", "r564" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.", "label": "Interest Payable Current And Noncurrent", "terseLabel": "Accrued interest" } } }, "localname": "InterestPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePromissoryNotesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r82", "r161" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 10070.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income Interest", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r193", "r567" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment Policy [Text Block]", "terseLabel": "Available-for-Sale Investments" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsSummaryOfCashEquivalentsAndInvestmentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investment Type Categorization [Member]", "terseLabel": "Investments" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsSummaryOfCashEquivalentsAndInvestmentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments Debt And Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r189", "r535", "r551", "r600", "r624" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r470" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease Cost Table [Text Block]", "terseLabel": "Summary of Lease Costs and Cash Payments" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r464" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee Leases Policy [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee Operating Lease Liability Maturity Table [Text Block]", "terseLabel": "Schedule of Future Minimum Lease Payments Required under Operating Lease" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r471" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsRequiredUnderOperatingLeaseDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://rainthera.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsRequiredUnderOperatingLeaseDetails2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee Operating Lease Liability Payments Due", "totalLabel": "Total minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsRequiredUnderOperatingLeaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r471" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsRequiredUnderOperatingLeaseDetails": { "order": 10030.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsRequiredUnderOperatingLeaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r471" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsRequiredUnderOperatingLeaseDetails": { "order": 10050.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Three", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsRequiredUnderOperatingLeaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r471" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsRequiredUnderOperatingLeaseDetails": { "order": 10040.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Two", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsRequiredUnderOperatingLeaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r471" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsRequiredUnderOperatingLeaseDetails2": { "order": 10010.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee Operating Lease Liability Undiscounted Excess Amount", "negatedLabel": "Less: amount representing interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsRequiredUnderOperatingLeaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r465" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee Operating Lease Term Of Contract", "terseLabel": "Initial term of operating lease" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r43", "r109", "r166", "r194", "r239", "r240", "r241", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r408", "r410", "r411", "r438", "r482", "r483" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10010.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r33", "r109", "r194", "r438", "r484", "r539", "r561" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities And Stockholders Equity", "totalLabel": "Total liabilities, convertible preferred stock, and stockholders\u2019 equity (deficit)" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities And Stockholders Equity [Abstract]", "terseLabel": "Liabilities, convertible preferred stock, and stockholders\u2019 equity (deficit)" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r45", "r109", "r194", "r239", "r240", "r241", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r408", "r410", "r411", "r438", "r482", "r483", "r484" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10090.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputDiscountRateMember": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate to determine present value of future cash flows.", "label": "Measurement Input Discount Rate [Member]", "terseLabel": "Measurement Input, Discount Rate" } } }, "localname": "MeasurementInputDiscountRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input Expected Term [Member]", "terseLabel": "Measurement Input, Expected Term" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r310" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsSummaryOfCashEquivalentsAndInvestmentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r150", "r159" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature Of Operations", "terseLabel": "Organization and Nature of Operations" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r94" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10030.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided By Used In Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Financing Activities [Abstract]", "terseLabel": "Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r94" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10020.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided By Used In Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Investing Activities [Abstract]", "terseLabel": "Investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r94", "r95", "r98" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10010.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided By Used In Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r6", "r66", "r68", "r74", "r76", "r98", "r109", "r122", "r126", "r127", "r128", "r129", "r131", "r132", "r138", "r163", "r164", "r167", "r168", "r170", "r194", "r239", "r240", "r241", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r424", "r438", "r546", "r565" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10140.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 10010.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income Loss", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails", "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows", "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements Policy Policy [Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r84" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 10060.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income Expense", "totalLabel": "Total other income (expense), net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income Expense [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_NonvotingCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock securities that do not empower a holder to vote on corporate resolutions or the election of directors.", "label": "Nonvoting Common Stock [Member]", "terseLabel": "Non-voting Common Stock" } } }, "localname": "NonvotingCommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r160" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number Of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 10110.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r163", "r164", "r167", "r168", "r170" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 10050.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income Loss", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r466", "r472" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease Cost", "terseLabel": "Total operating lease expense" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndCashPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r462" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsRequiredUnderOperatingLeaseDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://rainthera.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsRequiredUnderOperatingLeaseDetails2": { "order": 10020.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease Liability", "totalLabel": "Present value of operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsRequiredUnderOperatingLeaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r462" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsRequiredUnderOperatingLeaseDetails": { "order": 10010.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10150.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease Liability Current", "terseLabel": "Operating lease liability, current portion" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsRequiredUnderOperatingLeaseDetails", "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r462" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsRequiredUnderOperatingLeaseDetails": { "order": 10020.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10100.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease Liability Noncurrent", "terseLabel": "Operating lease liability, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsRequiredUnderOperatingLeaseDetails", "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r463", "r467" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease Payments", "terseLabel": "Operating cash flows used for operating lease" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndCashPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r461" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10180.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease Right Of Use Asset", "terseLabel": "Operating lease right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r469", "r472" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease Weighted Average Discount Rate Percent", "terseLabel": "Weighted-average incremental borrowing rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsRequiredUnderOperatingLeaseDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r468", "r472" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease Weighted Average Remaining Lease Term1", "terseLabel": "Weighted-average remaining lease term (in years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsRequiredUnderOperatingLeaseDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r387" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards, Amount" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfFederalAndStateNetOperatingLossCarryforwardsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfFederalAndStateNetOperatingLossCarryforwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r388" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]", "terseLabel": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfFederalAndStateNetOperatingLossCarryforwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r13", "r14", "r15", "r44" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10140.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities Current", "terseLabel": "Other accrued liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r55", "r484" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidAndOtherCurrentAssetsDetails": { "order": 10060.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsMiscellaneousNoncurrent": { "auth_ref": [], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfOtherNonCurrentAssetsDetails": { "order": 10030.0, "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.", "label": "Other Assets Miscellaneous Noncurrent", "terseLabel": "Other" } } }, "localname": "OtherAssetsMiscellaneousNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfOtherNonCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r41" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfOtherNonCurrentAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10200.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets Noncurrent", "terseLabel": "Other assets", "totalLabel": "Other non-current assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfOtherNonCurrentAssetsDetails", "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]", "terseLabel": "Other comprehensive income:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r61", "r63" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 10020.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax", "terseLabel": "Unrealized loss on investments" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r49" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10110.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncome": { "auth_ref": [ "r79" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 10100.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income", "terseLabel": "Other income" } } }, "localname": "OtherNonoperatingIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPrepaidExpenseCurrent": { "auth_ref": [ "r8", "r11", "r219" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidAndOtherCurrentAssetsDetails": { "order": 10030.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Other Prepaid Expense Current", "terseLabel": "Prepaid other" } } }, "localname": "OtherPrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over Allotment Option [Member]", "terseLabel": "Underwriters Option" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r93" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10090.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments Of Stock Issuance Costs", "negatedLabel": "Payments of issuance costs related to the initial public offering" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": { "auth_ref": [ "r88" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10120.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.", "label": "Payments To Acquire In Process Research And Development", "negatedLabel": "Payment of in-process research and development expense" } } }, "localname": "PaymentsToAcquireInProcessResearchAndDevelopment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r89" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10110.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments To Acquire Property Plant And Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireShortTermInvestments": { "auth_ref": [ "r90" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10100.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Payments To Acquire Short Term Investments", "negatedLabel": "Purchases of short-term investments" } } }, "localname": "PaymentsToAcquireShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r326", "r350" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitSummaryOfStockOptionActivitiesDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitTables", "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionGrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitSummaryOfStockOptionActivitiesDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitTables", "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionGrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r26", "r277" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock Par Or Stated Value Per Share", "terseLabel": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock Shares Authorized", "terseLabel": "Preferred Stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r10", "r34", "r35" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidAndOtherCurrentAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10230.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense And Other Assets Current", "terseLabel": "Prepaid and other current assets", "totalLabel": "Prepaid and Other Current Assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidAndOtherCurrentAssetsDetails", "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r9", "r11", "r218", "r219" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidAndOtherCurrentAssetsDetails": { "order": 10010.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Insurance", "terseLabel": "Prepaid insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r92" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10080.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds From Convertible Debt", "terseLabel": "Proceeds from issuance of convertible promissory notes" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r91" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10040.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds From Issuance Initial Public Offering", "terseLabel": "Proceeds from initial public offering" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r91" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds From Issuance Of Common Stock", "terseLabel": "Proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "auth_ref": [ "r91" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10070.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.", "label": "Proceeds From Issuance Of Convertible Preferred Stock", "terseLabel": "Proceeds from issuance of convertible preferred stock, net of issuance costs", "verboseLabel": "Convertible preferred stock for aggregate purchase price" } } }, "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "auth_ref": [ "r91" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.", "label": "Proceeds From Issuance Of Preferred Stock And Preference Stock", "terseLabel": "Net proceeds from issuance of preferred stock" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePromissoryNotesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": { "auth_ref": [ "r91", "r351" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10060.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.", "label": "Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans", "terseLabel": "Issuance of common stock for vesting of restricted shares" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": { "auth_ref": [ "r86", "r87", "r176" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10130.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds From Sale And Maturity Of Available For Sale Securities", "terseLabel": "Maturities of available for sale investments" } } }, "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r91", "r351" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10050.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds From Stock Options Exercised", "terseLabel": "Proceeds from stock option exercises" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r39", "r226" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property Plant And Equipment By Type [Axis]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r38", "r224" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails": { "order": 10010.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Gross", "terseLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property Plant And Equipment [Line Items]", "terseLabel": "Property Plant And Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r18", "r19", "r226", "r484", "r552", "r562" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10170.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and Equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails", "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r37", "r226", "r604", "r605" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property Plant And Equipment Policy [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r18", "r226" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property Plant And Equipment [Text Block]", "terseLabel": "Schedule of Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r18", "r224" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property Plant And Equipment Type [Domain]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property Plant And Equipment Useful Life", "terseLabel": "Estimated useful lives of assets" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r317", "r476", "r477" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r317", "r476", "r479", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party Transactions By Related Party [Axis]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r474", "r475", "r477", "r480", "r481" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r365", "r517", "r608" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 10120.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research And Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research And Development Expense [Member]", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitSummaryOfStockBasedCompensationExpenseRecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research And Development Expense Policy", "terseLabel": "Research and Development Costs" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentInProcess": { "auth_ref": [], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10150.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.", "label": "Research And Development In Process", "terseLabel": "In-process research and development expense" } } }, "localname": "ResearchAndDevelopmentInProcess", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsSummaryOfCashEquivalentsAndInvestmentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r29", "r305", "r359", "r484", "r560", "r578", "r583" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10080.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings Accumulated Deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r118", "r119", "r120", "r123", "r130", "r132", "r202", "r356", "r357", "r358", "r395", "r396", "r422", "r574", "r576" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RoyaltyExpense": { "auth_ref": [ "r80" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.", "label": "Royalty Expense", "terseLabel": "Royalty payments" } } }, "localname": "RoyaltyExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale Of Stock Name Of Transaction [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale Of Stock Price Per Share", "terseLabel": "Public offering price per share" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r142" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r142" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]", "terseLabel": "Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r392" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]", "terseLabel": "Components of Provision for Income Taxes" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r384" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]", "terseLabel": "Components of Deferred Income Tax Assets and Liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r141" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]", "terseLabel": "Schedule of Computation of Basic and Diluted Net Loss per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]", "terseLabel": "Computation of Provision for Income Taxes by Applying Federal Statutory Income Tax Rate to Income Before Taxes" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r325", "r347", "r361" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]", "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitSummaryOfStockBasedCompensationExpenseRecognizedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r325", "r347", "r361" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]", "terseLabel": "Summary of Stock-Based Compensation Expense Recognized" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of noncurrent assets.", "label": "Schedule Of Other Assets Noncurrent [Text Block]", "terseLabel": "Schedule of Other Non-Current Assets" } } }, "localname": "ScheduleOfOtherAssetsNoncurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r39", "r226" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule Of Property Plant And Equipment [Table]", "terseLabel": "Schedule Of Property Plant And Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r478", "r479" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule Of Related Party Transactions By Related Party [Table]", "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r326", "r350" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureIssuanceDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitSummaryOfStockOptionActivitiesDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionGrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r330", "r335", "r338" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]", "terseLabel": "Summary of Stock Option Activities" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r341" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]", "terseLabel": "Weighted-Average Assumptions Used in Black-Scholes Option Pricing Model to Determine Fair Value of Stock Option Grants" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r51", "r106", "r147", "r148", "r273", "r275", "r276", "r277", "r278", "r279", "r280", "r282", "r286", "r292", "r295", "r296", "r297", "r302", "r303", "r304", "r305" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule Of Stock By Class [Table]", "terseLabel": "Schedule Of Stock By Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.", "label": "Selling General And Administrative Expenses Policy [Text Block]", "terseLabel": "General and Administrative Expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r96" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10170.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share Based Compensation", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Based Compensation Allocation And Classification In Financial Statements [Abstract]" } } }, "localname": "ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Discount rate from fair value on offering date that participants pay for shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Offering Date", "terseLabel": "Purchase of common stock at discount from market price, offering date" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionGrantsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionGrantsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum", "terseLabel": "Expected volatility, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionGrantsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum", "terseLabel": "Expected volatility, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionGrantsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionGrantsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum", "terseLabel": "Risk-free interest rate, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionGrantsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum", "terseLabel": "Risk-free interest rate, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionGrantsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureIssuanceDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitSummaryOfStockOptionActivitiesDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionGrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate", "terseLabel": "Maximum contribution made by employees compensation" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized", "terseLabel": "Shares authorized for issuance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant", "terseLabel": "Stock options, grant equity-based awards issued" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r337" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitSummaryOfStockOptionActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period", "negatedLabel": "Total Options Forfeited or cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitSummaryOfStockOptionActivitiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross", "terseLabel": "Stock options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitSummaryOfStockOptionActivitiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant date fair values of option grants" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r350" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitSummaryOfStockOptionActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r332", "r350" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number", "periodEndLabel": "Total Options Outstanding, Ending balance", "periodStartLabel": "Total Options Outstanding, Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitSummaryOfStockOptionActivitiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward", "terseLabel": "Total Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitSummaryOfStockOptionActivitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price", "periodEndLabel": "Weighted-Average Exercise Price Per Share", "periodStartLabel": "Weighted-Average Exercise Price Per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitSummaryOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward", "terseLabel": "Weighted-Average Exercise Price Per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitSummaryOfStockOptionActivitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r340" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Vested and exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitSummaryOfStockOptionActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number", "terseLabel": "Total Options, Vested and exercisable as of December 31, 2021" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitSummaryOfStockOptionActivitiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price Per Share, Vested and exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitSummaryOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r338" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitSummaryOfStockOptionActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number", "terseLabel": "Total Options, Vested and expected to vest as of December 31, 2021" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitSummaryOfStockOptionActivitiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price Per Share, Vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitSummaryOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum", "terseLabel": "Percentage of outstanding number of shares of common stock" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued under share-based payment arrangement.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period", "terseLabel": "Shares issued in period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r324", "r328" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price Per Share, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitSummaryOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price Per Share, Forfeited or cancelled" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitSummaryOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price Per Share, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitSummaryOfStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r326", "r329" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share Based Compensation Option And Incentive Plans Policy", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r342", "r360" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1", "terseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionGrantsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options forfeited.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant date fair values of options forfeited" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2", "terseLabel": "Weighted-Average Remaining Contract Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitSummaryOfStockOptionActivitiesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1", "terseLabel": "Weighted-Average Remaining Contract Term, Vested and exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitSummaryOfStockOptionActivitiesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1", "terseLabel": "Weighted-Average Remaining Contract Term, Vested and expected to vest" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitSummaryOfStockOptionActivitiesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares Outstanding", "periodEndLabel": "Balance, Shares", "periodStartLabel": "Balance, Shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r21", "r540", "r541", "r557" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails": { "order": 10020.0, "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments", "weight": 1.0 }, "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10220.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short Term Investments", "terseLabel": "Short-term investments", "verboseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails", "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r105", "r117" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r25", "r26", "r27", "r106", "r109", "r135", "r136", "r137", "r139", "r141", "r147", "r148", "r149", "r194", "r239", "r243", "r244", "r245", "r248", "r249", "r277", "r278", "r282", "r286", "r294", "r438", "r617" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Statement Class Of Stock [Axis]", "terseLabel": "Class of Stock" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureIssuanceDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePromissoryNotesAdditionalInformationDetail", "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets", "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical", "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r54", "r72", "r73", "r74", "r118", "r119", "r120", "r123", "r130", "r132", "r146", "r202", "r294", "r305", "r356", "r357", "r358", "r395", "r396", "r422", "r449", "r450", "r451", "r452", "r453", "r454", "r574", "r575", "r576", "r632" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Statement Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePromissoryNotesAdditionalInformationDetail", "http://rainthera.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitTables", "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets", "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical", "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Stockholders Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r118", "r119", "r120", "r146", "r518" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitTables", "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets", "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical", "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r53", "r261", "r294", "r295", "r305" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period Shares Conversion Of Convertible Securities", "terseLabel": "Conversion of convertible preferred stock to common stock, shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r26", "r27", "r294", "r305" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period Shares New Issues", "terseLabel": "Issuance of common stock upon IPO, net of issuance cost, shares", "verboseLabel": "Number of shares issued and sold" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r294", "r305" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period Shares Restricted Stock Award Gross", "terseLabel": "Vesting of restricted shares, Shares", "verboseLabel": "Shares issued in connection with vesting of restricted stock" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r26", "r27", "r294", "r305", "r333" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock Issued During Period Shares Stock Options Exercised", "negatedLabel": "Total Options, Exercised", "terseLabel": "Exercise of stock options, shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitSummaryOfStockOptionActivitiesDetails", "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r54", "r294", "r305" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period Value Conversion Of Convertible Securities", "terseLabel": "Conversion of convertible preferred stock to common stock" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r26", "r27", "r294", "r305" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period Value New Issues", "terseLabel": "Issuance of common stock upon IPO, net of issuance cost" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r26", "r27", "r294", "r305" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Stock Issued During Period Value Restricted Stock Award Gross", "terseLabel": "Vesting of restricted shares" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r54", "r294", "r305" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period Value Stock Options Exercised", "terseLabel": "Exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r26", "r27", "r294", "r305" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period Shares", "terseLabel": "Shares subject to repurchase" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r27", "r31", "r32", "r109", "r171", "r194", "r438", "r484" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10040.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders Equity", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders' equity (deficit)" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets", "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders Equity [Abstract]", "terseLabel": "Stockholders\u2019 equity (deficit):" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r107", "r278", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r290", "r291", "r293", "r305", "r308" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders Equity Note Disclosure [Text Block]", "terseLabel": "Convertible Preferred Stock and Stockholders' Equity (Deficit)" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.", "label": "Stockholders Equity Note Stock Split Conversion Ratio1", "terseLabel": "Reverse stock split conversion ratio" } } }, "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails" ], "xbrltype": "pureItemType" }, "us-gaap_StockholdersEquityReverseStockSplit": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.", "label": "Stockholders Equity Reverse Stock Split", "terseLabel": "Reverse stock split description" } } }, "localname": "StockholdersEquityReverseStockSplit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r455", "r485" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r455", "r485" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r455", "r485" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Subsidiary Sale Of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": { "auth_ref": [ "r375", "r379", "r381" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.", "label": "Summary Of Income Tax Contingencies [Text Block]", "terseLabel": "Changes in Gross Unrecognized Tax Benefits" } } }, "localname": "SummaryOfIncomeTaxContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r60" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Balance Sheet Details" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureBalanceSheetDetails" ], "xbrltype": "textBlockItemType" }, "us-gaap_TangibleAssetImpairmentCharges": { "auth_ref": [ "r5", "r227" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.", "label": "Tangible Asset Impairment Charges", "terseLabel": "Impairment losses on long-lived assets" } } }, "localname": "TangibleAssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [ "r239", "r243", "r244", "r245", "r248", "r249" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 10030.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity Carrying Amount Attributable To Parent", "periodEndLabel": "Temporary equity, balance", "periodStartLabel": "Temporary equity, balance", "terseLabel": "Total convertible preferred stock" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheets", "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": { "auth_ref": [ "r16", "r274" ], "lang": { "en-us": { "role": { "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.", "label": "Temporary Equity Par Or Stated Value Per Share", "terseLabel": "Convertible preferred stock, Par value" } } }, "localname": "TemporaryEquityParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_TemporaryEquitySharesAuthorized": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity Shares Authorized", "terseLabel": "Convertible preferred stock, Shares authorized" } } }, "localname": "TemporaryEquitySharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesIssued": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity Shares Issued", "terseLabel": "Convertible preferred stock, Shares issued" } } }, "localname": "TemporaryEquitySharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity Shares Outstanding", "periodEndLabel": "Temporary equity, balance, Shares", "periodStartLabel": "Temporary equity, balance, Shares", "terseLabel": "Convertible preferred stock, Shares outstanding" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical", "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of new stock classified as temporary equity issued during the period.", "label": "Temporary Equity Stock Issued During Period Value New Issues", "terseLabel": "Issuance of Series B convertible preferred stock, net of issuance costs of $320" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r184", "r185", "r190", "r191", "r192", "r267", "r292", "r413", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r617", "r618", "r619", "r620", "r621", "r622", "r623" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]", "terseLabel": "Financial Instruments" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsSummaryOfCashEquivalentsAndInvestmentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r122", "r123", "r124", "r125", "r134", "r172", "r173", "r199", "r200", "r201", "r202", "r204", "r205", "r238", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r393", "r394", "r395", "r396", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r439", "r440", "r442", "r443", "r444", "r445", "r446", "r447", "r473", "r519", "r520", "r521", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r628", "r629", "r630", "r631", "r632" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Type Of Adoption [Member]", "terseLabel": "Accounting Standards Update" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Type Of Arrangement [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureLicenseAndClinicalSupplyAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r113", "r310", "r549" ], "lang": { "en-us": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "U S Government Agencies Debt Securities [Member]", "terseLabel": "U.S. Agency Bonds" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsSummaryOfCashEquivalentsAndInvestmentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r113", "r310", "r318", "r549" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "U S Treasury Securities [Member]", "terseLabel": "U.S. Government Securities" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureInvestmentsSummaryOfCashEquivalentsAndInvestmentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r367", "r377" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Balance at end of year", "periodStartLabel": "Balance at beginning of year", "verboseLabel": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesChangesInGrossUnrecognizedTaxBenefitsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r378" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions", "terseLabel": "Additions based on tax positions related to current year" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesChangesInGrossUnrecognizedTaxBenefitsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r151", "r152", "r154", "r155", "r156", "r157", "r158" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use Of Estimates", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r384" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance Deferred Tax Asset Change In Amount", "terseLabel": "Valuation allowance increase" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r141" ], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails": { "order": 10020.0, "parentTag": "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "weight": -1.0 } }, "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number Diluted Shares Outstanding Adjustment", "negatedLabel": "Less: weighted-average unvested common stock" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "calculation": { "http://rainthera.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number Of Share Outstanding Basic And Diluted", "terseLabel": "Weighted-average shares used to compute net loss per share, basic and diluted", "totalLabel": "Weighted-average shares used to compute net loss per share, basic and diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails", "http://rainthera.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number Of Shares Outstanding [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://rainthera.com/20211231/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 9 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r117": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31010-122693" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r145": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r159": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(27)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(1)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27405-111563" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563" }, "r189": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.A)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r233": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r235": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S65", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r308": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/subtopic&trid=2235116" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.15)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r405": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL120154346-209984" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r481": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r535": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803" }, "r551": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r60": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "http://asc.fasb.org/topic&trid=2122208" }, "r600": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=123877278&loc=SL120174030-210619" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r609": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r610": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r611": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r612": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r613": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r614": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r615": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r616": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r617": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r618": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r619": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r620": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r621": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r622": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r623": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r624": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403" }, "r625": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r626": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r627": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(c),9(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" } }, "version": "2.1" } ZIP 82 0001564590-22-008531-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-22-008531-xbrl.zip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Ϳ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�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�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